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BACKGROUND & AIMS 
Carpal tunnel syndrome (CTS) is a common occupational injury that is caused by an 
increase in pressure within the carpal tunnel structure which, in turn, causes compression of 
the median nerve. Although several factors are believed to be associated with increased risk 
of CTS, the direct causes of this injury remain unknown and it is generally accepted that 
CTS, with the exception of acutely caused CTS, is a multifactorial condition. Although it is 
generally accepted that an increase in pressure within the carpal tunnel structure, which 
contains nine flexor tendons, causes compression of the median nerve, the involvement of 
these tendons and other connective tissue structures in the aetiology of CTS cannot be 
excluded. In support of this, pathology of these connective structures have been proposed 
as being comorbid conditions or a precursor of CTS, cause CTS and/or can lead to an 
increase in carpal tunnel pressure. 
 
Several studies have suggested that specific non-occupational risk factors, such as 
anatomical, systemic and chronic factors as well as mostly repetition- and force-related 
occupational risk factors are associated with CTS. Although genetic influences in the 
aetiology of CTS have been proposed, this area has received little attention. Common DNA 
sequence variants on the other hand have previously been reported to associate with 
common exercise-associated tendon, such as chronic Achilles tendinopathy, and ligament 
injuries. 
 
The aim of this thesis was to determine whether common DNA sequence variants within 
several genes that have been associated or implicated in the aetiology of exercise-related 
musculoskeletal soft tissue injuries, are associated with altered risk of CTS by using a 




 To determine whether four variants within the matrix metalloproteinase genes 
(MMPs), MMP10 rs486055 (C/T), MMP1 rs1799750 (1G/2G), MMP3 rs679620 (A/G) 
and MMP12 rs2276109 (A/G), clustered on chromosome 11q22 are associated with 
altered risk of CTS (Chapter 4). 
 To determine whether three variants within the COL5A1 gene, rs13946 (C/T), 
rs12722 (C/T) and rs71746744 (-/AGGG) are associated with altered risk of CTS 
(Chapter 5). 
 To determine whether variants within two proteoglycan genes, BGN rs1126499 (C/T) 
and ACAN rs1516797 (G/T), are associated with altered risk of CTS (Chapter 6). 
 To determine whether variants within the cell signalling pathway, IL-1β rs16944 
(C/T), IL-6 rs1800795 (C/G), IL-6R rs2228145 (A/C), CASP8 rs3834129 (I/D) and 
VEGFA rs699947 (C/A), are associated with altered risk of CTS (Chapter 7). 
 
A secondary aim of this research was to determine whether there are any interactions 
between the different variants that are associated with altered risk of CTS. Inferred 
haplotypes were therefore constructed from the appropriate variants.  
 
METHODS 
This study was hypothesis-driven, following a case-control, genetic association study design. 
A total of 103 self-reported Coloured participants (94 female and 9 male), with a history of bi- 
or unilateral carpal tunnel release surgery (CTS), were recruited for this study from various 
Occupational Health clinics in the Western Cape region of South Africa.  In addition, 150 
apparently healthy, unrelated, self-reported Coloured participants (133 female and 17 male) 
without any reported history of CTS symptoms or surgery were recruited as control (CON) 
participants. The CON and CTS participants were matched for the type of occupation and 
years of exposure for wrist activity. This study sample investigated is an admixed population, 




potentially contain more genetic variation compared to the South African populations of 
Caucasian ancestry.  For this reason, this admixed population can be and has been used 
previously to refine genetic loci in their potential associations with multifactorial conditions. 
Participants were genotyped for the following variants: MMP10 rs486055 (C/T), MMP1 
rs1799750 (1G/2G), MMP3 rs679620 (A/G), MMP12 rs2276109 (A/G) (Chapter 4), COL5A1 
rs13946 (C/T), COL5A1 rs12722 (C/T), COL5A1 rs71746744 (-/AGGG) (Chapter 5), BGN 
rs1126499, ACAN rs1516797 (Chapter 6), IL-1β rs16944 (C/T), IL-6 rs1800795 (C/G), IL-6R 
rs2228145 (A/C), CASP8 rs3834129 (I/D) and VEGFA rs699947 (C/A) (Chapter 7),  by 
means of restriction fragment length polymorphism (RFLP) or real-time PCR. Inferred 
haplotypes were also constructed of appropriate variant combinations. 
 
RESULTS  
The main findings of this study were that several DNA sequence variants were 
independently associated with altered risk of CTS. In Chapter 5, the TT genotype of COL5A1 
rs13946 was significantly over-represented in the CON (69.3%) compared to the CTS 
(50.6%) group (p=0.007, OR=0.45, 95% CI=0.26-0.79, Sensitivity=50.6%, 
Specificity=30.7%). When the rs12722 variant was genotyped, two adjacent polymorphisms, 
rs146776422 (C/T) /rs55748801 (G/A) (W/M where W=CG), were genotyped 
simultaneously. The WW+CC genotype combination (41.7% p=0.008, OR=0.45, 95% 
CI=0.26-0.80) and WW+CT (40.3%, p=0.009, OR=2.0, 95% CI=1.2-3.4) genotypes were 
significantly over- and under-represented in the CON group, respectively, when compared to 
the CTS group (24.5% WW+CC, 59.2% WW+CT). In Chapter 6 the CC genotype of BGN 
rs1126499 was also over-represented in the CON group (CC vs CT + TT, p-0.0498, 
OR=0.55, 95% CI=0.30-0.99). Finally, the AA genotype of IL-6R rs2228145 was over-
represented in the CON group (AA vs AC + CC, p=0.003, OR=0.41, 95% CI 0.22-0.75) in 





Various inferred haplotypes and pseudo-haplotypes were also found to be associated with 
altered risk of CTS.  
 
No independent associations were identified with CTS for the MMP10 rs486055 (C/T), 
MMP1 rs1799750 (1G/2G), MMP3 rs679620 (A/G), MMP12 rs2276109 (A/G), COL5A1 
rs71746744 (-/AGGG), ACAN rs1516797 (G/T), IL-1β rs16944 (C/T), IL-6 rs1800795 (C/G), 
CASP8 rs3834129 (I/D) and VEGFA rs699947 (C/A) variants.  
 
DISCUSSION & CONCLUSION 
The first main novel findings of this thesis were that variants within (1) the 3’-UTR of 
COL5A1, (2) BGN and (3) IL-6R genes were independently associated with CTS within a 
self-reported Coloured South African population. Specifically, the COL5A1 TT genotype of 
rs13946 (C/T) and the combined WW+CC genotypes of rs146776422/rs55748801 (W/M) 
and rs12722 (C/T) were significantly over-represented in the asymptomatic control 
participants. The upstream COL5A1 3’-UTR rs71746744 (−/AGGG) variant was however not 
independently associated with CTS. Similarly, the BGN CC genotype of rs1126499 (C/T) as 
well as the IL-6R AA genotype of rs2228145 (A/C) was significantly over-represented in the 
control participants. Variants within MMP genes, the ACAN gene as well as IL-1β, IL-6, 
CASP8 and VEGFA genes were not independently associated with CTS. The second main 
finding of this thesis was that the independently associated COL5A1, BGN and IL-6R 
variants also interacted to modulate the risk of CTS.  
 
The association of the COL5A1 gene variants, within the 3’-UTR, have been extensively 
investigated in musculoskeletal soft tissue injuries, chronic Achilles tendinopathy and 
anterior cruciate ligament (ACL) injuries in Caucasian populations. This was the first study to 
investigate these variants in a Coloured population and occupational setting. The  findings of 




rs146776422/rs55748801 and rs12722 was associated being associated with reduced risk of 
CTS in a South African Coloured population. Interestingly, the rs13946 variant, that was not 
associated with chronic Achilles tendinopathy or ACL injury, was associated with altered risk 
of CTS with the TT genotype being associated with reduced risk. In contrast, the rs71746744 
variant, previously associated with chronic Achilles tendinopathy, was not associated with 
CTS. This indicates that the region within the COL5A1 3’-UTR involved in the aetiology of 
CTS is slightly different from that of other soft tissue injuries 
 
Similar to Type V collagen, biglycan (encoded by BGN) is also an important regulator of 
fibrillogenesis and these two matrix building blocks interact to regulate collagen 
fibrillogenesis which allows it to maintain the structure of the ECM. The findings in chapter 6, 
where the CC genotype of the BGN rs1126499 variant played a protective role against CTS, 
are in agreement with previously published results, confirming that the C-allele of rs1126499 
contributes to a protective role of BGN for some musculoskeletal soft tissue injuries. The 
rs1126499 variant also interacted with COL5A1 variants to significantly modify the risk of 
CTS. Interestingly, the ACAN rs1516797 variant, previously reported to alter the risk of ACL 
injuries, was not associated with risk of CTS.  
 
The expression of structural proteins, such a type V collagen and MMPs, are regulated by 
signalling cascades in response to stimuli such as repetitive mechanical loading, which is 
often mentioned as a risk factor for CTS and other occupational and recreational overuse 
injuries. Previous studies have also shown altered expression of several inflammatory, 
apoptosis and angiogenesis genes in these injuries. Therefore, variants within five genes (IL-
β, IL-6, IL-6R, CASP8 and VEGFA) involved in this proposed cell signalling pathway were 
also investigated for their potential association with CTS risk. Only the interleukin-6 receptor 




interactions between other cytokine gene variants (IL-1β and IL-6) were observed and IL-6R 
also interacted with COL5A1 to modify the risk of CTS. 
 
Although none of the matrix metalloproteinase (MMP) gene variants associated 
independently with CTS, a previous interaction between MMP3 rs679620 and COL5A1 
rs12722 was found in chronic Achilles tendinopathy as well as ACL injuries in female 
participants. Therefore the same investigation was undertaken in the current study, revealing 
a similar interaction as was previously reported in ACL ruptures, but not in chronic Achilles 
tendinopathy.  
 
In conclusion, this thesis investigated the association of genes that have previous been 
associated with chronic Achilles tendinopathy and/or anterior cruciate ligament ruptures with 
CTS. Various variants were, for the first time, shown to independently associate with altered 
risk for CTS and various gene-gene interactions were also observed, highlighting the 
complexity of this multifactorial injury. These novel findings therefore highlight the possible 
important role that genetic factors, and by implication pathology of the flexor tendons and 
other connective tissue structures within the carpal tunnel, have, at least in part, in the 
aetiology in CTS. 
  




CHAPTER 1: RISK FACTORS FOR CARPAL TUNNEL SYNDROME 
 
1.1 INTRODUCTION & SCOPE OF THE THESIS 
Carpal tunnel syndrome (CTS) is considered to be one of the most problematic and common 
work-related injuries; accounting for up to 90% of all entrapment neuropathies of the upper 
limb1–4.  
 
This, and other occupational injuries, has a large negative financial impact within the 
industrial sector in terms of loss of time from work and actual cost of the injury (treatment, 
surgery, rehabilitation etc.).  More specifically, a total of US $310 million was spent, between 
1990 and 1994, on workman’s compensation claims as a result of CTS in the United States 
alone2. This included not only medical costs, but also disability and job modification costs2. 
Furthermore, this injury also has a major negative impact on the individual suffering from the 
injury. This includes not only pain of the injury itself, but also loss of time from work, inability 
to perform certain tasks and eventually, not being able to work at all. Although common 
worldwide, idiopathic CTS is rarely seen in Black South African populations5,6. Even though 
there is no published data to support this, there seems to be a high prevalence of CTS 
amongst Coloured, blue-collar workers in the Western Cape (Dr H de Wet, personal 
communication), the population group investigated in this thesis. South African populations 
who self-identify as Coloured have a complex history of ancestrally derived admixture. This 
ethnic group is ancestrally derived from admixtures of one or more of the indigenous African 
populations (Khoe- and San-speaking or Bantu-speaking), immigrants from Western Europe, 
or slave labourers from West Africa, Indonesia, Madagascar, Java, India and Malaysia. The 
term “Coloured” in South Africa is therefore a name that encompasses a wide range of 




It is well accepted that CTS is a multifactorial condition, with several intrinsic and extrinsic 
risk factors playing a role in its aetiology8. These risk factors will be discussed briefly in 
section 1.5 of this chapter and systematically reviewed in subsequent chapters (Chapters 2 
and 3) of this thesis. Although no specific studies have investigated the association of 
genetic variants with CTS, investigators have nevertheless suggested that there is, at least 
in part, a genetic component to this injury8. The primary objective of this thesis was therefore 
to identify specific genetic elements that could potentially predispose an individual to CTS.  
Although the exact mechanisms of CTS are poorly understood, it is generally accepted that 
an increase in the pressure within the carpal tunnel structure causes compression of the 
median nerve and the associated symptoms9,10. Together with the median nerve the carpal 
tunnel also contains nine flexor tendons and peritendinous subsynovial connective tissue 
(SSCT)11. Although, at the structural level, research has focused on the median nerve, the 
involvement of these tendons and the SSCT in the aetiology of CTS cannot be excluded. In 
support of this, tendinopathy and tenosynovitis have both been mentioned as being 
comorbid conditions or a precursor of CTS12. Furthermore, flexor tenosynovitis can lead to 
an increase in carpal tunnel pressure3 and it has also been suggested that fibrosis of the 
SSCT could be a cause of CTS13. 
With this in mind, the specific candidate genes investigated in this thesis were selected 
based on their structural and biological function within tendons. In addition they have all 
previously been associated with tendon and/or ligament overuse injuries as a result of 
participation in physical activity (Section 1.6). The hypothesis tested in this thesis is that 
common genetic polymorphisms previously shown to associate with exercise-associated 
tendon/ligament overuse injuries could also be associated with occupational overuse injuries 
that potentially involve tendons and other connective tissue structures. A genetic 
association, case-control study design following a candidate gene approach was used to 
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determine whether specific DNA sequence variants are associated with the risk of CTS 
(Chapters 4 to 7). 
In preparation for the systematic reviews (Chapters 2 and 3), genetic association 
experimental chapters (Chapters 4 to 7) and the final discussion chapter (Chapter 8), the 
following sections will provide a brief overview of the gross anatomy of the carpal tunnel 
(Section 1.2), the mechanisms of CTS injuries (Section 1.3), the epidemiology of CTS 
injuries (Section 1.4), the risk factors for CTS injuries (Section 1.5) and the previously 
identified genetic risk factors of tendon overuse injuries in sport (Section 1.6).  
1.2 GROSS ANATOMY OF THE CARPAL TUNNEL 
CTS is the resulting condition of the compression of the median nerve which runs through 
the carpal tunnel in the anterior portion of the wrist. This tunnel contains the median nerve, 
nine tendons which are surrounded by synovial sheaths and is bordered by the rigid carpal 
bones and intercarpal ligaments on the medial, lateral and posterior sides and the flexor 
retinaculum on the anterior side (Figure 1.1)14,15. 
The median nerve supplies sensory and motor innervation to the thumb, index, middle and 
radial half of the ring finger14. The nine tendons, one flexor pollicis longus tendon, four flexor 
digitorum superficialis tendons and four flexor digitorum profundus tendons, are attached to 
their respective muscles to form musculo-tendinous units responsible for the movement of 
the digits. Finally, the flexor retinaculum is a fibrous band that attaches to the tubercle of the 
scaphoid and ridge of the trapezium on the radial side and to the pisiform and hook of the 
hamate on the ulnar side that forms the anterior border of the carpal tunnel structure. It 
provides mechanical protection of the contents of the carpal tunnel as well as having a minor 





consists of three different parts of which the transverse carpal ligament is only one part 




Figure 1.1 A schematic diagram of a cross-section of the wrist illustrating the location of the median 
nerve, the flexors tendons and the flexor retinaculum within the carpal tunnel structure. Figure 
adapted from Katz & Simmons, 200215 
 
 
1.3 MECHANISM OF INJURY 
Although the mechanisms of injury are poorly understood, it is generally accepted that 
median nerve compression, resulting in CTS, is caused by either an increase in the contents 
of the carpal tunnel or a decrease in the size of the tunnel. There are four proposed 
categories of injury namely (i) acute, (ii) chronic, (iii) overuse and (iv) idiopathic. However, it 
is important to keep in mind that there is often overlap between these different categories 
and that these just serve as a basic guideline for CTS injuries. Different terms are often used 
in the literature to describe these four categories. For the purpose of this thesis, however, 
the following categories will be used.   





This is the only mechanism of CTS injury where an actual inciting event takes place. An 
acute cause of CTS is most often the result of a rapid increase in the pressure within the 
carpal tunnel leading to a sudden increase in pressure on the median nerve, resulting in the 
typical CTS symptoms of pain, numbness and paraesthesia in the affected digits. This acute 
injury can be caused by a fracture of the radius, dislocation as well as direct insult to the 
area, such as burns or injections1.  
 
1.3.2 Chronic 
 CTS, as a result of a chronic injury/insult, typically has a longer onset and can be due to 
many different conditions, including causes localised to the carpal tunnel area (local causes), 
causes localised to the region in which the carpal tunnel is located (regional causes) and 
finally causes affecting the whole body (systemic causes)1. The potential causes are outlined 
in Table 1.1. These causes all compromise the space, either directly or indirectly, within the 
carpal tunnel which causes increased pressure on the median nerve.  
 
1.3.3 Overuse 
Similar to chronic causes, overuse as mechanism of CTS injury has a gradual onset but is 
different due to the fact that overuse is an extrinsic mechanism whereas chronic causes are 
intrinsic, local, regional or systemic, in nature. Overuse of the hands/wrists as a mechanism 
for CTS injury is highly debated1,8 but generally believed to play a role in the aetiology of this 
condition when other potential causes have been excluded. Extreme range of motion, 
specifically flexion and extension of the wrist, especially when performed in conjunction with 
weight-bearing activity, increase the pressure within the carpal tunnel, significantly3. 
Increased pressure within the carpal tunnel therefore leads to increased pressure on the 

























• Long-term haemodialysis 
 




Idiopathic CTS, also referred to as spontaneous CTS3, is the onset of CTS symptoms with 
no apparent cause. Idiopathic CTS specifically emphasizes the lack of a systemic cause of 
injury (as described under Chronic injuries) and refers to spontaneous CTS in an otherwise 
healthy hand/arm8.  
 
1.4 EPIDEMIOLOGY OF CTS 
The incidence of CTS, being the number of new injuries per unit of time, is not often reported 
but the few studies that do report incidence, show large differences between different 
countries. No information about the incidence of CTS in South Africa is available, but in a 
recent study, Atroshi et al., (2011) described the incidence of physician reported CTS in 




females in Sweden to be 324 per 100 000 person years compared to that in the US, being 
542 per 100 000 person years. Similarly, the incidence of CTS in Swedish males was 125 
compared to 303 in the US, per 100 000 person years17. Similarly, a study described the 
incidence in the general population of a restricted area of Italy to be 506 per 100 000 person 
years in females and 139 in males18.  
 
The prevalence of CTS, being the amount of injuries present in the population at a fixed 
time-point, in the general population is generally reported to be between 1 and 5 %17,18 
depending on the criteria used to define the condition. However the prevalence of CTS has 
been reported to be as high as 61% in occupations involving repetitive use of the upper 
limbs19. 
 
From these figures it is clear that the incidence and prevalence can vary greatly between 
different circumstances, specifically geographical location and sex, highlighting these as 
potential risk factors for CTS. These factors will be discussed in the following section and in 
more detail in the following chapter.  
 
1.5 RISK FACTORS FOR CTS 
CTS is generally accepted to be a multifactorial condition and the factors that are proposed 
to alter the risk of developing this condition can be divided into two categories that will be 
discussed below. Although these risk factors will be extensively reviewed in Chapters 2 and 
3, they are briefly summarised in the following sections. 
 
1.5.1 Non-occupational  
There are several non-occupational risk factors, also known as intrinsic risk factors, which 
are proposed to increase the risk of CTS. Age, sex and BMI are some of the most important 





a higher BMI20,21 being at higher risk of developing CTS. The size of the wrist, referred to as 
wrist ratio (wrist depth divided by wrist width) is also believed to influence CTS risk22.  
 
The presence of several medical conditions including diabetes, rheumatoid arthritis, 
osteoarthritis and thyroid disorders is also thought to increase the risk of CTS1,8. 
Furthermore, factors that can alter fluid balance in the body, such as pregnancy or 
menopause1,23 are also believed to increase the risk of CTS. CTS symptoms caused by 
pregnancy will often disappear after pregnancy, but in some cases further treatment is 
required23.  
 
Although the studies are limited, several authors have suggested that genetic or familial 
factors8–10 are potential intrinsic risk factors. These and other intrinsic, or non-occupational 
risk factors, will evaluated and discussed in Chapter 2.  
 
Although not traditionally believed to play a large role in the aetiology, psychosocial factors 
have been investigated for its potential role in the development of CTS. Specifically, 
individuals with poor psychological well-being with little job control are believed to be at 
increased risk for developing CTS26. These psychosocial risk factors will be evaluated and 
discussed in Chapter 3. 
 
1.5.2 Occupational  
Important factors that are proposed to alter the risk of CTS are occupational of nature, also 
known as extrinsic risk factors. Occupational factors that are generally believed to increase 
the risk of CTS include keyboard/computer use27, repetitive motion of the hands/arms3, 
weight-bearing activity3 and the hands/arms being exposed to vibration28. These 
occupational factors that could potentially play a role in the modification of CTS risk will be 
discussed and evaluated in Chapter 3.  




1.6 GENETIC RISK FACTORS FOR TENDON AND LIGAMENT INJURIES 
 
1.6.1 Overview 
Overuse injuries are commonly seen in sporting activities with tendon injuries contributing 
between 30 and 50% of all sporting injuries with this injury rate being dominated by Achilles 
tendon injuries29. In addition, participation in sporting activities, in particular those that 
involve a sudden deceleration or change in direction, may place an individual at greater risk 
of anterior cruciate ligament (ACL) rupture30. Although the incidence is low in the general 
population31,32, these acute injuries are considered one of the most severe injuries sustained 
in a sporting population33. 
 
As with CTS, the mechanisms of overuse and acute exercise-associated musculoskeletal 
soft tissue injuries are also poorly understood. However several extrinsic and intrinsic risk 
factors have been identified for these injuries, with a genetic component being an important 
intrinsic risk factor34. Previous research has identified several DNA sequence variants within 
genes that are responsible for the structural and biological maintenance and function of 
tendons and ligaments, to be associated with chronic Achilles tendinopathy35 and ACL 
ruptures36. Although the focus of this thesis is the proposed involvement of the tendon 
structures in CTS, researchers have previously identified similarities and differences with 
respect to the association of genetic risk factors with chronic Achilles tendinopathy and ACL 
ruptures34. As outlined in the following sections, the association of DNA sequence variants 
with both these injuries will therefore be considered in this thesis. A detailed overview of the 
DNA sequence variants that have been reported to associate with altered risk of chronic 
Achilles tendinopathy and/or ACL ruptures is however beyond the scope of this thesis and 
has been extensively reviewed34–37. Only the DNA sequence variants included in the studies 







1.6.2 The Collagen Fibril 
Both tendons and ligaments are collagenous structures, which have a similar composition 
and hierarchical structure34. Although two-thirds of these tissues consist of water, the basic 
structural unit of both tissues is the collagen fibril (Figure 1.2). The fibril consists 
predominately of type I collagen with other collagens, such as type V collagen, and non-
collagen, such as the proteoglycans, macromolecules also being an important structural 
component of the fibril. The collagen fibril and other structural components of tendons and 
ligaments are synthesised and maintained by the fibroblast cells, known as tenocytes in 
tendons, which are embedded between the collagen fibrils within the tendon and ligament. 
Although the fibroblasts are a minor structural component of connective tissues, like tendons 
and ligaments, they are able to respond to mechanical loading and other stimuli34,38. The 
cells will usually respond appropriately to these stimuli, resulting in adaptation or healing of 
the tissue. It has however been proposed that “abnormal” stimuli, such as excessive 
unaccustomed mechanical loading of the tissue, can result in a response by the fibroblasts 
that may lead to maladaptation of the tissue, eventually leading to injury39  
 
An overview of the collagen family and the structure of the collagen fibril is also beyond the 
scope of this introduction and has been recently reviewed40. Type V collagen, which is a 
focus of this thesis plays a vital role in collagen fibril formation41. The major isoform is a 
heterotrimer, consisting of two α1 and one α2 chains. These chains are encoded by the 
COL5A1 and COL5A2 genes respectively42. Rare mutations within these genes cause 
Ehlers-Danlos syndrome (EDS), a severe Mendelian connective tissue disorder43. In addition 
common DNA sequence variants within the 3’-untranslated region (UTR) of the COL5A1 
gene have been associated with chronic Achilles tendinopathy as well as ACL ruptures in 
females44–46. The role of COL5A1 in severe connective tissue disorders, common 
musculoskeletal soft tissue injuries and other phenotypes will be discussed in more detail in 
the introduction of chapter 5.     
 





 Figure 1.2 Schematic diagram of the collagen fibril, the basic unit of tendons and ligaments. This 
collagen fibril consists predominately of Type I collagen with other collagens, such as Type III and 
type V collagen also being important structural components of the fibril. Types XII and XIV collagen, 
associated with the surface of the fibril are known as Fibril-associated collagens with interrupted triple 
helices (FACITs). Other structural components of the fibril, such as other collagen types, 
proteoglycans and glycoproteins are not shown. Figure adapted from Collins & Raleigh (2009)34. 
 
 
Similar to the collagens, the proteoglycans, such as aggrecan and biglycan, are important 
structural components of tendons and other connective tissues47. More specifically, 
aggrecan is responsible for many of the physical properties of the fibrocartilage regions in 
tendons48–51, whereas biglycan, the other proteoglycan investigated in this thesis, is an 
important regulator of tendon development, aging and healing52. Biglycan also plays a vital 
role in fibrillogenesis48–51. Rare mutations within the aggrecan (ACAN) gene cause either 
dominant familial osteochondritis dissecans (a joint disorder) or recessive skeletal 
dysplasia53,54, while common variants have previously been associated with various 
multifactorial conditions55,56. Inferred haplotypes constructed from variants within the 
biglycan (BGN) gene are associated with ACL ruptures in females56. Since BGN is located 





the association of BGN variants with CTS was investigated in chapter 6 of this thesis. The 
structure of proteoglycans and its functions in tendons and tendinopathy has previously been 
reviewed57 and the role of ACAN and BGN in connective tissue disorders and 
musculoskeletal soft tissue injuries will be discussed in more detail in the introduction of 
chapter 6. 
 
Similarly, variants within the genes that play an important role in the remodelling of the ECM, 
such as matrix metalloproteinases (MMPs), cytokines and growth factors, have also been 
associated with AT and/or ACL injuries58–60. This remodelling is dependent on the balance 
between tissue degradation, among other proteins, a family of 25 MMP endopeptidases, and 
their antagonists, the tissue inhibitors of metalloproteinases (TIMPs)61–63. Specifically, with 
respect to variants within the MMP3 gene, the GG, CC and AA genotypes of rs679620, 
rs591058 and rs650108, respectively, were all independently associated  with increased risk 
of chronic Achilles tendinopathy64. Furthermore, the MMP3 rs679620 and COL5A1 rs12722 
variants have also been reported to interact to modify the risk of chronic Achilles 
tendinopathy64. Although four functional variants within MMP10 (rs486055 C/T), MMP1 
(rs1799750 1G/2G), MMP3 (rs679620 G/A) and MMP12 (rs2276109 A/G), which clustered 
together on chromosome 11q22, are not independently associated with risk of ACL ruptures, 
these variants interacted to modify the risk of non-contact ACL ruptures within males and 
females59. The role of the MMPs in musculoskeletal tissue disorders and CTS will be 
discussed in Chapter 4. 
 
The expression of structural proteins, such a type V collagen and MMPs, are regulated by 
signaling cascades in response to stimuli such as repetitive mechanical loading. Previous 
studies have shown that altered expression of several genes that encode for pro-
inflammatory cytokines, such as interleukin-1β and interleukin-6, as well as Caspase-8 or 
Vascular endothelial growth factor (VEGF), involved in apoptosis and angiogenesis, in 




tendon and ligament injuries60,65,66. Although variants within the IL-1β (rs16944) and IL-6 
(rs1800795) were not independently associated, inferred haplotypes constructed from these 
and other interleukin variants together with COL5A1 rs12722 have been reported to modify 
the risk of chronic Achilles tendinopathy60. This highlights that a pathway-based approach 
may be more informative to fully elucidate the role of genetic risk factors in multifactorial 
conditions, such as tendinoapthy60. In addition, the CASP8 rs3834129 variant has been 
reported to independently associate with altered risk of Achilles tendinopathy65 whilst the 
VEGFA rs699947 variant has been reported to independently associate with altered risk of 
ACL rupture66. The association of interleukin, CASP8 and VEGFA gene variants with CTS 
will be investigated in chapter 7. 
 
The main aim of this thesis was therefore to determine whether DNA sequence variants 
within matrix metalloproteinase (MMP10, MMP1, MMP3 and MMP12), collagen (COL5A1), 
proteoglycan (ACAN and BGN) and regulatory genes (IL-1β, IL-6, CASP8 and VEGFA), 
which have previously been associated with exercise-associated injuries, are also 
associated with a common occupational overuse injury, namely, CTS. As discussed in 
chapter 7, the association of the IL-6R (rs2228145) gene, which encodes for the IL-6 
receptor and hasn’t previously been associated with exercise-associated musculoskeletal 
soft tissue injuries, with CTS was also investigated. 
 
 










As discussed in the previous chapter carpal tunnel syndrome (CTS) is a common 
neuropathy accounting for up to 90% of all entrapment neuropathies of the upper limb. 
Although the exact aetiology of CTS is not fully understood, researchers have suggested 
that, in addition to the repetitive use of the upper limbs, several other non-occupational risk 
factors are also associated with CTS. Since there is, to our knowledge, no recent systematic 
review of these risk factors in the scientific literature, the objective of this chapter of the 
thesis is therefore to critically assess the published evidence on non-occupational risk 




2.2.1 Search strategy 
Three electronic databases, PubMed, Web of Knowledge (including Biological abstracts, 
Medline and Web of Science) and Springerlink, were searched using the keywords 
“CARPAL TUNNEL SYNDROME RISK” or “CARPAL TUNNEL SYNDROME RISK 
FACTORS”. The database search was performed for all articles published online until 
January 2014. Review articles were initially included in order to include their reference lists. 
A three-step method was followed to identify the articles that were included in this review. 
Titles, abstracts and full texts were screened. Articles were excluded at each step if they met 






Table 2.1 A three-step method was followed to identify the articles that were included in the 
systematic review of risk factors associated with carpal tunnel syndrome (CTS). Titles, abstracts and 
full texts were screened and excluded at each step if they met the exclusion criteria. 
  Exclusion criteria 
1 Unrelated to the topic 
2 Commentaries, book chapters, letters, editorials, conference proceedings, case 
reports, conference, abstracts or non-peer reviewed articles 
3 Studies examining hand/upper limb injuries without reference to CTS/median 
nerve. 
4 Studies of other medical/systemic conditions (eg diabetes, amyloidosis) without 
specific reference to CTS 
5 Considered only self-reported CTS 




All the references within the included articles were also reviewed using the same criteria to 
identify any additional articles not identified during the initial screening process of the 
databases. All the identified articles were appraised according to the inclusion criteria listed 
in Table 2.2. 
 
 
Table 2.2 The identified articles were included in the systematic review of risk factors associated with 
carpel tunnel syndrome (CTS) if they met the following inclusion criteria. 
Inclusion criteria 
1 The article must include original data 
2 The article must be published in English 
3 The article must include a minimum of one potential risk factor for CTS 
4 Medically called/diagnosed (probable or operated CTS) 
5 The article must include a point or risk estimate (eg, OR), with the 95% CI indicated 
  
 




2.2.2 Data extraction 
Study design, study population and the results of each identified article was reviewed in the 
appraisal step. Studies reporting risk estimates were identified. These included relative risk 
(RR), odds ratio (OR), incidence rate ratio (IRR) and hazard ratio (HR). These risk estimates 
are routinely used as measures of injury risk67. In order to avoid Type I and II errors made by 
rounding, the upper and lower 95% confidence interval cut-off values to indicate decreased 
and increased risk was set at 0.9 and 1.1, respectively. Studies reporting a p-value were 
included only if accompanied by a risk estimate since p-values are considered a measure of 
statistical significance but has limited value in the interpretation and estimation of risk. P-
values were, however, reported if provided.  
 
2.2.3 Level of evidence and certainty 
Each article was reviewed using two established methods: 1) level of evidence and 2) level 
of certainty. Level of evidence, a ranking system for research articles, was determined by 
using previously described definitions36,68,69. High-quality prospective cohort studies are 
considered level I; retrospective studies and lesser-quality prospective studies are level II, 
these include prospective studies with small sample sizes or weaker risk estimates (eg OR 
instead of IRR); case-control studies are level III; case series are level IV; and expert 
opinions are level V36,68. Only articles with a level of evidence of I, II or III were included in 
this review.  
 
The level of certainty, namely low, moderate and high level of certainty, for each risk factor 
was calculated by analysing all the included published studies for each risk factor. This 
classification system was based on previously published definitions by the US Preventative 
Services Task Force70. The levels of certainty were defined as follows: 1) high certainty is 
“The available evidence includes consistent results from level I studies. These studies 
provide a good estimate of risk and are unlikely to be strongly affected by future studies.”70, 





that there is risk associated with the injury, but confidence in the estimate is constrained by 
factors such as the sample size and quality of studies, as well as inconsistency of findings 
across individual studies. As more information becomes available, the magnitude of risk 
could change or even alter the conclusion”70 and 3) low certainty is “The available evidence 
is insufficient to assess risk. Evidence is insufficient because of the limited number or size of 
studies and inconsistency of findings across individual studies. More information may allow 
an estimation of risk”70. 
 
In various sections, different variables were grouped under one umbrella risk factor. 
Although this is not ideal, this was done for simplicity purposes to avoid having an excessive 
amount single risk factors investigated only by one study. Furthermore, groupings in this 
systematic review was made on the risk factor’s effect on risk i.e. increased, decreased or 
no effect on risk. Although there are several methods of grouping risk factors, this method 
was chosen to increase the understanding of the effect of a particular risk factor on risk and 
to prevent confusion. 
 
2.3 RESULTS & DISCUSSION  
 
The article selection process is outlined in Figure 2.1. Initially 2492 unique titles (duplicates 
excluded) were identified from the three electronic databases. Based on the titles alone, 
1355 articles were excluded and an additional 586 articles were excluded when the 
abstracts were also reviewed. Seventy-eight articles were finally included in this study from 
the initial database searches after the full texts of 551 articles were reviewed. When all the 
references within the articles that fit the inclusion criteria were also analysed using the same 
exclusion and exclusion criteria, an additional 4 articles were identified and included in the 
systematic review. Forty-one, non-occupational risk factors were identified from the 70 full 
text articles include in this review. The risk factors were divided into the following categories 




(1) biological, (2) behavioural and social, (3) medication, (4) medical conditions and injuries 




Figure 2.1 Outline of the literature search procedure. In round 1, a total of 2492 unique titles 
(duplicates excluded) were identified using the electronic database searched. After the three-step 
method, the number of articles were reduces to 1137 abstracts and then 551 full text articles. A total 
of 66 articles were included. When all the references of the articles that fit the inclusion criteria were 
analysed, using the same exclusion and exclusion criteria and three-step method (as in round one), 
an additional 4 articles were identified and included in the systematic review. A final selection of 70 
articles was therefore included in this review.  
 
 
2.3.1  Biological 
The following section will review the role of eight intrinsic biological, namely ethnicity, age, 
sex, height, weight, BMI (or obesity), hand/wrist structure/dimension and genetic factors as 







Six studies have examined ethnicity as an intrinsic risk factor for CTS (Table 2.3). Three 
cross sectional studies have suggested that ethnicity is a risk factor71–73, each defining 
different ethnic groups in their investigations. However three prospective cohort (Level I) 
studies found ethnicity to have no effect on the risk of CTS74–76. Since ethniticity has only 
been identified as a risk factor in cross sectional studies (Level III), which have not been 
confirmed in prospective studies, it  was assigned a low level of certainty.  
 
 















al. 199771 CS 
General 
population 145/29929 Non-white AOR: 16.69 (95% CI 5.22 - 53.32) III 
Tanaka et 
al. 199572 CS 
Working 
population 675/176525 
White vs Non-white Multivariate OR: 4.20 
(95%CI 1.78 - 9.92) III 
Sapuan et 





Malay vs non-Malay in 3rd trimester of 
pregnancy: OR 2.262, 95% CI 1.10–4.46; p = 
0.024 
III 





PC Industrial workers 204/3311 
Hispanic IRR: 0.64 (95% CI 0.35 - 1.08)                                                                                 
African-american: IRR: 0.66 (95% CI 0.41 - 
1.02)                                                                                            
Asian: IRR 0.99 (95% CI 0.44 - 1.94)                                                                                 





PC Industrial workers 140/525 
Non-white (asian mix) RR: 1.19 (95% CI 0.63 - 
2.23) II 
Nathan et 
al. 200276 PC 
Industrial 
workers 34/222 
White vs Non-white: OR 1.25 (95% CI 0.34 - 
4.53); Multivariate OR 1.11 (95% CI 0.25 - 
4.89), p=0.890 
II 
      
CS, cross sectional; PC, prospective cohort; AOR, adjusted odds ratio; OR, odds ratio; CI, confidence 
interval; IRR, incidence rate ratio; RR, risk ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 










Older age, especially in females, is often reported as an intrinsic risk factor for CTS in the 
literature77. Of the 31 studies that examined age as a modifiable risk factor for CTS (Table 
2.4), 16 found an age-related increase in risk24,74,76,78–90, two found an age-related decrease 
in risk91,92, while 27 reported no association with CTS risk24,71,72,75,76,78,79,89,90,93–110. 
 
Four prospective and one retrospective studies investigating industrial workers found an 
increase in CTS risk in higher age groups74,76,78,79,86. Three of these studies investigated 
various age groups and found that workers older than 20, 30, 40 and 50 years74,76,78,86, 
respectively, are at increased risk of CTS. Interestingly, Harris-Adamson et al. (2013),  
Violante et al. (2007) and Wolf et al. (2009) found that risk increases with an increase in 
age74,78,86. In contrast, Frost et al. (1998) found that workers between 35 and 49 years are at 
increased risk, but that being older than 50 years has no effect on CTS risk79.    
 
The majority of the prospective (n=7) and retrospective (n=2) studies investigating industrial 
workers have however reported that age or age groups are not associated with risk of 
CTS75,76,78,79,93–96,108. The single prospective and single retrospective studies that reported 
decreased risk of CTS in age groups older than 60 years as well as older than 70 years of 
age,  considered only breast cancer patients and did not investigate workers or the working 
population specifically91,92. The relevance of these findings, in a working population, should 
therefore be investigated.  
 
Although all different age groups were investigated together in this review and revealed 
contradictory information, a more in-depth investigation on the different age groups could 
potentially report different results and is thus warranted. Future research in the form of 
prospective studies should aim to investigate different age groups instead of considering age 





As summarised in table 2.4 numerous level III studies have also reported that age either 
increases or has no effect on the risk for CTS. Therefore, because of the contradicting 
evidence of the high quality (levels I and II), as well as the level III, studies age was assigned 






















PC Industrial workers 204/3311 
≥ 30 and <40 years: IRR 2.20 (95% CI 1.38 - 
3.57), Multivariate HR 2.12 (95% CI 1.34 - 3.34), 
p<0.01                                                                                                                         
≥40 and <50 years: IRR 3.10 (95% CI 2.01 - 
4.88), Multivariate HR 2.84 (95% CI 1.85 - 4.37), 
p<0.01                                                                                                                                
≥50 years: IRR 3.55 (95% CI 2.26 - 5.66), 




al., 200778 PC 
Working 
population 153/1939 
41-45 years: Univariate OR 2.5 (95% CI 1.4 - 
4.4), Multivariate OR 2.2 (95% CI 1.2-4.1)                                                                              
>50 years: Univariate OR 3.0 (95% CI 1.7 - 5.4), 
Multivariate OR 1.7 (95% CI 0.9 - 3.3) 
II 
Nathan et 
al., 200276 PC 
Industrial 
workers 34/222 
≥50 years: Univariate OR 6.58 (95% CI 2.08 - 
20.84), p=0.001, Multivariate OR 15.88 (95% CI 
3.03 - 83.40), p=0.001 
II 





20–24 years: Adjusted IRR 2.05 (95% CI 1.93 - 
2.17)                                                                         
25-29 years: Adjusted IRR 3.19 (95% CI 3.00 - 
3.39)                                                                            
30-35 years: Adjusted IRR 4.36 (95% CI 4.09 - 
4.65)                                                                                   
36-39 years: Adjusted IRR 7.19 (95% CI 6.75 - 
7.67)                                                                                    
≥40 years: Adjusted IRR 11.63 (95% CI 10.09 - 
12.41) 
II 








35-49 years                                                                                             
Either hand: AOR 2.3 (95% CI 1.15 - 4.63);                                         
Dominant hand: AOR 3.24 (95% CI 1.15 - 9.15);                                                        
Non-dominant hand: AOR 1.82 (95% CI 0.80 - 
4.15)                                                                                                                                              
II 
Tseng et 
al., 201280 CC 
General 
population 15802/31604 
20-39 years: Univariate OR 6.69 (95% CI 6.13 - 
7.29)                                                            
Multivariate OR 6.25 (95% CI 5.72 - 6.83)                                                                             
40-59 years: Univariate OR 13.4 (95% CI 12.3 - 
14.6)                                                         
Multivariate OR 11.4 (95% 10.5 - 12.5)                                                                                         
≥60 years: Univariate OR 9.33 (95% CI 8.46 - 
10.3)                                                        









131/940 Per 10 year increase: Logistic regression OR 1.55 (95% CI 1.31 - 1.86)   III 

























25-34 years: OR 3.79 (95% CI 1.69 - 8.52) 
p=0.001                                                               
35-44 years: OR 8.08 (95% CI 3.55 - 18.4) 
p<0.001                                                                 




al., 200283 CC 
Hospital 
patients 791/981 
41-60 years: OR 1.91 (95% CI 1.58 - 2.31), 
Multiple regression OR 1.35, p<0.001 III 
Rosecranc
e et al., 
200284 
CS Construction workers  91/1024 
p<0.001 when comparing workers with and 
without CTS                                                                                 
>31 years:  AOR 4.12 (95% CI 2.10 – 8.08) 
III
Atroshi et 
al., 200785 CS 
General 
population 97/1906 
≥40 years: Adjusted PR 2.48 (95% CI 1.33 - 
4.60), p=0.004 III 
Werner et 







10 year difference                                                                                   
MM51: AOR 3.3 (95% CI 3.3 - 3.4)                         
MM82: AOR 3.5 (95% CI 3.4 - 3.5) 
III 
Jianmongk











Age quintile 3: Multivariate OR 5.29 (95% CI 
1.79 - 15.66), p<0.005                                                       
Age quintile 4: Multivariate OR 7.42 (95% CI 
2.34 - 23.50), p<0.001                                                   
Age quintile 5: Multivariate OR 38.3 (95% CI 
12.1 - 121.29), p<0.001 
III 
Hakim et 





46-50 years: OR 1.99 (95% CI 1.42 - 2.79)                                                                       




al., 200690 CS 
Female floor 
cleaners 70/75 
Age quartile 4: Univariate OR 3.82 (95% CI 1.43 




 Sestak et 









61-70 years: Univariate OR 0.48 (95% CI 0.30 - 
0.76), p=0.002; Multivariate OR 0.53 (95% CI 
0.33 - 0.85), p=0.008                                                               
>70 years: Univariate OR 0.51 (95% CI 0.31 - 
0.84), p=0.009; Multivariate OR  0.58 (95% CI 
0.33 - 1.00), p=0.05 
II 
Mieog et 






61-70 years OR 0.49 (99% CI 0.25 - 0.95), 
p=0.006,  AOR 0.47 (95% CI 0.23 - 0.94), 
p=0.005                                                                          
>70 years: OR 0.33 (99% CI 0.12 - 0.89), 
p=0.004,  AOR 0.36 (99% CI 0.12 - 1.02), 
p=0.012 
II 
No effect on risk 







 ≤44.3 years: Univariate HR 1.102 (95% CI 1.03 
- 1.18), p=0.008; Multivariate HR  1.076 (95% CI 
0.99 - 1.17), p=0.09                                                                                              
>44.3 years: Univariate HR 0.955 (95% CI 0.89 - 
1.03), p=0.02; Multivariate HR  0.959 (95% CI 
0.89 - 1.04), p=0.10  

























84/2837 Univariate IRR 1.08 (9% CI 1.06 - 1.10)                                                          Multivariate IRR 1.06 (95% CI 1.05 - 1.08) I 
Violante et 
al., 200778 PC 
Working 
population 153/1939 
31-35 years: Univariate OR 1.2 (95% CI 0.7 - 
2.2), Multivariate OR 1.1 (95% CI 0.6 - 2.1)                                                                                      
36-40 years: Univariate OR 1.6 (95% CI 0.9 - 
2.8), Multivariate OR 1.4 (95% CI 0.8 - 2.6) 
II 




30-39 years: Univariate OR 2.5 (95% CI 0.93 - 
6.77), p=0.070,  Multivariate OR 2.19 (95% CI 
0.70 - 6.88), p=0.170                                                                               
40-49 years: Univariate OR 1.14 (95% CI 0.31 
- 4.27), p=0.840,  Multivariate OR 1.13 (95% 
CI 0.25 - 5.04) 
II 
Gorsche et 
al., 199975 PC 
Industrial 
workers 140/525 
10 year increments: RR 1.304 (95% CI 0.921 - 









36/173 AOR 1.00 (95% CI 0.95 - 1.05),p=0.969 II 
Roquelaure 
et al., 200196 PC 
Blue-collar 
workers 34/100 
40-49 years: OR 0.7 (95% CI 0.2 - 2.0)                                                                                        
≥50 years: OR 2.1 (95% CI 0.5 - 8.2) II 









Female                                                                                                                     
30-39 years: OR 1.55 (95% CI 0.47 - 5.11)                                                            
≥40 years: OR 1.09 (95% CI 0.33 - 3.56)                                                 
Male                                                                                                            
30-39 years: OR 1.05 (95% CI 0.34 - 3.25)                                                                  
≥40 years: OR 0.46 (95% CI 0.10 - 2.04)                                                                          
II 








 ≥50 years                                                                                                     
Either hand: AOR 1.15 (95% CI 0.45 - 2.95),                                       
Dominant hand: AOR 1.37 (95% CI 0.35 - 
5.41)                                                      Non-




al., 199572 CS 
Working 
population 675/176525 
Per year increment: Multivariate OR 1.03 (95% 
CI 1.021.04) III 
Silverstein et 





63/657 AOR 1.07 (95% CI 1.04 - 1.10) III 
Rigouin et 
al., 201398 CS 
Working 
population 156/3554 
1 year increments                                                                                      
Men: OR 1.05 (95% CI 1.02 - 1.08), p=0.001                                          




our et al., 
200899 
CS Industrial workers 47/348 
Multivariate OR 1.08 (95% CI 0.99 - 1.18), 
p=0.05 III 
Bonfiglioli et 




26/324 Multivariate OR 1.11 (95% CI 1.04 - 1.18) III 




-40 years: OR 1.9 (95% CI 1.1 - 3.2)                                                                                              
41-50 years: OR 1.0 (95% CI 0.5 - 2.2)                                                                                              
>50 years: OR 1.1 (95% CI 0.3 - 3.9) 
III 
 






















Possible                
34/479 
Definite 
Increasing age: AOR 1.04 (95% CI 1.02 - 1.06), 




CS Engineers 25/177 Univariate OR: 1.07 (95% CI 1.02 - 1.13), p=0.004 III 




OR 1.23 (95% CI 1.08 - 1.39), AOR 1.38 (95% 
CI 1.09 - 1.74) III 
Bland 200589 CS EEG Patients 2408/1747 
Age per year: Univariate OR 1.031 (95% CI 
1.027 - 1.036), p<0.001                                                                       
Age quintile 2: Multivariate OR 1.52 (95% CI 
0.53 - 4.39), p=0.430 
III 
Hakim et al., 
200224 CC 
Female-female 
twin pairs 520/3154 
51-55 years: OR 1.26 (95% CI 0.90 - 1.78)                                                                                   
AOR (for age and BMI) 1.30 (95% CI 0.92 - 
1.83)                                                                                                     
56-59 years: OR 1.29 (95% CI 0.90 - 1.86)                                                                                      
AOR (for age and BMI) 1.33 (95% CI 0.92 - 
1.92)                                                                                                     
≥60 years: OR 1.24 (95% CI 0.91 - 1.68)                                                                                          
AOR (for age and BMI) 1.28 (95% CI 0.94 - 
1.75) 
III 





19/333 OR 1.02 (95% CI 0.97 - 1.06) III 
Eleftheriou et 
al., 2012106 CS 
Computer 
workers  
A: 51/4103                         
B: 167/2944 
Case def A: ≥45: Univariate RR 1.38 (95% CI 
0.81 - 2.35)                                                                         
Logistic Regression OR 1.16 (95% CI 0.53 - 
2.55)                                                                                  
Case def B: ≥45: Univariate RR 1.31 (95% CI 
1.02 - 1.68), p=0.003                                                             
Logistic Regression OR 1.48 (95% CI  0.90 - 
2.43), p=0.117 
III 




OR 1.0 (95% CI 0.9 - 1.1)                                                                                                  
Women: OR 0.9 (95% CI 0.9 - 1.0) III 
Tanaka et al. 
199771 CS 
General 
population 145/29929  ≥40 years: AOR 1.2 (95% CI 0.81 - 1.77) III 
Mondelli et 
al., 200690 CS 
Female floor 
cleaners 70/75 
Age quartile 2: Univariate OR 1.65 (95% CI 0.66 
- 4.11);  Mulivariate OR 1.32 (95% CI 0.44 - 
4.00)                                                                      
Age quartile 3: Univariate OR 2.53 (95% CI 0.94 
- 6.79); Multivariate OR 1.5 (95% CI 0.45 - 4.96) 
III 








Model 1                                                                                                         
30-39 years: OR 1.21 (95% CI 0.69 - 2.14)                                          
40-49 years: OR 1.55 (95% CI 0.89 - 2.70)                                           
≥50 years: OR 1.22 (95% CI 0.63 - 2.39)                                                                                                        
Model 2:                                                                                                       
30-39 years: OR 1.85 (95% CI 0.91 - 3.76)                                          
40-49 years: OR 2.11 (95% CI 1.05 - 4.22                                         
≥50 years: OR 1.71 (95% CI 0.77 - 3.82)                                                                                                       
Model 3:                                                                                                            
30-39 years: OR 1.93 (95% CI 0.95 - 3.95)                                                           
40-49 years: OR 2.20 (95% CI 1.09 - 4.44)                                                                          
≥50 years: OR 1.71 (95% CI 0.76 - 3.83) 
III 
Solomon et 





45-64 years: OR 1.2 (95% CI 1.0 - 1.5), AOR 1.1 
(95% CI 0.8 - 1.6)                                                                                             
≥65 years: OR 0.9 (95% CI 0.8 - 1.1), AOR 1.0 
(95% CI 0.7 - 1.3) 
III 





From previous page: 
PC, prospective cohort; RR, risk ratio; RC, retrospective cohort; CC, case control; CS, cross sectional; 
AOR, adjusted odds ratio OR; odds ratio; CI, confidence interval; IRR, incidence rate ratio; HR, 
hazard ratio;  
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
1 MM5: median sensory peak latency of > 0 5 ms longer than the ulnar sensory peak latency 
2 MM8: median sensory peak latency of > 0 5 ms longer than the ulnar sensory peak latency  
3 Case definition A: Participants with personal medical history of CTS or surgery due to CTS 
4 Case definition B: Case definition A and participants identified through clinical examination (score 
≥12)  





Female sex is the second biological factor frequently reported to increase risk of CTS77. Of 
the 33 studies investigating sex as risk factor (Table 2.5), 19 found female sex to be 
associated with increased risk71,72,74,76,78,80,81,83,86,88,94,99,101,106,107,110–113 whereas 14 found no 
effect of sex on risk of CTS75,79,85,89,93,95–97,102,103,105,109,113,114. 
 
Female sex was reported to cause an increase in CTS risk in five prospective and one 
retrospective studies74,76,78,86,94,111 with a combined number of 288 CTS cases in a combined 
study population of 6148 in the two level I prospective studies74,94 (Figure 2.2 A and B). 
Another 13 level III studies have also reported that female sex increases CTS 
risk71,72,80,81,83,88,99,101,106,107,110,112,113 (Figure 2.2 A and B). Although, five prospective and one 
retrospective studies have found female sex has no effect on risk of CTS75,79,93,96,114, only 
one high quality prospective (level I) study reported 35 CTS cases in a study population of 
50193. Another eight level III studies found sex to have no effect on CTS 
risk85,89,97,102,103,105,109,113.   
 
Although there is contradictory evidence from prospective studies in the literature, one high 
quality study with a large sample size found female sex to increase the risk of CTS. The 
prospective studies, however, that reported that sex did not modify CTS were of a poorer 




quality with smaller sample sizes. Sex was, therefore, assigned a moderate level of 




Figure 2.2 Forest plot of the studies that found sex to be associated with increased risk in (A) studies 
reporting incidence rate ratio (IRR) and (B) studies reporting odds ratio (OR) or relative risk (RR) with 
the 95% Confidence intervals (CI) indicated. In the Maghsoudipour et al. (2008) and Moghtaderi et al. 






























PC Industrial workers 204/3311 
Female:  IRR 1.69 (95% CI 1.27 - 2.27)                                                            












Female: Univariate IRR 3.18 (95% CI 1.85 - 
5.54), Multivariate IRR 2.85 (95% CI 1.51 - 
5.37) 
I 




3 Female: Adjusted IRR 3.29 (95% CI 3.23 - 3.35) II 
Violante et 
al., 200778 PC 
Working 
population 153/1939 
Female: Univariate OR 4.7 (95% CI 3.0 - 
7.8)                                                                                        
Multivariate OR 4.0 (95% CI 2.3 - 6.7) 
II
Nathan et 
al., 200276 PC 
Industrial 
workers 34/222 
Female: Univariate OR 1.53 (95% CI 1.06 - 
2.23), Multivariate OR 5.11 (95% CI 1.68 - 
15.53), p=0.02                                                        
II 









538711    
Surgically 
treated: 31148 
(1) Diagnosed CTS, female: IRR 2.58 
(95% CI 2.56 - 2.59)                                                                       
(2) Surgically treated CTS, female: 









128/109 Female: OR 9.95 (95% CI 2.46 - 40.17), p=0.001 III 
Tseng et 
al., 201280 CC 
General 
population 15802/31604 
Female: Univariate OR 2.09 (95% CI 2.01 - 
2.17)                                                                    








626/3618 Female: OR 1.7 (95% CI 1.3 - 2.1)                                                     AOR 1.6 (95% CI 1.3 - 2.0) III 
Becker et 
al., 200283 CC 
Hospital 
patients 791/981 
Female: OR 3.66 (95% CI 2.84 - 4.71), 
Multiple regression OR 1.87, p<0.001  III 
Chiang et 








CS Computer workers  
A: 51/4101                         
B: 167/2942 
Case def B: Female: Univariate RR 3.41 
(95% CI 1.83 - 6.37), p<0.001, Logistic 










131/940 Female:  Logistic regression OR 2.24 (95% CI 1.43 - 3.50)                             III 
Maghsoudi
pour et al., 
200899 
CS Industrial workers 47/348 
Male vs Female: Univariate OR 7.73 (95% 
CI 1.88 - 32.52), p=0.00,  Multivariate OR 
0.27 (95% CI 0.30 - 2.09), p=0.21  
III 
Jianmongk






96/566 Female: OR 2.35 (95% CI 1.18 - 4.67), p=0.018 III 

















al. 199771 CS 
General 
population 145/29929 Female: AOR 2.31 (95% CI 1.48 - 3.60) III 
Raman et 
al., 2012101 CS 
Office 
workers 88/382 
Female: OR 2.2 (95% CI 1.4 - 3.5), AOR 4.7 
(95% CI 2.1 - 10.3) III 
Tanaka et 
al., 199572 CS 
Working 
population 675/176525 
Female: Multivariate OR 2.23 (95% CI 1.52 - 
3.27) III 






high level of 
hand activity 
57/420 Female - Ratings based model : Multivariate OR 2.21 (95% CI 1.17 - 4.15) III 
No effect on risk 






35/501 Female: Univariate HR 2.3 (95% CI 1.00 - 5.25), p=0.005 I 
Gorsche et 
al., 199975 PC 
Industrial 
workers 140/525 
Female:  Relative Risk 1.90 (95% CI 0.99 - 
3.66), p=0.055 Adjusted Relative Risk 1.88 
(95% CI 0.97 - 3.65) 
II 
Werner et 
al., 2005114 PC 
Assembly 
workers 20/169 














36/173 Male: AOR 1.24 (95% CI 0.58 - 2.67)                  II 








Female                                                                                                    
Either hand: AOR 1.44 (95% CI 0.65 - 3.19),                                                           
Dominant hand: AOR 1.13 (95% CI 0.36 - 
3.57),                                                          
Non-dominant hand: AOR 2.20 (95% CI 0.91 - 
5.30) 
II 




ng facitlity  









63/657 AOR 1.74 (95% CI 0.99 - 3.05) III 
Atroshi et 
al., 200785 CS 
General 
population 97/1906 
Female - Adjusted PR 1.54 (95% CI 0.94 - 
2.52), p=0.084 III 






high level of 
hand activity 
57/420 
HAL TLV Model                                                                                       












Possible                
34/479 
Definite 
Female: AOR 1.03 (95% CI 0.74 - 1.43)                                                          


























CS Engineers 25/177 Female: Univariate OR 1.30 (95% CI 0.46 - 3.70), p=0.624 III 
Leclerc et 








Female - Model 1: OR 1.58 (95% CI 0.89 - 
2.83)                                                           
Model 2: OR 1.49 (95% CI 0.73 - 304),                                                                         
Model 3: OR 1.65 (95% CI 0.80 - 3.42) 
III 
      
PC, prospective cohort; IRR, incidence rate ratio; CI, confidence interval; OR, odds ratio; RC, 
retrospective cohort; CC, case control; CS, cross sectional; AOR, adjusted odds ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
1 Case definition A: Participants with personal medical history of CTS or surgery due to CTS 
2 Case definition B: Case definition A and participants identified through clinical examination (score 
≥12)  




Three studies have evaluated height as an intrinsic risk factor for CTS (Table 2.6). All the 
studies to date have identified that tall stature decreases the risk of CTS in both men and 
women while short stature is not associated with risk. A single prospective study (level II) 
reported that a tall stature with either a short or long forearm leads to a decreased risk of 
CTS in both univariate and multivariate analyses [Tall stature, short forearm: Univariate OR 
0.4 (95% CI 0.2 - 0.7), Multivariate OR 0.5 (95% 0.3 - 0.9); Tall stature, long forearm: 
Univariate OR 0.5 (95% CI 0.3 - 0.7), Multivariate OR 0.6 (0.4 - 0.9)]78. A single case-control 
study also reported a decreased risk for CTS in men taller than 175 cm and women taller 
than 165 cm in both an univariate and multivariate analyses (women ≥165 cm and men 
≥175cm: Univariate OR 0.4, 95% CI 0.3 - 0.7; Multivariate OR 0.5, 95% CI 0.3 - 0.8) 115 .  
 
The same prospective study which reported that tall stature decreased risk of CTS reported 
that short sature was however not a risk factor for CTS78. A cross sectional study, which did 




not supply any specific information on tall and short stature groups, reported that height was 
not a risk factor116. Due to the low number of studies available that considered height as a 
risk factor, it was assigned a low level of certainty. 
 















al. 200778 PC 
Working 
population 153/1939 
Tall stature, short forearm: Univariate OR 0.4 (95% 
CI 0.2 - 0.7), Multivariate OR 0.5 (95% 0.3 - 0.9)                                                                                                                     
Tall stature, long forearm: Univariate OR 0.5 (95% CI 
0.3 - 0.7), Multivariate OR 0.6 (0.4 - 0.9) 
II 
Mattioli et 
al. 2009115 CC 
General 
population 191/286 
≥165 cm (women) & ≥175cm (men): Univariate OR 
0.4 (95% CI 0.3 - 0.7), Multivariate OR 0.5 (95% CI 
0.3 - 0.8) 
III 
No effect on risk 
Violante et 
al. 200778 PC 
Working 
population 153/1939 
Short stature, long forearm: Univariate OR 0.6 (95% 




CC General population 156/473  Risk Ratio: 0.96 (95% CI 0.93 - 0.98) III 
      
PC, prospective cohort; OR, odds ratio; CI, confidence interval; CC, case control  
a CON in case-control studies represent the controls, while in the other study designs it represents the 




Only four studies: one prospective92, two case-control116,117 and one cross-sectional103 
studies, have investigated weight as an isolated extrinsic risk factor for CTS (Table 2.7). 
None of these investigations found weight to be associated with CTS, due to these findings 
and the limited number of studies it was difficult to be conclusive and weight was therefore 




















No effect on risk 







70-79kg: OR 1.57 (99% CI 0.71 - 3.46), p=0.14; 
AOR 1.75 (99% CI 0.77 - 3.96), p=0.077                                                                                                                               
≥80: OR 2.17 (99% CI 1.01 - 4.63), 0.009; AOR 2.17 
(99% CI 0.98 - 4.77), p=0.012 
II 





1264/1264 Weight gain: OR 1.37 (95% CI 0.99 - 1.89) III 
De Krom et 
al., 1990116 CC 
General 




CS Engineers 25/177 Univariate OR 1.03 (95% CI 1.00 - 1.05), p=0.027 III 
      
RC, retrospective cohort; OR, odds ratio; AOR, adjusted odds ratio; CC, case control; CI, confidence 
interval; CS, cross sectional 
a CON in case-control studies represent the controls, while in the other study designs it represents the 




Together with female sex and increased age, increased BMI or obesity is often mentioned in 
the literature as a risk factor for CTS77. Out of the 53 studies that considered BMI or obesity 
as a risk factor (Table 2.8), 26 found an association with increased risk71,74,80,81,83–
85,87,96,100,101,104,109,112,115,117–127 of CTS while 36 reported no effect on risk24,27,75,76,78,79,89,90,93–
99,101–103,106,108,109,113–116,123,125–134. Only one level III study found a decreased risk (odds ratio of 
0.214, 95% confidence interval between 0.065 and 0.702) for CTS in orthopaedic patients 
with a BMI less than 18.5 128.  
 
Only one level I and two level II studies reported a BMI ≥30 to be associated with an 
increased risk of CTS74,96,118. Another 23 level III studies found an increased risk of CTS with 
a higher BMI or individuals who are overweight or obese71,80,81,83–85,87,100,101,104,109,112,115,117,119–
127.  In contrast, ten level I and II and 26 level III studies found an increased BMI to have no 
effect on CTS risk24,27,75,76,78,79,89,90,93–99,101–103,106,108,109,113–116,123,125–134. 




Although different BMI groups were investigated together in this review and revealed 
contradictory information, a more in-depth investigation on the BMI groups could potentially 
report different results and is thus warranted. Future research in the form of prospective 
studies should aim to investigate different BMI groups instead of considering age as a whole. 
 
Even though obesity and being overweight is often mentioned as a risk factor in the literature 
and readily accepted as such, the conflicting evidence and large amount of studies that 
found no effect on risk with an increased BMI causes this risk factor to be assigned a low 
level of certainty.  
 
Table 2.8 Summary of all the studies that have investigated BMI and/or obesity as a risk factor for 
















PC Industrial workers 204/3311 
≥30: IRR 1.89 (95% CI 1.42 - 2.52), Multivariate 
HR 1.67 (95% CI 1.26 - 2.21), p=0.00 I 






high level of 
hand activity 
29/318 
≥30                                                                         
Model 1: Multivariate HR 3.19 (95% CI 1.28 - 
7.98)                                                                     




al., 200196 PC 
Blue-collar 
workers 34/100 
>30: OR 4.8 (95% CI 1.2 - 19.4), p<0.05                                                                








128/109 Increased BMI: OR 1.75 (95% CI 1.50 - 2.04), p=0.000 III 






Obese: Univariate OR 3.33 (95% CI 2.67 - 4.15), 
Multivariate OR 2.30 (95% CI 1.82 - 2.91) III 




>30: OR 2.90 (95% CI 2.25 - 3.73)                                                                            
Multiple regression OR 1.85, p<0.001  III 




≥30 : Univariate OR 3.4 (95% CI 1.9 - 6.1), 
Multivariate OR 3.3 (95% CI 1.6 - 6.6) III 




≥25 and <30: AOR 1.6 (95% CI 1.2 - 2.2); 
Multivariate OR 1.6 (95% CI 1.1 - 2.1)                                                                                                                                                                 
≥30: AOR 2.3 (95% CI 1.7 - 3.1); Multivariate OR 
2.1 (95% CI 1.6 - 2.9) 
III 
Stallings et 
al., 1997122 CC 
Hospital 
patients 300 
Obese: OR 3.92 (95% CI 2.65 - 5.79), p<0.001                                                  


























25.1-30: Univariate OR 1.66 (95% CI 1.48 - 
1.86), Multivariate OR 1.63 (95% CI 1.45 - 1.84); 
Operated CTS: AOR 1.79 (95% CI 1.41 - 2.27)                                                                                                    
30-40: Univariate OR 2.28 (95% CI 1.80 - 3.70), 
Multivariate OR 2.06 (95% CI 1.79 - 2.38); 
Operated CTS: AOR 2.74 (95% CI 2.07 - 3.63)                                                                                                  
>40: Univariate OR 2.58 (95% CI 1.80 - 3.70), 
Multivariate OR 2.22 (95% CI 1.53 - 3.21); 
Operated CTS: AOR 2.60 (95% CI 1.27 - 5.30) 
III 




Obesity (women): OR 2.17 (95% CI 1.41 - 4.15)                                                       
Obesity (total): OR 2.32 (95% CI 1.35 - 3.98) III 





1264/1264 Obese: OR 2.01 (95% CI 1.58 - 2.55) III 




High BMI: Multivariate OR 1.14 (95% CI 1.06 - 
1.23), p=0.001 III 
Wieslander et 
al., 1989127 CC 
Hospital 
patients 38/76 
Group 2                                                                                                      
10% above reference weight: OR 3.4 (95% CI 
1.2- 9.8), p=0.02                                   
III 




Overweight: Adjusted PR 2.17 (95% CI 1.32 - 
3.56), p=0.002 III 
Armstrong et 




131/940 Per 5 point increase: Logistic regression OR 1.32 (95% CI 1.15 - 1.52) III 
Tanaka et al. 
199771 CS 
General 
population 145/29929 ≥25: AOR 2.00 (95% CI 1.33 - 3.02) III 









Model 1, ≥27 to <31: OR 2.16 (95% CI 1.35 - 
3.45),                                                               
Model 2, ≥27: OR 2.16 (1.41 - 3.29)                                                                                     
Model 3, ≥27: OR 2.23 (95% CI 1.46 - 3.40)                                                                      
III 
Rosecrance et 
al., 200284 CS 
Construction 
workers  91/1024 
>28.6 (compared to <23.5) AOR 4.9 (95% CI 
2.40 - 10.02) III 
Bonfiglioli et 




26/324  ≥30: Multivariate OR 4.97 (95% CI 1.56 - 15.84), p=0.007 III 
Forst et al., 
2007121 CS 
Spine 
surgeons 107/264 ≥30 : Multivariate OR 2.04 (95% CI 1.11 - 3.76) III 




Overweight: AOR 2.0 (95% CI 1.1 - 3.7)                                                            
Obese: AOR 2.8 (95% CI 1.3 - 5.8) III 






13/327 ≥28: Multivariate OR 4.1 (95% CI 1.2 - 14.4), p=0.029 III 








Obese                                                                                                          
MM5: OR 4.0 (95% CI 2.4 - 6.4)                                                                  
MM8: OR 7.4 (95% CI 3.3 - 16.6)                                                                                                                                        
10 point difference                                                                                            
MM5: OR 3.4 (95% CI 3.3 - 3.5)                                                                 
MM8: OR 3.5 (95% CI 3.4 - 3.6)  
III 




OR 1.43 (95% CI 1.17 - 1.75), AOR 1.58 (95% 
CI 1.18 - 2.12) III 




Obese (vs normal): OR 2.2 (95% CI 1.2 - 4.1), 
AOR 3.7 (95% CI 1.5 - 9.6) III 

















Fung et al., 
2007128 CC 
Orthopaedic 
patients 166/111 <18.5: OR 0.214 (95% CI 0.065 - 0.702) III 
No effect on risk 






35/501 Per unit increase: Univariate HR 1.073 (95% CI 1.03 - 1.12), p=0.003 I 






84/2837 Univariate IRR 1.10 (9% CI 1.07 - 1.13)                                                          Multivariate IRR 1.09 (95% CI 1.04 - 1.14) I 








25-30                                                                                                             
Either hand: AOR 1.00 (95% CI 0.53 - 1.91)                                           
Dominant hand: AOR 1.48 (95% CI 0.61 - 
3.60)                                                                     
Non-dominant hand: AOR 0.75 (95% CI 0.34 
- 1.66)                                                                                                                                      
≥30                                                                                                          
Either hand: AOR 1.42 (95% CI 0.55 - 3.67)                                                           
Dominant hand: AOR 2.13 (95% CI 0.63 - 
7.12)                                                                    









36/173 AOR 1.02 (95% CI 0.94 - 1.10), p=0.713 II 




RR 1.006 (95% CI 0.921 - 1.099), p=0.888                                                                   




al,. 200196 PC 
Blue-collar 
workers 34/100 >27: OR 2.2 (95% CI 0.6 - 8.5) II 





29 >27: OR 2.29 (95% CI 0.9 - 5.9) II 




Per 5-point increase: OR 2.47 (95% CI 1.03 
- 5.93), p=0.04 II 




Overweight, slim wrist (vs normal weight, 
slim wrist): OR 1.0 (95% CI 0.5 - 2.2), AOR 
1.5 (95% CI 0.7 - 3.4)                                                                                     
Normal weight, robust wrist: OR 1.1 (95% CI 
0.7 - 1.7), AOR 1.1 (95% CI 0.7 - 1.7)                                                                                                                                
Overweight, robust wrist: 1.3 (95% CI 0.9 - 
2.0), AOR 1.4 (95% CI 0.9 - 2.2) 
II 




21.59-23.67 (Quintile 2): Univariate OR 2.52 
(95% CI 0.62 - 10.35), p=0.200; Multivariate 
OR 3.01 (95% CI 0.65 - 13.80), p=0.15                                                                                                                               
23.68-25.85 (Quintile 3): Univariate OR 2.37 
(95% CI 0.56 - 10.04), p=0.240; Multivariate 
OR 2.40 (95% CI 0.51 - 11.24), p=0.26                                                                                                                                      
25.86 - 28.23 (Quintile 4): Univariate OR 
3.55 (95% CI  0.91 - 13.96), p=0.07; 
Multivariate OR 4.45 (95% CI 0.98 - 20.15)                                                                                                                                            
≥28.24 (Quintile 5): Univariate  OR 4.02 
(95% CI 1.02 - 15.87), p=0.040; Multivariate 
















Results Level of Evidence 
Leclerc et 







131/467 Female, increased BMI: OR 2.38 (95% CI 1.04 - 5.47) II 




23-25: OR 0.901 (95% CI 0.475 - 1.710)                                                                             
25-30: OR 1.815 (95% CI 0.925 - 3.559)                                                              





CC General population 206/211 
Normal: AOR 0.63 (95% CI 0.28 - 1.45)                                                                 
Overweight: AOR 1.29 (95% CI 0.53 - 
3.14)                                                          
Obese: AOR 1.86 (95% CI 0.72 - 4.80), 
Overall p<0.001                                 
Increasing BMI (working population): 
Multivariate OR 1.06 (95% CI 1.02 - 1.11) 
III 
 Mattioli et 
al., 2009115 CC 
General 
population 191/286 
25-29: Univariate OR 1.6 (95% CI 1.0 - 




al., 2011130 CC 
Hospital 
patients 68/138 
28.1 vs 32.8: OR 1.11 (95% CI 1.00 - 










<18.5: Univariate OR 0.69 (95% CI 0.44 - 
1.09), Multivariate OR 0.64 (95% CI 0.40 
- 1.01); Operated CTS: AOR 0.74 (95% 
CI 0.28 - 1.94) 
III 







Female: OR 1.120 (95% CI 1.048 - 
1.198), p=0.001                                                       




pour et al., 
200899 
CS Industrial workers 47/348 
Multivariate OR 0.94 (95% CI 0.86 - 
1.04), p=0.27 III 
Leclerc et 







151/1059  ≥31 - Model 1: OR 1.91 (95% CI 1.09 - 3.37) III 






high level of 
hand activity 
57/420 
Quantitative model                                                                                          
≥30 versus <30 if exerts/min cat=1: OR 
0.77 (95% CI 0.24 - 2.48)                                                                                                                                     
≥30 versus <30 if exerts/min cat=2: OR 
1.60 (95% CI 0.52 - 5.00)                                                                                                                                     
≥30 versus <30 if exerts/min cat=3: OR 
2.26 (95% CI  1.01 - 5.10)                                                                                                                           
Ratings-based model                                                                              






Univariate OR 1.052 (95% CI 1.039 - 
1.065), p<0.001 III 































Possible                
34/479 
Definite 
Increasing BMI: AOR 1.08 (95% CI 1.05 - 




an et al., 
2002132 
CC Hospital patients 210/320 
Per unit increase: OR 1.11 (95% CI 1.05 - 
1.16), p<0.001 III 
Rigouin et 
al., 201398 CS 
Working 
population 156/3554 
Per unit increase                                                            
Male: OR 1.10 (95% CI 1.02 - 1.17), 
p=0.009                                          




al., 2012101 CS 
Office 
workers 88/382 
Overweight (vs normal): OR 1.0 (95% CI 




CS Computer workers  
A: 51/4101                         
B: 
167/2942 
Case def A, ≥25: Univariate RR 1.22 
(95% CI 0.72 - 2.06)                                                                                        
Case def B, ≥25: Univariate RR 1.07 





CC Hospital patients 38/76 
Group 1 - 10% above reference weight: 
OR 2.0 (95% CI 0.8 - 4.8)                                   III 
Hakim et 





21.1-23: OR 0.94 (95% CI 0.71 - 1.25), 
AOR 0.91 (95% CI 0.69 - 1.22)                                                                                                         
23.1-25: OR 0.91 (95% CI 0.66 - 1.24), 
AOR 0.89 (95% CI 0.65 - 1.23)                                                                                                     
25.1-28: OR 0.86 (95% CI 0.60 - 1.22), 
AOR 0.84 (95% CI 0.59 - 1.21)                                                                                                       
≥28.1: OR 0.85 (95% CI 0.58 - 1.24), 
AOR 0.85 (95% CI 0.57 - 1.23) 
III 
Ali et al., 
200627 CS 
Computer 
workers  85/563 ≥25: OR 1.0 (95% CI 0.6 - 1.6), p=1.000 III 
Mondelli et 
al., 200690 CS 
Female floor 
cleaners 70/75 
>25: OR 1.79 (95% CI 0.85 - 3.78), 
Multivariate OR 1.3 (95% CI 0.68 - 4.44) III 
Awada et 
al., 1998126 CC 
Hospital 
patients 100/100 
Obesity (men): OR 1.44 (95% CI 0.51 - 
4.06) III 
De Krom et 
al., 1990116 CC 
General 













Logistic regression OR 1.02 (95% CI 1.00 
- 1.03), p=0.025 III 
      
CS, cross sectional; PC, prospective cohort; RC, retrospective cohort; AOR, adjusted odds ratio; CI, 
confidence interval; OR, odds ratio; PR, prevalence ratio; IRR, incidence rate ratio; RR, relative risk 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
1 Case definition A: Participants with personal medical history of CTS or surgery due to CTS 








2.3.1.7 Hand/Wrist structure/dimension 
Only seven level III studies have considered hand/wrist structure or dimensions as an 
intrinsic risk factor for CTS (Table 2.9). Two of these found an increase in risk with a 
difference in hand/wrist structure, specifically a wrist index (wrist depth/wrist width) of greater 
than 0.781 or an increase in digit index (digit 3 length x 100/hand length) or shape index 
(hand width x 100/hand length)131. Four studies found no effect on risk105,112,131,132. Only one 
study found that an increased wrist circumference led to a decreased risk of developing 
CTS112.  
 
Many authors have argued that the structure of the wrist, in particular any parameter that will 
result in the narrowing of the carpal tunnel which reduces the available space for the median 
and flexor tendons, will increase the risk of CTS77. However, there is a lack of high quality 
studies providing evidence for this hypothesis. In a case control study wrist circumference 
was found to predict a decreased risk of CTS whereas wrist ratio (wrist depth divided by 
wrist width) had no effect on risk112.  
 
Considering the low quality and conflicting results of the studies, it is clear that more 
research in the form of high quality, prospective studies need to be performed to get a better 
idea of whether the effect of hand/wrist shape and dimensions has an influence the risk of 
developing CTS. Because of the low quality and small number of studies in this category, 














Table 2.9 Summary of all the studies that have investigated hand/wrist structure/dimension as a risk 














al., 200881 CS 
Newly hired 
manual workers 131/940 
Wrist index ≥0.7: Logistic regression OR 
2.53 (95% CI 1.70 - 3.78) III 






Female                                                                                                    
Digit index (Per 1 unit increase): OR 1.375 
(95% CI 1.164 - 1.624), p<0.001                                                                                                   







CC Hospital patients and relatives 128/109 
Wrist circumference: OR 0.819 (95% CI 
0.763 - 0.877), p=0.000 III 
No effect on risk 









CC Hospital patients and relatives 128/109 
Wrist ratio: OR 1.12 (95% CI 1.03 - 1.21), 
p=0.008 III 
Kouyoumdjia
n et al., 
2002132 
CC Hospital patients 210/320 Per 0.01 unit increase: OR 1.11 (95% CI 1.07 - 1.16), p<0.001 III 






Female                                                                                                     
Wrist index (per 0.01 unit increase): OR 
1.157 (95% CI 1.099 - 1.219), p<0.001                                                                                        
Hand length/body height ratio (per 1 unit 
increase): OR 1.246 (95% CI 0.650 - 2.287), 
p=0.508                                                               
Male                                                                                                        
Wrist index: OR 1.257 (95% CI 1.073 - 
1.471), p=0.266                                               
Shape index: OR 1.041 (95% CI 0.878 - 
1.233), p=0.646                                         
Digit index: OR 1.177 (95% CI 0.880 - 
1.574), p=0.272                                                     
Hand length/body height ratio: OR 1.069 
(95% CI 0.381 - 2.998), p=0.99 
III 
 
CS, cross sectional; OR, odds ratio; CI, confidence interval 
a CON in case-control studies represent the controls, while in the other study designs it represents the 










2.3.1.8 Familial CTS 
Although a family history and genetic factors are often mentioned as risk factors135, only 
eight studies have considered family history as a potential modifier of risk for developing 
CTS (Table 2.10). One case-control study that investigated 520 female twin pairs found a 
decreased risk of CTS with regards to a genetic component or heritability24.  
 
Only one level II study found familial factors to influence CTS risk, the number of siblings 
with this condition influenced the risk to develop CTS significantly136. Three other level III 
studies also found an increase in risk if a family member suffers from CTS100,115,129.  Two 
prospective studies, however, found a positive family history to have no effect on risk of 
CTS78,93. Similarly, two level III studies also found no effect of family history on CTS risk89,115.  
 
Even though there are a few studies that investigated the effect of familial CTS, this does not 
give any information about potential specific genetic variants that could potentially be 
involved in the aetiology of CTS, yet ‘genetic make-up’ is often referred to as playing a vital 
role in this condition8. Considering the limited information available on this specific risk 
factor, it was assigned a low level of certainty. Future research should aim to investigate 























Table 2.10 Summary of all the studies that have investigated familial factors as a risk factor for carpal 
















RC Swedish database 2250/27436 
One sibling with CTS: SIR 4.08 (95% CI 2.07 - 
7.84)                                                                      














CC General population 206/211 
Family history: AOR 2.09 (95% CI 1.28 - 3.41), 




al., 2009115 CC 
General 
population 191/286 
Sibling: OR 8.1 (95% CI 2.3 - 29.2), Multivariate 
OR 6.6 (95% CI 1.5 - 29.4) III 
Decreased risk 
Hakim et 





Heritability/Genetic component: OR 0.46 (95% 
CI 0.34 - 0.58)                                                                          
AOR (1): OR 0.46 (95% CI 0.32 - 0.59)                                                                  
AOR (2): OR 0.47 (95% CI 0.34 - 0.59) 
III 
No effect on risk 






35/501 Family history: Univariate HR 2.1 (95% CI 1.04 - 4.35), p=0.04 I 
Violante et 
al., 200778 PC 
Working 
population 153/1939 
Family history: OR 1.4 (95% CI 0.9 - 2.4), 
Multivariate OR 1.2 (95% CI 0.7 - 2.0) II 
Mattioli et 
al., 2009115 CC 
General 
population 191/286 
Parent: OR 1.1 (95% CI 0.6 - 2.2), Multivariate 





Family history: OR 1.257 (95% CI 1.038 - 1.523), 




RC. Retrospective cohort; SIR, standardized incidence ratio; CS, cross sectional; OR, odds ratio; CI, 
confidence interval; AOR, adjusted odds ratio; PC, prospective cohort; HR, hazard ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 







2.3.2 Behavioural and Social 
The following section will review the role of six extrinsic behavioural and social factors, 
namely smoking, alcohol use, socio-demographic, geographical location, hobbies and 
exercise as risk factors for CTS. 
 
2.3.2.1 Smoking 
Out of the 20 studies that investigated the influence of smoking on the risk of developing 
CTS (Table 2.11), only one level III, cross-sectional study found an increased risk in both the 
unadjusted and adjusted analyses (OR 7.29 (95% CI 3.49 - 15.23), p<0.001, Multivariate OR 
4.68 (95% CI 1.80 - 11.80), p=0.001)99. Two studies reported a decreased risk for 
smokers89,119.  However, upon multivariate analyses, the effect of smoking in one of the two 
studies was lost89.  
 
Eighteen studies found no association between smoking and risk of 
CTS27,71,74,76,78,79,91,93,96,101,103,106,115,117,119,123,125,127. This included previous smokers74,93,115,123, 
current smokers74,93,96,103,115,127 and individuals who have smoked at some point in their lives, 
termed “ever smoked” or “ever smokers”27,71,76,78,79,91,106,117,125. The number of packs per year 
also made no difference to the risk of CTS103,123. Violante et al. found no effect of ever 
smoking on risk of CTS in their univariate analysis, but upon multivariate analysis they found 
an increase in risk78, but because of the lack of association in the initial analyses, this result 
should be interpreted with caution.  
 
The low level of evidence and small number of studies (n=3) that found an effect of smoking 
on CTS risk, together with the fact that multivariate analyses further decreased this to only 
two studies compared to the large amount of studies finding no evidence of smoking being a 
risk factor were considered contradictory. Smoking was therefore assigned a low level of 
certainty to be a risk factor of CTS. 
 




Table 2.11 Summary of all the studies that have investigated smoking as a risk factor for carpal 














our et al., 
200899 
CS Industrial workers 47/348 
Univariate OR 7.29 (95% CI 3.49 - 15.23), 





200589 CS EEG Patients 2408/1747 
OR 0.549 (95% CI 0.477 - 0.632), p<0.001, 
Multivariate OR 1.11 (95% CI 0.94 - 1.29) III 
Coggon et 
al., 2013119 CC 
General 
population 475/799 
Current smoker: AOR 0.6 (95% CI 0.5 - 0.8); 
Multivariate OR 0.6 (95% CI 0.4 - 0.8) III 




PC Industrial workers 204/3311 
Current smoker: IRR 1.09 (95% CI 0.78 - 1.51)                                                             
Previous smoker: IRR 1.05 (95% CI 0.70 - 
1.54) 
I 







Current smoker: Univariate HR 1.3 (95% CI 
0.68 - 2.65)                                                      
Previous smoker: Univariate HR 1.3 (95% CI 
0.67 - 2.63) 
I 
Nathan et 
al., 200276 PC 
Industrial 
workers 34/222 
Univariate OR 1.74 (95% CI 0.84 - 3.60), 




al., 200778 PC 
Working 
population 153/1939 
Ever vs never: OR 1.3 (95% CI 0.9 - 1.8), 
Multivariate OR 1.7 (1.2 - 2.4) II 
Roquelaure 
et al., 200196 PC 
Blue-collar 
workers 34/100 Current smoker: OR 0.5 (95% CI 0.1 - 2.2) II 








103/6083 Ever: Univariate OR 1.28 (95% CI 0.86 - 1.89), p=0.22 II 




e & chemical) 
81/1060 
Ever vs never, either hand: AOR 0.65 (95% CI 
0.34 - 1.24); Dominant hand: AOR 0.47 (95% 
CI 0.21 - 1.08); Non-dominant hand: AOR 0.63 
(95% CI 0.29 - 1.37) 
II 
Tanaka et al. 
199771 CS 
General 




CS Computer workers  
A: 51/4101                         
B: 167/2942 
Case def A - Ever vs non: Univariate RR 1.74 
(95% CI 1.02 - 2.93), p=0.003; Logistic 
regression OR 1.99 (95% CI 1.01 - 3.54), 
p=0.043                                                                                                                       
Case def B - Ever vs non: Univariate RR 1.22 





CS Engineers 25/177 
Current smoker: Univariate OR 1.25 (95% CI 
0.14 - 11.2), p=0.842                                        




al., 2009115 CC 
General 
population 191/286 
Current smoker: OR 1.1 (95% CI 0.7 - 1.7)                                                   









Smoker: OR 1.02 (95% CI 0.92 - 1.12), 
Multivariate OR 1.03 (95% CI 0.93 - 1.13); 


























CC Hospital patients 38/76 Current smoker: OR 1.5 (95% CI 0.7 - 3.5) III 
Ali et al., 
200627 CS 
Computer 
workers  85/563 Smoker: OR 1.6 (95% CI 1.0 - 2.6), p=0.06 III 
Ferry et al., 
2000117 CC 
Female survey 
responders 1264/1264 Smoker: OR 1.05 (95% CI 0.89 - 1.23) III 
Coggon et 
al., 2013119 CC 
General 
population 475/799 
Ex-smoker: AOR 1.1 (95% 0.8 - 1.4); 
Multivariate OR 1.1 (95% CI 0.8 - 1.4)                                                                                                                                                    III 




Previous smoker: AOR 1.0 (95% CI 0.5 - 1.8); 
Occational smoker: AOR 2.4 (95% CI 0.9 - 
6.3)                                                                                                                 
Current smoker, <10 pack-years: AOR 1.4 
(95% CI 0.5 - 3.7); 10-20 pack-years: OR 1.8 
(95% CI 0.6 - 4.7); >20 pack-years: 1.5 (95% 
CI 0.6 - 3.7) 
III 
 
CS, cross sectional; OR, odds ratio; CI, confidence interval; AOR, adjusted odds ratio; PC, 
prospective cohort; IRR, incidence rate ratio; HR, hazard ratio; RC, retrospective cohort; CC, case 
control 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
1 Case definition A: Participants with personal medical history of CTS or surgery due to CTS 




2.3.2.2 Alcohol use 
Out of a total of five studies that investigated alcohol use as a possible risk factor for CTS 
(Table 2.12), only one cross-sectional study found an increase in risk with increased alcohol 
consumption27. The other four studies found no effect of various types of alcohol use (light, 
moderate, excessive) on CTS risk78,93,115,123 and this factor was therefore assigned a low 
level of certainty.  
 
 




Table 2.12 Summary of all the studies that have investigated alcohol use as a risk factor for carpal 













Ali et al., 
200627 CS 
Computer 
workers  85/563 Increase - OR 1.7 (95% CI 1.1 - 2.8), p=0.04 III 
No effect on risk 





35/501 HR 1.3 (95% CI 0.66 - 2.55), p=0.45 I 
Violante et 
al., 200778 PC 
Working 
population 153/1939 
1-2 drinks p/w: OR 0.7 (95% CI 0.4 - 1.0), 
Multivariate OR 0.7 (95% CI 0.4 - 1.2)                                                                                                                                                                  
2-4 drinks p/w: OR 0.1 (95% CI 0.0 - 0.5), 
Multivariate OR 0.2 (95% CI 0.1 - 1.0)                                                                                                                                                                    
1-2 drinks p/d: OR 1.0 (95% CI 0.6 - 1.4), 
Multivariate OR 1.1 (95% CI 0.7 - 1.8)                                                                                                                                                                 
3-4 drinks p/d: OR 0.3 (95% CI 0.1 - 0.7), 
Multivariate OR 0.6 (95% CI 0.2 - 1.4)                                                                                                                                                                      
>4 drinks p/d: OR 0.8 (95% CI 0.3 - 2.3), 
Multivariate OR 2.3 (95% CI 0.7 - 7.2) 
II 
Mattioli et 
al., 2009115 CC 
General 
population 191/286 
1-2 drinks p/w: OR 0.8 (95% CI 0.5 - 1.4), 
Multivariate OR 0.8 (95% CI 0.4 - 1.6)                                                                                                                                                                     
3-6 drinks p/w: OR 0.5 (95% CI 0.2 - 1.1), 
Multivariate OR 0.4 (95% CI 0.1 - 1.1)                                                                                                                                                                     
1-2 drinks p/d: OR 0.9 (95% CI 0.5 - 1.4), 
Multivariate OR 0.8 (95% CI 0.5 - 1.5)                                                                                                                                                                   
>3 drinks p/d: OR 0.6 (95% CI 0.3 - 1.1), 
Multivariate OR 0.7 (95% CI 0.3 - 1.6) 
III 




Light: AOR 0.9 (95% CI 0.3 - 2.2)                                                                                       
Moderate: AOR 0.8 (95% CI 0.3 - 2.0)                                                                                                       
Excessive: AOR 1.3 (95% CI 0.5 - 3.3) 
III 
 
CS, cross sectional; OR, odds ratio; CI, confidence interval; PC, prospective cohort; HR, hazard ratio; 
RC, retrospective cohort; CC, case control 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 
2.3.2.3 Socio-demographic factors 
Twelve studies investigated educational and social factors as possibly playing a role in the 
aetiology of CTS (Table 2.13). Only one level III study that investigated 15 802 participants 
found an increase in risk, OR 1.38 (95% CI 1.32 - 1.45), with a higher income level80 but this 
effect was lost when a multivariate analysis was performed, Multivariate OR 1.15 (95% CI 
1.09 - 1.22). On the other hand, two level III studies found a decreased risk of CTS with a 
higher education level99,115. According to the authors, a possible explanation of this 





stage in life99, therefore decreasing the exposure of occupational activities that may 
contribute to development of CTS.  
 
There was only one prospective study that considered educational level as risk factors and 
found it to have no effect on CTS risk74. Eight level III studies also found no effect on risk 
with an difference in education71,100,104,120, income71,129, urbanization80, social class117 or 
home/leisure activity24.  
.  
Considering the low number of studies considering education, income and other socio-
economic variables, they were all grouped together under an umbrella of 
educational/social/income factors. These are all proxies for broad socio-occupational 
groupings115 and future research should aim to rather investigate these broad groupings 
than several, smaller individual risk factors. Educational/social factors were, as a result, 
assigned a low level of certainty.  
 
2.3.2.4 Geographical location 
Geographical location as risk factor was considered in only two studies (Table 2.14) of which 
both level II found that living in the USA leads to increased risk compared to the UK, 
Southern Hemisphere and Hong Kong, which did not alter the risk of CTS91,92.  
 
Owing to the limited number of studies investigating this variable, geographical location was 
assigned a low level of certainty as a modifier of CTS risk.  
  






Table 2.13 Summary of all the studies that have investigated socio-demographic factors as a risk 

















Higher income: OR 1.38 (95% CI 1.32 - 1.45), 
Multivariate OR 1.15 (95% CI 1.09 - 1.22) III 
Decreased risk 
Mattioli et 
al., 2009115 CC 
General 
population 191/286 
High school diploma or above: OR 0.2 (95% CI 
0.2 - 0.4) III 
Maghsoudip
our et al., 
200899 
CS Industrial workers 47/348 
Multivariate OR 0.19 (95% CI 0.05 - 0.66), 
p=0.009 III 




PC Industrial workers 204/3311 
High school graduate or above: IRR 0.66 (95% 
CI 0.46 - 0.99) I 
Bonfiglioli et 




26/324 >8 years: Multivariate OR 2.15 (95% CI 0.75 - 6.17), p=0.155 III 
Anton et al., 
2002104 CS 
Dental 
hygienists 8/81 Education (years): OR 1.22 (95% CI 0.71 - 2.10) III 




Education (>12 vs ≤12 years): OR 1.17 (95% CI 
0.77 - 1.78)                                                                              
Income (≥$20 000 vs <$20 000): OR 1.51 (95% 
CI 0.95 - 2.41) 
III 






Social class (III vs I & II): OR 1.05 (95% CI 0.84 - 
1.31)                                                                  
IV: OR 1.23 (95% CI 1.02 - 1.50) 
III 






Home (low vs high level): OR 1.13 (95% CI 0.83 
- 1.64), AOR 1.21 (95% CI 0.95 - 1.55)                                                                                                                        
Leisure (low vs high level): OR 1.04 (95% CI 
0.70 - 1.55), AOR 1.00 (95% CI 0.80 - 1.26) 
III 




Urbanization - moderate: Univariate OR 0.97 
(95% CI 0.90 - 1.04), Multivariate OR 1.03 (95% 
CI 0.95 - 1.12)                                                                                                  
High: Univariate OR 1.08 (95% CI 1.02 - 1.15), 
Multivariate OR 1.07 (95% CI 0.98 - 1.14) 
III




Year: Multivariate OR 0.82 (95% CI 0.74 - 0.92), 
p=0.001 III 
Nordstrom et 
al., 1997129 CC 
General 
population 206/211 
Income below poverty level: AOR 1.72 (95% CI 
0.82 - 3.59), p=0.140 III 
 
CC, case control; CS, cross sectional; OR, odds ratio; CI, confidence interval; PC, prospective cohort; 
IRR, incidence rate ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 







Table 2.14 Summary of all the studies that have investigated geographical location as a risk factor for 




















for breast cancer 
103/6083 
North America: OR 2.20 (95% CI 1.35 - 3.58), 
p=0.002; Multivariate OR 1.98 (95% CI 1.18 -  





RC Female breast cancer patients 79/4578 
USA: OR 2.54 (99% CI 1.10 - 5.90), p=0.0042;  
Multivariate OR 1.27 (99% CI 0.48 - 3.38), p0.53 II 








for breast cancer 




RC Female breast cancer patients 79/4578 
UK: OR 1.64 (99% CI 1.64 (95% CI 0.73 - 3.70), 
p=0.12; Multivariate OR 1.03 (99% CI 0.43 - 2.48), 
p=0.92                                                                                                                    
Central and eastern Europe: OR 0.07 (99% CI 
0.01 - 1.01), p=0.010; Multivariate OR 0.09 (99% 
CI 0.01 - 1.31), p=0.021                                                                                                                             
Southern hemisphere & Hong Kong: OR 1.98 
(99% CI 0.68 - 5.79), p=0.10; Multivariate OR 2.18 
(99% CI 0.70 - 6.78), p=0.76                                                                                                                             
II 
 
PC, prospective cohort; RC, retrospective cohort; CC, case control; CS, cross sectional; OR, odds 
ratio; CI, confidence interval;  
a CON in case-control studies represent the controls, while in the other study designs it represents the 




Four studies investigated different hobbies or recreational activities as possible modifier of 
CTS risk (Table 2.15). Only one prospective study found an increase in risk for knitting and 
gardening, both activities involving repetitive hand movement93 whilst the same study found 
no effect on risk for computer work and maintenance hobbies. Only one other level III study 
found knitting to increase risk of CTS100. Another two prospective studies and one cross 
sectional study found no effect of hobbies in general on risk of CTS74,76,90.   
 
Considering the low number of studies finding any effect of hobbies on CTS, this risk factor 
was assigned a low level of certainty. 

























Knitting                                                               
HR 2.5 (95% CI 1.26 - 4.87), p=0.009                                            
Gardening                                                                   









26/324 Knitting                                                                  OR 2.0 (95% CI 0.68 - 5.87), p=0.206 III 
No effect on risk 







HR 0.7 (95% CI 0.36 - 1.41), p=0.33                                         
Maintenance                                                           






PC Industrial workers 204/3311 
Non-occupational hand intensive 
activity                                                                   
IRR 0.66 (95% CI 0.47 - 0.94); 




al., 200690 CS 
Female floor 
cleaners 70/75 
Other                                                                
Univariate OR 1.54 (95% CI 0.79 - 
3.03); Multivariate OR 1.73 (95% CI 
0.75 - 0.98) 
III 
 
PC, prospective cohort; HR, hazard ratio; IRR, incidence rate ratio; CC, case control; CS, cross 
sectional; OR, odds ratio; CI, confidence interval;  
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
2.3.2.6 Exercise 
Exercise, as a risk factor for developing CTS, was investigated by eight studies (Table 2.16). 
There were no prospective studies that found altered risk of CTS with exercise. However, 
three level III studies found a decrease in risk with exercise, which included sport 
participation, any physical activity as well as frequency of exercise101,106,129. In contrast, three 
prospective studies found no effect on risk in workers who exercised by means of walking93 , 
general avocational physical activity76 or aerobic, non-hand intensive activity, for more than 3 
hours per week74. Similarly, four level III studies found no effect of various forms and 





participation, aerobic activity, exercise defined as causing shortness of breath as well as any 
physical activity101,103,106,123.   
 
Considering the lack of good quality, prospective studies; exercise as a modifier for risk of 
CTS was assigned a low level of certainty.  
 
Table 2.16 Summary of all the studies that have investigated exercise as a risk factor for carpal 














al., 1997129 CC 
General 
population 206/211 
3 months, 3 hours a week sport participation: 
AOR 0.55 (95% CI 0.35 - 0.87), p=0.01; 
Multivariate AOR 0.57 (95% CI 0.35 - 0.95), 
p=0.031 
III 
Raman et al., 
2012101 CS Office workers 88/382 ≥2 hr/wk: OR 0.3 (95% CI 0.2 - 0.7) III 
Eleftheriou et 
al., 2012106 CS 
Computer 
workers  
A: 51/4101                         
B: 167/2942 
Case def A: Univariate RR 0.40 (95% CI 0.19 - 
0.84); Logistic regression OR 0.38 (95% CI 
0.16 - 0.87), p=0.023 
III 




PC Industrial workers 204/3311 
≥3 hr/wk: IRR 0.99 (95% CI 0.65 - 1.50); 
Multivariate HR 0.82 (95% CI 0.55 - 1.22), 
p=0.32 
I 






35/501 Walking                                                              HR 1.9 (95% CI 0.98 - 3.84), p=0.06                                               I 




Avocational activity                                                           
Univariate OR 0.83 (95% CI 0.57 - 1.21), 






CS Engineers 25/177 
Exercise frequency: Univariate OR 1.23 (95% 
CI 0.74 - 2.05)                                                                                      
Aerobic activity (hr/week): Univariate OR 1.09 
(95% CI 0.93 - 1.27)                                                                    
Upper extremity activity - hobbie/exercise 
(hr/week): Univariate OR 1.01 (95% CI 0.98 - 
1.05) 
III




2-3 times a week: AOR 1.1 (95% CI 0.6-1.9)                                                                              
≥4 times a week: AOR 1.2 (95% CI 0.6 - 2.0) III 
Raman et al., 
2012101 CS Office workers 88/382 1 hr/wk: OR 0.8 (95% CI 0.5 - 1.5) III 
Eleftheriou et 
al., 2012106 CS 
Computer 
workers  
A: 51/4101                         
B: 167/2942 
Case def B: Univariate RR 0.72 (95% CI 0.54 - 
0.96); Logisitic regression: OR 0.72 (95% CI 
0.44 - 1.20), p=0.217 
III 
 
PC, prospective cohort; IRR, incidence rate ratio; RC, retrospective cohort; CC, case control; CS, 
cross sectional; OR, odds ratio; CI, confidence interval;  




a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
1 Case definition A: Participants with personal medical history of CTS or surgery due to CTS 
2 Case definition B: Case definition A and participants identified through clinical examination (score 
≥12)  
 
2.3.3 Medication  
The following section will review the role of six specific treatment(s)/medication use, namely 
corticosteroids, chemotherapy, contraceptive, hormone replacement therapy, radiotherapy 
as well as other medical treatments, as risk factors for CTS. 
 
2.3.3.1 Corticosteroid use 
Although generally considered as a risk factor for injury44, only two level III studies reported 
on the use of corticosteroids to alter CTS risk (Table 2.17). Both level III studies reported an 
increase risk with the use of this medication110,125 but owing to the low number of studies 
providing evidence towards this, corticosteroid use as risk factor for CTS could only be 
assigned a low level of certainty.  
 
Table 2.17 Summary of all the studies that have investigated corticosteroid use as a risk factor for 


















626/3618 OR 1.9 (95% CI 1.4 - 2.4), AOR 1.6 (95% CI 1.2 - 2.1) III 
Geoghegan et 





Univariate OR 1.64 (95% CI 1.39 - 1.93); 
Multivariate OR 1.07 (95% CI 0.90 - 1.27)                                                                                                                                            
Operated CTS: AOR 0.98 (95% CI 0.71 - 1.37) 
III 
      
CC, case control; OR, odds ratio; CI, confidence interval; AOR, adjusted odds ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 










Two level II studies investigated the effect of chemotherapy on risk of CTS (Table 2.18). 
Mieog et al. (2012) found this treatment to have no effect on risk92 whereas Sestak et al. 
(2009) initially found an increase in risk, but upon multivariate analysis found no effect91. 
Chemotherapy as risk factor for CTS was therefore assigned a low level of certainly, 




Table 2.18 Summary of all the studies that have investigated chemotherapy as a risk factor for carpal 






















Univariate OR 1.73 (95% CI 1.14 - 2.62), 
p=0.01; Multivariate OR 1.36 (95% CI 0.85 - 
2.14), p=0.200 
II 
No effect on risk 





79/4578 OR 1.01 (99% CI 0.53 - 1.93), p=0.96 II 
      
PC, prospective cohort; RC, retrospective cohort; OR, odds ratio; CI, confidence interval 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 
2.3.3.3 Contraceptive use 
Of the seven studies investigating contraceptive use as a modifier in the risk of CTS (Table 
2.19), only two level III studies found use of contraceptives to be associated an increased 
risk107,117. The other investigations found current use, use in the past and number of years of 
contraceptive use to have no effect on risk82,90,96,116,117,125. Contraceptive use as risk factor for 
CTS was therefore assigned a low level of certainty.  




Table 2.19 Summary of all the studies that have investigated contraceptive use as a risk factor for 

















Oral contraceptive use - former: OR 1.45 
(95% CI 1.18 - 1.78) III 





30/177 OR 2.0 (95% CI 1.2 - 5.4) III 
No effect on risk 
Roquelaure et 
al., 200196 PC 
Blue-collar 
workers 34/100 OR 1.0 (95% CI 0.3 - 2.8) II 
Geoghegan et 





Combined Oral Contraceptive Pill: 
Univariate OR 1.12 (95% CI 0.97 - 1.29), 
Multivariate OR 0.82 (95% CI 0.71 - 0.95)                                                                                 
Operated CTS: AOR 0.83 (95% CI 0.59 - 
1.17) 
III




Oral contraceptive use - current: OR 0.87 
(95% CI 0.74 - 1.03)                                                                          
Months of oral contraceptive use - 1-48: 
OR 1.30 (95% CI 0.99 - 1.70); 49-108: OR 
1.14 (95% CI 0.99 - 1.31);                                                                                         
Months of contraceptive use - >108: OR 
0.98 (95% CI 0.87 - 1.11) 
III 
De Krom et 
al., 1990116 CC 
General 
population 156/473 
Use during the past 5 years                                      
1-4 years: Risk Ratio 0.7 (95% CI 0.3 - 
1.6);                                                                       
≥5: Risk Ratio 2.0 (95% CI 0.8 - 5.2) 
III 




OR 1.61 (95% CI 0.70 - 3.68), Multivariate 
OR 1.52 (95% CI 0.58 - 4.04) III 
Morgenstern 




127/931 Multivariate OR 0.84 (95% CI 0.46 - 1.56), p=0.590 III 
      
CC, case control; OR, odds ratio; CI, confidence interval; PC, prospective cohort; AOR, adjusted odds 
ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 









2.3.3.4 Hormone replacement therapy  
Although the main aspect of this section is focused on hormone replacement therapy (HRT) 
as risk factor for CTS, several other hormonal conditions have been added for simplicity 
purposes.  
 
Ten studies considered various forms of hormonal influences on the risk of developing CTS 
(Table 2.20). Six of these found an increased risk for CTS91,92,110,116,117,125, of which two level 
II studies found an increased risk in participant currently or previously using HRT91,92. 
However, upon multiple regression or adjustment, the effect of the therapy disappeared in 
both studies. Of the studies that found hormonal factors to have no effect on risk, two 
prospective studies considered hormone receptor status, which is defined as the receptor 
status of estrogen and progesterone (i.e. positive or negative) and used  in the diagnosis 
and treatment of breast cancer,91 and hormone use76 whereas one retrospective study 
investigated time since menopause and previous oophorectomy92.   
 
Four case control (level III) studies also found an increased risk of CTS with various 
hormonal influences110,116,117,125. Five level III studies further investigated various hormonal 
influences but found none to have a modifying effect on CTS 24,82,99,116,117.  
 
The lack of studies with a high level of evidence lead to HRT and other hormonal factors  
being assigned a low level of certainty, however, future research should aim to investigate all 














Table 2.20 Summary of all the studies that have investigated hormone replacement therapy and other 




















for breast cancer 
103/6083 
HRT: Univariate OR 1.72 (95% CI 1.16 - 2.54), 
p=0.007; Multivariate OR 1.31 (95% CI 0.86 - 1.99), 





RC Female breast cancer patients 79/4578 
Previous use of HRT: OR 2.49 (99% CI 1.33 - 4.67), 




CC General population 156/473 
Hysterectomy with oophorectomy: Risk Ratio 2.0 
(95% CI 1.1 - 3.6)                                                                        
Years since last menstrual period <1: Risk Ratio 6.5 





CC Female survey responders 1264/1264 
Any menstrual disorder: OR 1.36 (95% CI 1.11 - 
1.66)                                                        Pre-






CC General practice patients 3391/13564 
HRT: Univariate OR 1.39 (95% CI 1.23 - 1.57), 
Multivariate OR 0.95 (95% CI 0.84 - 1.08)                                                                                                                                    
Operated CTS - HRT: OR 0.86 (95% CI 0.67 - 1.09)                                                              
Thyroxine: Univariate OR 1.82 (95% CI 1.46 - 2.27), 
Multivariate OR 1.36 (95% CI 1.08 - 1.70);                                                                                                       









626/3618 Estrogen replacement use: OR 2.0 (95% CI 1.2 - 3.6), AOR 1.8 (95% CI 1.0 - 3.2) III 








for breast cancer 
103/6083 
Hormone receptor status - negative: Univariate OR 
0.86 (95% CI 0.42 - 1.78), p=0.69                                                                                                                                         
Hormone receptor status - unknown: Univariate OR 





PC Industrial workers 34/222 
Hormone use: Univariate OR 0.58 (95% CI 0.07 - 






RC Female breast cancer patients 79/4578 
Time since menopause <5 years: OR 1.97 (99% CI 
0.91 - 4.25), p=0.024;                                                                                                                                            
Time since menopause 5-9 years: OR 1.47 (99% CI 
0.69 - 3.12 ), p=0.190                                                                                                                                       
Previous oophorectomy: OR 1.08 (99% CI 0.38 - 
3.02), p=0.850 
II 






























Peri-menopausal: OR 1.46 (95% CI 1.06 - 2.00); AOR 
1.53 (95% CI 1.01 - 2.32)                                                                                                                                                 
Post-menopausal: OR 1.20 (95% CI 0.93 - 1.55); AOR 
1.43 (95% CI 0.89 - 2.29);                                                                                                                                    
Hysterectomy: OR 1.33 (95% CI 1.06 - 1.65), OR (after 
accounting for menopause): 1.12 (95% CI 0.70 - 1.75); 
AOR 1.20 (95% CI 0.89 - 1.63)                                                                                                    
HRT: OR 0.87 (95% CI 0.67 - 1.13); AOR 0.85 (95% 
CI 0.62 - 1.16)                                                 
Thyroxine replacement therapy: OR 1.15 (95% CI 0.78 





CC General population 156/473 
Age at menopause                                                                                  
<45: Risk Ratio 1.3 (95% CI 0.5 - 3.6);                                                               
45-50: Risk Ratio 0.8 (95% CI 0.3 - 2.1)                                                                                         
Age at menopause (women >59 years)                                                   
<45: Risk Ratio 0.9 (95% CI 0.2 - 3.8)                                                                                                    
45-50: Risk Ratio 1.1 (95% CI 0.3 - 3.6)                                                                                                      
Years since last menstrual period                                                          
2-5: Risk Ratio 2.4 (95% CI 0.8 - 7.5)                                                                                  
Age at menarche                                                                                             
<12: Risk Ratio 0.6 (95% CI 0.3 - 1.2)                                                                    
>15: Risk Ratio  0.8 (95% CI 0.4 - 1.6)                                                                                                 
Number of pregnancies                                                                              
1-2: Risk Ratio 0.8 (95% CI 0.4 - 1.5)                                                                            





CC Female survey responders 1264/1264 
HRT: OR 1.39 (95% CI 0.90 - 2.08)                                                                       
Endogenous Hormonal factors                                                                        
1: OR 1.27 (95% CI 0.58 - 2.80); 2: OR 1.18 (95% CI 
0.93 - 1.50)    ≥3: OR 1.10 (95% CI 0.91 - 1.33)                                                                 






CS Industrial workers 47/348 
Hormone disease: Univariate OR 0.92 (95% CI 0.11 - 
7.55), p=0.94;                                                              












Use of exogenous oestrogens: Multivariate OR 0.58 
(95% CI 0.23 - 1.46), p=0.24                                                                                                                                                                     
Currently pregnant: Multivariate OR 1.27 (95% CI 0.52 
- 3.09), p=0.60 
III 
      
PC, prospective cohort; HRT, hormone replacement therapy; OR, odds ratio; CI, confidence interval; 
RC, retrospective cohort; CC, case control;; AOR, adjusted odds ratio  
a CON in case-control studies represent the controls, while in the other study designs it represents the 















The two cohort studies that investigated radiotherapy, found that this treatment has no effect 
on risk of CTS91,92 (Table 2.21). Radiotherapy was therefore assigned a low level of 
certainty.  
 
Table 2.21 Summary of all the studies that have investigated radiotherapy as a risk factor for carpal 












No effect on risk 








103/6083 Radiotherapy: Univariate O R 1.15 (95% CI 0.76 - 1.74), p=0.500 II 





79/4578 OR 2.33 (95% CI 1.08 - 5.03), p=0.005; AOR 1.67 (95% CI 0.60 - 4.66), p=0.200 II 
      
PC, prospective cohort; OR, odds ratio; CI, confidence interval; RC, retrospective cohort 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 
2.3.3.6 Other medication/treatment 
Different types of medication or treatment, each assessed by a single study and not 
previously evaluated in section 2.3.3, is discussed below (Table 2.22). Five studies, of which 
two were level II, found an increase in CTS risk with various treatments, including 
Anastrozole and exemestane medication, medication for hypertension, insulin, metformin, 
sulphonyl and heamodialysis91,92,103,110,125. Two studies investigated diuretic use, but found it 
to have no effect on CTS risk82,92.   
 
As a result of insufficient research on these different types of medication/treatments as 








Table 2.22 Summary of all the studies that have investigated other medication/treatment as a risk 






















Anastrozole vs Tamoxifen(ref): Univariate OR 
3.55 (95% CI 2.22 - 5.65), p<0.001; 
Multivariate OR 3.55 (95% CI 2.22 - 5.66), 
p<0.001 
II 






Exemestane vs Tamoxifen (ref): OR 9.75 
(99% CI 3.49 - 27.24), p<0.001; AOR 9.90 





CS Engineers 25/177 
Blood pressure medication: Univariate OR 
4.08 (95% CI 1.24 - 13.4), p=0.020; 








626/3618 Haemodialysis: OR 8.4 (95% CI 4.0 - 17.7), AOR 9.0 (95% CI 4.2 - 19.6) III 
Geoghegan et 





Insulin: Univariate OR 2.24 (95% CI 1.57 - 
3.17), Multivariate OR 1.52 (95% CI 1.06 - 
2.18)                                                                                                                             
Metformin: Univariate OR 1.87 (95% CI 1.32 - 
2.66), Multivariate OR 1.20 (95% CI 0.84 - 
1.72)                                                                                                       
Sulphonyl: Univariate OR 2.18 (95% CI 1.61 - 
2.95), Multivariate OR 1.45 (95% CI 1.07 - 
1.97)  
III 
No effect on risk 





79/4578 Diuretic use: OR 1.41 (95% CI 0.22 - 9.10), p=0.64 II 
Morgenstern 




127/931 Diuretic use: Multivariate OR 2.66 (95% CI 1.00 - 7.04), p=0.050 III 
      
PC, prospective cohort; OR, odds ratio; CI, confidence interval; RC, retrospective cohort; AOR, 
adjusted OR; CS, cross sectional; CC, case control 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 




2.3.4 Medical conditions & Injuries 
The following section will review the role of seven specific medical conditions and injuries, 
namely diabetes, thyroid disorders, rheumatoid arthritis, osteoarthritis, hypertension, gout, 
previous musculoskeletal disorders/injuries as well other factors, which included various 
medical conditions investigated only by one study, as risk factors for CTS. 
 
2.3.4.1 Diabetes 
Often mentioned to be a risk factor for CTS, diabetes was investigated in 16 studies for its 
role in influencing the risk of this condition (Table 2.23). Five studies, of which only one was 
a level II study, found it to be associated with increased risk80,110,117,126,137, reporting between 
an 1.4 and 4.5-fold increase in risk (for male and female participants combined). On the 
other hand, a total of eleven studies, including two level I studies consisting of 35 and 204 
participants, respectively, found no effect of diabetes on CTS risk74,81,83,92,93,106,114–116,119,125.  
 
Although diabetes was assigned a low level of certainty because of the conflicting evidence 
found, there is a promising trend towards this condition not influencing CTS risk and future 
research should investigate this further.  
 
Table 2.23 Summary of all the studies that have investigated diabetes as a risk factor for carpal 













Wessel et al., 
2013137 RC 
Patients with 
trigger digits 84/216 
Multivariate OR 1.876 (95% CI 1.1 - 3.3), 
p=0.026 II 




Total: OR 4.51 (95% CI 2.91 - 7.00); Men: OR 
6.39 (95% CI 2.37 - 17.23); Women: OR 3.78 
(95% CI 2.31 - 6.18) 
III 
Ferry et al., 
2000117 CC 
Female survey 
responders 1264/1264 OR 1.83 (95% CI 1.68 - 4.98) III 
Solomon et 



























Univariate OR 3.59 (95% CI 3.06 - 4.21), 
Multivariate OR 2.04 (95% CI 1.72 - 2.41) III 
No effect on risk 










PC Industrial workers 204/3311 
IRR 1.08 (95% CI 0.43 - 2.26); Multivariate HR 
0.64 (95% CI 0.30 - 1.40), p=0.27 I 
Werner et al., 
2005114 PC 
Assembly 
workers 20/169 OR 6.55 (95% CI 1.08 - 39.59), p=0.04 II 





79/4578 OR 0.82 (95% CI 95% 0.27 - 2.48), p=0.65 II 
Geoghegan et 




3391/13564 OR 1.83 (95% CI 0.68 - 4.98) III 
Armstrong et 




131/940 Logistic regression OR 2.71 (95% CI 1.02 - 7.15) III 




Univariate OR2.3 (95% CI 0.8 - 6.7), 
Multivariate OR 2.6 (0.7 - 8.7) III 
Coggon et al., 
2013119 CC 
General 
population 475/799 AOR 1.1 (95% CI 0.7 - 1.7) III 
Eleftheriou et 
al., 2012106 CS 
Computer 
workers  
A: 51/4101                         
B: 167/2942 
Case def B - Univariate RR 1.26 (95% CI 0.65 
- 2.44) III 
De Krom et 
al., 1990116 CC 
General 
population 156/473 
Risk Ratio 0.6 (95% CI 0.2 - 2.0)                                                                                                            
During pregnancy: RR 1.6 (95% CI 0.7 - 3.7) III 




OR 1.82 (95% CI 1.08 - 3.06); Multivariate OR 
1.49, p=0.012 III 
      
RC, retrospective cohort; OR, odds ratio; CI, confidence interval; CC, case control; AOR, adjusted 
OR; CS, cross sectional; PC, prospective cohort; IRR, incidence rate ratio; HR, hazard ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
1 Case definition A: Participants with personal medical history of CTS or surgery due to CTS 




2.3.4.2 Thyroid disorders 
Eight studies investigated thyroid disorders (including hypo- and hyperthyroidism) as risk 
factor for CTS (Table 2.24). Only two level III studies found an increased risk of CTS in 




participants suffering from hypothyroidism80,110 whereas six studies found thyroid disorders to 
have no effect74,92,93,106,115,116.  
 
Table 2.24 Summary of all the studies that have investigated thyroid disorders as a risk factor for 


















626/3618 Hypothyroidism: OR 1.9 (95% CI 1.2 - 3.1), AOR 1.7 (95% CI 1.1 - 2.8) III 






Hypothyroidism: Univariate OR 2.62 (95% CI 
2.22 - 3.10), Multivariate OR 1.38 (95% CI 
1.16 - 1.65) 
III 
No effect on risk 










PC Industrial workers 204/3311 
Thyroid disease: HR 1.81 (95% CI 1.01 - 
3.01); Multivariate HR 1.24 (95% CI 0.72 - 
2.12), p=0.44 
I 





79/4578 Hypothyroidism: OR 1.56 (95% CI 0.59 - 4.14), p=0.24 II 




Thyroid disorder: Univariate OR 1.3 (95% CI 
0.7 - 2.2) III 
Eleftheriou et 
al., 2012106 CS 
Computer 
workers  
A: 51/4101                         
B: 167/2942 
Case def A - Hypothyroidism: Univariate RR 
1.58 (95% CI 0.76 - 3.29)                                                                                              
Case def B - Hypothyroidism: Univariate RR 
0.91 (95% CI 0.58 - 1.42)                                                                                                                          
Case def B - Hyperthyroidism: Univariate RR 
0.78 (95% CI 0.33 - 1.80) 
III 
De Krom et 
al., 1990116 CC 
General 
population 156/473 
Thyroid disease (women): Risk Ratio 1.0 (95% 
CI 0.4 - 2.6) III 
      
CC, case control; OR, odds ratio; CI, confidence interval; PC, prospective cohort; HR, hazard ratio 
RC, retrospective cohort; RR, relative risk 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
1 Case definition A: Participants with personal medical history of CTS or surgery due to CTS 




Since hypothyroidism is often associated with significant weight gain, it is possible that an 





than the thyroid disorder itself. Further research should investigate this possibility. As a 
consequence of the small number of investigations on this risk factor, it was assigned a low 
level of certainty.  
 
2.3.4.3 Rheumatoid arthritis 
Rheumatoid arthritis (RA), an autoimmune disorder characterized by joint inflammation138, is 
also increasingly mentioned as a risk factor for CTS. Nine studies investigated RA as a 
modifier of CTS risk (Table 2.25) of which five, including one level I study,  found participants 
with RA to be at increased risk of CTS80,93,110,115,125. In contrast, four studies, also including 
one level I study that investigated 204 industrial workers, found RA to have no effect on CTS 
risk74,106,117,119. Considering the conflicting evidence presented to determine whether RA is in 
fact a true risk factor for CTS, it was assigned a low level of certainty.  
 
2.3.4.4 Osteoarthritis 
Similar to RA (section 2.3.4.3), osteoarthritis (OA) is also often mentioned as potential risk 
factor in the aetiology of CTS. A total of six studies investigated OA for risk of this condition 
(Table 2.26). Only two level III studies found an increased risk of CTS in participants with 
OA117,125. Ferry et al. investigated various forms of OA and found that OA of the spine is 
associated with increased risk of CTS whereas participants who did not specify the type of 
OA or the type of arthritis they were suffering from, had no difference in their risk of 
developing CTS117. Besides this finding, four other studies also found no effect of OA on 
CTS risk92,93,113,119. Considering the contradicting evidence and low number of good quality 














Table 2.25 Summary of all the studies that have investigated rheumatoid arthritis as a risk factor for 


























626/3618 Inflammatory arthritis: OR 3.1 (95% CI 2.4 - 4.1), AOR 3.1 (95% CI 2.2 - 4.2), p<0.01 III 
Geoghega
n et al., 
2004125 
CC General practice patients 3391/13564 
Univariate OR 3.31 (95% CI 2.34 - 4.67); 
Multivariate OR 2.23 (95% CI 1.57 - 3.17); 




al., 201280 CC 
General 
population 15802/31604 
Univariate OR 3.65 (95% CI 3.22 - 4.13), 
Multivariate OR 2.21 (95% CI 1.94 - 2.52) III 
Mattioli et 
al., 2009115 CC 
General 
population 191/286 
Univariate OR 2.6 (95% CI 1.4 - 4.9), 
Multivariate OR 2.2 (95% CI 1.0 - 4.6) III 





PC Industrial workers 204/3311 
IRR 1.66 (95% CI 0.60 - 3.69); Multivariate 
HR 1.13 (95% CI 0.50 - 2.57), p=0.77 I 
Ferry et 
al., 2000117 CC 
Female survey 
responders 1264/1264 OR 1.31 (95% CI 0.63 - 2.70) III 
Coggon et 
al., 2013119 CC 
General 




CS Computer workers  
A: 51/4101                         
B: 167/2942 
Case def A - Univariate RR 2.32 (95% CI 
0.67 - 7.89)                                                                     
Case def B - Univariate RR 1.38 (95% CI 
0.68 - 2.80) 
III 
      
PC, prospective cohort; HR, hazard ratio; CI, confidence interval; CC, case control; OR, odds ratio; 
AOR, adjusted odds ratio; IRR, incidence rate ratio; RC, retrospective cohort; RR, relative risk 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
1 Case definition A: Participants with personal medical history of CTS or surgery due to CTS 






Table 2.26 Summary of all the studies that have investigated osteoarthritis as a risk factor for carpal 





















Univariate OR 2.62 (95% CI 2.29 - 2.99), 
Multivariate OR 1.89 (95% CI 1.65 - 2.17 )       
Operated CTS: AOR 1.92 (95% CI 1.50 - 2.47) 
III 
Ferry et al., 
2000117 CC 
Female survey 
responders 1264/1264 OA - spine: OR 2.16 (95% CI 1.52 - 3.06) III 
No effect on risk 






35/501 Univariate HR 2.2 (95% CI 0.92 - 5.33), p=0.08 I 





79/4578 OR 1.93 (95% CI 0.89 - 4.19), p=0.029 II 




OA - unspecified: OR 1.23 (95% CI 0.82 - 
1.85)       
Unspecified arthritis: OR 1.49 (95% CI 1.02 - 
2.17) 
III 






high level of 
hand activity 
57/420 Arthritis1: OR 2.03 (95% CI 1.02 - 4.04) III 
Coggon et 
al., 2013119 CC 
General 
population 475/799 AOR 1.0 (95% CI 0.8 - 1.4) III 
CC, case control; OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; PC, prospective 
cohort; HR, hazard ratio; RC, retrospective cohort  
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
1 Type of arthritis not specified 
2.3.4.5 Hypertension 
Although not commonly thought to be associated with altered risk of CTS, four studies 
investigated hypertension as playing a possible role in CTS risk (Table 2.27). Not 
surprisingly, only one of these studies found participants of the general population suffering 
from hypertension to be at increased risk80 whereas three studies, including one prospective 
study, found it to have no effect93,113,117. Considering the lack of sufficient evidence to 
support hypertension as a risk factor for CTS, it was assigned a low level of certainty.  




Table 2.27 Summary of all the studies that have investigated hypertension as a risk factor for carpal 

















Univariate OR 2.93 (95% CI 2.57 - 3.35), 
Multivariate OR 1.84 (95% CI 1.60 - 2.11) III 
No effect on risk 






35/501 Univariate HR 1.2 (95% CI 0.57 - 2.47), p=0.65 I 





1264/1264  OR 1.12 (95% CI 0.84 - 1.49)                                                                                                                                                                                                                                      III 






high level of 
hand activity 
57/420 OR 1.89 (95% CI 1.01 - 3.53) III 
      
CC, case control; OR, odds ratio; CI, confidence interval; PC, prospective cohort; HR, hazard ratio; 
CS, cross sectional 
a CON in case-control studies represent the controls, while in the other study designs it represents the 




Only two studies investigated gout as potentially modifying the risk of CTS (Table 2.28). 
One, a case-control study, reported gout to be associated with increased risk of CTS in 
members of the general population80 whilst a prospective study, reported it to have no effect 
on CTS risk in industrial workers74. Subsequently, gout as a modifier of CTS risk was also 























Univariate OR 3.21 (95% CI 2.79 - 3.70), 
Multivariate OR 2.29 (95% CI 1.97 - 2.67)                                                                                          III 




PC Industrial workers 204/3311 
IRR 2.23 (95% CI 0.81 - 4.94); Multivariate HR 
1.57 (95% CI 0.72 - 3.44), p=0.26 I 
      
CC, case control; OR, odds ratio; CI, confidence interval; PC, prospective cohort; IRR, incidence rate 
ratio; HR, hazard ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 
2.3.4.7 Previous MSD/injury 
A common intrinsic risk factor for soft tissue injury is a previous injury34 and previous 
musculoskeletal disorder (MSD) or injury was investigated for their effect on CTS risk in 14 
studies (Table 2.29). Several different MSD and injuries were combined in this section for 
simplicity purposes and should ideally, in future investigations, be investigated individually. 
Nine investigations found an increased risk of CTS with previous 
MSD/injury74,79,92,93,101,115,117,125,137 whereas nine found previous injury to have no effect on 
future risk of CTS79,81,82,93,114–117,129. 
 
Two prospective studies found previous injury and distal upper extremity musculoskeletal 
disorder (DUE MSD) to increase the risk of developing CTS between 2 and 4.8-fold74,93. The 
same study by Garg et al. found that, although DUE MSD increases the risk of CTS, 
previous wrist fracture has no effect on future risk93.  
 
Several types of wrist injury of MSD were investigated by various level II and III studies. 
Interestingly, both studies that investigated the condition “trigger finger” found that it leads to 




an increased risk of CTS115,137. Furthermore, neck pain, brachial neuralgia and shoulder 
tendonitis did not indicate increased risk for CTS81,117 but arm fracture, epicondylitis (tennis 
elbow), limb or joint pain was an indication for CTS117.Owing to the limited number of studies 
and range of different types of MSD and/or injury, this risk factor was assigned a low level of 
certainty. 
 
Table 2.29 Summary of all the studies that have investigated previous musculoskeletal disorder/injury 
















PC Industrial workers 204/3311 
Previous injury: IRR 2.13 (95% CI 1.39 - 
3.18), Multivariate HR 1.58 (95% CI 1.05 - 
2.37), p=0.03 
I 







DUE MSD                                                                            
1-2: Univariate HR 2.9 (95% CI 1.45 - 5.83), 
p=0.003                                                                                                 
≥3: Univariate HR 4.8 (95% CI 1.39 - 16.37), 
p=0.01 
I






Previous MS injury: OR 2.60 (99% CI 1.41 - 
4.78), p<0.0001; AOR 2.17 (99% CI 1.10 - 
4.25), p=0.0031 
II 




e & chemical) 
81/1060 
Wrist trauma                                                                      
Either hand: AOR 3.87 (95% CI 1.74 - 8.60);                
Dominant hand: AOR 5.14 (95% CI 1.40 - 
18.97) 
II 
Wessel et al., 
2013137 RC 
Patients with 
tigger digits 84/216 
Multiple trigger digits: Multivariate OR 3.618 
(95% CI 2.1 - 6.3), p<0.001 II 




Any MSD: OR 2.38 (95% CI 1.98 - 2.87)                                                                           
Arm fracture: OR 2.70 (95% CI 1.31 - 5.58), 
AOR 2.50 (95% CI 1.15 - 5.45)                                                                                                                                             
Tennis Elbow: OR 2.00 (95% CI 1.59 - 2.51), 
AOR 1.88 (95% CI 1.48 - 2.39)                                                                                                                                                  
Limb pain: OR 1.68 (95% CI 1.30 - 2.18), 
AOR 1.39 (95% CI 1.05 - 1.85)                                                                                                                        
Joint pain: OR 2.03 (95% CI 1.54 - 2.66), 
AOR 1.61 (95% CI 1.20 - 2.16)                                                                   
III 
Raman et al., 
2012101 CS Office workers 88/382 
Previous wrist injury: OR 1.9 (95% CI 1.1 - 
3.3) III 
Geoghegan et 





Wrist fracture: Univariate OR 2.58 (95% CI 
1.91 - 3.48), Multivariate OR 2.29 (95% CI 
1.67 - 3.12)                                                                                                                  
Operated CTS: AOR 4.09 (95% CI 2.37 - 
7.06) 
III 




Trigger finger: Univariate OR 3.8 (95% CI 
2.0 - 7.3), Multivariate OR 2.7 (95% CI 1.3 - 
5.8)  
III 
No effect on risk 



























e & chemical) 
81/1060 Wrist trauma (non-dominant hand): AOR 3.10 (95% CI 1.00 - 9.66) II 
Werner et 
al., 2005114 PC 
Assembly 
workers 20/169 
Wrist/hand/finger tendonitis at baseline: OR 
4.74 (95% CI 1.09 - 20.43),p=0.04 II 
Nordstrom et 
al., 1997129 CC 
General 
population 206/211 
Other MS condition: AOR 1.92 (95% CI 1.04 - 
3.54), p=0.03; Multivariate OR 2.41 (95% CI 
1.24 - 4.67), p=0.009 
III 




Neck pain: OR 1.68 (95% CI 1.08 - 2.62), AOR 
1.15 (95% CI 0.71 - 1.86)                                                                                                                     
Brachial Neuralgia: OR 1.89 (95% CI 1.09 - 
3.30), AOR 1.65 (95% CI 0.90 - 3.02) 
III 
De Krom et 
al., 1990116 CC 
General 
population 156/473 
Wrist fracture: Risk Ratio 0.7 (95% CI 0.3 - 
1.5) III 
Armstrong et 




131/940 Shoulder tendinitis: Logistic regression OR 2.55 (95% CI 0.97 - 6.73) III 
Mattioli et 
al., 2009115 CC 
General 
population 191/286 
Wrist fractures: Univariate OR 0.7 (95% CI 0.3 
- 1.4) III 
Morgenstern 




127/931 Broken wrist: Multivariate OR 1.13 (95% CI 0.54 - 2.37), p=0.75 III 
      
PC, prospective cohort; IRR, incidence rate ratio; CI, confidence interval; HR, hazard ratio CC, case 
control; OR, odds ratio; AOR, adjusted odds ratio; HR, hazard ratio; CS, cross sectional; DUE MSD, 
distal upper extremity musculoskeletal disorder 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 
2.3.4.8 Other medical conditions 
Thirteen studies investigated one or more other medical condition (not listed above) as being 
potential risk factors for CTS (Table 2.30). Of these, eleven studies found an increase in risk 
with various medical conditions76,78–80,92,94,101,116,117,123,139. Only one level I prospective study 
found an increase in risk with more than one predisposing condition94. Four level II studies 
investigated lymphoedema, hot flushes, endocrine conditions and any other medical 
conditions that predispose to CTS and found that these conditions increased the risk of 
developing CTS76,78,79,92. It should be kept in mind that “hot flushes” is likely to be the effect 




of a hormonal condition and should therefore be interpreted with caution in the aetiology of 
CTS.  
In contrast, two level III studies found headaches, fibrosis and coronary artery disease to 
lead to a decrease in CTS risk117,123. Furthermore, four studies found various other medical 
conditions were not associated with CTS risk90,92,99,123.  
 
A low level of certainty was assigned to each one of the abovementioned medical conditions, 
considering the lack of adequate good quality studies verifying these associations.  
 
Table 2.30 Summary of all the studies that have investigated other medical conditions as a risk factor 



















Predisposing diseases                                                          
≥1: Univariate IRR 3.16 (95% CI 1.49 - 
6.17), Multivariate IRR 1.91 (95% CI 1.26 - 
2.91) 
I 






Lymphoedema: OR 4.36 (95% CI 1.27 - 
14.92), p=0.002; AOR 2.69 (95% CI 95% CI 
0.74 - 9.79), p=0.048                                                                                                         
Hot flushes: OR 2.82 (95% CI 1.53 - 5.20), 
p<0.001; AOR 1.66 (95% CI 0.84 - 3.31), 
p=0.057 
II 




Pathologies facilitating CTS onset: 
Univariate OR 3.4 (95% CI 2.2 - 5.1), 
Multivariate OR 2.3 (95% CI 1.5 - 3.6) 
II 




Endocrine condition: Univariate OR 1.35 
(95% CI 0.48 - 3.83), p=0.56; Multivariate 
OR 0.23 (95% CI 0.04 - 1.24), p=0.080 
II 




e & chemical) 
81/1060 
Any - Either hand: AOR 2.12 (95% CI 0.79 - 
5.71)                                                      
Dominant hand: AOR 2.30 (95% CI 0.65 - 
8.17)                                                        
Non-dominant hand: AOR 2.05 (95% CI 0.59 
- 7.18)                                                                               
II 




Psychiatric illness - nonpsychotic: OR 1.31 
(95% CI 1.11 - 1.54)                                                         
Respiratory complaints: OR 1.68 (95% CI 

























Uraemia: Univariate OR 2.31 (95% CI 1.99 - 
2.68), Multivariate OR 1.52 (95% CI 1.28 - 
1.76)                                                                                                                                                                             
Acromegaly: Univariate OR 2.26 (95% CI 
2.01 - 2.54), Multivariate OR 1.47 (95% CI 
1.29 - 1.66) 
III 
Raman et al., 
2012101 CS Office workers 88/382 
Co-morbid conditions - 1: OR 3.5 (95% CI 
1.8 - 6.8), AOR 4.9 (95% CI 2.0 - 12.3)                                                                                                                                                            
2: OR 4.0 (95% CI 1.8 - 9.2), AOR 3.3 (95% 
CI 1.1 - 9.7)                                                                                                  
≥3: OR 14.6 (95% CI 5.8 - 36.8), AOR 14.9 
(95% CI 4.8 - 46.5) 
III 




High-sensitive C-reactive protein (high): 
AOR 1.7 (95% CI 1.1 - 2.8) III 




Varicosis (men): Risk Ratio 12.0 (95% CI 3.6 
- 4.01) III 





100 TTR amyloid deposition: Logistic regression OR 15.79 (95% CI 3.29 - 75.68) III 
Decreased risk 




Headache: OR 0.71 (95% CI 0.58 - 0.87)                                                                   
Fibrosis: OR 1.44 (95% CI 1.16 - 1.79), AOR 
1.27 (95% CI 1.01 - 1.59)     
III 




Coronary artery disease: AOR 0.3 (95% CI 
0.1 - 0.9) III 
No effect on risk 






Endocrine/metabolic medical history: OR 
1.06 (95% CI 0.51 - 2.21), p=0.840                                                                                                                                    
Osteoporosis: OR 1.28 (95% CI 0.28 - 5.96), 
p=0.670                                                                   
Arthralgia: OR 0.94 (95% CI 0.15 - 6.01), 
p=0.93                                                                                   
Myalgia: OR 3.12 (95% CI 0.47 - 20.67), 
p=0.12                                                              
II 




Other diseases: Univariate OR 1.42 (95% CI 
0.56 - 3.63); Multivariate OR 1.47 (95% CI 
0.45 - 4.79) 
III 
      




















LDL Cholesterol - 130-189: AOR 1.1 (95% 
CI 0.6 - 1.9)                                                                                      
≥190: AOR 1.5 (95% CI 0.8 - 2.9)                                                                                                                 
HDL Cholesterol - 40-60: AOR 0.9 (95% CI 
0.5 - 1.7)                                                                                                                 
≤40: AOR 1.5 (95% CI 0.7 - 2.8)                                                                                                           
Total cholesterol - AOR 200-239: AOR 1.5 
(95% CI 0.7 - 3.0)                                                                          
≤240: AOR 1.8 (95% CI 0.9 - 3.6)                                                                                                      
Triglycerides - 151-199: AOR 1.1 (95% CI 
0.5 - 2.3)                                                                                    
≥200: AOR 1.7 (95% CI 0.9 - 3.1)                                                                                                       
Insulin resistance - 2nd tertile: AOR 1.2 
(95% CI 0.7 - 2.2)                                                                              
3rd tertile: AOR 1.7 (95% CI 0.9 - 3.3)                                                                                  
Metabolic syndrome: AOR 1.5 (95% CI 0.9 - 
2.5)                                                                                          
Intermittent claudication: AOR 0.4 (95% CI 
0.1 - 2.7)                                                                                         
Cerebrovascular disease: AOR 0.3 (95% CI 
0.1 - 2.3)                                                                            
Heart failure: AOR 0.6 (95% CI 0.1 - 2.6)                                                                                   
Arrhythmia: AOR 0.6 (95% CI 0.2 - 1.9)                                                                                           
Valvular heart disease: AOR 07 (95% CI 0.1 
- 3.2)                                                                  
III 
Maghsoudipou
r et al., 200899 CS 
Industrial 
workers 47/348 
Rheumatologic disease: Univariate OR 0.88 
(95% CI 0.85 - 0.91), p=0.61 III 
      
PC, prospective cohort; IRR, incidence rate ratio; CI, confidence interval; HR, hazard ratio CC, case 
control; OR, odds ratio; AOR, adjusted odds ratio; HR, hazard ratio; CS, cross sectional; DUE MSD, 
distal upper extremity musculoskeletal disorder 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
2.3.5 Other 
A total of 16 studies considered various other single risk factors that were not previously 
investigated (Table 2.31). Only one retrospective study (level II) found that the type of 
primary surgery a participant had, influenced their future risk of developing CTS92. A single 
case control study found that sleeping position on the side could lead to a decreased risk of 
CTS130 and six other investigations found various variables to have no effect on the risk of 
CTS92,103,107,119,123,129. 
 







Table 2.31 Summary of all the studies that have investigated other, single factors as risk factor for 



























Other: OR 2.76 (95% CI 1.13 - 6.76), 
p=0.004; Multivariate OR 1.33 (95% CI 








CS Industrial workers 47/348 
Univariate OR 2.37 (95% CI 1.19 - 4.71), 
p=0.01; Multivariate OR 0.85 (95% CI 






Ali et al., 
200627 CS 
Computer 
workers  85/563 
OR 1.8 (95% CI 1.2 - 2.7), p=0.03; AOR 































CS General population 79/6175 
Increased: AOR 3.7 (95% CI 1.5 - 9.0)                                                                                                               





CS Dental hygienists 8/81 
OR 1.17 (95% CI 0.99 - 1.38), AOR 1.23 






CC Manufacturing workers 65/65 
≥3:  Logistic model OR 3.2 (95% CI 1.6 - 












Con rate 2: OR 2.31 (95% CI 2.01 - 
2.64)                                                                           
Con rate 3: OR 3.77 (95% CI 3.29 - 
4.31)                                                                           








CC Hospital patients 68/138 
<60 years old: OR 8.7 (95% CI 1.9 - 







m et al., 
1997129 
CC General population 206/211 
AOR 0.69 (95% CI 0.47 - 1.02), p=0.06; 














CC General population 
15802/3160
4 
Univariate OR 2.42 (95% CI 1.71 - 3.43), 




























CC Hospital patients 68/138 
>60 years old: OR 0.12 (95% CI 0.02 - 
0.79), p<0.05 III 













Wide local excision: OR 2.03 (95% CI 
1.02  4.02), p=0.0077; Multivariate OR 






m et al., 
1997129 


















CC General population 475/799 
1: AOR 1.1 (95% CI 0.8 - 1.6)                                                                                                        






CS General population 79/6175 
Increased: AOR 0.9 (95% CI 0.4 - 2.2)                                                                                                











30/177 Tubal ligation: OR 0.6 (95% CI 0.2 - 2.0)                                                                                    Other: OR 1.1 (95% CI 0.4 - 2.8) III 
       
RC, retrospective cohort; OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; CC, case 
control; CS, cross sectional 
a CON in case-control studies represent the controls, while in the other study designs it represents the 





In conclusion, of the 28 non-occupational and non-psychosocial risk factors (excluding 
“other” risk factors) that were reviewed, only sex was found to have moderate certainty to 
have an effect on the modification of risk for CTS (Table 2.32). Specifically, the current 
research suggests that females are at increased risk of CTS. Interestingly, there was little 





obesity, diabetes and wrist ratio, commonly believed to increase risk of CTS, were 
associated. Future research in the form of good quality, prospective studies, should 
investigate these factors further. This systematic review also highlighted the limited number 
of good quality prospective studies investigating other non-occupational and non-
psychosocial risk factors for CTS within the literature. 
 
In addition this review also highlighted that the level of certainty for a familial predisposition 
or genetic component, which is the focus of this thesis, is currently low. Studies that only 
included self-diagnosed or suspected CTS, without a medical professional or nerve 
conduction studies, were excluded from this systematic review. Furthermore, very few 
studies investigated participants who have had carpal tunnel release surgery, which would 
be considered the most extreme phenotype, and would therefore be an ideal sub-population 
to investigate in future studies. 
 
There are limitations to this systematic review. Firstly, many of the variables were 
considered only by univariate analyses compared to other which were considered by both 
uni- and multivariate analyses. Future systematic reviews could potentially only focus on 
multivariate analyses, which are considered to be of higher quality than univariate analyses. 
Secondly, in various sections, different variables were grouped under one umbrella risk 
factor (such as hormonal influences and hobbies). Although this is not ideal, this was done 
for simplicity purposes to avoid having an excessive amount single risk factors investigated 
only by one study. Lastly, groupings in this systematic review was made on the risk factor’s 
effect on risk i.e. increased, decreased or no effect on risk. Although there are several 
methods of grouping risk factors, this method was chosen to increase the understanding of 
the effect of a particular risk factor on risk and to prevent confusion.  
 




In conclusion, future, prospective studies with large sample sizes should aim to investigate 
these and other risk factors in order to create a better understanding of the role these factors 
play in the aetiology of CTS. Furthermore, a meta-analysis to investigate the combination 
and/or interaction of different studies would provide more information on the effect of 
different risk factors in this multifactorial condition. The next chapter of this thesis will review 










Table 2.32 Summary of the level of certainty of carpal tunnel syndrome risk factors 
  Level of Certainty 
  
High Moderate Low 
(1) Biological   
 - Sex Ethnicity 
   Height 
   Weight 
   BMI 
   Age 
 
  Hand/wrist structure/dimension 
   Genetic/Familiar 
(2) Behavioural and Social  
 - - Education/Social 
   Alcohol use 
   Exercise 
   Hobbies 
   Smoking 
   Geographic location 
(3) Medication   








(4) Medical Conditions and Injuries 
 - - Diabetes 
 Thyroid disorders 




 Previous MSD/injury 
      Medical condition 
 
  










In the previous chapter the level of evidence and certainty, namely low, moderate and high, 
of 19 non-occupational and non-psychosocial risk factors in the aetiology of carpal tunnel 
syndrome (CTS) was systematically reviewed. The current research suggests that there is a 
moderate level of certainty that females are at increased risk of CTS. The current level of 
certainty of the remaining 18 factors, which include obesity, diabetes and wrist ratio, was 
however low. Occupational and psychosocial20,26 factors are also often mentioned and 
investigated as potential risk factor for CTS8. Specifically those exposed to repetitive work, 
vibration exposure to the upper limb and forceful work, as well as individuals with poor 
psychological well-being with little job control are believed to be at increased risk for 
developing CTS20,26. Since there is, to our knowledge, also no recent systematic review of 
these risk factors in the scientific literature, the objective of this chapter of the thesis is 
therefore to critically assess the published evidence on occupational and psychosocial risk 




The search strategy and method of data extraction, as well as the method for determining 
level of evidence and level of certainty was described in the previous chapter (section 2.2.1 








3.3 RESULTS AND DISCUSSION 
The article selection process has been previously described in section 2.3 and is outlined for 
this systematic review in figure 3.1. Eighteen occupational risk factors and 11 psychosocial 
risk factors were identified from the 58 full text articles included in this review. The risk 
factors were divided into the following categories (1) current and previous occupations, (2) 
specific occupational exposure, (3) biomechanical factors and (4) psychosocial factors. 
 
 
Figure 3.1 Outline of the literature search procedure. In round 1, a total of 2492 unique titles 
(duplicates excluded) were identified using the electronic database searched. After the three-step 
method, the number of articles were reduces to 1137 abstracts and then 551 full text articles. A total 
of 58 articles were included. When all the references of the articles that fit the inclusion criteria were 
analysed, using the same exclusion and exclusion criteria as previously described and three-step 
method (as in round one), an additional 4 articles on occupational and/or psychosocial risk factors 
were identified and included in the systematic review. A final selection of 58 articles was therefore 
included in this review. 
 





3.3.1 Current and Previous Occupations 
Most of the scientific literature has investigated an individual’s current occupation as a risk 
factor for CTS. A few studies have specifically examined computer work as a risk factors. 
Studies have also investigated whether current or previous exposure to the same occupation 
is a risk factor. 
 
3.3.1.1 Occupation 
Twenty-three studies considered an individual’s occupation as a potential risk factor for CTS 
(Table 3.1).  Of these, only one prospective cohort, level I study found an increased risk of 
CTS with specific occupations, including housekeeping/cleaning, material handlers, food and 
beverage services, data processing operators and lorry and bus drivers141. Five level II79,142–
145 and twelve level III studies27,80,81,86,87,102,109,115,121,146–148 also found that specific occupations 
lead to an increase in risk of CTS. It is interesting to note that blue-collar 
workers80,115,144,145,147 as well as slaughterhouse workers (including poultry 
processing)79,102,142 were at increased risk of CTS in various studies. These manual labour 
occupations are associated with repetitive hand/wrist movements which are believed to 
increase the risk of CTS.  
 
The same prospective studies (one level I and two level II) found unemployed people, 
pensioners, non-manual workers and those in crafts, sales, managing or service professions 
to be at a decreased risk of developing CTS141,144,145. Interestingly, these are all occupations 
that have, by definition, minimal repetitive hand/wrist movements.  
 
Two prospective, level I studies found no effect of various occupations including manual 
work, drivers, manufacturing, construction, fishermen etc. on CTS risk141,149. Similarly five 
level II studies79,95,143–145 and nine level III studies found no effect of various occupations, 





repetitive nature of the work, such as poultry processing and industrial/manufacturing 
occupations, on CTS24,27,80,84,88,100,109. 
 
As a consequence of the multiple and often different occupations investigated in these 
studies and the conflicting results regarding some occupations’ association with CTS, this 
risk factor was awarded a low level of certainty. However, there seems to be a trend towards 
an increased risk of CTS in blue-collar workers. Various different occupations were 
investigated together in this review and revealed contradictory information, a more in-depth 
systematic review on the individual occupations could potentially report different results and 
is thus warranted. Future studies should specifically investigate risk of CTS in individual 
occupational groups to determine whether these manual labour occupations, that often 
include high volumes of highly repetitive work, are associated with CTS.  
 
 
Table 3.1 Summary of all the studies that have investigated specific occupations as a risk factor for 














ol et al., 
1997141 
PC Hospital patients 
238/~1.1 
million 
Female                                                                                                              
Housekeepers/cleaners: SIR 7.2 (95% CI 2.8 - 13.4)                                                       
Material handlers: SIR 6.0 (95% CI 2.2 - 11.8)                                                                         
Food and beverage, processing: SIR 7.0 (95% CI 1.8 - 
15.3)                                                                                                    
Food and beverage, service: SIR 3.6 (95% CI 1.4 - 
6.7)                                                                             
Male                                                                                                                           
Housekeepers/cleaners: SIR 67.5 (95% CI 17.3 - 
148.0)                                                                            
Data processing operators: SIR 11.2 (95% CI 1.1 - 
31.8)                                                                    
Material handlers: SIR 5.5 (95% CI 1.4 - 12.3)                                                              






PC General population 
1168/38691
0 
Female                                                                                                                           
Lower-grade white collar workers: RR 2.0 (95% CI 1.8 
– 2.3)                                                                          
Blue collar workers: RR 2.9 (95% CI 2.5 - 3.4)                                                                  
Agriculture: RR 2.4 (95% CI 1.9 – 3.0)                                                                              
Manufacturing: RR 2.0 (95% CI 1.7 - 2.4)                                                                         
Service industries: RR 1.4 (95% CI 1.2 – 1.6)                                                                         
Male                                                                                                                                     
Blue collar workers: RR 3.8 (95% CI 3.0 – 4.7)                                                                              
Construction: RR 2.9 (95% CI 2.2 – 3.8)                                                              
Manufacturing: RR 1.9 (95% CI 1.5 - 2.4)                                                                                                            
II





















PC General population 
1168/38691
0 
Female                                                                                                                           
Lower-grade white-collar workers: RR 2.5 (95% CI 2.2 
– 3.0)                                                                                            
Blue collar workers: RR 3.0 (95% CI 2.5 - 3.6)                                                                                                                     
Agriculture: RR 2.5 (95% CI 2.0 - 3.2)                                                                              
Manufacturing: RR 2.1 (95% CI 1.7 - 2.5)                                                                         
Service industries: RR 1.7 (95% CI 1.5 - 2.1)                                                                          
Male                                                                                                                             
Blue collar workers: RR 4.2 (95% CI 3.3 - 3.5)            
Construction: RR 3.0 (95% CI 2.2 - 4.0)                                                              










All freezing workers: SIR 16.8 (95% CI 14.8 - 19.1)                                               
Production line workers: SIR 25.4 (95% CI 22.3 - 28.8)                                                       
Slaughter men: SIR 5.4 (95% CI 3.1 - 8.6)                                                                                        
Packers: SIR 22.8 (95% CI 19.0 - 27.2)                                                                                     





PC  General population 
 1987:113/3
55088                           
2001: 
672/364326 
Female                                                                                                                                
Unskilled or semi-skilled workers: AOR 1.5 (95% CI 












Either hand                                                                                                                   
Slaughterhouse workers (SHW): AOR 4.24 (95% CI 
1.77 - 10.13),                                                                                     
Non-deboning SHW: AOR 3.25 (95% CI 1.27 - 8.33)                                            
Deboning SHW: AOR 5.53 (95% CI 2.20 - 13.90)                                                      
Dominant hand                                                                                                                                                
Deboning SHW:  AOR 3.74 (95% CI 1.14 - 12.22)                                                                                                                                                                
Non-dominant hand                                                                                                                                                                   
Slaughterhouse workers: AOR 5.31 (95% CI 1.60 - 
17.61)                                                                                                                                 
Deboning SHW: AOR 8.43 (95% CI 2.44 - 29.07) 
II
Armstron






131/940 Working on assembly line                                                                                                   Logistic regression OR 2.86 (95% CI 1.64 - 5.01) III 
Ali et al., 
200627 CS 
Computer 
workers  85/563 
System administrator: OR 2.5 (95% CI 1.2 - 5.2), 












Model 1                                                                                                                                                 
Assembly: OR 4.54 (95% CI 2.27 - 9.09)                                                                     
Clothing: OR 4.12 (95% CI 1.95 - 8.71)                                                                                   
Food: OR 3.14 (95% CI 1.38 - 7.15)                                                                                





CS Military population 48957 
1 
Army soldiers                                                                                                                                
Junior enlisted: Adjusted IRR 1.53 (95% CI 1.47 - 
1.59)                                                                           
Senior enlisted: Ajusted IRR 3.18 (95% CI 3.06 -3.30)                                                                           





CS General population 
1564/~3584
36 
Bilateral CTS                                                                                                              
Technical/craft: OR 2.46 (95% CI 1.55 - 3.91), p<0.001                                                                     
Semi-routine manual/service: OR 1.8 (95% CI 1.28 - 
2.56), no p-value                                                                                                  
Unilateral CTS                                                                                                                





CS Spine surgeons 107/264 
Surgeon using Kerrison Rongeur instrument: 
Multivariate OR 2.72 (95% CI 1.54 - 4.81)                                                                                         





CS Hand clinic patients 218/1346 
Female vs population                                                                                
Managers/directors/senior officials: OR 3.5 (95% CI 
1.9 - 6.7)                                                                                         
Professional occupations: OR 3.6 (95% CI 2.4 - 5.4)                                                     
Skilled trade occupations: OR 3.6 (95% CI 2.4 - 5.1)                                                       



























158/348 MM5                                                                                                                              Industrial: OR 2.0 (95% CI 1.3 - 3.2) III 
Cartwrig








Possible                
34/479 
Definite 
Poultry: AOR 2.51 (95% CI 1.80 - 3.50), p<0.001                                                                               
Poultry job task                                                                                                                   
Cutting, eviscerating, Wash-up, trimming, deboning: 
AOR 1.57, p=0.066;                                                                                       
Receiving, hanging, killing, plucking: AOR 2.09, 
p=0.116;                                                                                        





CC General population 191/286 
Blue-collar/housewife                                                                          
OR 8.0 (95% CI 4.5 - 14.2), Multivariate OR 7.1 (95% 





CC General population 
15802/3160
4 
Blue-collar                                                                              
Univariate OR 1.36 (95% CI 1.30 - 1.42), Multivariate 











Female                                                                                                                               
Blue-collar workers                                                                                                           
25-29 years old: RR 5.2 (95% CI 3.7 - 7.3)                                                                      
30-34 years old: RR 4.9 (95%CI 3.8 - 9.3)                                                                                                                          
35-39 years old: RR 4.4 (95% CI 3.6 - 5.4)                                                                                                                       
40-44 years old: RR 3.5 (95% CI 3.0 - 4.2)                                                                                                                      
45-49 years old: RR 5.0 (4.3 - 5.9)                                                                                       
50-54 years old: RR 4.0 (95% CI 3.4 - 4.7)                                                                               
55-59 years old: RR 3.6 (95% CI 2.9 - 4.6)                                                                                                                    
Housewives                                                                                                                     
25-29 years old: RR 5.1 (95% CI 3.3 - 7.7)                                                                             
30-34 years old: RR 4.6 (95% CI 3.4 - 6.0)                                                                         
35-39 years old: RR 4.5 (95% CI 3.6 - 5.5)                                                                                
40-44 years old: RR 3.6 (95% CI 3.0 - 4.3)                                                                              
45-49 years old: RR 4.6 (95% CI 3.9 - 5.4)                                                                           
50-54 years old: RR 3.4 (95% CI 3.0 - 4.0)                                                                            
55-59 years old: RR 2.9 (95% CI 2.3 - 3.6)                                                                                                                                      
Male                                                                                                                                              
Blue-collar workers                                                                                                                         
25-29 years old : RR 5.9 (95% CI 2.5 - 13.5)                                                                    
30-34 years old: RR 3.5 (95% CI 2.2 - 5.8)                                                                                                         
35-39 years old: RR 7.1 (95% CI 4.4 - 11.6)                                                                                                             
40-44 years old: RR 6.0 (95% CI 4.0 - 9.2)                                                                                         
45-49 years old: RR 4.7 (95% CI 3.4 - 6.5)                                                                                            
50-54 years old: RR 3.6 (95% CI 2.6 - 5.0)                                                                                                            




ol et al., 
1997141 
PC Hospital patients 
238/~1.1 
million 
Female                                                                                                                                      
Not working (Unemployed): SIR 0.7 (95% CI 0.5 - 0.9)                                                                                    
Male                                                                                                                                               
Non-manual workers: SIR 0.5 (95% CI 0.2 - 0.9)                                                                  






PC General population 
1168/38691
0 
Female                                                                                                                           
Cafts, sales, managers: RR 0.5 (95% CI 0.3 – 0.9)                                                     
Technicians/ass. professionals: RR 0.6 (95% CI 0.5 - 
0.8)                                                                                                  
Pensioners/non-working people: RR0.2 (95% CI 0.2 – 
0.3)                                                                            
Male                                                                                                                                                 
Technicians/ass. Professionals: RR 0.6 (95% CI 0.4 - 
0.8)                                                                     
Pensioners/non-working people: RR 0.2 (95% CI 0.1 – 
0.4)                                                                                                
Service industries: RR 0.5 (95% CI 0.4 - 0.7)                                              
II 





















PC General population 
1168/38691
0 
Female                                                                                                                           
Technicians/ass. professionals: RR 0.6 (95% CI 0.5 - 
0.8)                                                                              
Male                                                                                                                                                 
Technicians/ass. Professionals: RR 0.6 (95% CI 0.4 - 
0.8)                                                                      
Service industries: RR 0.6 (95% CI 0.6 - 0.8) 
II 









Fishermen: SIR 0.92 (95% CI 0.62 - 1.39)                                                                                 
Officer: SIR1.34 (95% CI 0.65 - 2.79)                                                                                       
Non-officer: SIR 1.03 (95% CI 0.63 - 1.67) 
I
Rossign
ol et al., 
1997141 
PC Hospital patients 
238/~1.1 
million 
Female                                                                                                                                    
Data processing operators: SIR 3.1 (95% CI 1.0 - 6.3)                                                                             
Manual workers: SIR 1.8 (95% CI 1.4 - 2.2)                                                                      
Non-manual workers: SIR 0.8 (95% CI 0.6 - 1.1)                                                             
Child care: SIR 3.9 (95% CI 1.0 - 8.6)                                                                                
Hairdressers: SIR 3.0 (95% CI 0.8 - 6.7)                                                                     
Specialised educators: SIR 2.2 (95% CI 0.6 - 4.8)                                            
Manufacturing: SIR 1.2 (95% CI 0.6 - 2.1)                                                                       
Clerical occupations: SIR 1.0 (95% CI 0.7 - 1.4)                                                                 
Health care occupations: SIR 0.9 (95% CI 0.4 - 1.4)                                                           
Male                                                                                                                                          
Food and beverage, processing: SIR 2.7 (95% CI 0.3 - 
7.8)                                                                       Food 
and beverage, service: SIR 3.0 (95% CI 0.0 - 11.9)                                                                                
Manual workers: SIR 1.9 (95% CI 1.4 - 2.5)                                                                     
Lorry & Bus drivers: SIR 3.1 (95% CI 1.1 - 6.1)                                                                                                                                                                            
Hairdressers: SIR 4.2 (95% CI 0.0 - 16.5)                                                         
Manufacturing: SIR 1.6 (95% CI 0.6 - 3.2)                                                                         
Clerical occupations: SIR 1.3 (95% CI 0.4 - 2.7)                                                         
Health care occupations: SIR 0.7 (95% CI  0.0 - 2.8)                                                 






PC General population 
1168/38691
0 
Female                                                                                                                                                         
Farmers: RR 1.0 (95% CI 0.6 – 1.5)                                                                
Professionals: RR 0.7 (95% CI 0.5 – 1.0)                                                                         
Construction: RR 2.3 (95% CI 1.0 – 5.2)                                                                           
Male                                                                                                                                            
Farmers: RR 1.2 (95% CI 0.7 - 2.1)                                                                 
Craftsmen/sales/managers: RR 0.6 (95% CI 0.3 - 1.0)                                                               
Professionals: RR 0.7 (95% CI 0.4 - 1.2)                                                                                     
Lower grade white collar workers: RR 1.3 (95% CI 0.8 
- 2.0)                                                               






PC General population 
1168/38691
0 
Female                                                                                                                                                         
Farmers: RR 1.2 (95% CI 0.8 - 2.0)                                                                
Crafts/sales/managers: RR 0.5 (95% CI 0.3 - 1.2)                                                       
Professionals: RR 0.9 (95% CI 0.6 - 1.4)                                                                         
Construction: RR 4.7 (95% CI 1.0 - 13.0)                                                                           
Male                                                                                                                                            
Farmers: RR 1.3 (95% CI 0.8 - 2.3)                                                                 
Craftsmen/sales/managers: RR 0.8 (95% CI 0.4 - 1.6)                                                               
Professionals: RR 0.6 (95% CI 0.4 - 1.0)                                                                                     
Lower grade white collar workers: RR 1.3 (95% CI 0.8 
- 2.1)                                                               
Agriculture: RR 1.4 (95% CI 0.9 - 2.0)                                        
II 
Cartwrig











PC  General population 
 1987:113/3
55088             
2001: 
672/364326 
Male                                                                                                                                       
Unskilled or semi-skilled workers: AOR 1.1 (95% CI 































Dominant hand                                                                                                                    
Slaughterhouse workers (SHW): AOR 3.26 (95% CI 
1.09 - 9.71),                                                                                 
Non-deboning SHW:  AOR 2.90 (95% CI 0.90 - 9.39)                                                                                                          
Non-deboning SHW: AOR 3.01 (95% CI 0.82 - 11.30)                                                        
II 
Ali et al., 
200627 CS 
Computer 
workers  85/563 
Software developer: OR 1.0 (95% CI 0.6 - 1.9), p=0.90                                                                       
Others: OR 0.9 (95% CI 0.5 - 1.6), p=0.80 III 
Bonfigliol







Part-time cashiers: Multivariate OR 1.06 (95% CI 0.35 
- 3.21), p=0.916                                                                    






CC General population 
15802/3160
4 
Other: Univarate OR 1.10 (95% CI 1.04 - 1.16), 




















Model 2                                                                                                                                  
Clothing: OR  1.64 (95% CI 0.93 - 2.91);                                                                                                  
Food: OR 0.62 (95% CI 0.28 - 1.36)                                                                                                
Packaging: OR 1.43 (95% CI 0.78 - 2.61)                                                                                                                                            
Model 3                                                                                                                                                                    
Clothing: OR 1.25 (95% CI 0.74 - 2.12)                                                                                                                             
Food: OR 0.64 (95% CI 0.29 - 1.40)                                                                                                         















CS Construction workers  91/1024 
Sheet metal workers: AOR 2.04 (95% CI 0.82 - 5.03)                                                               
Operating engineers: AOR 1.00 (95% CI 0.46 - 2.18)                                                  





CS Hand clinic patients 218/1346 
Female vs population                                                                                                          
Technical occupations: OR 1.8 (95% CI 1.0 - 3.4)                                                                                                                             
Admin: OR 1.4 (95% CI 0.8 - 3.9)                                                                                       
Service: OR 1.4 (95% CI 0.8 - 2.4)                                                                 
Sales/customer service: OR 1.7 (95% CI 0.9 - 3.5)                                                 











158/348 MM8                                                                                                                                         Industrial: OR 1.7 (95% CI 0.9 - 3.4) III 
      
PC, prospective cohort; SIR, standardized incidence ratio; CI, confidence interval; RR, risk ratio; OR, 
odds ratio; AOR, adjusted odds ratio; RC, retrospective cohort; CS, cross sectional; CI, confidence 
interval 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
1 The total number of participants was not reported 
 
 





3.3.1.2 Computer work 
Eight studies have specifically examined computer work as a risk factor for CTS (Table 3.2). 
Two level III studies found an increase in risk with an increase in number of years, hours per 
day and cumulative keyboard strokes27,106. Surprisingly, one level III study found a decreased 
risk of CTS with computer work of more than one hour per day, compared to those working 
on a computer less than one hour per day85. Six studies found several different forms of 
computer use to have no effect on the risk of CTS. Of these, only one was a prospective 
study, which specifically investigated keyboard use and found no effect in uni- and 
multivariate analyses76.  
 
As a result of the small number of studies investigating computer use as risk for CTS, this 
factor was awarded a low level of certainty.  
 
Table 3.2 Summary of all the studies that have investigated computer use as a risk factor for carpal 













Ali et al., 
200627 CS 
Computer 
workers  85/563 
Years of computer work                                                                                                       
4-8 years: OR 2.3 (95% CI 1.4 - 3.8), p=0.001; AOR 
2.1 (95% CI 1.3 - 3.6), p=0.004                                                                                                        
>8 years: OR 3.3 (95% CI 1.7 - 6.6), p<0.001; AOR 
2.7 (95% CI 1.3 - 5.8), p=0.01                                                              
Time per day                                                                                                                            
8-12 hours per day: OR 3.4 (95% CI 1.2 - 9.5), 
p=0.020; AOR 3.6 (95% CI 1.3 - 10.3), p=0.02                                                                                                                                   
> 12 hours per day: 4.9 (95% CI 1.5 - 16.2), p=0.009; 
AOR 4.4 (95% CI 1.3 - 14.9), p=0.02 
III 
Eleftheri
ou et al., 
2012106 
CS Computer workers  
A: 51/4101                         
B: 167/2942 
Cumulative keyboard strokes                                                                                              
Case def A - ≥240500000: RR 2.38 (95% CI 1.38 - 
4.12); Logistic regression: OR 2.23 (95% CI 1.09 - 
4.52), p=0.026                                                                                                 
Case def B - ≥149500000: RR 2.60 (95% CI 1.80 - 







CS General population 97/1906 
Time per day                                                                                                                               
≥1 hour compared to <1 hour: Regression model - 
Adjusted PR 0.55 (95% CI 0.32 - 0.96), p=0.035 
III 




PC Industrial workers 34/222 
Keyboard use                                                                                                                   
Univariate OR 0.95 (95% CI 0.74 - 1.23), p=0.71; 





















CC General population 475/799 
Time per day                                                                                                                              




CS Office workers 88/382 
Time per day                                                                                                                          




CS General population 97/1906 
Time per day                                                                                                                               
<1 hour: Adjusted PR 0.93 (95% CI 0.52 - 1.70)                                                                           
1-4 hour: Adjusted PR 0.55 (95% CI 0.26 - 1.20)                                                                                              





CC General population 156/473 
Time per week                                                                                                                          
1-7 hours: RR 0.9 (95% CI 0.6 - 1.4)                                                                                    
8-19 hours: RR 0.8 (95% CI 0.3 - 2.5)                                                                                           






CS Engineers 25/177 
Time per week                                                                                                                                
22-28 hours: Univariate OR 0.92 (95% CI 0.14 - 5.86), 
p=0.929; Multivariate OR 1.285 (95% CI 0.18 - 9.23), 
p=0.80                                                                                                  
29-35 hours: Univariate OR 2.67 (95% CI 0.68 - 10.5), 
p=0.162; Multivariate OR 5.78 (95% CI 1.24 - 26.9), 
p=0.015                                                                                                    
>35 hours: Univariate OR 3.58 (95% CI 0.93 - 13.8), 
p=0.064; Multivariate OR 6.53 (95% CI 1.44 - 29.7), 
p=0.004                                                                                                                                                                     
Years of computer work                                                                                                       
Previous yr at >20 hrs/week on computer: Univariate 
OR 0.95 (95% CI 0.87 - 1.04), p=0.266                                                                                                                                       
Total yr at > 20 hrs/wk on computer: Univariate OR 
1.00 (95% CI 0.99 - 1.00), p=0.789                                                                                               
Computer use at work                                                                                                              
OR 1.73 (95% CI 0.94 - 3.18), p=0.76                                                                                                     
Additional hour on a computer per week                                                                                                         
OR 1.01 (95% CI 0.95 - 1.08), p=0.739                                                                                                               
Typing speed                                                                                                                                                  
Univariate OR 0.98 (95% CI 0.95 - 1.00), p=0.104; 
Multivariate OR 0.96 (95% CI 0.93 - 0.98), p=0.004                              
III 
      
CS, cross sectional; PC, prospective cohort; AOR, adjusted odds ratio; OR, odds ratio; CI, confidence 
interval; PR, prevalence ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
1 Case definition A: Participants with personal medical history of CTS or surgery due to CTS 
2 Case definition B: Case definition A and participants identified through clinical examination (score 
≥12)  
 
3.3.1.3 Current or previous exposure 
Sixteen studies investigated whether current or previous exposure to the same occupation, 
which includes overuse of the hand/wrist, modifies the risk of developing CTS (Table 3.3). 
Two prospective studies found that active workers who have worked less than one year as 





well as those with previous exposure to biomechanical overload are at higher risk of 
developing CTS74,78. A retrospective study also found that the peak risk of CTS is during 6-
10 years of exposure to the same occupation79. Furthermore, four cross-sectional studies 
(level III) also found increased exposure to lead to an increase in risk of CTS82,90,121,124.  
 
In contrast, one level III study found a decreased risk of CTS in members of the general 
population with a cumulative working hour count of 5464 to 15510 hours129. Furthermore, 
three prospective studies also found that exposure of more than 3.5 and 6 years, 
respectively, as well as any previous exposure, has no effect on risk of CTS in Danish 
seamen and industrial workers, respectively74,76,149. Eight level III studies also found no effect 
of previous and current exposure, cumulative working hours  between 3048-4857 and 4480-
5383 and job seniority, on the risk of developing CTS82,88,90,99,100,104,124,129,133.  
 
Considering the conflicting results when examining previous exposure as risk factor for CTS, 
it was assigned a low level of evidence and future research should aim to investigate this 
aspect further.  
 
 
Table 3.3 Summary of all the studies that have investigated current or previous exposure as risk 















n et al., 
201374 
PC Industrial workers 204/3311 
Years worked for recent hires (<1 year): Multivariate 




PC Working population 153/1939 
Previous exposure vs none: OR 1.6 (95% CI 1.1 - 2.4), 











Years of exposure                                                                                                                       
1-5 years: AOR 3.57 (95% CI 1.13 - 11.34)                                                                      
6-10 years: AOR 5.354 (95% CI 2.01 - 14.20)                                                                     
11-15 years: AOR 3.29 (95% CI 1.10 - 9.83)                                                                    
16-20 years: AOR 4.18 (95% CI 1.11 - 15.80)                                                                





CS Female floor cleaners 70/75 
Similar job at previous employer: Univariate OR 4.85 
(95% CI 2.38 - 9.88); Multivariate OR 12.15 (95% CI 































Job seniority                                                                                                                                    











127/931 >9 years: OR 3.13 (95% CI 1.94 - 5.08), AOR 1.74 (95% CI 0.96 - 3.16) III 
Decreased risk 
Nordstro
m et al., 
1997129 
CC General population 206/211 
Cumulative work hours                                                             
5464-6507: AOR 0.41 (95% CI 0.20 - 0.85); 
Multivariate OR 0.43 (95% CI 0.18 - 1.05)                                                                                                                                   
6647-15510: AOR 0.34 (95% CI 0.16 - 0.71); 
Multivariate OR 0.29 (95% CI 0.10 - 0.78)                                                                                       
III 
No effect risk 
 Harris-
Adamso
n et al., 
201374 
PC Industrial workers 204/3311 
Length of employment (at current company)                                                                                                                     
>3.5 and ≤7 years: Multivariate HR 0.63 (95% CI 0.39 
- 1.03), p=0.06                                                                                      
>7 and ≤15 years: Multivariate HR 1.04 (95% CI 0.62 - 
1.73), p=0.89                                                                                      











6-12 years: RR 0.78 (95% CI 0.46 - 1.32)                                                                               






PC Industrial workers 34/222 
Univariate OR 1.11 (95% CI 0.84 - 1.47), p=0.44; 
Multivariate OR 0.96 (95% CI 0.66 - 1.40), p=0.84 II 
Bonfigliol



















CS Female floor cleaners 70/75 
Length of employment                                                                                                                   
2nd quartile: Univariate OR 1.58 995% CI 0.62 - 4.03), 
Multivariate OR 0.83 (95% CI 0.26 - 2.69)                                                                                                                                  
3rd quartile: Univariate OR 1.33 (95% CI 0.51 - 3.46), 
Multivariate OR 0.77 (95% CI 0.24 - 2.43)                                                                                                                                                                
4th quartile: Univariate OR 2.25 995% CI 0.86 - 5.85), 














Length of employment: Logistic regression OR 1.02 
(95% CI 1.00 - 1.04), p=0.084                                                  
BMI*length of employment: Logistic regression OR 











Job seniority                                                                                                                                
>5 vs <3 years: Multivariate OR 2.7 (95% CI 0.6 - 










127/931 5-9 years: OR 1.1 (95% CI 0.64 - 1.87), AOR 0.91 (95% CI 0.53 - 1.58)                     III 





















CS Industrial workers 47/348 Multivariate OR 0.93 (95% CI 0.79 - 1.01), p=0.45 III 
Nordstro
m et al., 
1997129 
CC General population 206/211 
Cumulative work hours                                                         
3048-4857: AOR 1.51 (95% CI 0.84 - 2.70); 
Multivariate OR 1.54 (95% CI 0.74 - 3.20)                                                                                               
4480-5383: AOR 0.46 (95% CI 0.23 - 0.93); 





CS Dental hygienists 8/81 
Years as dental hygienist: OR 1.14 (95% CI 1.04 - 
1.26), AOR 1.08 (95% CI 0.91 - 1.28)                                                                                                        
Days per week as dental hygienist OR 1.30 (95% CI 
0.58 - 2.94)                                                                                              
Hours per week as dental hygienist: OR 1.04 (95% CI 
0.94 - 1.15)                                                                                           
Patients per day as dental hygienist: OR 1.35 (95% CI 
1.01 - 1.80), AOR 1.73 (95% CI 1.00 - 2.99)                                                                                                                            
Patients per week as dental hygienist OR 1.06 (95% 
CI 1.01 - 1.11), AOR 1.09 (95% CI 0.99 - 1.20)                                                                                                                             
Mins per patient as dental hygienist: OR 0.98 (95% CI 
0.91 - 1.05) 
III 
      
PC, prospective cohort; HR, hazard ratio; OR, odds ratio; CI, confidence interval; RR, risk ratio; CS, 
cross sectional; AOR, adjusted odds ratio; CC, case control;  
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 
3.3.2 Specific occupational procedures 
A total of 27 studies, which will be reviewed in this section, have investigated various 
occupational procedures for its potential effect on the modification of risk of CTS.  
 
3.3.2.1 Force exertion 
Fifteen studies investigated the effect of force exertion on the risk of CTS (Table 3.4). One 
prospective study found that increased time spent performing forceful exertion had an 
increased association with CTS. More specifically, spending between 20 and 60% of the day 
in forceful exertion lead to a 2.8-fold increase in risk whereas spending more than 60% in 
forceful exertion lead to a 19.5-fold increase in risk of CTS118. Another ten studies 
investigated various forms of force exertion and found it to be associated with increased risk 






Five studies, of which only two were prospective76,96, found that force exertion, including 
lifting force, frequency of force exertion and sometimes using sustained forceful motion, has 
no effect on risk of CTS97,109,128. 
 
Considering the large number of studies available showing an increase in risk compared to 
this higher quality studies reporting no effect on risk, force exertion as risk factor for CTS 
was assigned a low level of evidence.  
 
Table 3.4 Summary of all the studies that have investigated force exertion as risk factor for carpal 





















high level of 
hand activity 
29/318 
Model 1                                                                                                                                       
≥20% - <60%: Multivariate HR 2.83 (95% CI 1.18 - 
6.79                                                                            




















30/177 OR 1.8 (95% CI 1.1 - 2.9)                                                                                          Female: OR 1.6 (95% CI 1.1 - 3.0) III 
Thomse











CC Manufacturing workers 65/65 






CS Industrial workers 47/348 
>1 kgf: Univariate OR 13.31 (95% CI 4.67 - 37.90), 










131/940 Logistic regression OR 1.68 (95% CI 1.12 - 2.53) III 
Silverstei








Lifting force (male), ≥10%: OR 6.0 (95% CI 1.3 - 28.0)                                                                           
Frequency of force exertion                                                                                                        
≥1 - <5 (Female): OR 2.84 (95% CI 1.25 - 6.47)                                                            
Duty cycle of forceful exertions, ≥15 (men): OR 5.37 
(95% CI 1.16 - 24.86)                                                                            
Radial/ulnar deviation ≥4% AND lifting force ≥3%: OR 
3.20 (95% CI 1.47 - 6.96), AOR 4.85 (95% CI 2.12 - 
11.11)                                                           
III 
  





















CC Orthopaedic patients 166/111 
Forceful sustained motion                                                                                                 
- Seldom: OR 2.62 (95% CI 1.24 - 6.08), AOR 2.29 
(95% CI 0.90 - 5.85)                                                                                                                      
Frequent: OR 2.93 (95% CI 1.42 - 6.02), AOR 2.59 






CC Hospital patients 38/76 
High load on wrist                                                                                                               













151/1059 Just in time (Model 3): OR 2.24 (95% CI 1.40 - 3.57) III 




PC Industrial workers 34/222 
Univariate OR 1.00 (95% CI 0.75 - 1.34), p=0.97; 
















151/1059 Press with hand: Model 2: OR 1.41 (95% CI 0.92 - 2.15); Model 3: OR 1.37 (95% CI 1.04 - 2.43) III 
Silverstei








Lifting force                                                                                                                                       
Female <10%: OR 2.29 (95% CI 1.07 - 4.88), >10%: 
OR 1.42 (95% CI 0.51 - 3.97)                                                                             
Male <10%: OR 3.07 (95% CI 0.63 - 14.90)                                          
Frequency of force exertion                                                                                                           
Female                                                                                                                                         
≥5: OR 2.16 (95% CI 0.83 - 5.67)                                                                                             
Duty cycle, ≥3-14: OR 2.01 (95% CI 0.84 - 4.81)                                                                                                                    
≥15: OR 2.22 (95% CI 0.93 - 5.32)                                                                                           
Male                                                                                                                                         
≥1 - <5: OR 1.68 (95% CI 0.52 - 5.44)                                                                                      
≥5: OR 2.99 (95% CI 0.97 - 9.23)                                                                                      
Duty cycle, ≥3-14: OR 4.25 (95% CI 0.86 - 20.99)                                               
Radial/ulnar deviation ≥4% OR lifting force ≥3%: OR 
1.98 (95% CI 0.98 - 4.13), AOR 2.35 (95% CI 1.09 - 





CC Orthopaedic patients 166/111 
Forceful sustained motion - sometimes: OR 1.72 (95% 
CI 0.79 - 3.76), AOR 1.93 (95% CI 0.80 - 4.65) III 
      
PC, prospective cohort; HR, hazard ratio; OR, odds ratio; CI, confidence interval; RR, risk ratio; CS, 
cross sectional; AOR, adjusted odds ratio; CC, case control; kgf, kilogram force.  
a CON in case-control studies represent the controls, while in the other study designs it represents the 








Five studies investigating manual workers considered breaks during a working day as 
potentially modifying the risk of CTS (Table 3.5). Two level III studies found break time of 
more than 75 minutes and less than 15% of daily work time to be associated with increased 
risk of CTS99,140 whereas one level II and two level III found breaks to have no effect on the 
risk of CTS84,96,103.  
 
Break time during a working day, as risk factor for CTS, was therefore assigned a low level 
of certainty.  
 


















CS Industrial workers 47/348 
>75 min: Univariate OR 3.50 (95% CI 1.52 - 8.06), 







CC Manufacturing workers 65/65 
<15% of daily work time: Logistic model OR 6.0 (95% 
CI 1.8 - 20.2), p=0.004 III 










CS Engineers 25/177 
Break time per day: Univariate OR 0.84 (95% CI 0.54 - 
1.31), p=0.454; Multivariate OR 0.57 (95% CI 0.32 - 
1.02), p=0.044                                                                                          
Total number of breaks per day: Univariate OR 1.19 






CS Construction workers  91/1024 
Insufficient break time: OR 1.30, AOR 1.36 (95% CI 
0.68 - 2.73) III 
 
CS, cross sectional; CC, case control; PC, prospective cohort; OR, odds ratio; CI, confidence interval; 
AOR, adjusted odds ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 





3.3.2.3 Vibration and the use of power tools and/or machinery 
Vibration and the use of power tools and/or machinery as risk factor for CTS were reviewed 
by twelve studies (Table 3.6). These studies included those considering exposure to 
vibration as well as those considering the use of power tools and/or machinery. Ten level III 
studies found that vibration exposure increases the risk of CTS71,72,81,98,99,119,127,129,146,151. 
Nordstrom et al. (1997) found that using power tools for more than 6 hours per day 
increases the risk of CTS, even after multivariate analyses, whereas using the same tools for 
less than 6 hours has no effect on risk129. Rigouin et al. (2013) found that only females were 
susceptible for CTS as a result of vibration98, whereas Jenkins et al. (2012) found that it only 
had an effect in a participants who were socially deprived146. Another study considered 
vibration together with bending and twisting of the hand, but found that even without the 
extra hand movements, participants were still at higher risk to develop CTS72. The number of 
years of exposure to vibration also made no difference, with both exposure groups (1-20 
years and >20 years) being at higher risk127.  
 
In contrast, the study by Rigouin et al. (2013) found that, contrary to females, vibration 
exposure in males made no difference to risk of CTS98. Similarly, the other studies, including 
two level II and two level III study, also found vibration or the use of power tools to have no 
effect on risk of CTS76,96,129,151.  
 
As a result of the low quality of the studies finding an increased risk and the limited number 
of studies contradicting that finding, vibration and the use of power tools and/or machinery 






Table 3.6 Summary of all the studies that have investigated vibration or using power tools/machinery 














m et al., 
1997129 
CC General population 206/211 
Power tools                                                                                  
6-11 hr/day: AOR 2.52 (95% CI 1.13-5.62); 






CS Industrial workers 47/348 
Power tools                                                                            
Univariate OR 6.74 (95% CI 3.41 - 13.31), p=0.00; 





CC General population 475/799 
Vibration: AOR 2.6 (95% CI 1.8 - 3.9); Multivariate OR 




CS Working population 156/3554 
Vibration                                                                                   






CS General population 145/29929 Vibration: AOR 1.86 (95% CI 1.23 - 2.80) III 
Armstron




















CS Working population 675/176525 
Vibration (Bend & twist included): Multivariate OR 1.81 
(95% CI 1.27 - 2.57)                                                                                






CC Hospital patients 38/76 
Vibration                                                                                      
Group 1                                                                                                                                  
1-20 years: OR 2.7 (95% CI 1.1 - 6.7), p=0.04                                                                                  
>20 years: OR 4.8 (95% CI 1.5 - 15.6), p=0.01                                                              
Group 2                                                                                                                                         
1-20 years: OR 4.3 (95% CI 1.4 - 12.9), p=0.01                                                                         





CS General population 
1564/~3584
36 
Vibration in socially deprived group: OR 2.33 (95% CI 
1.84 - 2.95), p<0.001 III 




PC Industrial workers 34/222 
Vibration: Univariate OR 2.28 (95% CI 0.84 - 6.29), 











CS Working population 156/3554 
Vibration                                                                                         













Vibration                                                                                        
Former job: AOR 1.7 (95% CI 0.6 - 4.6)                                                                                      
Former and latest job: AOR 1.0 (95% CI 0.1 - 7.9) 
III
      
 


















m et al., 
1997129 
CC General population 206/211 
Power tool use - Hr/day                                                                                     
0.08-0.75 hour: AOR 0.60 (95% CI 0.27 - 0.36); 
Multivariate OR 0.53 (95% CI 0.17 - 1.64)                                                                                                                                          
1-2 hours: AOR 1.43 (95% CI 0.66 - 3.13); Multivariate 
OR 1.43 (95% CI 0.52 - 3.90)                                                                                                                    
2.5-5.5 hours: AOR 1.20 (95% CI 0.59 -2.45); 
Multivariate OR 1.58 (95% CI 0.63 - 4.00) 
III 
      
CC, case control; CS, cross sectional; OR, odds ratio; CI, confidence interval; AOR, adjusted odds 
ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 
3.3.2.4 Physical limit/demand 
Physical limit or demand, which includes number of working hours per week, was considered 
as risk factor for CTS by four studies (Table 3.7). Only one level III study that looked at 
female grocery checkers found working for more than 34 hours per week increased the risk 
of CTS 2.84-fold82. In contrast, one level II and three level III studies found working hours 
and high physical limit/demand to have no effect on the risk of developing CTS82,84,96,103.  
 
High physical limit/demand, including working hours per week, was assigned a low level of 







Table 3.7 Summary of all the studies that have investigated high physical workload/limit (including 






















Hours per week at work                                                                                                        
>34 hr/wk: OR 2.84 (95% CI 1.77 - 5.54), AOR 1.86 
(95% CI 1.12 - 3.08) 
III 










CS Construction workers  91/1024 















127/931 Hours per week at work: 26-34 hours: OR 1.62 (95% CI 1.02 - 2.57), AOR 1.53 (95% CI 0.95 - 2.44)                                               III 
      
CS, cross sectional; OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; PC, 
prospective cohort 
a CON in case-control studies represent the controls, while in the other study designs it represents the 




3.3.2.5 Working conditions/Environment 
Working conditions and work environment was investigated as potential risk factor for CTS 
by three studies (Table 3.8). None of the studies found any effect of these factors on risk of 
CTS, including various movements and hot/cold/humid conditions84,96,120. 
 
Working conditions and work environment was assigned a low level of certainty, due to the 
limited number of studies as well as the different variables that was investigating working 
conditions/environment as risk factors.  
 






3.3.2.6 Specific occupational actions 
Three studies looked at specific occupational actions associated with specific occupations, 
as a potential risk factor of CTS (Table 3.9). All three level III studies found these actions to 
have no effect on CTS risk. This includes specific dental procedures performed by dental 
hygienists104, working with solvents129 and using laser scanners and packing/lifting/unloading 
grocery bags in grocery checkers82. 
 
The limited number of studies considering specific occupational actions, as well as the wide 
variety of actions, lead to this risk factor to be assigned a low level of certainty.  
 
 
Table 3.8 Summary of all the studies that have investigated working conditions and environment as 












No effect on risk 
Roquelaure 
et al., 200196 PC 
Blue-collar 
workers 34/100 
High movement precision: OR 1.4 (95% CI 0.5 - 
4.1)                                                                       
High visual load: OR 1.1 (95% CI 0.4 - 3.6)                                                                          
Lack of freedom to change movements: OR 2.4 
(95% CI 0.6 - 11.2) 
II 
Rosecrance 
et al., 200284 CS 
Construction 
workers  91/1024 
Hot/cold/humid environment: OR 1.62, AOR 1.37 
(95% CI 0.83 - 2.26)                                                                                  
Work fast, short period: OR 1.59, AOR 1.38 (95% 
CI 0.80 - 2.39)                                                                          
Akward/cramped work: OR 1.01, AOR 0.99 (95% 
CI 0.61 - 1.59)                                                                                              
Work in same position: OR 1.13, AOR 1.11 (95% 
CI 0.70 - 1.75)                                                                                       
Working whilst hurt/injured: OR 1.25, AOR 1.11 
(95% CI 0.69 - 1.79)                                                                              
Work scheduling: OR 1.38, AOR 1.12 (95% CI 
0.59 - 2.13)                                                          
Tool characteristics: OR 1.50, AOR 1.39 (95% CI 
0.81 - 2.41)                                                                                              
Job training: OR 1.24, AOR 0.94 (95% CI 0.34 - 
2.50)                                                                        
III 




Cold environment: Multivariate OR 3.52 (95% CI 
1.08 - 11.47), p=0.037 III 
      
PC, prospective control; OR, odds ratio; CI, confidence interval; CS, cross sectional; AOR, adjusted 
odds ratio; CC, case control 
a CON in case-control studies represent the controls, while in the other study designs it represents the 





Table 3.9 Summary of all the studies that have investigated specific occupational actions as risk 












No effect on risk 
Anton et 
al., 2002104 CS 
Dental 
hygienists 8/81 
Hard calculus patients per week (hr): OR 0.99 (95% 
CI 0.88 - 1.12)                                                                                         
Hours probing per week (hr): OR 0.93 (95% CI 0.60 - 
1.44)                                                                                 
Hours scaling per week (hr): OR 1.05 (95% CI 0.94 - 
1.17)                                                                                     
Hours polishing per week (hr): OR 1.04 (95% CI 0.82 
- 1.32)                                                                                 
Hours flossing per week (hr): OR 1.63 (95% CI 0.85 
- 3.14)                                                                               






CC General population 206/211 
Contact with solvents (hr/day)                                                                                                   
0.08-0.75 hours: OR 0.63 (95% CI 0.37 - 1.10); 
Multivariate OR 0.44 (95% CI 0.21 - 0.90)                                                                                                                                           
1-11 hours: 1.43 (95% CI 0.79 - 2.59); Multivariate 
OR 0.80 (95% CI 0.36 - 1.79) 
III
Morgenste







Using laser scanner: Multivariate OR 0.99 (95% CI 
0.65 - 1.49), p=0.95                                                                       
Unloading baskets: Multivariate OR 0.97 (95% CI 
0.66 - 1.44), p=0.89                                                                             
Load and lift grocery bags: Multivariate OR 0.94 
(95% CI 0.35 - 2.57), p=0.91 
III 
 
CS, cross sectional; OR, odds ratio; CI, confidence interval; CC, case control 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 
3.3.2.7 Job Rotation 
Job rotation, defined as moving between a number of different job tasks through a certain 
period of time, as risk factor for CTS, was investigated by five studies (Table 3.10). Two of 
these studies, both level III, found that job rotation in male participants in the working 
population, as well as no job rotation, increase the risk of developing CTS98,140. In contrast, 
one level II and two level III studies found job and task rotation or lack thereof, has no effect 
on the risk of CTS96,97,99.  
 
Consequently, job rotation was assigned a low level of certainty as potential modifier of CTS 
risk.  





Table 3.10 Summary of all the studies that have investigated job rotation as risk factor for carpal 














al., 201398 CS 
Working 
population 156/3554 Male: Multivariate OR 2.45 (95% CI 1.41 - 4.24) III 
Roquelaur
e et al., 
1997140 
CC Manufacturing workers 65/65 
None: Logistic model OR 6.3 (95% CI 2.1 - 19.3), 
p=0.002 III 
No effect risk 
Roquelaur
e et al., 
200196 
PC Blue-collar workers 34/100 No rotation: OR 0.5 (95% CI 0.1 - 1.8) II 
Maghsoudi
pour et al., 
200899 
CS Industrial workers 47/348 
Univariate OR 0.90 (95% CI 0.49 - 1.67), p=0.75; 










                                                                                                                                
Work rotation: Female - AOR 1.24 (95% CI 0.60 - 
2.55), Male - AOR 1.18 (95% CI 0.46 - 3.03)                                                                                                                                      
Task rotation: Female - AOR 1.30 (95% CI 0.61 - 
2.77), Male - AOR 1.96 (95% CI 0.72 - 5.33) 
III 
      
CS, cross sectional; OR, odds ratio; CI, confidence interval; CC, case control; PC, prospective cohort; 
AOR, adjusted odds ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 




3.3.2.8 Number of occupational risk factors 
Two studies considered whether being exposed to multiple occupational risk factors 
influences the risk of CTS (Table 3.11). Both studies found that the risk of CTS increases 
with the addition of additional occupational risk factors127,140 whereas being exposed to only 
one127 or two or less140, has no effect on risk.  
 
Considering the limited number of studies looking specifically at the number of occupational 







Table 3.11 Summary of all the studies that have investigated number of occupational risk factor as 














e et al., 
1997140 
CC Manufacturing workers 65/65 
3: OR 5.6 (95% CI 1.6 - 24.5)                                                                                                            
4: OR 93.7 (95% CI 13.4 - 93.8)                                                                                            
≥5: OR 90.0 (95% CI 8.0 - 366.5) 
III 
Wieslande
r et al., 
1989127 
CC Hospital patients 38/76 
Group 1                                                                                                                                              
2 risk factors: OR 3.3 (95% CI 1.2 - 9.1), 
p<0.001                                                                      
>2 risk factors: OR 7.1 (95% CI 2.2 - 22.7), 
p<0.001 
III 
No effect risk 
Roquelaur
e et al., 
1997140 
CC Manufacturing workers 65/65 ≤2: OR 1.0 (95% CI 0.1 - 5.9) III 
Wieslande
r et al., 
1989127 
CC Hospital patients 38/76 
Group 1                                                                                                                                      
1 risk factor: OR 1.7 (95% CI 0.7 - 4.4) III 
      
CC, case control; OR, odds ratio; CI, confidence interval; AOR, adjusted odds ratio PC, prospective 
cohort;  
a CON in case-control studies represent the controls, while in the other study designs it represents the 




A total of seven studies considered other specific occupational procedures as potential risk 
factors for CTS (Table 3.12). Two level III studies found an increase in CTS risk with 
elementary operations of 10 seconds and less and manual workstation supply140 as well as 
working with temporary workers98. The five studies that found no effect on risk, including one 
level II and four level III studies,  investigated cycle time96,109, high loads on the wrist127, neck 
position during work119 and working overtime133, respectively.  
 
A low level of certainty was assigned to each one of the abovementioned factors, 
considering the lack of a large number of good quality studies verifying these associations.  
 
 






Table 3.12 Summary of all the studies that have investigated other specific occupational procedures 














e et al., 
1997140 
CC Manufacturing workers 65/65 
Elementary operation ≤10s: Logistic model OR 8.8 
(95% CI 1.8 - 44.4), p=0.008                                                             
Manual workstation supply: Logistic model OR 5.0 
(95% CI 2.2 - 21.2), p=0.001 
III 
Rigouin et 
al., 201398 CS 
Working 
population 156/3554 
Working with temporary workers                                                                                     
Female: Multivariate OR 1.99 (95% CI 1.23 - 3.25), 
p=0.005 
III 
No effect on risk 
Roquelaur
e et al., 
200196 
PC Blue-collar workers 34/100 
Cycle time:                                                                                
<30s: OR 0.7 (95% CI 0.2 - 2.3) II 
Leclerc et 








Cycle time:                                                                       
Model 2                                                                                                                                   
30-59s: OR 1.03 (95% CI 0.56 - 1.89)                                                                               
10-29s: OR 1.33 (95% CI 0.75 - 2.37)                                                                                            
<10s: OR 1.90 (95% CI 1.04 - 3.48) 
III 
Wieslande
r et al., 
1989127 
CC Hospital patients 38/76 
High load on wrist                                                                                                            
Group 1                                                                                                                                  
1-20 years: OR 1.7 (95% CI 0.7 - 3.9)                                                                                   
>20 years: OR 2.1 (95% CI 0.8 - 5.5)                                                                          
Group 2                                                                                                                                    
1-20 years: OR 2.1 (95% CI 0.8 - 5.2) 
III 
Coggon et 
al., 2013119 CC 
General 
population 475/799 
Neck position                                                                                                                         
Neck bent forward, >2 hours: AOR 1.2 (95% CI 0.9 - 
1.5)                                                                               
Work with neck twisted, >0.5 hours: AOR 1.3 (95% 













Overtime                                                                                                                                  
Model 1: Logistic regression OR 0.64 (95% CI 0.43 - 
0.96), p=0.030                                                                               
Model 2: Logistic regression OR 0.82 (95% CI 0.68 - 
1.00), p=0.047 
III
      
CC, case control; OR, odds ratio; CI, confidence interval; CS, cross sectional; PC, prospective cohort; 
AOR, adjusted odds ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 





3.3.3 Biomechanical Factors 
Factors that influence specifically the upper limbs, such as overuse, awkward positioning, 
carrying weight, increased strain or force as well as specific biomechanical stressors were 
investigated by various studies.  
 
3.3.3.1 Upper body movement 
Repetitive upper body movement, with specific emphasis on the movement of the upper 
limbs, is believed to increase the risk of developing CTS and eighteen studies investigated 
this risk factor (Table 3.13). Only one level II study found that an elbow posture that deviates 
from the neutral position lead to an increased risk of CTS114 whereas 10 level III 
studies71,72,81,99,116,119,120,128,129,151 also found increased risk with various upper body/upper 
limb movements.  
 
Similarly, one level II study96 found no effect of wrist flexion, extension and deviation as well 
as rapid trigger movements on the risk of developing CTS. Furthermore, another eight level 
III studies27,81,84,98,116,128,129,133 found no effect of these and other type of upper body and 
upper limb movements on the risk of CTS.   
 
As a consequence of the lack of consensus about the effect of upper body and upper limb 












Table 3.13 Summary of all the studies that have investigated upper body movement as a risk factor 
















PC Assembly workers 20/169 






PC Blue-collar workers 34/100 
Wrist flexion >45°: OR 0.6 (95% CI 0.1 - 3.2)                                                                                  
Wrist extension >45°: OR 1.2 (95% CI 0.4 - 3.4)                                                                               
Wrist deviation: OR 1.0 (95% CI 0.1 - 3.1)                                                                                           
Rapid trigger movements: OR 2.8 (95% CI 0.6 - 11.5), 





CC General population 475/799 
Bending/straightening of elbow > 1 hr/day: AOR 1.5 
(95% CI 1.2 - 1.9)                                                                                                    
Hand/finger movement, > 4 hr/day: AOR 1.7 (95% CI 
1.3 - 2.1); Multivariate OR 1.5 (95% CI 1.1 - 1.9)                                                                                 
III 
Nordstro
m et al., 
1997129 
CC General population 206/211 
Bending/twisting (hands) (hr/day)                                                                                                                          
3.5-6 hr/day: OR 2.33 (95% CI 1.24 - 4.36); 
Multivariate OR 2.65 (95% CI 1.83 - 5.92)                                                                                                                      
7-16 hr/day: OR 2.47 (95% CI 1.38 - 4.43); Multivariate 





CC Hospital patients 127/102 
Repetitive motion of wrist: Multivariate OR 2.15 (95% 




CC Orthopaedic patients 166/111 
Extension - frequent: OR 2.41 (95% CI 1.14 - 5.10), 
AOR 2.69 (95% CI 1.10 - 6.55)                                                                      
Flexion - seldom: OR 2.80 (95% CI 1.26 - 6.23), AOR 
3.16 (95% CI 1.28 - 7.80)                                                                     
Flexion - sometimes: OR 2.92 (95% CI 1.35 - 6.29), 
AOR 2.12 (95% CI 0.90 - 4.96)                                                                        
Flexion - frequent: OR 5.17 (95% CI 2.34 - 11.45), 





CC General population 156/473 
Working with flexed wrist (hrs/wk) 0-5 years ago                                                                                                    
1-7 hours: RR 1.5 (95% CI 1.3 - 1.9)                                                                                        
8-19 hours: RR 3.0 (95% CI 1.8 - 4.9)                                                                                  
20-40 hours: RR 8.7 (95% CI 3.1 - 24.1)                                                                                    
Working with extended wrist (hrs/wk) 0-5 years ago                                                              






CS Industrial workers 47/348 
Bending/twisting (wrist)                                                                                                    
Univariate OR 18.62 (95% CI 2.53 - 136.88), p=0.00; 
Multivariate OR 5.62 (95% CI 0.56 - 55.6), p=0.14                                                                                                                                        
Rapid hand movement                                                                                                        
Univariate OR: 3.17 (95% CI 1.30 - 7.69), p=0.004; 





CS General population 145/29929 Bending/twisting: AOR 5.50 (95% CI 3.21 - 9.42) III 
Armstron










CS Working population 675/176525 
Bend & twist (vibration included): Multivariate OR 5.23 
(95% CI 3.44 - 7.96)                                                                                     













Repetitive movements of hand/wrist ≥2h/day                                                                         
Former job: AOR 2.5 (95% CI 1.1 - 5.7)                                                                        
Latest job: AOR 2.4 (95% CI 1.3 - 4.5)                                                                                  


















 No effect on risk 
Ali et al., 
200627 CS 
Computer 
workers  85/563 
Hand flexed or extended: OR 1.3 (95% CI 0.8 - 
2.1), p=0.300 III 
Armstrong et 




131/940 Bend/twist hands: Logistic regression OR 1.72 (95% CI 1.07 - 2.76) III 
Nordstrom et 
al., 1997129 CC 
General 
population 206/211 
Bend or twist hands (hr/day)                                                                                                
0.25-1.75 hours per day: OR 1.34 (95% CI 0.64 - 
2.80); Multivariate OR 2.42 (95% CI 0.88 - 6.62)                                                                                                                             
2-3 hours per day: OR 1.23 (95% CI 0.60 - 2.53); 
Multivariate OR 1.27 (95% CI 0.50 - 3.26) 
III
Rigouin et 
al., 201398 CS 
Working 
population 156/3554 
Wrist bending and/or high physical demand                                                                                              
Female                                                                                                                                
One factor: Multivariate OR 1.64 (95% CI 0.97 - 
2.78), Both factors: Multivariate OR 1.57 (95% CI 
0.79 - 3.12), p=0.162                                                                                                 
Male                                                                                                                                         
One factor: Multivariate OR 1.64 (95% CI 0.87 - 
3.10), Both factors: Multivariate OR 2.21 (95% CI 
1.04 - 4.68), p=0.103                                                          
III




Extension                                                                                                                            
Seldom: OR 1.19 (95% CI 0.55 - 2.61), AOR 0.74 
(95% CI 0.30 - 1.84)                                                                            
Sometimes: OR 1.04 (95% CI 0.50 - 2.18), AOR 
0.75 (95% CI 0.32 - 1.77)                                                                                                                                   
Straight                                                                                                                                  
Seldom: OR 0.66 (95% CI 0.24 - 1.85), AOR 2.62 
(95% CI 0.82 - 8.43)                                                                           
Sometimes: OR 0.47 (95% CI 0.17 - 1.31), AOR 
1.44 (95% CI 0.72 - 2.87)                                                                              
Frequent: OR 0.43 (95% CI 0.15 - 1.21), AOR 1.02 













Flexion & extension: Logistic regression OR 1.00 
(95% CI 1.00 - 1.00), p=0.025                                                                             
Flexion & extension repetitions: Logistic regression 
OR 1.00 (95% CI 1.00 - 1.00), p=0.003                                                                                                                                      
Radial/Ulnar deviation repetitions: Logistic 
regression OR 1.00 (95% CI 1.00 - 1.00), p=0.003                                                                                                                                
Pronation (Model 1): Logistic regression OR 1.03 
(95% CI 1.00 - 1.06), p=0.051                                                                         
Pronation (Model 2): Logistic regression OR 1.06 
(95% CI 1.02 - 1.11), p=0.006 
III 
De Krom et 
al., 1990116 CC 
General 
population 156/473 
Extended wrist (hr/wk)                                                                                                        
1-7 hours: RR 1.4 (95% CI 1.0 - 1.9)                                                                                      
8-9 hours:  RR 2.3 (95% CI 1.0 - 5.2)                                                                                   
Extended & flexed wrist in combination                                                                                       
1-7 hours: RR 1.1 (95% CI 0.9 - 1.2)                                                                                     
8-19 hours: RR 1.2 (95% CI 0.8 - 1.7)                                                                             
20-40 hours: RR 1.4 (95% CI 0.7 - 2.9) 
III 
Rosecrance 
et al., 200284 CS 
Construction 
workers  91/1024 
Bend/twist back: OR 0.89, AOR 0.87 (95% CI 0.54 
- 1.41) III 
      
PC, prospective cohort; OR, odds ratio; CI, confidence interval; CS, cross sectional; CI, confidence 
interval AOR, adjusted odds ratio;  
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 





3.3.3.2 Biomechanical stressors 
Seven studies considered various biomechanical stressors as potentially modifying the risk 
of CTS (Table 3.14). Of the five investigations that found an increase in risk with certain 
biomechanical stressors, three were prospective studies (two level I and one level II). These 
studies considered specifically the working population and found that working between the 
action limit (AL) and threshold limit value (TLV), also known as the “borderline load”94 as well 
as working above the TLV, also known as “unacceptable loads” are associated with an 
increased risk of CTS78. The threshold limit ratio was also associated with increased risk118. 
Two level III studies also considered different models and job categories that they found to 
be significant in increasing the risk of CTS113,152.  
 
Six investigations, including two level I and two level II studies, found various biomechanical 
stressors, including values about the TLV, to have no effect on CTS risk78,93,94,96,113,152. 
Considering the conflicting results of various biomechanical stressors as risk factor for CTS, 




Table 3.14 Summary of all the studies that have investigated biomechanical stressors as risk factor 






























high level of 
hand activity 
29/318 Threshold limit ratio, Per unit increase (Model 2) : Multivariate HR 1.40 (95% CI 1.11 - 1.78) I 























PC Working population 153/1939 
Above TLV: OR 2.8 (95% CI 1.9 - 4.0), Multivariate OR 









high level of 
hand activity 
57/420 
HAL TLV Model - TLV (Cat 3): Multivariate OR 2.96 
(95% CI 1.51 - 5.80)                                                                                                     
Ratings based model - HAL TWA: Multivariate OR 
2.21 (95% CI 1.17 - 4.15)                                                                                        
Peak force match: Quantitative Model (Cat 3): 
Multivariate OR 2.74 (95% CI 1.32 - 5.68)                                                         
Exerts/min: Quantitative Model (Cat 3) if BMI ≥ 30: 












Job category                                                                                                                                  
HF-LR vs LF-LR (Men): Multivariate OR 2.8 (95% CI 
1.1 - 6.9), p=0.05                                                                                                  
LF-HR vs LF-LR (Women): Multivariate OR 7.4 (95% 
CI 1.9 - 2.8), p=0.05                                                                                                      
LF-HR vs LF, LR (All): Multivariate OR 4.7 (95% CI 1.8 
- 12.5), p=0.05                                                                                                
HF-LR vs LF-LR (All): Multivariate OR 3.21 (95% CI 
1.5 - 6.9), p=0.05 
III 










TLV for HAL Score                                                                                                                   
Per unit increase for score ≤ 12.5: HR 3.2 (95% CI 
0.78 - 13.2), p=0.11                                                                                                       
Per unit increase for score > 12.5: HR 0.21 (95% CI 
0.02 - 2.69), p=0.10                                                                                                            
Strain Index                                                                                                                             
SI > 6.1: HR 2.2 (95% CI 0.92 - 5.37), p=0.07                                                                                                         
Per unit increase for SI ≤ 13.5: HR 1.11 (95% CI 1.00 - 
1.23), p=0.005                                                                                             
















PC Blue-collar workers 34/100 
Ergonomic Score                                                                                                                 
Left hand, score >4: OR 0.6 (95% CI 0.2 - 1.6)                                                                          
Right hand, score >4: OR 0.8 (95% CI 0.3 - 2.6)                                                                





PC Working population 153/1939 
Between AL and TLV: OR 1.2 (95% CI 0.8 - 2.0), 











Job category                                                                                                                              
Female                                                                                                                                
High frequency, low repetition  (HF-LR) vs LF-LR: 
Multivariate OR 7.0 (95% CI 0.8 - 6.2)                                                                                                                               
Male                                                                                                                                          
Low frequency, high repetition (LF-HR) vs Low 
frequency, low repetition (LF-LR): Multivariate OR 2.2 
(95% CI 0.5 - 9.9)                                                                                                          
III 
      
 
 

























high level of 
hand activity 
57/420 
HAL TLV Model                                                                                                                        
TLV Cat 2 vs 1: Multivariate OR 2.28 (95% CI 0.58 - 
8.88)                                                                        
Ratings based Model                                                                                                                             
HAL TWA (0-8), if female: Multivariate OR 1.03 (95% 
CI 0.83 - 1.28)                                                                                                                                 
HAL TWA (0-8), if male: Multivariate OR 1.38 (95% CI 
1.05 - 1.81)                                                                                              
Peak worker RPE: Multivariate OR 1.14 (95% CI 1.01 - 
1.29)                                                                         
Quantitative Model                                                                                                                  
Peak force match Cat 2 vs 1: Multivariate OR 1.33 
(95% CI 0.58 - 3.04)                                                                                            
Exerts/min Cat 2 vs 1 if BMI < 30: Multivariate OR 1.40 
(95% CI 0.45 - 4.34)                                                                                                                 
Exerts/min Cat 3 vs 1 if BMI < 30: Multivariate OR 1.13 
(95% CI 0.44 - 2.93)                                                                           
Exerts/min Cat 2 vs 1 if BMI ≥ 30: Multivariate OR 2.92 
(95% CI 0.90 - 9.46) 
III 
      
PC, prospective cohort; IRR, incidence rate ratio; OR, odds ratio; CI, confidence interval; CS, cross 
sectional; AOR, adjusted odds ratio; CC, case control; AL, action limit; TLV, threshold limit value; 
HAL, hand activity level; HF-LR, high frequency, low repetition; LF-HR, low frequency, high repetition; 
LF-LR, low frequency-low repetition; SI, strain index; HR, hazard ratio; TWA, time weighted average; 
RPE, rate of perceived exertion 
a CON in case-control studies represent the controls, while in the other study designs it represents the 




3.3.3.3 Working overhead 
Only three level III studies investigated working overhead as a potential risk factor of CTS 
(Table 3.15). Working overhead for more than 1 hour per day was found to increase the risk 
of CTS by Coggon et al. (2013)119.  Adults whose former or current occupation involved 
working overhead was also at increased risk of CTS151. In contrast, working overhead was 
found to have no effect on risk by Rosecrance et al. (2002).  
 







Table 3.15 Summary of all the studies that have investigated working overhead as risk factor for 



























Former jobs: AOR 2.4 (95% CI 1.3 - 4.6)                                                                              
Latest job: AOR 2.1 (95% CI 1.2 - 3.7)                                                                                     
Both (former & latest job): AOR 2.7 (95% CI 1.4 - 5.2) 
III





CS Construction workers  91/1024 OR 1.66, AOR 1.70 (95% CI 1.06 - 2.72) III 
      
CS, cross sectional; CC, case control; OR, odds ratio; CI, confidence interval; AOR, adjusted odds 
ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 
3.3.3.4 Lift/carry weight 
Five studies investigated the effect of lifting and/or carrying weight as a potential modifier of 
CTS risk (Table 3.16). Three studies, including one prospective study looking at industrial 
workers, found this risk factor to be associated with an increase in CTS risk whereas three 
level III studies found it to have no effect on risk. Lifting and/or carrying weight was therefore 
assigned a low level of certainty.  
 
  





Table 3.16 Summary of all the studies that have investigated lifting and/or carrying weight as risk 
















PC Industrial workers 34/222 
Univariate OR 0.99 (95% CI 0.76 - 1.29), p=0.94; 
Multivariate OR 1.17 (95% CI 0.37 - 3.67) II 
Armstron

















>5kg, ≥2x/minute, 2h/day                                                   
Latest job: AOR 2.6 (95% CI 1.5 - 4.6)                                                                     
Both (Former & current job): AOR 4.8 (95% CI 2.7 - 
8.6)                                                                              
>20kg ≥10x/day - Latest job: AOR 1.9 (95% CI 1.1 - 
3.3)                                                                                        
Both (Former & Latest job): AOR 2.8 (95% CI 1.4 - 
5.6) 
III 















>5kg, ≥2x/minute, 2h/day - Former job: AOR 2.0 
(95% CI 0.9 - 4.0)                                                                                               
>20kg, ≥10x/day - Former job: AOR 1.1 (95% CI 0.5 






CS Construction workers  91/1024 OR 1.14, AOR 1.02 (95% CI 0.60 - 1.74) III 
      
PC, prospective cohort; CS, cross sectional; CC, case control; OR, odds ratio; CI, confidence interval; 
AOR, adjusted odds ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 
3.3.3.5 Job strain 
Two prospective cohort studies investigated job strain as potential risk factor for CTS (Table 
3.17). Harris-Adamson et al. (2013) found high job strain, defined as high demand and low 
control, to increase the risk of CTS 1.86-fold whereas active (high demand and high control) 
and passive (low demand and low control) job strain had no effect on risk of CTS74. Similarly, 
Burt et al. (2013) found that high, compared to low/passive job strain, also has no effect on 





As a result of the low number of studies considering job strain as risk factor, it was assigned 
a low level of certainty as potential modifier of CTS risk.  
 
















n et al., 
201374 
PC Industrial workers 204/3311 
High: Multivariate HR 1.86 (95% CI 1.11 - 3.14), 
p=0.02 I 
No effect on risk 
Harris-
Adamso
n et al., 
201374 
PC Industrial workers 204/3311 
Active: Multivariate HR 1.48 (95% CI 0.83 - 2.66), 
p=0.18                                                              
Passive: Multivariate HR 1.23 (95% CI 0.67 - 2.27), 










high level of 
hand activity 
29/318 High (Model 2): Multivariate HR 2.3 (95% CI 1.00 - 4.54) I 
      
PC, prospective cohort; HR, hazard ratio; CI, confidence interval 
a CON in case-control studies represent the controls, while in the other study designs it represents the 




Eight studies considered repetition as potential modifier of CTS risk (Table 3.18). Only one 
level III study found an increase in risk in those participants exposed to repetitive 
movements of the wrist for more than 20 years127. The same study found no effect on risk in 
participants exposed for less than 20 years. Similarly, another 6 studies, of which two are of 
prospective design, found various forms of repetition, including performing a similar 
movement for more than 50% of work time, repetition combined with force and frequent 
repetitive exposure, to have no effect on the risk of CTS76,84,96,105,107,121,128. 
 
Considering the lack of evidence that repetition modifies the risk of CTS, this risk factor was 
assigned a low level of certainty. It is, however, interesting to note that although there was 





not sufficient evidence to determine whether repetition is a true risk factor of CTS, there was 
a definite trend towards blue-collar workers (working class individuals performing manual 
labour) being more susceptible to developing CTS (section 3.3.1.1). Since manual labour 
occupations often involve highly repetitive hand/wrist action, future research should focus on 




















r et al., 
1989127 
CC Hospital patients 38/76 
Group 1 - >20 years: OR 4.6 (95% CI 1.8 - 11.9), 
p=0.002                                                                              
Group 2 - >20 years: OR 9.6 (95% CI 2.8 - 33.0), 
p<0.001 
III 
No effect on risk 
Nathan et 
al., 200276 PC 
Industrial 
workers 34/222 
Univariate OR 1.05 (95% CI 1.39 - 0.79), p=0.73; 
Multivariate OR 1.14 (95% CI 0.59 - 2.20), p=0.69 II 
Roquelaur
e et al., 
200196 
PC Blue-collar workers 34/100 
Similar movement for >50% of work time: OR 0.9 
(95% CI 0.2 - 4.8) II 
Chiang et 





Repetition x force                                                                                                                     
OR 1.1 (95% CI 0.7 - 1.8)                                                                                                     
Female: OR 1.5 (95% CI 0.8 - 2.8) 
III
Rosecranc
e et al., 
200284 
CS Construction workers  91/1024 OR 1.65, AOR 1.54 (95% CI 0.92 - 2.56) III 
Forst et 
al., 2007121 CS 
Spine 
surgeons 107/264 Multivariate OR 1.84 (95% CI 1.06 - 3.19), p=0.030 III 
Wieslande
r et al., 
1989127 
CC Hospital patients 38/76 
1-20 years (Group 1): OR 1.5 (95% CI 0.5 - 4.4)                                                                
1-20 years (Group 2): OR 2.3 (95% CI 0.7 - 7.9) III 
Fung et 
al., 2007128 CC 
Orthopaedic 
patients 166/111 
Seldom: OR 1.11 (95% CI 0.44 - 2.78), AOR 1.07 
(95% CI 0.37 - 3.15)                                                                           
Sometimes: OR 1.11 (95% CI 0.47 - 2.64), AOR 
0.68 (95% CI 0.24 - 1.91)                                                                     
Frequent: OR 1.45 (95% CI 0.68 - 3.13), AOR 0.93 
(95% CI 0.37 - 2.36) 
III 
Latko et 
al., 1999105 CS 
Workers at 
manufacturi
ng facility  
19/333 OR 1.22 (95% CI 0.98 - 1.53) III 
      






From previous page:  
CC, case control; CS, cross sectional; OR, odds ratio; CI, confidence interval; AOR, adjusted odds 
ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 
3.3.3.7 Grip force 
Five studies investigated grip force, including finger and power grip force, on the risk of 
developing CTS (Table 3.19).  
 






















63/657 Power grip force (female): OR 2.90 (95% CI 1.44 - 5.87)                                           III 








Grip forces                                                                                                                           
≥1h/day - Latest job: AOR 2.8 (95% CI 1.7 - 4.7)                                                                                      
Both (former & latest job): AOR 3.4 (95% CI 1.7 - 
6.6) 
III 









Finger in pinch grip: Logistic regression OR 1.24 
(95% CI 1.24 (95% CI 0.82 - 1.86)                                                           
Use finger/thumb for pressing :Logistic regression 











Pinchgrip force (female): OR 2.03 (95% CI 1.01 - 
4.08), Men: OR 1.00 (95% CI 0.40 - 2.45)                                                                                                                              
Powergrip force (male): OR 2.43 (95% CI 1.02 - 
5.80)                                                                                                                                                                                                    
III 







~825/5429 ≥1h/day - Former job: AOR 2.2 (95% CI 1.0 - 4.6) III 
Rosecranc
e et al., 
200284 
CS Construction workers  91/1024 
Grasp small objects: OR 1.91, AOR 1.44 (95% CI 




CC General population 156/473 
1-7 hours: RR 0.9 (95% CI 0.8 - 1.1)                                                                                        
8-19 hours: RR 0.8 (95% CI 0.5 - 1.3)                                                                                              
20-40 hours: RR 0.7 (95% CI 0.3 - 1.6) 
III
      
CS, cross sectional; OR, odds ratio; CI, confidence interval 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 





Only two cross-sectional studies found that females exposed to power grip force, as well as 
participants exposed to grip forces for an hour or more per day in their latest as well as 
former and latest job, to be at increased risk of CTS97,151. These same studies found pinch 
grip force in females and power grip force in males, as well as exposure of an hour or more 
of grip force in the participant’s former job, to have no effect on CTS risk97,151.  Similarly, 
another three level III studies also found various forms of grip force to have no effect on CTS 
risk81,84,116.  As a result of the limited number of studies available showing grip force to alter the 
risk of CTS, it was awarded a low level of certainty to modify the risk of CTS.  
 
3.3.4 Psychosocial factors 
Although not traditionally seen as a major risk factor for CTS, psychosocial factors have 
been implicated as potentially playing a role in CTS risk with certain psychosocial factors 
such as low job control being associated with increased risk20,26. 
 
3.3.4.1 General and Mental health 
Four studies considered the effect of general health on the risk of CTS (Table 3.20), while 
two level III studies investigated the association of mental or psychological problems with 
risk of CTS (Table 3.20). Two prospective cohort studies found that general health being 
“worse than others” 93 and good74, respectively, was associated with an increase in risk of 
CTS. These same studies found that having somewhat better, or similar health as others93, 
or having fair or poor health74 did not have any effect on risk of CTS. Similarly, two lower 
quality (level II and level III, respectively) studies found general health to not have any 
effect74,101. Leclerc et al. (1998) found that having psychological problems lead to an 
increase in CTS risk, whereas only having ‘some’ problems had no effect on risk109. A study 
by Coggon et al. (2013) also found that intermediate or poor mental health had no effect on 
the risk of developing CTS119. Only one prospective cohort study specifically considered 
depression as a potential risk factor for CTS and found that three different levels of 





feeling depressed had a 5.2-fold increase in risk whereas never being depressed reduced 
the risk of developing CTS 10-fold. Often having feelings of depression had no effect on 
risk93. 
 
Physical and mental exhaustion as potential risk factors for CTS was investigated by two 
level I studies (Table 3.20). Both studies found that various levels of exhaustion had no 
effect on CTS risk74,93 and as a result, exhaustion as risk factor for CTS was awarded a low 
level of certainty.  
 
Considering the limited number of studies, and the contradictory findings, general and 
mental health as modifier of CTS risk was awarded a low level of certainty. Considering that 
only one study has investigated depression as risk factor for CTS, it was also assigned a low 
level of certainty.  
 
 
Table 3.20 Summary of all the studies that have investigated general health as risk factor for carpal 






















General health - Worse than others: HR 3.04 (95% 
CI 1.27 - 7.25), p=0.03                                                                       





n et al., 
201374 
PC Industrial workers 204/3311 
General health - Good: IRR 1.7 (95% CI 1.20 - 2.44); 











Mental health - problems                                               
Model 1: OR 2.32 (95% CI 1.48 - 3.63)                                                            
Model 2: OR 2.32 (95% CI 1.40  3.82)                                                                                         











35/501 Depressed - Never: HR 0.1 (95% CI 0.01 - 0.68), p=0.02                                                                                                I 
  

























General health - Somewhat better than others: HR 
1.6 (95% CI 0.45 - 5.85), p=0.45                                                                                                                                 
General health - the same as others: HR 1.7 (95% 
CI 0.47 - 5.83), p=0.43                                                                      
Depressed - Often: HR 1.1 (95% CI 0.50 - 2.49), 




n et al., 
201374 
PC Industrial workers 204/3311 
General health - Fair/poor: IRR 1.76 (95% CI 1.03 - 





n et al., 
201374 
PC Industrial workers 204/3311 
Physical exhaustion - Moderate to severe: 
Multivariate HR 1.45 (95% CI 1.05 - 2.00), p=0.03                                          
Mental exhaustion - Moderate to severe: Multivariate 











Physical exhaustion                                                                             
Seldom: HR 1.2 (95% CI 0.36 - 4.28), p=0.73                                                                                                                 
Often: HR 1.8 (95% CI 0.50 - 6.23), p=0.38                                                                                            
Always: HR 3.4 (95% CI 0.81 - 14.18), p=0.10             
Mental exhaustion                                                                                                 
Seldom: HR 1.1 (95% CI 0.47 - 2.67), p=0.80                                                                               
Often: HR 2.7 (95% CI 1.07 - 6.59), p=0.04                                                                       






PC Blue-collar workers 34/100 
GHQ score ≥14/36: OR 1.2 (95% CI 0.4 - 3.7)                                                              
GHQ score ≥90%: OR 3.1 (95% CI 0.7 - 9.3); 





CS Office workers 88/382 
General health - Excellent/very good: OR 0.4 (95% 
CI 0.2 - 3.3)                                                                       












Mental health - some problems                                 
Model 1: OR 1.36 (95% CI 0.91 - 2.04)                                               
Model 2: OR 1.15 (95% CI 0.73 - 1.82)                                                                                                     





CC General population 475/799 
Mental health - intermediate: AOR 1.2 (95% CI 0.9 - 
1.7); Multivariate OR 1.3 (95% CI 0.9 - 1.7)                                                                                                                        
Mental health - poor: AOR 1.3 (95% CI 1.0 - 1.8); 
Multivariate OR 1.4 (95% CI 1.0 - 1.9) 
III 
      
PC, prospective cohort; CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; GHQ, 
general health questionnaire; CS, cross sectional; OR, odds ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
 
3.3.4.2 Job satisfaction and psychological demand 
Only three studies investigated job satisfaction in the working population, to determine 
whether it has any effect on CTS risk (Table 3.21). One level I study found that being 





CTS, but that being satisfied or apathetic has no effect on risk93. On the contrary, another 
level I and one level III study found that job satisfaction had no effect on risk74,119. Three 
studies investigated psychological demand in the working population as a potential modifier 
of CTS risk (Table 3.21). Only one level III study found that women working under high 
demand are at increased risk of developing CTS98. In contrast, one level II and one level III 
study found that high work demand and high decision latitude, both aspects of psychological 
demand, have no effect on the risk of CTS96,97. 
 
Job satisfaction was awarded a low level of certainty, owing to the limited number of studies 
showing its effect on CTS risk. Similarly, owing to the limited number of good quality studies, 
psychological demand was allocated a low level of certainty.  
 
3.3.4.3 Support 
Support, as risk factor for CTS, was considered by seven studies (Table 3.22). Two studies 
considered whether supervisor support, in a working population, plays a role in CTS risk. 
Both studies (level I and level III, respectively) showed that little or no support from the 
supervisor lead to an increase in CTS risk93,119 whilst a supervisor seldom or often showing 
appreciation had no effect on the risk of developing this condition93. Furthermore, the 
employer’s attitude, specifically whether participants feel that their employer cares (about 
them), was investigated by two studies. One level III, case control study, found that when 
participants slightly or strongly disagreed when asked whether they felt that their employer 
care, they were at increased risk whereas there was no risk when participants agreed with 
the statement, or when they had no specific employer129. In contrast, a prospective cohort 
study found that regardless of the answer given by participants, the employer attitude had no 
effect on CTS risk93. When social and/or co-worker support was considered, five studies 
(including two level I and two level II studies) found that various levels support had no effect 
on developing CTS. 





Support, from the employer, supervisor and co-workers, as risk factor for CTS, was awarded 





Table 3.21 Summary of all the studies that have investigated job satisfaction as risk factor for carpal 






















Job satisfaction                                                                           






CS Working population 156/3554 
Psychological demand:                                              
Women: Multivariate OR 1.90 (95% CI 1.17 - 3.09), 
p=0.009 
III 
No effect on risk 
Harris-
Adamso
n et al., 
201374 
PC Industrial workers 204/3311 
Job satisfaction                                                                    
Satisfied: Multivariate HR 1.43 (95% CI 1.03 - 1.99), 
p=0.03                                                     
Dissatisfied/very dissatisfied: Multivariate HR 1.28 











Job satisfaction                                                             
Satisfied: HR 2.9 (95% CI 0.86 - 9.61), p=0.31                                                                                       






PC Blue-collar workers 34/100 
Psychological demand: OR 1.0 (95% CI 0.3 - 3.1)                                                                                                            
High work demand: OR 1.7 (95% CI 0.5 - 5.4) II 
Silverstei








Psychological demand - High decision latitude:                                                               
Women: AOR 1.24 (95% CI 0.61 - 2.51)                                    





CC General population 475/799 
Job satisfaction                                                         
Dissatisfied: AOR 1.1 (95% CI 0.8 - 1.5) III 
      
PC, prospective cohort; CI, confidence interval; HR, hazard ratio; CC, case control; AOR, adjusted 
odds ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 































35/501 Supervisor shows appreciation - never: HR 4.4 (95% CI 1.13 - 16.9), p=0.51                  I 
Nordstro
m et al., 
1997129 
CC General population 206/211 
Employer cares                                                           
Slightly disagree: AOR 2.63 (95% CI 1.18 - 5.88)                                                                     
Strongly disagree: AOR 4.17 (95% CI 1.31 - 13.29) 
III
No effect on risk 
Harris-
Adamso
n et al., 
201374 
PC Industrial workers 204/3311 
Social support - High: Multivariate HR 0.54 (95% 










                                                                                   
Employer cares                                                                
Strongly agree: HR 0.3 (95% CI 0.09 - 1.03), 
p=0.06                                                                 
Neither/Nor: HR 0.6 (95% CI 0.23 - 1.64), p=0.33                                                            
Disagree: HR 1.5 (95% CI 0.50 - 4.33), p=0.48                                                              
Strongly disagree: HR 1.4 (95% CI 0.42 - 4.74), 
p=0.58                                                               
Supervisor shows appreciation                               
Seldom:  HR 1.5 (95% CI 0.42 - 5.60), p=0.03                                                                                                                                                         
Often: HR 2.3 (95% CI 0.67 - 8.04), p=0.18           
Social support                                                             
Never: HR 1.0 (95% CI 0.13 - 7.58, p=0.99                                                                





PC Assembly workers 20/169 






PC Blue-collar workers 34/100 





CC General population 475/799 
Supervisor - Little support: AOR 1.7 (95% CI 1.2 - 
2.4); Multivariate OR 1.6 (95% CI 1.1 - 2.3) III 
Silverstei








Social support                                                            
Women: AOR 0.66 (95% CI 0.32 - 1.34)                                                            
Men: AOR 1.81 (95% CI 0.75 - 4.34) 
III
Nordstro
m et al., 
1997129 
CC General population 206/211 
Employer cares                                                            
Slightly agree: AOR 1.52 (95% CI 0.89 - 2.60)                                                                          
No such person: AOR 0.78 (95% CI 0.37 - 1.67) 
III 
      
PC, prospective cohort; HR, hazard ratio; CI, confidence interval; CC, case control; AOR, adjusted 
odds ratio; OR, odds ratio 
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
 
  





3.3.4.4 Job control & targets/deadlines/bonuses 
Three studies investigated whether job control has an effect on CTS risk (Table 3.23). Job 
control is defined as the amount of control the worker has in determining how and when 
work is done including the timetable and breaks119. Having little control over task control and 
having ones work strongly controlled by supervisors both had no effect on CTS risk, in a 
study by Roquelaure et al. (2001)96. In a different study, a score was to the level of control 
each participant has where a lower score indicated less control compared to a higher score 
which indicated more control. This study concluded found that a lower score was associated 
with a decreased risk of developing CTS, whilst a higher score had no effect129.  Similarly, 
two studies investigated whether having specific targets, deadlines and bonuses had any 
effect on the risk of developing CTS (Table 3.23). Both studies found that it had no effect on 
CTS risk98,119 and it was therefore assigned a low level of certainty.  
 
Considering the little evidence showing that job control and targets/deadlines/bonuses 
influence the risk of CTS, it was awarded a low level of certainty as modifier of CTS risk. 
 
3.3.4.5 Other psychosocial factors 
A total of four studies considered various other single risk factors. This includes family 
problems, general tension and occupation-related psychosocial factors such as having 
strong structural constraints, lack of job clarity, low skill discretion, little recovery time and 
whether the participant would recommend their job to others or whether they would take the 
same job (Table 3.24). These studies, one level I, one level II and two level III, considered 
these single psychosocial factors but found them to have no effect on CTS risk93,96–98.  
 













Table 3.23 Summary of all the studies that have investigated job control as risk factor for carpal 














m et al., 
1997129 
CC General population 206/211 
Job control                                                                           
2.8-3.4: AOR 0.80 (95% CI 0.44 - 1.47); Multivariate 
OR 1.05 (95% CI 0.48 - 2.27) 
III 





PC Blue-collar workers 34/100 
Task control - Low score: OR 1.3 (95% CI 0.4 - 3.8)            
Work strongly controlled by supervisors: OR 0.5 
(95% CI 0.2 - 1.3), Logistic model: OR 0.5 (95% CI 





CC General population 475/799 
Job control                                                                       
Little: AOR 1.6 (95% CI 1.2 - 2.1); Multivariate OR 
1.4 (95% CI 1.1 - 2.0)                                                               
Targets, deadlines and bonuses                              
AOR 1.0 (95% CI 0.8 - 1.2) 
III 
Nordstro
m et al., 
1997129 
CC General population 206/211 
Job control                                                                          
3.6-3.8: AOR 0.36 (95% CI 0.18 - 0.71); Multivariate 
OR 0.34 (95% CI 0.14 - 0.82)                                                                                                                
4-4.4: AOR 0.46 (95% CI 0.24 - 0.86); Multivariate 
OR 0.64 (95% CI 0.29 - 1.42)                                                                                                                 
4.6-4.8: AOR 0.42 (95% CI 0.21 - 0.83); Multivariate 





CS Working population 156/3554 
Targets, deadlines and bonuses                                
Men: Multivariate OR 1.93 (95% CI 1.08 - 3.46), 
p=0.026 
III 
      
CC, case control; AOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio  
a CON in case-control studies represent the controls, while in the other study designs it represents the 
total study population without the CTS cases. 
  







Table 3.24 Summary of all the studies that have investigated other psychosocial risk factors for carpal 


























Seldom: HR 1.6 (95% CI 0.62 - 4.32), 
p=0.32                                                                                    
Often: HR 1.4 (95% CI 0.44 - 4.73), 
p=0.41                                                                                                   















Strongly recommend: HR 0.2 (95% CI 0.03 
- 1.54), p=0.12                                                                       
Neither/Nor: HR 1.1 (95% CI 0.47 - 2.43), 
p=0.87                                                                          
Discourage: HR 2.0 (95% CI 0.73 - 5.44), 
p=0.18                                                             
Strongly discourage: HR 2.5 (95% CI 0.83 















Likely: HR 3.2 (95% CI 0.93 - 10.81), 
p=0.07                                                                    
Neither/Nor: HR 2.3 (95% CI 0.51 - 10.17), 
p=0.28                                                               
Unlikely: HR 3.1 (95% CI 0.78 - 12.46), 
p=0.11                                                                        








PC Blue-collar workers 34/100 
Permanent tension during work: OR 0.3 
(95% CI  0.4 - 4.1)                                                         
Permanent time pressure: OR 1.3 (95% CI 
0.6 - 11.2) 
II 












CS Working population 156/3554 
Men: Multivariate OR 1.77 (95% CI 1.01 - 







CS Working population 156/3554 
Men: Multivariate OR 2.02 (95% CI 0.81 - 
5.07)                                                       
Women: Multivariate OR 1.73 (95% CI 













63/657 Women: AOR 1.04 (95% CI 0.51 - 2.12)                                                      Men: AOR 1.28 (95% CI 0.52 - 3.16) III 
       
PC, prospective cohort; HR, hazard ratio; CI, confidence interval; CS, cross sectional; OR, odds ratio 
AOR, adjusted odds ratio;  
a CON in case-control studies represent the controls, while in the other study designs it represents the 










In conclusion, 29 occupational and psychosocial risk factors (excluding “other” risk factors) 
were reviewed. All the risk factors were found to only have a low certainty of having an effect 
on the modification of risk for CTS (Table 3.25). Interestingly, there was little evidence to 
support the hypothesis that the occupational factors, specifically repetitive action of the 
hands/wrists and working with vibratory tools, commonly believed to increase risk of CTS 
were associated. However, it is very likely that this finding is not as a result of the lack of a 
true association but rather the lack of good quality, prospective studies investigating these 
factors in the literature and this should be the focus of future research.  
 
Furthermore, this review also highlighted that the overall level of certainty for occupational 
involvement, which is partly the focus of his thesis, is currently low. It is however interesting 
to note that blue-collar workers, specifically, seemed to be at increased risk of CTS. Several 
blue-collar worker occupations are often associated with repetitive work, and future studies 
should focus on this group of workers.  
 
As stated in the previous chapter, only studies that included diagnosed CTS (by a medical 
professional, electro-diagnostic examination or surgical cases) were included in this 
systematic review and very few studies investigated specifically participants who have had 
carpal tunnel release surgery, which would be considered the most extreme phenotype.  
 
As mentioned in the previous chapter, there are limitations to this systematic review. 1)   
Many of the variables were considered only by univariate analyses compared to other which 
were considered by both uni- and multivariate analyses. Future systematic reviews could 
potentially only focus on multivariate analyses, which are considered to be of higher quality 
than univariate analyses. 2) In various sections, different variables were grouped under one 
umbrella risk factor (such as occupation or exposure). Although this is not ideal, this was 





done for simplicity purposes to avoid having an excessive amount single risk factors 
investigated only by one study. Lastly, groupings in this systematic review was made on the 
risk factor’s effect on risk i.e. increased, decreased or no effect on risk. Although there are 
several methods of grouping risk factors, this method was chosen to increase the 
understanding of the effect of a particular risk factor on risk and to prevent confusion. 
 
In conclusion, large, prospective studies focusing on occupational and psychosocial risk 
factors are needed to investigate whether these factors do, in fact, play a role in the 
aetiology of CTS. Furthermore, a meta-analysis to investigate the combination and/or 
interaction of different studies would provide more information on the effect of different risk 









Table 3.25 Summary of the level of certainty of carpal tunnel syndrome risk factors 
  Level of Certainty 
  
High Moderate Low 
(1) Previous and current Occupations 
 - - Occupation 
 - - Computer work 
 - - Current/Previous exposure 
(2) Specific Occupational Exposure 
 - - Force Exertion 
 - - Breaks 
 - - Vibration 
 - - Physical limit/demand 
 - - Working conditions/Environment 
 - - Specific Occupational actions 
 - - Job rotation 
 - - Number of Occupational factors 
(3) Biomechanical factors  
 - - Upper body movement 
 - - Biomechanical stressors 
 - - Working overhead 
 - - Lift/carry weight 
 - - Job strain 
 - - Repetition 
 - - Grip force 
(4) Psychosocial  
 - - General and Mental health 
 
- - Job satisfaction and psychological demand 
 - - Support 
 
- - Job control and Targets/deadlines/bonuses 




CHAPTER 4: MATRIX METALLOPROTEINASE (MMP) GENES ON CHROMOSOME 




As reviewed in chapter one, previous studies have proposed a possible involvement of 
tendon or tendon-structures in the aetiology of CTS (Section 1.6). In support of this both 
tendinopathy and tenosynovitis have been proposed as being comorbid conditions or a 
precursor of CTS12. Furthermore, flexor tenosynovitis can lead to an increase in carpal 
tunnel pressure3 which could lead to compression of the median nerve and it has also been 
suggested that fibrosis of the SSCT could be a cause of CTS13. Several investigators have 
also suggested that there could be a familial or genetic predisposition to CTS24,153–156.  Since 
investigators have previously shown that several genetic DNA sequences variants are 
associated with chronic Achilles tendinopathy157, it has therefore been hypothesised that 
some of these variants could also be associated with CTS (Section 1.6). 
 
Specifically, variants rs679620 (A/G, E45K), rs591058 (T/C) and rs650108 (G/A) within the 
matrix metalloproteinases 3 (MMP3), as well as variant rs4789932 (C/T) tissue inhibitors of 
metalloproteinases 2 (TIMP2) genes have been reported to be associated chronic Achilles 
tendinopathy58,158. The MMPs, a family of 25 endopeptidases, are involved in the remodelling 
of the collagen fibril, the basic building block of tendons and other connective tissues (refer 
to figure 1.2). This remodelling is dependent on a balance between tissue degradation and 
formation maintained by, among other proteins, the MMPs and their antagonists, TIMPs61–63. 
Several other genes encoding for the MMPs, which include amongst others MMP10, MMP1 
and MMP12, are clustered together with MMP3 on human chromosome 11q22 (Figure 4.1). 
The stromelysins, MMP3 and MMP10 are key MMPs, able to degrade several structurally 






Figure 4.1 The cluster of four MMP genes spanning a 105.4 kb region on chromosome 11q2259, 
which were investigated. The grey boxes represent the genes each containing one of the four 
polymorphisms investigated in this study. All four genes are orientated in the 3’–5’ direction. The 
MMP3 and MMP10 single nucleotide polymorphisms (SNPs) are both non-synonymous, while the 
MMP1 and MMP12 polymorphisms are both functional promoter variants. Figure adapted from 
Posthumus et al. (2012)59.  
 
 
 I, II, III, IV, V, VII, IX, X, XI collagens, laminin, fibronectin, elastin, gelatins and 
proteoglycans61–63. In addition MMP3 and MMP10 are also able to activate several MMPs by 
removing the propeptide from the pro-MMP159–161. MMP1 is a collagenase, responsible for 
degrading the triple-helical region of most subtypes of collagen whereas MMP12 is a 
metalloelastase, responsible for the degradation of elastin and other ECM proteins62.  
 
In addition to the independent association of MMP3 variants with chronic Achilles 
tendinopathy a haplotype constructed from the MMP10 C/T rs486055, MMP1 G/GG 
rs1799750, MMP3 G/A rs679620 and MMP12 A/G rs2276109 variants are also associated 
with altered risk for anterior cruciate ligament (ACL) ruptures59.  The MMP1 (G/GG) 




rs1799750 variant is also associated with knee osteoarthritis in the Turkish population with 
the G allele being over-represented in the patients and the GG allele being over-represented 
in the control group162. Although the results should be interpreted with caution because of 
the small sample size, the GG/GG genotype of MMP1 rs1799750163 and the T allele of the -
799 MMP-8 variant (rs11225395, C/T)164 is associated with increased risk for primary 
posterior tibial (PPT) tendinopathy in Brazilian females. 
 
The MMP3 and MMP10 variants both contain non-synonymous SNPs. MMP3 rs679620 
(G/A) results in a glutamate to lysine substitution at position 4559 whilst MMP10 rs486055 
(C/T) results in a arginine to lysine substitution at position 5359. MMP1 and MMP12 both 
contain functional promoter polymorphisms, rs1799750 (G/GG)165 and rs2276109 (A/G)166, 
that alters transcriptional activity with the GG and the A alleles resulting in increased 
transcriptional activity of the MMP1 and MMP12 genes respectively 165,166. 
 
Considering (i) the important role of that the MMPs play in ECM homeostasis, (ii) the 
possibility of a tendon/tendon-like structure involvement in the aetiology of CTS, and (iii) 
independent and/or gene-gene associations of MMP10, MMP1, MMP3 and MMP12 have 
been reported for other musculoskeletal disorders, the aim of the study presented in this 
chapter was to determine whether the MMP10 rs486055 (C/T), MMP1 rs1799750 (G/GG), 









A total of 103 self-reported Coloured participants (94 female and 9 male), with a history of bi- 
or unilateral carpal tunnel release surgery (CTS), were recruited for this study and 
subsequent studies of this thesis from various Occupational Health clinics in the Western 
Cape region of South Africa from May 2012 to March 2013. Bilateral carpal tunnel release 
surgery was performed in 53.2% (47 female and 3 male) of the CTS participants, while 
35.1% (30 female and 3 male) only had surgery on their dominant hand and 9.6% (7 female 
and 2 male) had surgery on their non-dominant hand. Two (2.1%) participants, one male and 
one female, who reported being ambidextrous had carpal tunnel surgery on their right hand. 
Nine of the participants did not report the operated hand. Seven (7.1%) of the 99 CTS 
participants who answered the question were pregnant at the onset of CTS symptoms.   
 
South African populations who self-identify as Coloured have a complex history of 
ancestrally derived admixture. This ethnic group within the Western Cape region of South 
Africa is ancestrally derived from admixtures of one or more of the indigenous African 
populations (Khoe- and San-speaking or Bantu-speaking), immigrants from Western Europe, 
or slave labourers from West Africa, Indonesia, Madagascar, Java, India and Malaysia. The 
term “Coloured” in South Africa is therefore a name that encompasses a wide range of 
people who are unique to this country7. This admixed study sample investigated is predicted 
to potentially contain more genetic variation compared to the South African populations of 
Caucasian ancestry246.  For this reason, this admixed population can be considered ideal to 
use in the characterisation and refining of the genetic interval containing functional genomic 
motifs that are relevant to both the common occupational and recreational, multifactorial 
soft tissue injuries246. 
 




The diagnosis of CTS was initially made by an Occupational Medical Practitioner (OMP) and 
then confirmed by an Orthopaedic Surgeon. Nerve conduction studies were performed in 
some cases but since it is not a requirement of the Commissioner for Workman’s 
compensation in South Africa, this information was not recorded.  In addition, 150 apparently 
healthy, self-reported Coloured participants (133 female and 17 male) without any reported 
history of CTS symptoms or surgery were recruited as control (CON) participants from 
appropriate industries within the Western Cape region during the same period. The CON 
and CTS participants were matched for the type of occupation and years of exposure for 
wrist activity. Although a case-control ratio of 1:1 is generally accepted as sufficient, 
increasing the number of controls per case will improve the quality of the study. In this study, 
every CTS case was matched to 1.5 control (CON) participants.  
 
Prior to participation in this study, all participants were informed about the procedures and 
gave written informed consent (according to the Declaration of Helsinki) (Appendix A). In 
addition, a questionnaire containing personal details as well as self-reported personal and 
family medical history questionnaires was completed by each participant (Appendix A). This 
study was approved by the Human Research Ethics Committee of the Faculty of Health 
Sciences within the University of Cape Town (HREC 158/2011) (Appendix A). This case-
control genetic association study is reported using the recommendations outlined in the 
genetic association study specific STREGA initiative167. 
 
The CTS and CON groups were matched for age of surgery (age of recruitment was used 
for the CON group), sex, height and country of birth (Table 4.1). Both groups were similarly 
matched for weight and BMI after adjusting for the significant difference (p<0.001) in age of 
recruitment between the CTS (45.6 ± 10.6, n=103) and CON (40.3 ± 9.7, n=149) groups. 





overweight (BMI: >25 to ≤30 kg.m-2), respectively, while 58.4% (n=59) CTS and 44.5% 
(n=65) CON participants were obese (BMI: >30 kg.m-2). 
 
Participants within the CTS (27.2%, n=28) and CON (15.3%, n=23) groups self-reported 
similar histories (p=0.118) of medical condition(s), such as diabetes (9.7 % CTS, n=10 vs 
8.0% CON, n=12), osteoarthritis (OA, 7.8 % CTS, n=8 vs 5.3% CON, n=8), rheumatoid 
arthritis (RA, 3.9 % CTS, n=4 vs 0.7% CON, n=1), thyroid disorders (1.9 % CTS, n=2 vs 
0.7% CON, n=1), diabetes and OA (1.0 % CTS, n=1 vs 0.0% CON), RA and OA (0.0 % CTS 
vs 0.7% CON, n=1), diabetes and RA (1.0 % CTS, n=1 vs 0.0% CON), diabetes and thyroid 
disorder (1.0 % CTS, n=1 vs 0.0% CON), RA and systemic lupus erthematosus (1.0 % CTS, 
n=1 vs 0.0% CON), suggested to be associated with CTS. 
 
Table 4.1 General characteristics of the carpal tunnel syndrome (CTS) and control (CON) groups. 
  CTS (n=103) CON (n=150) p-value 
Age of recruitment (yrs) 45.6 ± 10.6 (103) 40.3 ± 9.7  (148) <0.001 
Age of surgery (yrs) 42.1 ± 10.7 (91) 40.3 ± 9.7 (148)a 0.181 
Sex (% Female) 91.3 (103) 88.7 (150) 0.535 
Height (cm) 159.9 ± 7.6 (101) 160.4  ± 7.7 (148) 0.684 
Weight (kg) 82.8 ± 18.0 (102) 78.5 ± 19.1 (147) 0.193b 
BMI (kg/m2) 32.4 ± 6.9 (101) 30.4 ± 6.8 (146) 0.905b 
Country of birth (% SA) 99.0 (99)c 100.0 (140) 0.414 
 
Values are expressed as a mean ± standard deviation or a frequency (%). The number of participants 
(n) with non-missing data is indicated in parentheses. The maximum number (n) of participants in 
each group is also indicated. 
Significant p-values are indicated in bold. 
a age at recruitment.  
b co-varied for age at recruitment. 
c One participant was born in Namibia. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter; SA, South Africa. 
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Sixty-two percent (n=64) of the CTS and 42.2 % (n=62) of the CON participants self-reported 
a history of one or more other medical conditions (p=0.102).  These included hypertension 
(46.6% CTS, n=48 vs 26.0% CON, n=39), hypercholesterolemia (18.4% CTS, n=19 vs 3.3% 
CON, n=5), asthma (4.9% CTS, n=5 vs 3.3% CON, n=5), angina (6.8% CTS, n=7 vs 0.7% 
CON, n=1) and other conditions (4.9% CTS, n=5 vs 4.7% CON, n=7), which included 
hypotension, malignant disease, anaemia, aortic valve stenosis, epilepsy, kidney disease, 
spinal stenosis, Hirschsprung’s disease and autonomic insufficiency. 
The majority of the participants (27.2% CTS, n=28 and 40.3% CON, n=75) included in this 
study with non-missing data were general poultry processing workers or general workers 
within other industries where repetitive action is performed with the upper limbs (Table 4.2). 
The other major self-reported occupations included administration (22.3% CTS, n=23 and 
11.6% CON, n=17) and nursing (10.7% CTS, n=11 and 8.2% CON, n=12). As summarised 
in Table 4.2 the remaining participants were recruited from several high risk occupations 







Table 4.2 Occupations of the carpal tunnel syndrome (CTS) and control (CON) participants.  
Occupation CTS CON 
 n=103 n=146 
General worker    
 Poultry processing 22.3 (23) 22.6 (49) 
 Other industries a 4.9 (5) 17.7 (26) 
Administrator 22.3 (23) 11.6 (17) 
Nurse 10.7 (11) 8.2 (12) 
Packer 8.7 (9) 6.8 (10) 
Seamstress  7.8 (8) 7.5 (11) 
Operator 7.8 (8) 10.2 (15) 
Food Handler 4.9 (5) 2.7 (4) 
Other b 10.7 (11) 1.4 (2) 
 
Values are expressed as a frequency (%) with the number of participants (n) in parentheses. The 
maximum number (N) of participants with non-missing data in each group is also indicated. 
a includes bottle packer/cleaners, general workers in dairy industry, barrel makers and rotators, 
cleaners, fitters, wrappers.  




There was no significant difference (p=0.077) in the number of participants who reported 
spending their whole working day (100%) performing manual labour requiring the use of their 
hands between the CTS (78.0%, n=79 of 101) and CON (87.9%, n=131 of 149) groups. 
There was however a significant difference (p=0.015) between CTS (Median = 50%, 
interquartile range 5% - 100%) and CON (Median = 100%, interquartile range 10% - 100%) 
groups for the percentage time spent standing during a normal working day. There was no 
significant difference (p=0.295) in number of participants who reported repetitive leisure 




activities of the wrist (e.g. knitting/crocheting, gardening and kneading/rolling dough) within 
the CTS (51.5%, n=50 of 97) and CON (43.9%, n=65 of 148) groups.   
 
There were two related participants in both the CTS and the CON groups (mother and 
daughter). Similar results were obtained when the analyses were repeated after excluding 
one of the related participants.  
 
4.2.2 DNA Extraction  
Approximately 5 ml of venous blood was collected into an EDTA vacutainer tube from each 
participant by venepuncture of the forearm. DNA was extracted at the MRC/UCT Research 
Unit for Exercise Science & Sports Medicine, University of Cape Town, South Africa, as 
previously described by Lahiri and Nurnberger168 with some modifications as described by 
Mokone et al.44. Briefly, blood samples were transferred to 15ml sterile polypropylene tubes 
to which 10ml TKM1 buffer (10mM Tris-HCl pH 7.6, 10mM KCl, 10mM MgCl2 and 2mM 
EDTA) containing 2.5% Nonidet P-40, was added to lyse the red blood cells. Samples were 
then incubated at room temperature for 10 minutes after which the white blood cells (WBC) 
were pelleted by centrifuging at 1200 X g for 10 minutes at room temperature. Samples were 
then washed at least once with one volume TKM1 buffer. The washed WBC pellets were 
resuspended in 800μl TKM2 buffer (10mM Tris-HCl pH 7.6, 10mM KCl, 10mM MgCl2, 0.4M 
NaCl2 and 2mM EDTA) containing 50μl of 10% SDS. Samples were then incubated for at 
least 60 minutes at 550C for lyses of the WBC. After the addition of 150μl of 5M NaClO4 and 
500μl chloroform, samples were mixed thoroughly by means of vortexing. All samples were 
transferred to new 1.5ml microfuge tubes and proteins were precipitated by centrifuging at 
15000 X g (13 000 rpm) for 5 minutes at room temperature. Five hundred μl of the top 
aqueous layer from each sample was transferred to a new 1.5ml microfuge tube containing 
1ml of absolute ethanol in order to precipitate the DNA. The DNA was then pelleted by 
centrifugation at 15000 X g for 2 minutes at room temperature after which it was air dried for 





1mM EDTA, pH 8.0). Finally, each tube was incubated at 650C for 15 minutes in a heating 
block. DNA was then stored at 40C until PCR analysis. Purity and concentration of a subset 
of DNA samples was calculated using nanodrop analysis on the Biotek Synergy HT (Life 
Technologies, Applied Biosystems, Foster City, California, USA). 
 
4.2.3 Genotyping 
All DNA samples (n=253) were all genotyped at the MRC/UCT Research Unit for Exercise 
Science & Sports Medicine, University of Cape Town, South Africa for the MMP10 rs486055 
(C/T), MMP1 rs1799750 (1G/2G), MMP3 rs679620 (A/G) and MMP12 rs2276109 (A/G) 
variants as previously described59 using custom designed fluorescence-based Taqman® 
polymerase chain reaction (PCR) assays (Applied Biosystems, Foster City, California, USA) 
(Figure 4.1).  Allele-specific primer and probe sets (Table 4.3) were used along with a pre-
made PCR mastermix containing ampliTaq DNA polymerase Gold (Applied Biosystems, 
Foster City, California, USA) in a final reaction of 8μl following the manufacturer’s 
recommended cycling conditions which consisted of a 95°C hold step for 10 minutes, 
followed by 40 cycles of a denaturing step of 92°C for 15 seconds and a 60°C 
annealing/extension step of 1 minute. The PCR reactions were carried out in the Applied 
Biosystems StepOnePlus real-time PCR System (Life Technologies, Applied Biosystems, 
Foster City, California, USA) (Figure 4.2). 
  
 





Figure 4.2 Typical allelic discrimination plots using the Taqman® Genotyping assay for (A) MMP10 
rs486055 (C/T), (B) MMP1 rs1799750 (G/GG), (C) MMP3 rs679620 (A/G) and (D) MMP12 rs2276109 
(A/G) on the StepOnePlus™ Real-time PCR System.  
 
 
A number of positive controls of known genotype and DNA-free controls were randomly 
included on PCR plate for quality control purposes. In addition, a subset of samples 
(approximately 10%) was genotyped twice using the same methodology to ensure 
genotyping was consistent. In order to avoid genotyping errors, samples that failed twice to 
amplify during PCR for a particular variant were considered to be unsuccessfully genotyped 
and no further attempts were made to genotype them at that specific locus. A total of 85% 
(n=88 of 103) CTS and 86% (n=129 of 150) CON participants were successfully genotyped 
for MMP1 rs1799750 whilst 92% (n=95 or 103) CTS and 85% (n=127 of 150) CON 
participants were successfully genotyped for MMP3 rs679620. Ninety-four percent (94%, 
n=97 of 103) of CTS and 87% (n=131 of 150) CON participants were successfully genotyped 
for MMP10 rs486055 and finally, 93% (n=96 of 103) CTS and 87% (n=131 of 150) CON 





Table 4.3 MMP Primer and probe sequences used for genotyping 
Polymorphism Primer/Probe Sequence 
MMP10 rs486055 Forward GGAACTTCTGCATTCCTTGGATTTTT 
 Reverse ACAACCTCGAAAAGGATGTGAAACA 
 Probe VIC-ACTGTCCTTTCTTCTAAAC 
 Probe FAM-ACTGTCCTTTTTTCTAAAC 
MMP1 rs1799750 Forward ACATGTTATGCCACTTAGATGAGGAAA 
 Reverse CGTCAAGACTGATATCTTACTCATAAACAATACTTC 
 Probe VIC-TGAGATAAGTCATATCCTTTC 
 Probe FAM-TGAGATAAGTCATATCTTTC 
MMP3 rs679620 Forward GTAAGAGTGACCTAAAAACTATACTTATTCTGTTAGAAA 
 Reverse ACCACTGTCCTTTCTCCTAACAAAC 
 Probe VIC-TGTTTCACATCTTTTTTGAGGTC 
 Probe FAM-TTCACATCTTTTTCGAGGTC 
MMP12 rs2276109 Forward TGCTTTTGTTTGCATGTTTTTGAGATAGA 
 Reverse CCGGGTTCTGTGAATATGAATCCT 
 Probe VIC®-TGAGTGACTCATAGTTGAT 
 Probe FAM®-AGTGACTCACAGTTGAT 
 
Primer and probe sets were incorporated into a PCR mastermix and used as described in section 
4.2.3.  
 
4.2.4 Statistical Analysis 
No allele frequency data was available for the Coloured, South African population in the 
public databases (http://www.ncbi.nlm.nih.gov/snp/). For this reason, the sample size for this 
study was calculated based on the range of the reported minor allele frequencies (0.6 to 
10.5% for MMP10 rs486055, 37.5 to 47.9% for MMP1 rs1799750, 23.0 to 48.3% for MMP3 
rs679620 and 0.0 to 15.9 for MMP12 rs2276109 [Table 4.4]) previously described for 
populations in this public database.  Quanto V.1.2.4 was used to determine the statistical 
power for a given sample size and minor allele frequency26. A sample size of approximately 




100 cases and 150 controls was found to be adequate to detect a genetic effect size ranging 
from 2.05 to 2.80 at a power of 80% and a significance level of 5%, assuming a minor allele 
frequencies ranging from 0.5 to 48.3%. 
 
Data was analysed using STATISTICA (version 11, StatSoft Inc., Tulsa, Oklahoma, USA) 
and Graphpad Prism (version 5, GraphPad Software, San Diego, CA, USA, 
http://www.graphpad.com). A Pearson’s chi-squared test or a Fisher’s exact test was used to 
determine any significant differences between the genotype distributions or any other 
categorical data of the groups. An analysis of variance (ANOVA) was used to detect any 
significant differences between CTS and CON groups for continuous data. Where 
appropriate, values were adjusted for the effect of age at recruitment. A Mann-Whitney U 
test was used to detect significant differences between the CTS and CON groups for non-
parametric data. Statistical significance was accepted at p<0.05. Hardy-Weinberg 
equilibrium (HWE) was established using the program Genepop web version 4.0.10 
(http://genepop.curtin.edu.au/)169,170. Linkage disequilibrium (LD) was calculated using 
CubeX: cubic exact solution (www.oege.org/software/cubex/)171. Inferred haplotypes were 
constructed from MMP10 rs486055 (C/T), MMP1 rs1799750 (G/GG), MMP3 rs679620 (A/G) 
and MMP12 rs2276109 (A/G) variants using Chaplin (version 1.2.2, Emory University School 
of Medicine, Atlanta, Georgia, USA)172,173. No adjustments were made for multiple testing  
considering no obvious appropriate method currently exists174,175. The Bonferroni adjustment 
was considered too conservative since the statistical tests in this and following studies are all 
performed on the same group of participants175. Adjustment for multiple testing was also 
considered inappropriate since there is an a priori hypothesis that the gene variants 















rs486055 (C/T) HAPMAP-YRI 116 T 0.9 
 HAPMAP-GIH 172 T 5.2 
 HAPMAP-LWK 180 T 0.6 
 HAPMAP-MEX 100 T 5.0 
 HAPMAP-MKK 286 T 1.7 
 HAPMAP-TSI 172 T 10.5 
rs1799750 (G/GG) CAUC1 60 GG 43.3 
 AFR1 48 GG 37.5 
 HISP1 46 G 47.0 
 PAC1 48 G 47.9 
rs679620 (G/A) HAPMAP-YRI 216 A 38.9 
 HAPMAP-GIH 174 A 25.3 
 HAPMAP-LWK 174 A 23.0 
 HAPMAP-MKK 282 A 30.5 
 HAPMAP-TSI 172 A 48.3 
rs2276109 (A/G) HAPMAP-YRI 120 G 0.0 
 HAPMAP-GIH 176 G 7.4 
 HAPMAP-MEX 100 G 9.0 
 HAPMAP-MKK 286 G 3.1 
 HAPMAP-TSI 176 G 15.9 
 
HAPMAP-YR, Yoruba in Ibadan Nigeria; HAPMAP-GIH, Gujarati Indians in Houston TX USA; 
HAPMAP-LWK, Luhya in Webuye Kenya; HAPMAP-MEX, Mexican ancestry in Los Angeles CA USA; 
HAPMAP-MKK, Maasai in Kinyawa Kenya; HAPMAP-TSI, Toscani in Italy; CAUC1, individuals of self-
described CAUCASIAN heritage; AFR1, of self-described AFRICAN/AFRICAN AMERICAN heritage; 
HISP1, individuals of self-described HISPANIC heritage; PAC12, individuals of self-described 
PACIFIC RIM heritage 






4.3.1 General characteristics 
Similar to all the participants recruited for this thesis (section 4.2.1), the CTS and CON 
groups of all participants successfully genotyped for at least one of the investigated variants 
were matched for age of surgery (age of recruitment was used for the CON group), sex, 
height and country of birth (Table 4.5). As with the entire cohort, both groups were similarly 
matched for weight and BMI after adjusting for the significant difference (p<0.001) in age of 
recruitment between the CTS (45.5 ± 10.7, n=101) and CON (40.5 ± 9.8, n=141) groups. 
Twenty-two percent (n=22) and 34.0% (n=47) of the CTS and CON participants were 
overweight (BMI: >25 to ≤30 kg.m-2), respectively, while 58.5% (n=58) CTS and 43.5% 
(n=60) CON participants were obese (BMI: >30 kg.m-2).  
 
Similar to the all the participants recruited for this thesis (section 4.2.1), bilateral carpal 
tunnel release surgery was performed in 50 (53.2%) of the CTS participants successfully 
genotyped for at least one of the investigated variants, while 33 (35.1%) only had surgery on 
their dominant hand and 9 (9.6%) had surgery on their non-dominant hand. Two (2.1%) 
participants who reported being ambidextrous had carpal tunnel surgery on their right hand.  
 
Participants within the CTS (25.7%, n=26) and CON (14.9%, n=21) groups self-reported 
similar histories (p=0.266) of medical condition(s), such as diabetes (8.9 % CTS, n=9 vs 
7.8% CON, n=11), osteoarthritis (OA, 7.9 % CTS, n=8 vs 5.0% CON, n=7), rheumatoid 
arthritis (RA, 4.0 % CTS, n=4 vs 0.7% CON, n=1), thyroid disorders (1.0 % CTS, n=1 vs 
0.7% CON, n=1), diabetes and OA (1.0 % CTS, n=1 vs 0.0% CON), RA and OA (0.0 % CTS 
vs 0.7% CON, n=1), diabetes and RA (1.0 % CTS, n=1 vs 0.0% CON), diabetes and thyroid 
disorder (1.0 % CTS, n=1 vs 0.0% CON), RA and systemic lupus erthematosus (1.0 % CTS, 






Table 4.5 General characteristics of the carpal tunnel syndrome (CTS) and control (CON) groups of 
participants successfully genotyped for at least one of the investigated variants for the variants 
investigated in this study. 
  CTS (n=101) CON (n=141) p-value 
Age of recruitment (yrs) 45.5 ± 10.7 (101) 40.5 ± 9.8  (140) <0.001 
Age of surgery (yrs) 42.0 ± 10.7 (90) 40.5 ± 9.8 (140)a 0.284 
Sex (% Female) 91.1 (101) 87.9 (141) 0.530 
Height (cm) 160.0 ± 7.7 (99) 160.5  ± 7.9 (140) 0.622 
Weight (kg) 82.8 ± 18.1 (100) 78.4 ± 19.0 (139) 0.185b 
BMI (kg/m2) 32.4 ± 7.0 (99) 30.3 ± 6.7 (138) 0.138b 
Country of birth (% SA) 99.0 (97)c 100.0 (132) 0.426 
 
Values are expressed as a mean ± standard deviation or a frequency (%). The number of participants 
(n) with non-missing data is indicated in parentheses. The maximum number (n) of participants in 
each group is also indicated. 
Significant p-values are indicated in bold. 
a age at recruitment.  
b co-varied for age at recruitment. 
c One participant was born in Namibia. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter; SA, South Africa. 
 
 
Sixty-two percent (n=62) of the CTS and 42.0% (n=58) of the CON participants self-reported 
a history of one or more other medical conditions (p=0.004).  These included hypertension 
(45.5% CTS, n=46 vs 26.6% CON, n=37), hypercholesterolemia (18.8% CTS, n=19 vs 3.6% 
CON, n=5), asthma (5.0% CTS, n=5 vs 3.4% CON, n=5), angina (6.9% CTS, n=7 vs 0.7% 
CON, n=1) and other conditions (5.0% CTS, n=5 vs 5.0% CON, n=7), which included 
hypotension, malignant disease, anaemia, aortic valve stenosis, epilepsy, kidney disease, 
spinal stenosis, Hirschsprung’s disease and autonomic insufficiency. 
 
 




Similar to all the participants recruited for this thesis (section 4.2.1), the majority of the 
participants (27.7% CTS, n=28 and 51.8% CON, n=75) who were successfully genotyped for 
at least one of the four MMP variants, with non-missing data were general poultry processing 
workers or general workers within other industries where repetitive action is performed with 
the upper limbs (Table 4.6). The other major self-reported occupations included 
administration (21.8% CTS, n=22 and 10.6% CON, n=15) and nursing (9.9% CTS, n=10 and 
8.5% CON, n=12). As summarised in Table 4.6 the remaining participants were recruited 
from several high risk occupations which included work where the hands/wrists are used for 
a high percentage of the normal working day.   
 
Similar to all participants recruited for this thesis (section 4.2.1), there was also no significant 
difference (p=0.115) between the number of participants, successfully genotyped for at least 
one of the four MMP variants, who reported spending their whole working day (100%) 
performing manual labour requiring the use of their hands between the CTS (78.8%, n=78 of 
99) and CON (87.1%, n=122 of 140). Similarly, there was a significant different (p=0.041) 
between CTS (Median = 50%, interquartile range 10% - 100%) and CON (Median = 100%, 
interquartile range 10% - 100%) participants who were successfully genotyped, for the 
percentage time spent standing during a normal working day. There was no significant 
difference (p=0.351) in number of successfully genotyped participants who reported 
repetitive leisure activities of the wrist (e.g. knitting/crocheting, gardening and 
kneading/rolling dough) within the CTS (55.6%, n=49 of 95) and CON (32.9%, n=60 of 140) 
groups. 
 
There were no genotype effects on any of the other physiological characteristics of the 







Table 4.6 Occupations of the carpal tunnel syndrome (CTS) and control (CON) participants who were 
successfully genotyped for at least one of the variants investigated in this study. 
Occupation CTS CON 
 n=101 n=137 
General worker    
 Poultry processing 22.7 (23) 31.9 (45) 
 Other industries a 5.0 (5) 18.4 (26) 
Administrator 21.8 (22) 10.6 (15) 
Nurse 9.9 (10) 8.5 (12) 
Packer 8.9 (9) 6.4 (9) 
Seamstress  7.9 (8) 7.8 (11) 
Operator 7.9 (8) 9.2 (13) 
Food Handler 5.0 (5) 2.8 (4) 
Other b 10.9 (11) 1.4 (2) 
 
Values are expressed as a frequency (%) with the number of participants (n) in parentheses. The 
maximum number (N) of participants with non-missing data in each group is also indicated. 
a includes bottle packer/cleaners, general workers in dairy industry, barrel makers and rotators, 
cleaners, fitters, wrappers.  





There were no significant differences between in any of the genotypes and allele 
distributions between the CTS and CON groups for any of the MMP variants. All four 
variants were in Hardy-Weinberg equilibrium (Table 4.7). Similar genotype distributions were 
observed when participants with a history of a medical condition believed to be associated 
with CTS were excluded from the analysis (Supplementary table 4.5, Appendix B).   




Table 4.7 Genotype frequency distributions of the MMP10 rs486055, MMP1 rs1799750, MMP3 
rs679620 and MMP12 rs2276109 polymorphism in carpal tunnel syndrome (CTS) and control (CON) 
groups for all participants (All) as well as the female participants (Female). 
 
All Female 
CTS CON CTS CON 
MMP10 rs486055 n=97 n=131 n=88 n=114 
 CC Genotype 91.8 (89) 90.1 (118) 92.1 (81) 88.6 (101) 
 CT Genotype 8.3 (8) 9.9 (13) 8.0 (7) 11.4 (13) 
 TT Genotype 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 
Genotype p-value  0.818 0.482 
 T Minor Allele 4.1 (8) 5.0 (13) 4.0 (7) 5.7 (13) 
Allele p-value 0.673 0.428 
HWE 1.000 1.000 
MMP1 rs1799750 n=88 n=129 n=79 n=113 
 GG Genotype 22.7 (20) 17.8 (23) 24.1 (19) 19.5 (22) 
 GGG Genotype 42.1 (37) 47.3 (61) 40.5 (32) 48.7 (55) 
 GGGG Genotype 35.2 (31) 34.9 (45) 35.4 (28) 31.9 (36) 
Genotype p-value 0.621 0.517 
 G Minor Allele 43.8 (77) 41.5 (107) 44.3 (70) 43.8 (99) 
Allele p-value 0.637 0.923 
HWE 0.269 0.311 
MMP3 rs679620 n=95 n=127 n=86 n=110 
 GG Genotype 42.3 (43) 51.2 (65) 46.5 (40) 47.3 (52) 
 GA Genotype 46.3 (44) 37.8 (48) 44.2 (38) 40.9 (45) 
 AA Genotype 8.4 (8) 11.0 (14) 9.3 (8) 11.8 (13) 
Genotype p-value 0.424 0.813 
 A Minor Allele 31.6 (60) 29.9 (76) 31.4 (54) 32.3 (71) 
Allele p-value 0.708 0.853 
HWE 0.754 0.742 
MMP12 rs2276109 n=96 n=131 n=87 n=114 
 AA Genotype 87.5 (84) 90.1 (118) 87.4 (76) 88.6 (101) 
 AG Genotype 12.5 (12) 9.9 (13) 12.6 (11) 11.4 (13) 
 GG Genotype 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 
Genotype p-value 0.668 0.829 
 G Minor Allele 6.3 (12) 5.0 (13) 6.3 (11) 5.7 (13) 
Allele p-value 0.552 0.795 
HWE 1.000 1.000 
 
Values are expressed as a frequency (%) with the number of participants (n) in parentheses. The 
maximum number (N) of participants in each group is also indicated. Significant p-values are 





The MMP12 rs2276109 variant was in linkage disequilibrium (LD) with MMP3 rs679620 
(CTS D’=1.000 and CON D’=1.000), MMP1 rs1799750 (CTS D’=1.000 and CON D’=0.674) 
and MMP10 rs486055 (CTS D’=1.000 and CON D’=1.000). Similarly MMP1 rs1799750 was 
in LD with MMP10 rs486055 (CTS D’=0.661 and CON D’=0.535). However the MMP3 
rs679620 variant was not in LD with MMP10 rs486055 (CTS D’=0.169 and CON D’=0.667) 
nor with MMP1 rs1799750 (CTS D’=0.536 and CON D’=0.393).  
 
4.3.3 Inferred Haplotypes 
Five of the inferred haplotypes constructed from the four variants out of a possible sixteen 
had a frequency greater than 2% (Figure 4.3A). There were no significant differences 
between the CTS and CON groups for any of the haplotypes. Inferred haplotypes were also 
constructed from the two most informative variants, MMP1 rs1799750 and MMP3 rs679620. 
All four haplotypes had a frequency greater than 2% (Figure 4.3B). There were also no 
significant differences between the CTS and CON groups for any of the haplotypes.  
 
 





Figure 4.3 Inferred haplotypes constructed from the (A) MMP10 rs486055, MMP1 rs1799750, MMP3 
rs679620 and MMP12 rs2276109 polymorphisms and (B) the MMP1 rs1799750 and MMP3 rs679620 








The main finding of this study was there was no individual association between the MMP10 
rs486055, MMP1 rs1799750, MMP3 rs679620 or MMP12 rs276109 variants and CTS. 
Similarly, there were also no associations between any of the inferred haplotypes 
constructed from all four variants or from MMP1 rs1799750 and MMP3 rs679620 with CTS.  
 
A previous study has shown that the MMP3 rs679620 variant and two other MMP3 variants 
were independently associated with risk of Achilles tendinopathy (AT) and that rs679620 
also interacts with a variant (rs12722, C/T) with a functional region of the COL5A1 gene, 
which codes for the α1 chain of type V collagen, to alter the risk of AT58. Furthermore, 
inferred haplotypes constructed of the same four MMP variants investigated in this study 
have previously been associated with altered risk of anterior cruciate ligament (ACL) 
injuries59. The MMP1 rs1799750 variant is also independently associated with primary 
posterior tibial (PPT) tendinopathy in Brazilian females163. Considering these findings, and 
the suggested role of flexor tendon involvement in the compression of the median nerve in 
CTS3,176, the four MMP gene variants investigated in this study were considered plausible 
candidates for potential association with altered risk of CTS. The MMP10 rs486055 and 
MMP3 rs679620 variants are both non-synonymous polymorphisms that result in amino acid 
changes within pro-MMP10 and pro-MMP3, respectively59, whereas the MMP1 rs1799750 
and MMP12 rs2276109 variants are both promoter polymorphisms that have been shown to 
alter transcriptional activity165,166. The MMP1 rs1799750 polymorphism is manifested as 
either the presence or absence of an extra guanine at -160 7bp that creates, in the presence 
of the extra guanine (GG), an Ets binding site (5’-GGA-3’) that leads to increased 
transcription. The GG allele has been shown to  have significantly higher transcription of 
MMP1 than the G allele165. The MMP12 rs2276109 polymorphism in turn influences the 




binding of transcription factor activator protein-1 (AP-1) which is involved in regulating gene 
expression. More specifically, the A allele has been shown to increase the affinity of AP-1166. 
 
The MMP10 rs486055 and MMP3 rs679620 variants are both non-synonymous SNPs. 
MMP3 rs679620 results in a G to A substitution that causes a change from glutamate to 
lysine whereas the MMP10 rs486055 G to A substitution results in a change from an 
arginine to a lysine. The specific consequence of these amino acid changes remains 
unknown, but neither of these non-synonymous SNPs were predicted to be damaging when 
analyzed using the SIFT (Sorting Intolerant From Tolerant) program59,177. The four variants 
included in this study have all been independently associated with complex phenotypes, 
including rheumatoid arthritis178, osteoarthritis162, lumbar disk degeneration179 and idiopathic 
scoliosis180  
 
Although, in this study, there was no association between the investigated variants and CTS, 
it does not exclude the possibility that other variants within the MMP1, MMP3, MMP10 and 
MMP12 could potentially be associated with altered risk of CTS. One such example is the 
MMP3 5A/6A polymorphism. This variants has been associated with several multifactorial 
conditions62 and plays in important role in the regulation of MMP gene expression181.   
 
Several other MMP genes, including MMP7, MMP8, MMP13 and MMP20, also form part of 
the cluster of MMP genes on chromosome 11, together with the four investigated in this 
study. As previously mentioned, the MMP8 rsrs11225395 variant is associated with primary 
posterior tibial (PPT) tendinopathy in Brazilian females164. Furthermore, variants within other 
MMPs, which include MMP2 and MMP9, have been associated with vascular remodelling. 
MMP2 is produced and activated in the flexor tenosynovium in early CTS182.  Variants within 






The balance between degradation, mediated by the MMPs, and inhibition of degradation, 
mediated by the TIMPs is very important in the maintenance of the ECM62. It has been 
proposed that an over- or under production of MMPs in comparison to TIMPs are related to 
pathology62 but it is unknown whether a change in production of MMPs will alter the risk of 
CTS. Considering the important role of the TIMPs in the maintenance of the ECM, future 
work should also consider variants in the family of the four TIMP genes, especially 
considering the previous association of TIMP2 with Achilles tendinopathy158. The ADAMs (a 
disintegrin and metalloproteinase) and ADAMTSs (a disintegrin and metalloproteinase with 
thrombospondin motifs) are, like the MMPs and TIMPs also proteins involved in the 
regulation of the ECM and other connective tissues. Variants within the ADAM and ADAMTS 
genes could therefore also be considered as ideal candidates for the investigation of 
connective tissue disorders and should be investigated in the future.  
 
In conclusion, the four MMP gene variants investigated in this study were not associated 
with risk of CTS in a South African Coloured population. However, this finding does not 
exclude other variants within the same and other MMP genes to potentially be associated 
with CTS. 






CHAPTER 5: THE COL5A1 GENE IS ASSOCIATED WITH INCREASED RISK OF 
CARPAL TUNNEL SYNDROME 
 
 
The data presented in this chapter was published in the following peer-reviewed 
article: Marilize Burger, Hanli de Wet, Malcolm Collins. The COL5A1 gene is associated 




In the previous chapter variants within four MMP genes were shown not to be associated 
with altered risk for CTS in the population investigated in this thesis.  These genes encode 
for distinct endopeptidases, which are involved in collagen fibril remodelling. The collagen 
fibril consists predominately of type I collagen together with other collagens, such as type V 
collagen, and non-collagen macromolecules (refer to figure 1.2). The major isoform of type V 
collagen, which regulates fibrillogenesis41, is a heterotrimer consisting of two α1 and one α2 
chains, which are encoded by the COL5A1 and COL5A2 genes respectively42.  
 
Two functional copies of the COL5A1 gene are required for normal development during 
embryogenesis, since mutations that inactivate both copies of the gene result in death in 
utero in a murine model183,184. Mutations, which inactivate a single copy of the gene (known 
as haploinsufficiency), cause a severe autosomal dominant condition known as classical 
type Ehlers-Danlos syndrome (EDS)42. This condition is characterized by, amongst other 
features, skin hyper-extensibility and joint hypermobility42. In addition, common DNA 
sequence variants within COL5A1 contribute to more complex, less severe multifactorial 
traits, which arise as a result of the interaction of environmental exposures on the genetic 





(UTR) have been associated with chronic Achilles tendinopathy44,45, and other exercise-
associated phenotypes185–188. 
 
Specifically the CC genotype of the COL5A1 3’-UTR rs12722 (C/T) variant (Figure 5.1) was 
associated with decreased risk of developing chronic Achilles tendinopathy44,45, anterior 
cruciate ligament ruptures in females46, an age-related increase in sit-and-reach range of 
motion189 and exercise associated muscle cramping186, while the TT genotype was 
associated with superior endurance running performance187,188. Furthermore, the -/- 
genotype of the downstream COL5A1 3’-UTR rs71746744 (-/AGGG) variant (Figure 5.1) 
was significantly over-represented in the participants with chronic Achilles tendinopathy185, 
while the AGGG/AGGG genotype was shown to be associated with increased running 
performance and a decreased range of motion (ROM)190.   The -/- and TT genotypes of two 
other tightly linked COL5A1 3’-UTR variants, rs16399 (ATCT/-) and rs1134170 (A/T) 
respectively, downstream of rs71746744 have also been shown to be associated with 
chronic Achilles tendinopathy185. Although seemingly unrelated, these phenotypes are all 
directly or indirectly associated with the mechanical properties of musculoskeletal soft 
tissue184. 
 
In addition, it has been proposed that these COL5A1 3’-UTR variants are believed to be 
functional, altering COL5A1 messenger RNA (mRNA) stability within the cytoplasm of the 
tenocyte191. Specifically, the COL5A1 rs12722 T, rs71746744 AGGG, rs16399 deletion (-) 
and rs1134170 T alleles are associated with increased COL5A1 mRNA stability185. Altered 
COL5A1 mRNA stability has been proposed to result in altered type V collagen production, 
changes in collagen fibril diameter and packing density, and potentially altering the 
mechanical properties of connective tissues184.   
 
Since it has been suggested that there could be a genetic predisposition to CTS24,153–156,192, 




and that the flexor tendons within the carpal tunnel structure could be directly involved in the 
aetiology3,12,176, it is therefore tempting to speculate that DNA sequence variants within the 
functional COL5A1 3’-UTR are also associated with CTS. The aim of this study was to 
determine whether three COL5A1 DNA sequence variants, rs13946 (T/C), rs12722 (C/T) 
and rs71746744 (-/AGGG), are associated with CTS (Figure 5.1).  Since it has previously 
been reported that rs71746744, rs16399 and rs1134170 are tightly linked, only rs71746744 
was included in this study. Although rs13946 (C/T) was not previously associated with 
chronic Achilles tendinopathy44,45, it was nevertheless identified as one of the functional 
variants within the COL5A1 3’-UTR191, and was therefore included in this study.   Based on 
previous findings, it was hypothesised that the CC genotype of rs12722 will be under-
represented in the CTS population, while the -/- genotype of rs71746744 will be over-
represented.  
 
The primary aim of this study was to determine whether three COL5A1 DNA sequence 
variants, rs13946 (T/C), rs12722 (C/T) and rs71746744 (-/AGGG), are associated with CTS 
(Figure 5.2).  Since it has previously been reported that rs71746744, rs16399 and 
rs1134170 are tightly linked, only rs71746744 was included in this study. Based on previous 
findings, we hypothesise that the CC genotype of rs12722 will be under-represented in the 
CTS population, while the -/- genotype of rs71746744 will be over-represented. Since it has 
previously been reported that COL5A1 and MMP3 variants interact to modulate risk for 
chronic Achilles tendinopathy58, the secondary aim of this study was to investigate whether 
















Figure 5.1 A schematic representation of the exon (vertical lines) and intron (horizontal lines) 
boundaries of the COL5A1 gene located on chromosome 9q34. The 3’-end of the gene spanning 
exons 65 to 66 has been enlarged. Exon 66 encodes for the terminal amino acids of the α1(V) chain 
(black box), the stop codon and the 3’-untranslated region (UTR) (clear box). The five variants 
(indicated in black boxes), (i) rs13946 (T/C), (ii) rs12722 (C/T), (iii) rs71746744 (-/AGGG), (iv) rs16399 
(ATCT/-) and (v) rs1134170 (A/T), discussed in this chapter are all located within the 3’-UTR. Only 
rs13946, rs12722 and rs71746744 were included in this study. The sequences flanking the variants 
and the polymorphic nucleotide changes, with the wild type nucleotide indicated on top, are indicated 
in the grey boxes. As illustrated in the figure, each variant produces three possible genotypes. The 
phenotypes, as well as the population group investigated, shown to be associated with specific 
variants within the COL5A1 3’-UTR are indicated by dashed brackets.  
 
 




ACCAAGAAAG GCTACCAGAA GACGGTTCTG GAGATCGACA CCCCCAAAGT GGAGCAGGTG 60 
                   Forward Primer  DpnII     
 
CCCATCGTGG ACATCATGTT CAATGACTTC GGTGAAGCGT CACAGAAATT TGGATTTGAA 120  
  
GTGGGGCCGG CTTGCTTCAT GGGCTAGGAG CCGCCGAGCC CGGGCTCCCG AGAGCAACCT 180  
 
CGTGACCTCA GCATGCCATT CGTTCGTGAG TGTCCCGTGC ACGTCCTGAC CCTGGACAGT 240 
                                   rs13946 (C/T)  DpnII 
 
GAAGGCTTCT CCCTCCCCTC CCACCTGACT TCATCTACGC CTCGGCACCA CGGGGTGTGG 300 
 
GACCCCAGCC CGGAGAGAAC AGAGGGAAGG AGCCGCGCCC CCACCTGGAG CTGAATCACA 360 
                                   BstUI 
                       rs146776422(C/T) rs55748801(G/A) 
 
TGACCTAGCT GCACCCCAGC GCCTGGGCCC GCCCCACGCT CTGTCCACAC CCACGCGCCC 420 
                                           rs12772 (C/T) BstUI  
 
CGGGAGCGGG GCCATGCCTC CAGCCCCCCA GCTCGCCCGA CCCATCCTGT TCGTGAATAG 480  
 
GTCTCAGGGG TTGGGGGAGG GACTGCCAGA TTTGGACACT ATATTTTTTT CTAAATTCAA 540  
  
CTTGAAGATG TGTATTTCCC CTGACCTTCA AAAAATGTTC CAAGGTAAGC CTCGTAAAGG 600  
  
TCATCCCACC ATCACCAAAG CCTCCGTTTT TAACAACCTC CAACACGATC CATTTAGAGG 660 
                                                  DpnII 
  
CCAAATGTCA TTCTGCAGGT GCCTTCCCGA TGGATTAAAG GTGCTTATGT TTTTGTGAGT 720 
         Reverse Primer        
 
TTTAAGTAAA TATTTGTATT GTATTGTTAT AAATGTTAAG TGTGCCTGGC TTTCAATCAT 780 
   
GCACGGAAAC CCAGTCTCAG TCCCACGGAC AGAATGGGCG AGGCATGGAT TCTGGGTTGC 840  
  
AGTACCGTTC TGATTAGAAA TAGGAAGTCT CCCCACCCCC GCCCTGGCCA AGAACGTGCA 900 
 
ATAAATTGGA AGTTTGCCCC GGGGCAGCAA GAATTTATGC TGCCATTGAA AAGCAGGTAC 960 
   
CAGTGCCCCT TTTCAGACAG TTTTTGATTC GCTCTAGACT TTTTTTTTTT TTAATAGGGA 1020 
                                                   rs71746744 (-/AGGG) 
 
Figure 5.2 Nucleotide sequence of the 5’-end (nucleotides 1 to 1020) of the COL5A1 exon 66 
(pubmed accession no. NM_000093) containing the 3’-untranslated region (UTR).  The sequence 
highlighted in grey (nucleotides 1-147) represents the translated region of exon 66 and the stop 
codon, TAG (underlined). Nucleotide numbers are annotated on the right side of the sequence.  The 
positions of key variants within the 3’-UTR are highlighted in black with the text in white. The 
sequence contains the wild-type nucleotides of the polymorphic sites.  The accession numbers and 
nucleotide substitutions of the selected variants are indicated. The reverse and forward primers used 
to amplify a 667 bp PCR product are also indicated (bold underlined). The DpnII and BstUI restriction 
sites within the PCR product are annotated on the sequence (double underlined). Both the BstUI and 








5.2.1 Participants & DNA Extraction 
The same participants, described in section 4.2.1, were also analysed in this study. DNA 
extraction was performed as described in section 4.2.2. 
 
5.2.2 Genotyping 
All DNA samples (n=253) were all genotyped for the COL5A1 rs13946 (T/C), rs12722 (C/T) 
and rs71746744 (I/II) variants at the MRC/UCT Research Unit for Exercise Science & Sports 
Medicine, University of Cape Town, South Africa. At least 6 positive controls of known 
genotype and 4 DNA-free controls were randomly included on each PCR plate for quality 
control purposes. In addition, a subset of samples (approximately 10%) was genotyped twice 
using the same methodology to ensure genotyping was consistent. In order to avoid 
genotyping errors, samples that failed twice to amplify during PCR for a particular variant 
were considered to be unsuccessfully genotyped and no further attempts were made to 
genotype them at that specific locus.  
 
5.2.2.1  COL5A1 rs13946 and rs12722  
A 667 bp DNA amplicon containing the rs13946 single nucleotide polymorphism (SNP, C/T) 
and rs12722I SNP (C/T) RFLPs within the COL5A1 3’-UTR was PCR (polymerase chain 
reaction) amplified as previously described by Greenspan and Pasquinelli (1994) 193 and 
modified by Mokone et al. (2006)44. The PCR reaction was performed in a final volume of 
60μl containing at least 100ng DNA, 20pmol of the forward and reverse primers (Table 5.1), 
2.0mM MgCl2, 50mM KCl, 10mM Tris-HCl (pH 8.3), 200μmol of dNTPs (dATP, dTTP, dCTP 
and dGTP) and 1 unit of DNA Taq polymerase (New England Biolabs, Ipswich, 
Massachusetts, USA). The amplification was performed with an initial denaturing step for 3 
minutes at 94°C, 35 x cycles of denaturing for 1 min at 94°C, annealing for 1 minute at 53°C, 




extension for 1.5 minute at 72°C and the final extension step for 8 minutes at 72°C on a 
thermal cycler (Hybrid, PCR Express, Middle sex, UK).  
 
Table 5.1 Primer and probe sequences used for genotyping of variants within the COL5A1 3’-
untranslated region 









C – 612, 40, 
15 




T – 351, 316 








Primer and probe (where applicable) sets were incorporated into a PCR mastermix and used as 
described in materials and methods. The restriction endonuclease and DNA fragment sizes are 
indicated where applicable. 
SNP, single nucleotide polymorphism 
Bp, base pair 
 
The 667 bp PCR products were digested with the restriction endonucleases, DpnII or BstUI, 
and the resultant amplicons were resolved together with a 100bp molecular weight marker 
and SYBER® Gold nucleic acid gel stain (Invitrogen Molecular ProbesTM, Oregon, USA) on 
6% non-denaturing polyacrylamide gels (Figure 5.3A and B). The gels were photographed 
under UV light using an Uvitec photodocumentation system (Uvitec Limited, Cambridge, UK) 
and genotypes were determined based on the resultant DNA fragment sizes (Table 5.2). 
Eighty-eight % (n=91 of 103) of the cases and 85 % (n=127 of 150) of the controls were 
successfully genotyped for COL5A1 rs13946, whereas 96% (n=99 of 103) of the cases and 






Figure 5.3 Typical 6% non-denaturing polyacrylamide gels showing the genotypes of the (A) COL5A1 
DpnII rs13946 and (B) COL5A1 BstUI rs12722 restriction fragment length polymorphisms (RFLPs). 
Digestion of the 667 bp PCR product with (A) DpnII produce 612 bp, 40 bp and 15 bp fragments for 
the T-allele and 418 bp, 144 bp,  40 bp and 15 bp for the C-allele and (B) with BstUI. Within this 
population group, the 667 bp PCR product contains two informative polymorphic BstUI restriction 
sites. The first site contains the well characterised SNP rs12722 (C/T). The BstUI site is present in the 
C allele and destroyed in the T allele. The second upstream polymorphic BstUI site overlaps two rare 
adjacent SNPs, rs146776422 (C/T) and rs55748801 (G/A). The CG wild-type (designated as W in this 
study) alleles of these two adjacent SNPs contains a BstUI site which is destroyed by either of the 
alternative nucleotides (CA, TG or TA, designated as M in this study). Four alleles of the BstUI RFLP 
are therefore produced, which have been designated WC, WT, MC and MT (Table 3.2). The WC 
alleles produce 316, 271 and 80 bp fragments, while the WT alleles produce 351 and 316 bp 
fragments. The MC and MT alleles produce 398 and 271 bp and 667 bp fragments respectively (not 
shown). 
 
The genotypes of three participants designated with a WM + CT genotype using the BstUI 
RFLP method was further confirmed by Sanger sequencing of the PCR amplified 667bp 
DNA fragment by the Central Analytical Facility (University of Stellenbosch, Stellenbosch, 
South Africa) as previously described 191. BioEdit 7.0.5.2 
(www.mbio.ncsu.edu/bioedit/bioedit.html) was used to analyze the obtained sequence 













Table 5.2 The DNA fragment sizes of the BstUI digested 667 bp PCR product of the COL5A1 3’-
untranslated region, which contains two informative polymorphic BstUI restriction sites. The first site 
contains variant rs12722 (C/T). The BstUI site is present in the C allele and destroyed in the T allele. 
The second site contains two rare adjacent variants, rs146776422 (C/T) and rs55748801 (G/A). The 
CG wild-type (designated as W) allele of these two adjacent variants contains a BstUI site, while the 
site is destroyed by either the alternative sequence variations (CA, TG or TA, designated as M). Four 
alleles are therefore produced after digestion with BstUI, which have been designated WC, WT, MC 
and MT. The sizes of the digested fragments are indicated with a tick. The corresponding genotypes 




Fragment Sizes (bp) 
Genotype 
667 396 351 316 271 80 
WC       - 
WT       - 
MC       - 
MT       - 
WC, WC       WW + CC
WC, WT       WW + CT
WC, MC       WM + CC
WC, MT       WM + CT 
WT, WT       WW + TT 
WT, MC       WM + CT 
WT, MT       WM + TT 
MC, MC       MM + CC 
MT, MC       MM + CT 









COL5A1   CGTGACCTCA GCATGCCATT CGTTCGTGAG TGTCCCGTGC ACGTCCTGAC CCTGGACAGT 240 
Variant                             T                          T (rs13946) 
Restriction Site                                                    DpnII 
Participant A  ---------- ---------- ---------- ---------- ---------T ---------- 
Participant B  ---------- ---------- ---------- ---------- ---------T ---------- 
Participant C  ---------- ---------- ---------- ---------- ---------T ---------- 
 
COL5A1   GAAGGCTTCT CCCTCCCCTC CCACCTGACT TCATCTACGC CTCGGCACCA CGGGGTGTGG 300 
Variant                                                      T    A 
Participant A  ---------- ---------- ---------- ---------- ---------- ---------- 
Participant B  ---------- ---------- ---------- ---------- ---------- ---------- 
Participant C  ---------- ---------- ---------- ---------- ---------- ---------- 
 
COL5A1   GACCCCAGCC CGGAGAGAAC AGAGGGAAGG AGCCGCGCCC CCACCTGGAG CTGAATCACA 360 
Variant          C                (rs146776422) TA (rs55748801) 
Restriction Site                                    BstUI 
Participant A  ---------- ---------- ---------- -----Y---- ---------- ---------- 
Participant B  ---------- ---------- ---------- -----Y---- ---------- ---------- 
Participant C  ---------- ---------- ---------- -----Y---- ---------- ---------- 
 
COL5A1   TGACCTAGCT GCACCCCAGC GCCTGGGCCC GCCCCACGCT CTGTCCACAC CCACGCGCCC 420 
Variant                                                             T (rs12722) 
Restriction Site                                                           BstUI 
Participant A  ---------- ---------- ---------- ---------- ---------- ---Y------ 
Participant B  ---------- ---------- ---------- ---------- ---------- ---Y------ 
Participant C  ---------- ---------- ---------- ---------- ---------- ---Y------ 
 
COL5A1   CGGGAGCGGG GCCATGCCTC CAGCCCCCCA GCTCGCCCGA CCCATCCTGT TCGTGAATAG 480  
Variant    GG                                     T 
Participant A  ---------- ---------- ---------- ---------- ---------- ---------- 
Participant B  ---------- ---------- ---------- ---------- ---------- ---------- 
Participant C  ---------- ---------- ---------- ---------- ---------- ---------- 
 
 
Figure 5.4 DNA sequence, corresponding to nucleotides 181 to 480, of the COL5A1 exon 66 
(pubmed accession no. NM_000093). Nucleotide numbers are annotated on the right side of the 
sequence.  The positions of variants within this region of the 3’-UTR are highlighted in black with the 
text in white. The sequence contains the wild-type nucleotides of the polymorphic sites. The minor 
nucleotides are annotated below the sequence. The accession numbers of selected variants are 
indicated. The polymorphic DpnII and BstUI restriction sites are also indicated (underlined). The 
corresponding sequence data from participants A, B and C are aligned, with the dashes (-) indicating 
identical sequence. Since total genomic DNA was sequences from each participant, the Y represents 
a C for one copy of the gene and a T on the other copy.  
 
5.2.2.2 COL5A1 rs71746744 (-/AGGG) variant 
DNA samples were genotyped for the COL5A1 rs71746744 (-/AGGG) variant in the 3’-UTR 
of the COL5A1 gene using a custom designed fluorescence-based Taqman® polymerase 
chain reaction (PCR) assay (Applied Biosystems, Foster City, California, USA).  Allele-
specific primer and probe sets (Table 5.1) were used along with a pre-made PCR mastermix 
containing ampliTaq DNA polymerase Gold (Applied Biosystems, Foster City, California, 
USA) in a final reaction of 8 μl following the manufacturer’s recommended cycling conditions 
as described in section 4.2.3. The PCR reactions were carried out in the Applied Biosystems 




StepOnePlus real-time PCR System (Life Technologies, Applied Biosystems, Foster City, 
California, USA). Eighty-one % (n=83 of 103) of the cases and 83% (n=124 of 150) of the 
controls were successfully genotyped for COL5A1 rs71746744 (Figure 5.5). 
 
 




5.2.3 Statistical Analysis 
No allele frequency data was available for the Coloured, South African population in the 
public databases (http://www.ncbi.nlm.nih.gov/snp/). For this reason, the sample size for this 
study was calculated based on the range of the reported minor allele frequencies, 10.5 to 
43.0% for COL5A1 rs13946, 13.6 to 43.4% for COL5A1 rs12722 and 14.2% for COL5A1 
rs71746744, previously described for populations in this public database (Table 
5.3).  Quanto V.1.2.4 was used to determine the statistical power for a given sample size 
and minor allele frequency26. A sample size of approximately 100 cases and 150 controls 
was found to be adequate to detect a genetic effect size ranging from 2.05 to 2.80 at a 
power of 80% and a significance level of 5%, assuming a minor allele frequency ranging 






Table 5.3 Minor allele frequencies of the investigated polymorphisms in different populations. 






rs13946 (T/C) HAPMAP-YRI 226 C 38.4 
 HAPMAP-GIH 176 C 21.6 
 HAPMAP-LWK 180 C 12.8 
 HAPMAP-ASW 98 C  11.5 
 HAPMAP-MEX 100 C 43.0 
 HAPMAP-MKK 286 C 10.5 
 HAPMAP-TSI 176 C 23.3 
 HAPMAP-CEU 226 C 23.5 
rs12722 (C/T) HAPMAP-YRI 118 T 13.6 
 HAPMAP-JPT 82 T 15.9 
 HAPMAP-HCB 86 T 22.1 
 HAPMAP-CEU 106 C 43.4 
rs71746744 (-/AGGG) South African 106 I 14.21 
 
HAPMAP-YR, Yoruba in Ibadan Nigeria; HAPMAP-GIH, Gujarati Indians in Houston TX USA; 
HAPMAP-LWK, Luhya in Webuye Kenya; HAPMAP-ASW, African ancestry in Northwest USA; 
HAPMAP-MEX, Mexican ancestry in Los Angeles CA USA; HAPMAP-MKK, Maasai in Kinyawa 
Kenya; HAPMAP-TSI, Toscani in Italy; HAPMAP-CEU, Utah residents with Northern and Western 
European ancestry; HAPMAP-JPT, Japanese in Tokyo, Japan; HAPMAP-HCB, Han Chinese in 
Beijing, China. 
1 Participants in a South African road running event190. 
 
Data was analysed using STATISTICA (version 11, StatSoft Inc., Tulsa, Oklahoma, USA) 
and Graphpad Prism (version 5, GraphPad Software, San Diego, CA, USA, 
http://www.graphpad.com). A Pearson’s chi-squared test or a Fisher’s exact test was used to 
determine any significant differences between the genotype distributions or any other 
categorical data of the groups. An analysis of variance (ANOVA) was used to detect any 
significant differences between CTS and CON groups for continuous data. Where 
appropriate, values were adjusted for the effect of age at recruitment. A Mann-Whitney U 




test was used to detect significant differences between the CTS and CON groups for non-
parametric data. Statistical significance was accepted at p<0.05. Hardy-Weinberg 
equilibrium (HWE) was established using the program Genepop web version 4.0.10 
(http://genepop.curtin.edu.au/)169,170 Linkage disequilibrium (LD) was calculated using 
CubeX: cubic exact solution (www.oege.org/software/cubex/)171. Inferred haplotypes were 
constructed from rs13946 (C/T), rs146776422/rs55748801 (W/M), rs12722 (C/T) and 
rs71746744 (-/AGGG), as well as rs12722 and each of the four MMP variants (MMP10 
rs486055, MMP1 rs1799750, MMP3 rs679620 and MMP12 rs2276109) genotyped in 
Chapter 4, using Chaplin (version 1.2.2, Emory University School of Medicine, Atlanta, 
Georgia, USA)172,173 and Hapstat software (version 3.0, University of North Carolina at 
Chapel Hill, North Carolina, USA)194. No adjustments were made for multiple testing  
considering no obvious appropriate method currently exists174,175. The Bonferroni adjustment 
was considered too conservative since the statistical tests in this and following studies are all 
performed on the same group of participants175. Adjustment for multiple testing was also 
considered inappropriate since there is an a priori hypothesis that the gene variants 










5.3.1 General characteristics 
The general characteristics of the participants recruited for this thesis were previously 
reported in section 4.2.1. The general characteristics for all participants successfully 
genotyped for at least one of the investigated variants in this chapter are shown in Table 5.4 
and were similar to all the participants recruited for this thesis (Table 4.1). Briefly, both 
groups were matched for age of surgery (age of recruitment was used for the CON group), 
sex, height and country of birth (Table 5.4). Both groups were also matched for weight and 
BMI after adjusting for the significant difference (p<0.001) in age of recruitment between the 
CTS (45.6 ± 10.6, n=103) and CON (40.3 ± 9.7, n=148) groups. There were two related 
participants in both the CTS and the CON groups (mother and daughter). Similar results 
were obtained when the analyses were repeated after excluding one of the related 
participants. 
 
Participants with a TT genotype for COL5A1 rs12722 were significantly older (p=0.025) at 
recruitment (48.2 ± 12.3 n=21) than those with either a CT (41.8 ± 10.3, n=102) or CC 
genotype (41.7 ± 10.0, n=116). There were no additional genotype effects on age of 
recruitment, age of surgery, height, weight or BMI for COL5A1 rs13946, 
rs146776422/rs55748801 , rs12722, rs71746744, or the combined 
rs146776422/rs55748801 and rs12722 genotypes (Supplementary tables 5.1 – 5.5, 
Appendix B). There were also similar COL5A1 genotype distributions between the normal 
weight, over-weight and obese CON and/or CTS participants (data not shown). 
  




Table 5.4 General characteristics of the carpal tunnel syndrome (CTS) and control (CON) groups 
successfully genotyped for at least one of the investigated variants.  
 CTS (n=103) CON (n=149) p-value 
Age of recruitment (yrs) 45.6 ± 10.6 (103) 40.3 ± 9.7 (148) <0.001 
Age of surgery (yrs) 42.1 ± 10.7 (91) 40.3 ± 9.7 (148)a 0.197 
Sex (% Female) 91.3 (103) 88.6 (149) 0.535 
Height (cm) 159.9 ± 7.6 (101) 160.4 ± 7.7 (148) 0.632 
Weight (kg) 82.8 ± 18.0 (102) 78.5 ± 19.1 (147) 0.198b 
BMI (kg/m2) 32.4 ± 6.9 (101) 30.4 ± 6.8 (146) 0.155b 
Country of birth (% SA) 99.0 (99)c 100.0 (140) 0.414 
 
Values are expressed as a mean ± standard deviation or a frequency (%). The number of participants 
(n) with non-missing data is indicated in parentheses. The maximum number (N) of participants in 
each group is also indicated. 
Significant p-values are indicated in bold. 
a age at recruitment.  
b co-varied for age at recruitment. 
c One participant was born in Namibia. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter; SA, South Africa 
 
 
Similar to the all the participants recruited for this thesis (section 4.2.1), bilateral carpal 
tunnel release surgery was performed in 50 (53.2%) of the CTS participants successfully 
genotyped for at least one of the investigated variants, while 33 (35.1%) only had surgery on 
their dominant hand and 9 (9.6%) had surgery on their non-dominant hand. Two (2.1%) 
participants who reported being ambidextrous had carpal tunnel surgery on their right hand.  
 
Participants within the CTS (27.2%, n=28) and CON (15.4%, n=23) groups, who were 
successfully genotyped for at least one of the investigated variants, self-reported similar 
histories (p=0.199) of medical condition(s), such as diabetes (9.7 % CTS, n=10 vs 8.1% 





(RA, 3.9 % CTS, n=4 vs 0.7% CON, n=1), thyroid disorders (1.9 % CTS, n=2 vs 0.7% CON, 
n=1), diabetes and OA (1.0 % CTS, n=1 vs 0.0% CON), RA and OA (0.0 % CTS vs 0.7% 
CON, n=1), diabetes and RA (1.0 % CTS, n=1 vs 0.0% CON), diabetes and thyroid disorder 
(1.0 % CTS, n=1 vs 0.0% CON), RA and systemic lupus erthematosus (1.0 % CTS, n=1 vs 
0.0% CON), suggested to be associated with CTS. 
 
Sixty-two percent (n=64) of the CTS and 42.5 % (n=62) of the CON participants who were 
successfully genotyped for at least one of the investigated variants self-reported a history of 
one or more other medical conditions (p=0.003).  These included hypertension (46.6% CTS, 
n=48 vs 26.2% CON, n=39), hypercholesterolemia (18.4% CTS, n=19 vs 3.4% CON, n=5), 
asthma (4.9% CTS, n=5 vs 3.4% CON, n=5), angina (6.8% CTS, n=7 vs 0.7% CON, n=1) 
and other conditions (4.9% CTS, n=5 vs 4.7% CON, n=7), which included hypotension, 
malignant disease, anaemia, aortic valve stenosis, epilepsy, kidney disease, spinal stenosis, 
Hirschsprung’s disease and autonomic insufficiency. 
 
Similar to all the participants recruited for this thesis (section 4.2.1, table 4.2), the majority of 
the participants (27.2% CTS, n=28 and 50.3% CON, n=75) who were successfully 
genotyped for at least one of the five investigated variants, with non-missing data were 
general poultry processing workers or general workers within other industries where 
repetitive action is performed with the upper limbs. The other major self-reported 
occupations included administration (22.3% CTS, n=23 and 11.4% CON, n=17) and nursing 
(10.7% CTS, n=11 and 8.1% CON, n=12).  
 
Similar to all participants recruited for this thesis (section 4.2.1), there was also no significant 
difference (p=0.053) between the number of participants, successfully genotyped for at least 
one of the three investigated variants, who reported spending their whole working day 
(100%) performing manual labour requiring the use of their hands between the CTS (78.0%, 




n=79 of 101) and CON (87.8%, n=130 of 148). Similarly, there was a significant different 
(p=0.017) between CTS (Median = 50%, interquartile range 5% - 100%) and CON (Median = 
100%, interquartile range 10% - 100%) participants who were successfully genotyped, for 
the percentage time spent standing during a normal working day. There was no significant 
difference (p=0.295) in number of successfully genotyped participants who reported 
repetitive leisure activities of the wrist (e.g. knitting/crocheting, gardening and 




The TT genotype of COL5A1 rs13946 was significantly over-represented in the CON 
(69.3%) compared to the CTS (50.6%) group (p=0.007, OR=0.45, 95% CI=0.26-0.79, 
Sensitivity=69.3%, Specificity=49.5%, Table 5.5). Similarly the TT genotype was also 
significantly over-represented in the CON when only the female participants were analysed 
(p=0.004).  There were however no significant differences in the genotype distributions 
between the CTS and CON groups for COL5A1 rs146776422/rs55748801 (p=0.835), 
rs12722 (p=0.273) and rs71746744 (p=0.986) (Table 5.5). Similarly there were also no 
significant differences in any of these genotypes distributions between the CTS and CON 
groups when only the female participants were analysed. All four variants were in Hardy-
Weinberg equilibrium. Similar genotype distributions were observed when participants with a 
history of a medical condition believed to be associated with CTS were excluded from the 











Table 5.5 Genotype frequency distributions of the COL5A1 3’-untranslated region (UTR) rs13946 
(C/T), rs12722 (C/T) and rs71746744 (-/AGGG), as well as the adjacent rs146776422 (C/T) and 
rs55748801 (G/A), variants in carpal tunnel syndrome (CTS) and control (CON) groups for all 
participants (All) as well as the female participants (Female). 
COL5A1 Genotype 
All Female 
CTS CON CTS CON 
rs13946 n=91 n=127 n=83 n=110 
 TT 50.6 (46) 69.3 (88) 50.6 (42) 71.8 (79) 
 CT 40.7 (37) 27.6 (35) 42.2 (35) 25.5 (28) 
 CC 8.8 (8) 3.2 (4) 7.2 (6) 2.7 (3) 
Genotype p-value 
b
 0.007 0.004 
C Minor allele 29.1 (53) 16.9 (43) 28.3 (47) 15.5 (34) 
Allele p-value 0.003 0.002 
HWE 0.554 0.828 
rs146776422/rs55748801 n=98 n=139 n=89 n=123 
 WW (CG/CG) 
a
 89.9 (88) 88.5 (123) 89.9 (80) 87.8 (108) 
 WM 10.2 (10) 10.8 (15) 10.1 (9) 11.4 (14) 
 MM 0.0 (0) 0.7 (1) 0.0 (0) 0.8 (1) 
Genotype p-value 
c
 0.835 0.668 
M Minor allele 5.1 (10) 6.1 (17) 5.1 (9) 6.5 (16) 
Allele p-value 0.692 0.677 
HWE 0.544 0.530 
rs12722 n=99 n=141 n=90 n=125 
 CC 43.4 (43) 51.8 (73) 43.3 (39) 53.6 (67) 
 CT 44.4 (44) 41.1 (58) 45.6 (41) 40.0 (50) 
 TT 12.1 (12) 7.1 (10) 11.1 (10) 6.4 (8) 
Genotype p-value 0.273 0.236 
T Minor allele 34.3 (68) 27.7 (78) 33.9 (61) 26.4 (66) 
Allele p-value 0.131 0.108 
HWE 1.000 0.873 
rs71746744 n=83 n=124 n=74 n=108 
 AGGG/AGGG 39.8 (33) 39.5 (49) 37.8 (28) 38.0 (41) 
 AGGG/- 43.4 (36) 42.7 (53) 44.6 (33) 44.4 (48) 
 -/- 16.9 (14) 17.7 (22) 17.6 (13) 17.6 (19) 
Genotype p-value 0.986 1.000 
D Minor allele 38.6 (64) 39.1 (97) 39.9 (59) 39.8 (86) 
Allele p-value 0.919 1.000 
HWE 0.192 0.360 
Legend appears on following page. 




From previous page:  
Values are expressed as a frequency (%) with the number of participants (n) in parentheses. The 
maximum number (N) of participants in each group is also indicated. Significant p-values are 
indicated in bold. 
a The genotyping method was unable to distinguish between the adjacent rs146776422 (C/T) and 
rs55748801 (G/A) variants. The CG wild-type allele of these adjacent variants, which contains a BstUI 
restriction site, was designated as a W, while the three alternative nucleotide combinations CA, TG 
and TA were designated as an M. The BstUI restriction site is destroyded in all three alternative 
sequence combinations. 
b TT vs CT and CC. 
c WW vs WM and MM. 
HWE, Hardy-Weinberg equilibrium.  
 
The rs71746744 variant was in linkage disequilibrium (LD) with rs13946 (CTS D’=0.612 and 
CON D’=0.764), rs146776422/rs55748801 (CTS D’=1.000 and CON D’=1.000) and rs12722 
(CTS D’=0.941 and CON D’=0.761). Although rs146776422/rs55748801 and rs12722 were 
in LD (D’=1.000) within the CON group, they were not in LD (D’=0.267) within the CTS 
group. Similarly rs13946 was in LD with rs146776422/rs55748801 in the CTS group 
(D’=1.000) but not in the CON group (D’=0.000). The rs13946 variant was in linkage 
disequilibrium (LD) with rs12722 (CTS D’=0.735 and CON D’=0.822). 
 
When the combined COL5A1 rs146776422/rs55748801 and rs12722 genotypes (BstUI 
RFLP) were analysed, there was a significant difference (p=0.026) in the combined 
genotypes distributions between the CTS and CON participants (Figure 5.6A). Similarly 
there were also significant difference (p=0.009) in the combined genotypes distributions 
when only the female participants were analysed (Figure 5.6B). Specifically the WW+CC 
(p=0.008, OR=0.45, 95% CI=0.26-0.80, Sensitivity=41.7%, Specificity=75.5%) and WW+CT 
(p=0.009, OR=2.0, 95% CI=1.2-3.4, Sensitivity=59.2%, Specificity=59.7%) genotypes were 
significantly over- and under-represented in the CON group respectively (Figure 5.6A). 
Similarly the WW+CC (p=0.014, OR=0.47, 95% CI=0.26-0.85) and WW+CT (p=0.001, 









Figure 5.6 The combined genotype frequency distributions of the COL5A1 BstUI restriction fragment 
length polymorphism (RFLP) for (A) all and (B) female participants in the carpal tunnel syndrome 
(CTS, solid bars) and control (CON, clear bars) groups.  
Continues on following page. 




From previous page: 
The COL5A1 BstUI RFLP can genotype the rs12722 (C/T) variant and the adjacent rs146776422 
(C/T) and rs55748801 (G/A) variants. Since the method is unable to distinguish between the adjacent 
variants, the CG wild-type allele of these adjacent variants, which contains a BstUI restriction site, 
was designated as a W, while the three alternative nucleotide combinations, CA, TG and TA were 
designated as a M. The BstUI restriction site is destroyed in all three alternative sequence 
combinations. The global p value and the significant differences between the groups for a specific 
genotype combination (asterisks) are indicated. The total number (n) of combined genotypes within 
the CON and CLS groups is also indicated in parenthesis on the graph. For all participants the allele 
phases of the WM and CT genotypes in the CTS and CON groups were 4 and 4 for WT/MC and 0 
and 2 for MT/WC, respectively.  
 
5.3.3 Inferred Haplotypes 
Five of the inferred haplotypes constructed from the COL5A1 rs13946 (T/C) 
rs146776422/rs5574880 (W/M) and rs12722 (C/T) variants out of a possible eight had a 
frequency greater than 2% (Figure 5.7A). The T-W-C inferred haplotype was significantly 
over-represented in the CON (51.2%) compared to the CTS (34.9%) group (p<0.001). The 
C-W-C inferred haplotype was significantly under-represented in the CON (15.9%) 
compared to the CTS (26.8%) group (p=0.005). Similarly, when inferred haplotypes were 
constructed from only the rs13946 (T/C) and rs12722 (C/T) variants, the T-C and C-C 
inferred haplotypes were significantly over- and under-represented (T-C p<0.001 and C-C 
p=0.006) in the CON (T-C 56.5% and C-C 15.9%) compared to the CTS (T-C 38.4% and C-
C 27.1%) group respectively (Figure 5.7B). Although rare, the C-T inferred haplotype was 
also significantly under-represented (p=0.034) in the CON (0.8%) compared to the CTS 
(2.4%) group. No additional informative haplotypes were identified when rs71746744 (-
/AGGG) was included in the analysis (data not shown).  
 
Since it has previously been reported that COL5A1 and MMP3 variants interact to modulate 
risk for chronic Achilles tendinopathy58, inferred pseudo-haplotypes were also constructed 
from the COL5A1 rs12722 (C/T) and each of the four MMP variants (as described in Chapter 





included. There were no significant difference between the CTS and CON groups for the 
inferred pseudo-haplotypes constructed from COL5A1 rs12722 (C/T) with MMP10 rs486055 
(C/T), MMP1 rs1799750 (GG/GGGG) or MMP12 rs2276109 (A/G) (Figure 5.8 A, B and D). 
The T-A inferred pseudo-haplotype constructed from COL5A1 rs12722 (C/T) and MMP3 
rs679620 (A/G) was however over-represented in the CTS group (14.8%), compared to the 
CON group (4.6%) (p=0.006, Figure 5.8C). 
  





Figure 5.7 Inferred haplotype frequency distributions constructed from the COL5A1 3’-untranslated 
region (UTR) variants for the control (CON, clear bars) and carpal tunnel syndrome (CTS, solid bars) 
groups. (A) Inferred haplotypes constructed from (i) rs13946 (C/T), (ii) combined rs146776422 (C/T) 
and rs55748801 (G/A) (designated as W/M, where W=CG) and (iii) rs12722 (C/T). (B) Inferred 
haplotypes constructed from (i) rs13946 (C/T) and (ii) rs12722 (C/T). Significant differences between 















Figure 5.8 Inferred pseudo-haplotypes constructed from the COL5A1 rs12722 (C/T) and (A) MMP10 
rs486055 (C/T), (B) MMP1 rs1799750 (GG/GGGG), (C) MMP3 rs679620 (A/G) and (D) MMP12 
rs2276109 (A/G) variants. 






An association of common C/T (rs12722) and -/AGGG (rs71746744) variants within the 
functional COL5A1 3′-untranslated region (UTR) with chronic Achilles tendinopathy in 
Caucasian populations has previously been reported (Figure 5.1)44,45,185,191. Based on these 
previous findings, it was hypothesised that the CC genotype of rs12722 (C/T) will be under-
represented in the CTS population, while the AGGG/AGGG genotype of rs71746744 (-
/AGGG) will be over-represented.  
 
The first main finding of this study was that although variants rs12722 and rs71746744 were 
not independently associated with CTS, the combined WW+CC genotypes of two additional 
adjacent variants, rs146776422 and rs55748801, with rs12722 were significantly under-
represented in the CTS population (Figure 5.9). This study identified two additional 
informative variants within the population group investigated, rs146776422 and rs55748801, 
which were genotyped together with rs12722.  The genotyping method (BstUI RFLP) used in 
this study was unable to distinguish between rs146776422 (C/T) and rs55748801 (G/A), 
therefore the CG wild-type alleles of these variants was designated as a W, while the three 
alternative combinations, CA, TG and TA were designated as an M. To date we have only 
identified the CG (W) wild type alleles of these adjacent variants within the previously 
genotyped Caucasian populations (n>1700 participants)45,46,186–189. Therefore all the 
previously reported association of the CC genotype of rs12722 with chronic Achilles 
tendinopathy in Caucasian populations could also be reported as an association of the 
combined WW+CC genotypes of rs146776422/rs55748801 (W/M) with rs12722 (C/T). In this 
study, a 2.1-fold decrease risk for CTS was noted for individuals with a WW+CC genotype. 
This was similar to the previously reported 2.4- and 2.6-fold decrease risk of chronic Achilles 
tendinopathy noted in South African and Australian Caucasian populations with the same 





ACL ruptures in females46, an age-related increase in lower limb range of motion 
measurements189 and decreased risk of exercise-associated muscle cramps186, while the TT 
genotype was associated with improved endurance running performance187,188.  
 
The COL5A1 3’-UTR variants rs12722 (C/T) and rs71746744 (-/AGGG) are believed to alter 
the stability of the COL5A1 messenger RNA (mRNA)185 . Specifically, we have previously 
shown that a 57 bp region of the 3′-UTR containing rs71746744 was functional and that it 
probably played an important role in the etiology of Achilles tendinopathy191.  It has been 
reported that the T and I alleles of rs12722 and rs71746744, respectively, are associated 
with increased mRNA stability, which is hypothesized to result in increased α1(V) chain and 
type V collagen production, decreasing the fibril diameter and packing density, and thereby 
potentially altering the mechanical properties of tendons and other connective tissues185,191 
The significant under-representation of the combined WW+CC genotypes for rs146776422, 
rs55748801 and rs12722 in the CTS population is in agreement with this hypothesis.  The 
lack of association of rs71746744 (-/AGGG) with CTS was however unexpected and 
probably further highlights the complex regulation of the COL5A1 gene by the 3’-UTR. The 
lack of LD between the rs146776422/rs55748801 and rs12722 variants as well as the 
rs13946 and rs146776422/rs55748801 variants in the CON groups further highlights the 
complexity in the genomic architecture of this region. 
 
  





Figure 5.9 A schematic representation of the exon (vertical lines) and intron (horizontal lines) 
boundaries of the COL5A1 gene located on chromosome 9q34. The 3’-end of the gene spanning 
exons 65 to 66 has been enlarged. Exon 66 encodes for the terminal amino acids of the α1(V) chain 
(black box), the stop codon and the 3’-untranslated region (UTR) (clear box). The three variants 
(indicated in black boxes), (i) rs13946 (C/T), (ii) rs12722 (C/T) and (iii) rs71746744 (-/AGGG), used in 
this study are all located within the 3’-UTR.  The sequences flanking the variants and the polymorphic 
nucleotide changes, with the wild type nucleotide indicated on top, are indicated in the grey boxes. As 
illustrated in the figure, each variant produces three possible genotypes. Variant  rs12722 (C/T) was 
genotyped by digesting a PCR amplified product with the restriction enzyme, BstUI, which has the 
recognition sequence 5’-CGCG-3’ (underlined in the grey boxes). Within the population group 
included in this study, the PCR products contain a second informative polymorphic BstUI restriction 
site. The variants simultaneously genotypes by the BstUI RFLP are boxed with a dashed line. The 
second upstream polymorphic BstUI site contains two rare adjacent variants, rs146776422 (C/T) and 
rs55748801 (G/A). Since the genotyping method used in this study is unable to distinguish between 
the adjacent variants, the CG wild-type allele of these adjacent variants, which contains a BstUI 
restriction site, was designated as a W, while the three alternative nucleotide combinations CA, TG 
and TA were designated as a M. The BstUI restriction site is destroyed in all three alternative 
sequence combinations. The phenotypes, as well as the population groups investigated, shown to be 







The second and also unexpected main finding of this study was that the TT genotype of the 
downstream COL5A1 3’-UTR variant rs13946 (Figure 3.1, DpnII RFLP) was significantly 
over-represented in the CON participants (p=0.007). This variant was previously not 
associated with chronic Achilles tendinopathy and ACL ruptures44–46. The T-C and C-C 
inferred haplotypes constructed from rs13946 (C/T) and rs12722 (C/T) were significantly 
over- and under-represented in the CON group respectively. These results highlight that a 
different functional region within the COL5A1 3’-UTR in close proximity to rs13946 is 
probably associated with CTS in this population group. Regulatory elements within the 3’-
UTR of eukaryotic genes, such as poly (A) signals195, protein196 and microRNA (miRNA) 
binding sites197,198 are emerging as important post-transcriptional regulators. MicroRNAs are 
a class of small (18–24 nucleotides) non-coding RNAs that can repressive translational by 
binding to specific sites of the mRNA197,198. Three putative miRNA binding sites, (i) hsa-miR-
377*, (ii) hsa-miR-330-5p, (iii) Hsa-miR886-5p, have recently been identified within the 
region of the COL5A1 3’-UTR shown to be associated with CTS (Y Abrahams, personal 
communication). Interestingly, the binding site for Hsa-miR886-5p is polymorphic and 
contains variant rs1134114 (C/T). The function of these putative miRNAs in the regulation of 
COL5A1 gene expression is currently unknown and warrants further work. Further work is 
also required to identify any important regulatory elements within this region of the 3’-UTR. 
 
Another interesting finding was that the T-A inferred pseudo-haplotype, constructed from the 
COL5A1 rs12722 (C/T) and MMP3 rs679620 (A/G) variants, was over-represented in the 
CTS group. Similar findings were reported in a previous study, with the T-A inferred pseudo-
haplotype being over-represented in female with ACL ruptures compared to an 
asymptomatic control group59. A different study reported that the T-G haplotype constructed 
from the same variants was associated with increased risk of chronic Achilles 
tendinopathy58. This study also reported that the GG genotype of MMP3 rs679620 was 
independently associated with risk of chronic Achilles tendinopathy. Even though there were 




no independent associations of MMP3 rs679620 reported in Chapter 4, this association of 
the COL5A1 and MMP3 T-A inferred pseudo-haplotype highlights the important role that 
gene-gene interactions may potentially play to modify the risk of CTS. This will be further 
investigated and discussed in the subsequent chapters of this thesis.  
 
It is highly unlikely that the reported associations within this study were as a result of medical 
conditions believed to be associated with CTS, since (i) the CON and CTS groups were 
similarly exposed to these conditions (section 5.3.1) and (ii) similar COL5A1 genotype 
distributions were reported when these associated medical conditions were excluded from 
the analysis. Further work is however required to confirm this finding.   
 
In conclusion, this is the first study to report that variants within the 3’-UTR of the COL5A1 
gene are associated with the CTS. This study also implicated a possible interaction between 








CHAPTER 6: PROTEOGLYCAN GENES AND CARPAL TUNNEL SYNDROME 
 
The data presented in this chapter was published in the following peer-reviewed 
article: Marilize Burger, Hanli de Wet, Malcolm Collins. The BGN and ACAN genes and 




In the previous chapter, it was reported that DNA sequence variants within a functional 
region of the COL5A1 3’-untranslated region (UTR) are associated with altered risk of CTS. 
Briefly, the COL5A1 encodes for the α1 chain of type V collagen, which is responsible for 
regulating fibrillogenesis41. Similarly, regions within the 3’-UTR of this gene have previously 
been associated with altered risk of Achilles tendinopathy (AT)44,45 and Anterior cruciate 
ligament (ACL) rupture in females46, while classic Ehlers-Danlos syndrome (EDS) is caused 
in most cases by rare mutations in COL5A142   
 
In addition to the collagens, the proteoglycans, such as biglycan and aggrecan, are also 
important structural components of tendons and other connective tissues34 (Figure 6.1). 
Similar to type V collagen, biglycan, which is encoded by the X-linked BGN gene, is also an 
important regulator of fibrillogenesis199. Mice deficient in biglycan and three other small 
leucine-rich proteoglycans (SLRPs), decorin, fibromodulin and lumican, have a similar 
physical phenotype to humans with classic EDS200,201. In these mice, fibrillogenesis is 
compromised resulting in collagen fibrils of highly irregular diameters and abnormal 
organization200,201. Recently, the association of the common variants, rs1126499 (C/T) and 
rs1042103 (G/A), within the BGN gene with ACL ruptures was investigated (Figure 6.2)56. 
Although not significant, there was a trend for the rs1126499 T allele to be associated with 










Figure 6.1 A schematic representation showing the interaction of the proteoglycans, biglycan and 
aggrecan, as well as the glycosaminoglycans (GAGs), with the collagen network. Multiple aggrecan 
core proteins bind hyaluronan via a link protein to form large aggregates; hyaluronan is able to directly 
interact with the collagen fibril. Figure adapted from Mannion et al. (2014) 
 
The aggrecan (ACAN) gene rs1516797  (G/T) variant within exon 4 was previously 
associated with lumbar disk height narrowing55 and altered risk of ACL injury56 (Figure 6.2). 
Specifically, the G-allele of rs1516797 was significantly associated with increased risk of the 
ACL rupture. Furthermore, increased mRNA expression of both ACAN and BGN have been 




reported in chronic tendinopathy49,202 and higher levels of these proteoglycans are present in 
tissues that are subject to increased forces49. Considering the repetitive wrist flexion and 
extension in certain occupations and the forces created by these activities3,203, is tempting to 
speculate that alterations in the proteoglycan content of the tendons within the carpal tunnel 






Figure 6.2 A schematic representation of the exon (rectangles) and intron (horizontal lines) structure 
of the BGN (chromosome Xq28) and ACAN (chromosome 15q26.1) genes. The translated exons are 
grey, while the untranslated regions are black. The variants of interest in this study, as well as another 
previously investigated variant rs1042103 (G/A), are indicated. 
 
 
The aim of the study presented in this chapter was therefore to determine whether the BGN 
rs1126499 and ACAN rs1516797 variants, are associated with CTS. The interaction of these 
proteoglycan gene variants with the previously associated COL5A1 variants in altering risk 







6.2.1 Participants & DNA Extraction 
The same participants, described in section 4.2.1, were also analysed in this study. DNA 
extraction was performed as described in section 4.2.2. 
 
6.2.2 Genotyping 
All DNA samples (n=253) were genotyped for the BGN rs1126499 (C/T) and ACAN 
rs1516797 (G/T) variants, located on human chromosomes X and 15, respectively, at the 
MRC/UCT Research Unit for Exercise Science & Sports Medicine, University of Cape Town, 
South Africa, using a fluorescence-based Taqman® PCR assay (Applied Biosystems, Foster 
City, California, USA) (Assay ID, rs1126499: C___2617574_1_; rs.1516797: 
C____331789_10).  Allele-specific primer and probe sets were used along with a pre-made 
PCR mastermix containing ampliTaq DNA polymerase Gold (Applied Biosystems, Foster 
City, California, USA) in a final reaction of 8 μl. The PCR reactions were carried out in the 
Applied Biosystems StepOnePlus real-time PCR System (Life Technologies, Applied 
Biosystems, Foster City, California, USA) following the manufacturer’s recommended cycling 
conditions (Figure 6.2 and 6.2B). A number of positive controls of known genotype and DNA-
free controls were randomly included on each PCR plate for quality control purposes. In 
addition, a subset of samples (approximately 10%) was genotyped twice using the same 
methodology to ensure genotyping was consistent. In order to avoid genotyping errors, 
samples that failed twice to amplify during PCR for a particular variant were considered to be 
unsuccessfully genotyped and no further attempts were made to genotype them at that 
specific locus. Ninety-two % (n=95 of 103) of the cases and 83% (n=125 of 150) of the 
controls were successfully genotyped for the BGN rs1126499 variant whereas 92% (n=95 of 
103) and 84% (n=126 of 150) were successfully genotyped for the ACAN rs1516797 cases 
and controls, respectively.   
 




6.2.3 Statistical Analysis 
No allele frequency data was available for the Coloured, South African population in the 
public databases (http://www.ncbi.nlm.nih.gov/snp/). For this reason, the sample size for this 
study was calculated based on the range of the reported minor allele frequencies, 0.06 to 
47.2% for BGN rs1126499 and 21.7 to 46.2% for ACAN rs1516797 previously described for 
populations in this public database (Table 6.1).  Quanto V.1.2.4 was used to determine the 
statistical power for a given sample size and minor allele frequency. A sample size of 
approximately 100 cases and 150 controls was found to be adequate to detect a genetic 
effect size ranging from 2.05 to 2.80 at a power of 80% and a significance level of 5%, 
assuming minor allele frequencies ranging from 0.5 to 47.2%. Non-missing data was 
analysed using STATISTICA (version 11, StatSoft Inc., Tulsa, Oklahoma, USA) and 
Graphpad Prism (version 5, GraphPad Software, San Diego, CA, USA, 
http://www.graphpad.com).  Since the BGN gene is located on the X chromosome, only 
female participants were analysed with regards to genotype and allele frequencies of the 
rs1126499 variant. A Pearson’s chi-squared test or a Fisher’s exact test was used to 
determine any significant differences between the genotype distributions or any other 
categorical data of the groups. An analysis of variance (ANOVA) was used to detect any 
significant differences between CTS and CON groups for continuous data. Statistical 
significance was accepted at p<0.05. Hardy-Weinberg equilibrium (HWE) was established 
using the program Genepop web version 4.0.10 (http://genepop.curtin.edu.au/)169,170 Inferred 
haplotypes were constructed from BGN rs1126499 (C/T), ACAN rs1516797 and/or COL5A1 
rs12722 (C/T) (Chapter 5) using Chaplin (version 1.2.2, Emory University School of 
Medicine, Atlanta, Georgia, USA)172,173. No adjustments were made for multiple testing  
considering no obvious appropriate method currently exists174,175. The Bonferroni adjustment 
was considered too conservative since the statistical tests in this and following studies are all 
performed on the same group of participants175. Adjustment for multiple testing was also 
considered inappropriate since there is an a priori hypothesis that the gene variants 








Figure 6.3 Typical allelic discrimination plots using the Taqman® Genotyping assay for (A) BGN 
rs1126499 (C/T) and (B) ACAN rs1516797 (G/T) on the StepOnePlus™ Real-time PCR System.   








Table 6.1 Minor allele frequencies of the investigated polymorphisms in different populations. 






rs1126499 (C/T) HAPMAP-YRI 224 T 31.4 
 HAPMAP-GIH 176 T 40.3 
 HAPMAP-LWK 180 T 0.06 
 HAPMAP-ASW 98 T 23.5 
 HAPMAP-MEX 100 T 45.0 
 HAPMAP-MKK 286 T 19.9 
 HAPMAP-TSI 176 C 47.2 
 HAPMAP-CEU 226 T 42.9 
rs1516797 (G/T) HAPMAP-YRI 226 T 21.7 
 HAPMAP-GIH 176 G 33.5 
 HAPMAP-LWK 180 T 37.2 
 HAPMAP-ASW 98 T 31.6 
 HAPMAP-MEX 100 G 24.0 
 HAPMAP-MKK 286 T 46.2 
 HAPMAP-TSI 176 G 27.8 
 HAPMAP-CEU 226 G 27.0 
     
HAPMAP-YR, Yoruba in Ibadan Nigeria; HAPMAP-GIH, Gujarati Indians in Houston TX USA; 
HAPMAP-LWK, Luhya in Webuye Kenya; HAPMAP-ASW, African ancestry in Northwest USA; 
HAPMAP-MEX, Mexican ancestry in Los Angeles CA USA; HAPMAP-MKK, Maasai in Kinyawa 
Kenya; HAPMAP-TSI, Toscani in Italy; HAPMAP-CEU, Utah residents with Northern and Western 








6.3.1 General characteristics 
The general characteristics of the participants recruited for this thesis were previously 
reported in section 4.2.1. The general characteristics for all participants successfully 
genotyped for at least one of the investigated variants in this chapter are shown in Table 6.2 
and were similar to all the participants recruited for this thesis (Table 4.1). The CTS and 
CON groups were matched for age of surgery (age of recruitment was used for the CON 
group), sex, height and country of birth (Table 6.2). Both groups were similarly matched for 
weight and BMI after adjusting for the significant difference (p<0.001) in age of recruitment 
between the CTS (45.6 ± 10.7, n=99) and CON (40.5 ± 9.9, n=135) groups. 
 
Bilateral carpal tunnel release surgery was performed in 48 (53.3%) of the CTS participants 
successfully genotyped for at least one of the investigated variants, while only 31 (34.4%) 
had surgery on their dominant hand and 9 (10.0%) had surgery on their non-dominant hand. 
Two (2.2%) participants who reported being ambidextrous had carpal tunnel surgery on their 
right hand.  
 
Participants within the CTS (24.2%, n=24) and CON (15.4%, n=21) groups self-reported 
similar histories (p=0.096) of medical condition(s), such as diabetes (9.1 % CTS, n=9 vs 
8.1% CON, n=11), osteoarthritis (OA, 6.8 % CTS, n=7 vs 5.1% CON, n=7), rheumatoid 
arthritis (RA, 2.9 % CTS, n=3 vs 0.7% CON, n=1), thyroid disorders (1.0 % CTS, n=1 vs 
0.7% CON, n=1), diabetes and OA 1.0 % CTS, n=1 vs 0.0% CON), RA and OA (0.0 % CTS 
vs 0.7% CON, n=1), diabetes and RA (1.0 % CTS, n=1 vs 0.0% CON), diabetes and thyroid 
disorder (1.0 % CTS, n=1 vs 0.0% CON), RA and systemic lupus erthematosus (1.0 % CTS, 
n=1 vs 0.0% CON), suggested to be associated with CTS. 
 
 




Table 6.2 General characteristics of the carpal tunnel syndrome (CTS) and control (CON) groups 
successfully genotyped for at least one of the investigated variants.  
 CTS (n=99) CON (n=136) p-value 
Age of recruitment (yrs) 45.6 ± 10.7 (99) 40.5 ± 9.9 (135) <0.001 
Age of surgery (yrs) 42.1 ± 10.8 (88) 40.5 ± 9.9 (135)a 0.242 
Sex (% Female) 90.9 (99) 88.2 (136) 0.758 
Height (cm) 159.9 ± 7.7 (97) 160.5 ± 7.9 (135) 0.726 
Weight (kg) 82.9 ± 18.2 (98) 78.4 ± 19.2 (134) 0.432b 
BMI (kg/m2) 32.5 ± 7.0 (97) 30.4 ± 6.7 (133) 0.343b 
Country of birth (% SA) 99.0 (96)c 100.0 (127) 0.508 
 
Values are expressed as a mean ± standard deviation or a frequency (%). The number of 
participants (n) with non-missing data is indicated in parentheses. The maximum number (n) 
of participants with non-missing data in each group is also indicated. 
Significant p-values are indicated in bold. 
a age at recruitment.  
b co-varied for age at recruitment. 
c One participant was born in Namibia. 




Sixty-three percent (n=62) of the CTS and 42.6 % (n=58) of the CON participants self-
reported a history of one or more other medical conditions (p=0.002).  These included 
hypertension (45.5% CTS, n=45 vs 27.1% CON, n=36), hypercholesterolemia (19.2% CTS, 
n=19 vs 3.8% CON, n=5), asthma (5.1% CTS, n=5 vs 3.0% CON, n=4), angina (7.1% CTS, 
n=7 vs 0.8% CON, n=1) and other conditions (5.1% CTS, n=5 vs 5.3% CON, n=7), which 
included hypotension, malignant disease, anaemia, aortic valve stenosis, epilepsy, kidney 






The majority of the participants (29.3% CTS, n=29 and 52.9% CON, n=72) included in this 
chapter of the thesis with non-missing data were general poultry processing workers or 
general workers within other industries where repetitive action is performed with the upper 
limbs (Table 6.3). The other major self-reported occupations included administration (21.2% 
CTS, n=21 and 11.8% CON, n=16) and nursing (10.1% CTS, n=10 and 8.8% CON, n=12). 
As summarised in Table 6.3 the remaining participants were recruited from several high risk 
occupations which included work where the hands/wrists are used for a high percentage of 
the normal working day. 
 
There was no significant difference (p=0.150) in the number of participants who reported 
spending their whole working day (100%) performing manual labour requiring the use of their 
hands between the CTS (79.2%, n=76 of 96) and CON (86.8%, n=118 of 136) groups. There 
was also no significant difference (p=0.067) between CTS (Median = 50%, interquartile 
range 10% - 100%) and CON (Median = 100%, interquartile range 10% - 100%) groups for 
the percentage time spent standing during a normal working day. There was no significant 
difference (p=0.419) in number of participants who reported repetitive leisure activities of the 
wrist (e.g. knitting/crocheting, gardening and kneading/rolling dough) within the CTS (50.5%, 














Table 6.3 Occupations of the carpal tunnel syndrome (CTS) and control (CON) participants, 
successfully genotyped for at least one of the investigated variants.  
Occupation CTS CON 
 n=99 n=136 
General worker    
 Poultry processing 23.2 (23) 33.8 (46) 
 Other industries a 6.1 (6) 19.1 (26) 
Administrator 21.2 (21) 11.8 (16) 
Nurse 10.1 (10) 8.8 (12) 
Packer 9.1 (9) 7.4 (10) 
Seamstress  7.1 (7) 8.1 (11) 
Operator 7.1 (7) 7.4 (10) 
Food Handler 5.1 (5) 2.9 (4) 
Other b 11.1 (11) 0.7 (1) 
 
Values are expressed as a frequency (%) with the number of participants (n) in parentheses. The 
maximum number (N) of participants with non-missing data in each group is also indicated. 
a includes bottle packer/cleaners, general workers in dairy industry, barrel makers and rotators, 
cleaners, fitters, wrappers.  
b includes sanders, engineering clerks, security, cashiers, kitchen attendant, ironing clothes, fire 
fighters. 
 
After adjusting for the effect of sex on BMI, there were no ACAN rs1516797 genotype effects 
on any of the other physiological characteristics of the participants (Supplementary table 6.1, 
Appendix B). Since the BGN gene is located on the X chromosome, only the female 
participants (90.0% of the participants) were analysed for the rs1126499 variant. There were 
no BGN genotype effects on age of recruitment, age of surgery, height, weight or BMI for the 








There was no significant difference in the genotype or allele distributions between the CTS 
and CON groups for the ACAN rs1516797 variant (Table 6.4).  
 
Table 6.4 Genotype frequency distributions of the ACAN rs1516797 (G/T) in carpal tunnel syndrome 
(CTS) and control (CON) groups for all participants (All) as well as the female participants (Female). 
 
All Female 
CTS CON CTS CON 
 n=95 n=126 n=86 n=110 
GG genotype 30.5 (29) 32.5 (41) 27.9 (24) 30.9 (34) 
GT genotype 47.4 (45) 42.9 (54) 47.7 (41) 42.7 (47) 
TT genotype 22.1 (21) 24.6 (31) 24.4 (21) 26.4 (29) 
Genotype p-value  0.795 0.786 
T allele 45.8 (87) 46.0 (116) 48.3 (83) 47.7 (105) 
Allele p-value 0.960 0.917 
HWE 0.140 0.159 
 
Genotype and minor allele frequencies are expressed as a percentage with the number of participants 
(n) in parentheses. The maximum number (n) of participants with non-missing data in each group is 
also indicated. 
HWE, Hardy-Weinberg equilibrium. 
 
There was however a significant difference (CC vs CT+TT, p=0.0498) between the CON and 
CTS groups for BGN rs1126499 where CC was over-represented (OR=0.545, 95% CI=0.30-
0.99; Sensitivity 0.581, 95% CI 0.471–0.687; Specificity 0.282, 95% CI 0.200-0.376) in the 
CON group (Figure 6.4). There was however no significant difference (p=0.205) n the 
rs1126499 allele frequency distribution between the CTS (132 C, 76.7% and 40 T, 23.3%) 
and CON (181 C, 82.3% and 39 T, 17.7%) groups. The ACAN rs1516797 variant was in 
Hardy-Weinberg equilibrium (HWE) in both groups (Table 6.4). Although the BGN rs1126499 
was in HWE in the CTS group (p=0.277), the CON group was not in HWE (p=0.005). Similar 
genotype distributions were observed when participants with a history of a medical condition 




believed to be associated with CTS were excluded from the analysis. However, there was no 
significant difference between the CTS and CON groups (CC vs CT+TT, p=0.418) 
(Supplementary table 6.3, Appendix B). Considering the low significant effect when all the 
participants were included and the low sample number, this is not a surprising finding. This, 
however, remains a limitation of the current study.  
 
 
Figure 6.4 Genotype frequency distributions BGN rs1126499 (C/T) in carpal tunnel syndrome (CTS) 
and control (CON) groups for the female participants. Because of the small sample size of the TT 
genotype in the CTS and CON groups, the CC genotype was compared with the combined CT and 
TT genotypes. The number of participants in each group is indicated. Significant differences between 
the groups are indicated with a solid line and asterisk with the p-value shown. 
 
 
6.3.3 Inferred Pseudo-Haplotypes  
All four possible pseudo-haplotypes constructed from the ACAN rs1516797 (G/T) and the 
BGN rs1126499 (C/T) variants were inferred when the female participants were analysed 











Figure 6.5 Inferred haplotypes constructed from the ACAN rs1516797 and BGN rs1126499 gene 
variants from female participants for carpal tunnel syndrome (solid bars) and controls (clear bars). 




Since the previously associated COL5A1 gene (Chapter 5) is also involved in collagen 
fibrillogenesis, inferred pseudo-haplotypes were constructed in the female participants from 
the COL5A1 rs13946 (T/C) and rs12722 (C/T) variants and BGN rs1126499 (C/T). Six of the 
possible eight inferred pseudo-haplotypes had a frequency greater than 2% (Figure 6.6). 
The C-C-C (24.9% CTS vs 12.3% CON) and T-T-T (11.2% CTS vs 7.6% CON) pseudo-
haplotypes were significantly over-represented in the CTS group (p=0.001 and p=0.033 
respectively) whilst the T-C-C (30.8% CTS vs 51.1% CON) pseudo-haplotype was 
significantly under-represented in the CTS group (p<0.001). 






Figure 6.6 Inferred haplotypes constructed from the COL5A1 rs13946 (C/T), COL5A1 rs12722 (C/T) 
and BGN rs1126499 (C/T) gene variants from female participants for carpal tunnel syndrome (solid 
bars) and controls (clear bars). Significant differences between the groups are indicated with a solid 
line and the p-value. 
 
 
6.3.4 COL5A1 & BGN Protection Scores 
Since, the TT COL5A1 rs13946, WW+CC COL5A1 rs146776422/rs55748801 + rs12722, 
and CC BGN rs1126499 genotypes were all independently associated with reduced risk of 
CTS (Chapter 5 and Figure 6.4), genotype-genotype interactions were investigated. Each of 
the individual “protective” genotypes contributed a score of 2 towards a participants′ 
genotype “protection” score. Participants with all the individual CTS “protective” genotypes 
therefore had a total score of 6, while those with none of the “protective” genotypes had a 
score of 0. Compared to the CTS group, the genotype “protection” score of 6 was 
significantly over-represented within the CON group (p<0.001, OR=0.19, 95% CI=0.07-0.51, 
sensitivity=0.07 (95% CI=0.02 – 0.16), specificity=0.71 (95% CI=0.61 – 0.80)) (Table 6.5 and 





within the CON group (p=0.002, OR=3.0, 95% CI=1.5-5.7, sensitivity=0.49 (95% CI=0.37 – 
0.61), specificity=0.71 (95% CI=0.65 – 0.84) (Table 6.5 and Figure 6.7A). When the BGN 
rs1126499 genotypes was excluded from the analyses, the two COL5A1 3′-UTR “protective” 
genotypes were also significantly over-represented (p=0.009, OR=0.39, 95% CI=0.19-0.79, 
sensitivity=0.15 (95% CI=0.08 – 0.24), specificity=0.69 (95% CI=0.60 – 0.77) within the CON 
participants when compared to the CTS participants (Table 6.5 and Figure 6.7B). In contrast, 
the genotype “protection” score of 0 was significantly under-represented within the CON 
group (p=0.005, OR=3.3, 95% CI=1.4-7.4, sensitivity=0.23 (95% CI=0.15 – 0.33), 
specificity=0.92 (95% CI=0.85 – 0.96) (Table 6.5 and Figure 6.7B). 
 










Figure 6.7 Genotype protective scores of the (A) COL5A1 rs13946 (T/C), rs12722 (C/T) and BGN 
rs1126499 (C/T) and (B) COL5A1 rs13946 (T/C) and rs12722 (C/T) variants for the carpal tunnel 
syndrome (CTS) (solid bars) and control (CON) (clear bars) groups, for female participants. Each of 
the three individual “protective” genotypes (rs13946, TT; rs12722, CC; rs11126499, CC) contributed a 
score of 2 towards a participants′ genotype “protection” score while the “risk” genotypes (rs13946, 
CC; rs12722, TT; rs11126499, TT) contributed 0. Participants with all three individual CTS “protective” 
genotypes therefore had a total score of 6 (A) or 4 (B), while those with none of the “protective” 
genotypes had a score of 0. 






Proteoglycans, such as aggrecan and the small leucine rich proteoglycan, biglycan, plays 
important structural roles in connective tissue such as tendons. It is vital in the regulation of 
ECM remodeling as well as collagen fibrillogenesis, through the interactions between the 
proteoglycans and the major structural component of tendons, the collagen network204,205. 
Considering the previous associations of variants within genes involved in fibrillogenesis with 
risk of injury (including COL5A1, chapter 5) and the role of proteoglycans in this process, this 
study investigated two variants within two genes encoding proteoglycans (ACAN rs1516797 
and BGN rs1126499) for its potential association with risk of carpal tunnel syndrome (CTS). 
The first main finding of this study was the independent association of BGN rs1126499 (C/T) 
with risk of CTS whilst there was no individual association of ACAN rs1516797 (G/T) variant 
with CTS.  
 
Biglycan interacts with the collagen fibrils (Figure 6.1) and is able to regulate collagen 
fibrillogenesis which allows it  to maintain the structure of the ECM204,206, Considering the 
role of biglycan in the regulation of fibrillogenesis and the location of the BGN gene on the X-
chromosome, together with the fact that CTS is more prevalent in females than males, it was 
considered an ideal gene to investigate for a possible role in altering risk for CTS. In this 
study, the CC genotype of the rs1126499 variant within this gene was significantly over-
represented in the CON group (p=0.0498, Figure 6.4) indicating a possible protective effect 
against CTS. Furthermore, in a previous study,  the C-allele was part of an inferred 
haplotype constructed from variants within the BGN gene shown to be over-represented in 
the control group compared to an ACL injury group56. This strengthens the evidence that the 
C-allele of rs1126499 having a protective role against injury. In addition,  although not 
significant, there was a trend for the opposite rs1126499 T-allele to be associated with 






for the BGN T-allele within an inferred haplotype constructed from the ACAN rs1516797 and 
BGN rs1126499 variants to be over-represented in the CTS group (Figure 6.5). The two 
studies are therefore in agreement, indicating a protective role of the BGN C-allele and a 
trend towards the increase in risk with the opposite T-allele. The function, if any, of this 
synonymous variant (S180S) within exon 4 of BGN is currently unknown and remains to be 
determined. It is also possible that rs1126499 is tightly linked to another functional variant(s) 
within or around the BGN gene.  
 
Aggrecan is a large structural proteoglycan with an extremely high fixed negative charge 
which creates an osmotic environment resulting in water retention, thereby stabilizing the 
collagen network207.The interaction between aggrecan and the collagen fibril remains 
unclear, but it is known that this proteoglycan interacts with hyalouronan within the ECM to 
form large aggregates (Figure 6.1) thereby suggesting an indirect interaction207. Aggrecan is 
found to be most abundant at regions in tendon with increased compression51 and 
considering the narrow space of the carpal tunnel and the increased forces within the wrist in 
maximum flexion and extension208, it is likely that higher levels of proteoglycans, are present 
in the tissues, such as the flexor tendons within the wrist, that are subject to these increased 
forces49. The G-allele of the rs1516797 variant was previously associated with altered risk of 
ACL injury56 and the same variant was also associated with lumbar disk height narrowing55. 
Although the ACAN rs1516797 variant investigated in this study was not independently 
associated with CTS, it does not exclude the possibility that additional variants within ACAN 
are associated. This is supported by the observation in this study that there was a tendency 
for inferred T-T haplotype constructed from the BGN and ACAN variants to be associated 
with increased risk of CTS. It is also likely that variants within other genes encoding for 
proteoglycans could be associated with risk of CTS.  For example, a variant within the 
decorin gene (DCN) was independently associated and several inferred haplotypes 




constructed from the ACAN, BGN and Lumican (LUM)-DCN variants were associated with 
altered risk of ACL injury56.  
 
The second main finding of this study was that inferred pseudo-haplotypes constructed from 
the COL5A1 rs13946 (C/T), rs12722 (C/T) and the BGN rs1126499 (C/T) variants were 
significantly associated with altered risk of CTS. Both type V collagen, partly encoded by the 
COL5A1 gene, and biglycan play an important role in fibrillogenesis. We have previously 
shown that the CC genotype of COL5A1 rs13946 variant is independently associated with 
increased risk of CTS whereas the WW+CC genotype of the rs146776422/rs55748801 and 
rs12722 variants are independently associated with decreased risk of CTS (Chapter 5). As 
previously mentioned, in this study, the CC genotype of BGN rs1126499 was also 
independently associated with decreased risk of CTS. In agreement with these independent 
associations, the T-C-C pseudo-haplotype constructed from COL5A1 rs13946 (C/T), 
COL5A1 rs12722 (C/T) and BGN rs1126499 (C/T) was significantly over-represented in the 
CON group, suggesting a protective role against CTS. The C-C-C and T-T-C inferred 
pseudo-haplotypes were however significantly over-represented in the CTS group. 
 
In addition to constructing inferred pseudo-haplotypes, a “protection” score for CTS was also 
calculated from the COL5A1 and BGN genotypes. As expected, those with a low “protective” 
score (≤2), were at 3-fold increased risk of developing CTS while those with a “protection” 
score of 6 were at a 5-fold decreased risk. Similarly when only the COL5A1 genotypes were 
included in the analysis, those with a low “protective” score of 0 were at a 3.3-fold increased 
risk of developing CTS while those with a “protection” score of 4 were at a 2.6-fold 
decreased risk. When analysed separately the “protective” genotypes of COL5A1 (rs13946) 
and BGN had a low specificity ranging from 28 to 31%, with a sensitivity of ranging from 51 
to 58%. The inclusion of all the COL5A1 and BGN genotypes in the protection model 






Similarly the specificity of the at risk model including all the genotypes was 98% with a 
sensitivity of 9%. This supports the hypothesis that not a single, but rather many genetic 
variants are associated with risk of CTS.  
 
Besides investigating only one variant within each of ACAN and BGN genes, another 
limitation of the study was the small sample size. This research should therefore be repeated 
in a larger sample.  
 
In conclusion, the BGN rs1126499 variants was found to be individually associated with 
altered risk of CTS and inferred pseudo-haplotypes of variants within the COL5A1 and BGN 
genes, both involved in collagen fibrillogenesis, are significantly associated with altered risk 
of this injury. Although the investigated ACAN variant was not associated with CTS, it does 
not exclude this and other ACAN variants to be important in the risk of CTS. 




CHAPTER 7: GENE VARIANTS WITHIN THE CELL SIGNALLING PATHWAY AND RISK 




In the previous chapters of this thesis, the association of DNA sequence variants within 
genes encoding for structural components of the collagen fibril, namely type V collagen 
(chapter 5), biglycan and aggrecan (chapter 6), and endopeptidases involved in the 
remodelling of the fibril, such as the MMPs (chapter 4), with modulating the risk of CTS has 
been investigated. The expression of structural proteins, such a type V collagen and MMPs, 
are regulated by signalling cascades in response to stimuli such as repetitive mechanical 
loading, which is often mentioned as a risk factor for CTS1,209 and other occupational, 
overuse injuries210. 
 
Previous studies have shown altered expression of several signal transduction cytokines, 
such as interleukin-1β and interleukin-6, as well as genes/proteins involved in apoptosis and 
angiogenesis, in tendon and ligament injuries37,41,65,66,211–214  (Figure 7.1). This chapter will 
therefore focus on the signalling pathways that (1) regulate the expression of ECM structural 
components, such as Type V collagen, and (2) lead to excessive tenocyte apoptosis60 in 
response to repetitive loading. 
 
The interleukin-1β protein, encoded by the IL-1β gene, is able to up-regulate its own 
expression and also that of other cytokines, such as interleukin-6, encoded for by the IL-6 
gene212. Furthermore, interleukin-1β, as well as vascular endothelial grown factor (VEGF), 
encoded by the VEGF gene,  has been shown to up-regulate the matrix metalloproteinases 
(MMPs)213. Increased levels of interleukin-6 also leads to the up-regulation of transforming 






regulates type V collagen 60,215. The proteoglycans, specifically biglycan, also stimulates the 
expression of IL-1β216.  Furthermore, interleukin-6 induces tenocyte apoptosis causing the 





Figure 7.1 Proposed pathways through which increased mechanical loading induces expression of 
IL-1β and IL-6, which in turn may act to influence the expression of type V collagen thereby potentially 
modulating the risk of tendinopathy.  IL-1β increases MMP expression by increasing expression of 
signal transduction mediators such as COX-2 and PGE2. Proteoglycans, specifically biglycan, 
stimulates the expression IL-1β, and is degraded by the MMPs. IL-6 induces tenocyte apoptosis 
causing the production of reactive oxygen species and subsequent activation of caspase-8. Up () 
and down () arrows refer to increased or decreased expression, respectively. Molecules 
investigated in this study, are boxed, the variants are given in brackets and have previously been 
shown to affect the expression of the proteins as indicated by the arrows. IL-6, interleukin-6; IL-1β, 
interleukin-1β; MMP, matrix metalloproteinase; TGF- β, transforming growth factor β; VEGF, vascular 
endothelial growth factor; CASP8, Caspase-8. (Figure adapted from September et al., 2011)60 
 
 
The functional variants within the IL-1β, IL-6, IL-6R (encodes for the IL-6 receptor), VEGFA 
and CASP8 genes have all been associated with various multifactorial conditions. The IL-1β 
rs16944 variant has been associated with conditions such as oesophageal cancer217 and 
keratoconus, a non-inflammatory corneal disorder characterized by progressive thinning of 




the corneal tissue218,219. The G-allele of IL-6 rs1800795 has, in turn, been associated with a 
1.4 fold increase in risk of developing lung cancer220. Although IL-1β rs16944 and IL-6 
rs1800795 were not independently associated, inferred haplotypes constructed from these 
and other interleukin variants together with COL5A1 rs12722 (Chapter 4) were significantly 
associated with altered risk of chronic Achilles tendinopathy (AT)60. This highlights that a 
pathway-based approach may be more informative to fully elucidate the role of genetic risk 
factors in multifactorial conditions, such as tendinopathy60. Although not included in the 
previously reported chronic Achilles tendinopathy study60, a non-synonymous variant in the 
interleukin-6 receptor gene, IL-6R rs2228145, was considered a plausible candidate to be 
included in this study. The IL-6R gene has been investigated for its role in anterior cruciate 
ligament injuries (M Rahim, personal communication) and has also been implicated in 
various conditions with an inflammatory component including coronary heart disease, 
rheumatoid arthritis and asthma221–223. In addition, the functional variant within the promoter 
region, VEGFA rs699947, has been associated with altered risk of ACL ruptures66 as well as 
risk of diabetic retinopathy224 and the CASP8 rs3834129 variant has been reported to 
independently associate with altered risk of Achilles tendinopathy65.  
 
The aim of this study was therefore to determine whether functional variants within several 
genes involved in the signal transduction, apoptosis and angiogenesis pathways, namely IL-
1β rs16944 (C/T), IL-6 rs1800795 (C/G), IL-6R rs2228145 (A/C), CASP8 rs3834129 (I/D) 









7.2.1 Participants & DNA Extraction 
The same participants, described in section 4.2.1, were also analysed in this study. DNA 
extraction was performed as described in section 4.2.2. 
 
7.2.2 Genotyping 
All DNA samples (n=253) were genotyped for the IL-1β rs16944 (C/T), IL-6 rs1800795 
(C/G), IL-6R rs2228145 (A/C), CASP8 rs3834129 (I/D) and VEGFA rs699947 (C/A) variants 
at the MRC/UCT Research Unit for Exercise Science & Sports Medicine, University of Cape 
Town, South Africa. At least 6 positive controls of known genotype and 4 DNA-free controls 
were randomly included on each PCR plate for quality control purposes. In addition, a subset 
of samples (approximately 10%) was genotyped twice using the same methodology to 
ensure genotyping was consistent. In order to avoid genotyping errors, samples that failed 
twice to amplify during PCR for a particular variant were considered to be unsuccessfully 
genotyped and no further attempts were made to genotype them at that specific locus.  
 
7.2.2.1 IL-1β rs16944 (-511C/T) 
The IL-1β rs16944 (C/T) was genotyped using the restriction fragment length polymorphism 
(RFLP) analysis. A 304 bp fragment containing the AvaI RFLP (SNP rs16944, C/T) was PCR 
amplified. The PCR reaction was performed in a final volume of 40μl containing at least 
100ng DNA, 20pmol of the forward and reverse primers (Table 7.1), 2.0mM MgCl2, 50mM 
KCl, 10mM Tris-HCl (pH 8.3), 200μmol of dNTPs (dATP, dTTP, dCTP and dGTP) and 1U of 
DNA Taq polymerase (New England Biolabs, Ipswich, Massachusetts, USA). The 
amplification was performed with an initial denaturation step of 94°C for 10 minutes, followed 
by 35 cycles of a denaturation step at 94°C for 25 seconds, annealing step at 54°C for 45 
seconds and an extension step at 72°C for 30 seconds followed by a final extension step of 




5 minutes at 72°C on a thermal cycler (Hybrid, PCR Express, Middle sex, UK). The 304 bp 
PCR product was digested with the restriction endonuclease, AvaI to produce 304 bp for the 
T allele and 190 bp and 114 bp for the C allele. The resultant fragments were separated 
together with a 100bp molecular weight marker and SYBER® Gold nucleic acid gel stain 
(Invitrogen Molecular ProbesTM, Oregon, USA) on a 2% agarose gel (Figure 5.2A). The gels 
were photographed under UV light using an Uvitec photodocumentation system (Uvitec 
Limited, Cambridge, UK) and genotypes were determined based on the resultant DNA 
fragment sizes. DNA from Ninety-seven % (n=100 of 103) of the cases and 85% (n=128 of 












Table 7.1 Primer and probe sequences used for genotyping 










T - 304 





G – 172, 56 
 
5’-TGGGGCTGATTGGAAACCTTATTAAF-3’ C – 123, 56, 49  
IL-6R rs2228145 
(C/A) 5’-GCTTGTCAAATGGCCTGTTG-3’ HindIII 
A - 259 
 5’-GCAATGCAGAGGAGCGTTC-3’ C – 181, 78 
CASP8 rs3834129  







VEGFA rs699947  
(-2578C/A) 
5’-GCCTTAGGACACCATACCGATG-3’ BglII C – 285 
  5’-GCTGCCCCAGGGAACAAAGTTG-3’   A – 206, 79  
 
Primer and probe (where applicable) sets were incorporated into a PCR mastermix and used as 
described in materials and methods. The restriction endonuclease and DNA fragment sizes are 
indicated where applicable. 















Figure 7.2 Typical 2% agarose gels showing the genotypes of the (A) IL-1β rs16944, (B) IL-6 
rs1800795, (C) IL-6R rs2228145 and (D) VEGFA rs699947 restriction fragment length polymorphisms 
(RFLPs). (A) Digestion of the 304 bp PCR product with AvaI produce a 304 bp fragment for the T-
allele and (190 bp + 144 bp) fragments for the C-allele. (B) Digestion of the 228 bp PCR product with 
NlaIII produce (172 bp + 56 bp) fragments for the G-allele and (123 bp + 56 bp + 49 bp) fragments for 
the C-allele. The 56 bp and 49 bp fragments migrated off the gel and are therefore not visible on the 
figure. (C) Digestion of the 259 bp PCR product with HindIII produce a 259 bp fragment for the A-
allele and (181 bp + 78 bp) fragments for the C-allele. (D) Digestion of the 285 bp PCR product with 











7.2.2.2 IL-6 rs1800795 (-174G/C)  
The IL-6 rs1800795 (-174G/C) was genotyped by means of restriction fragment length 
polymorphism (RFLP) analyses. A 228 bp fragment containing the NlaIII (SNP rs1800795, 
C/G) was amplified by means of PCR. The PCR reaction was performed in a final volume of 
15μl containing at least 100ng DNA, 20pmol of the forward and reverse primers (Table 7.1), 
2.0mM MgCl2, 50mM KCl, 10mM Tris-HCl (pH 8.3), 200μmol of dNTPs (dATP, dTTP, dCTP 
and dGTP) and 1 unit of Taq DNA polymerase (New England Biolabs, Ipswich, 
Massachusetts, USA). The amplification was performed with an initial denaturation step of 
94°C for 5 minutes, followed by 27 cycles of a denaturation step at 94°C for 30 seconds, 
annealing step at 56°C for 30 seconds and an extension step at 72°C for 40 seconds 
followed by a final extension step of 5 minutes at 72°C on a thermal cycler (Hybrid, PCR 
Express, Middle sex, UK). The 228 bp PCR amplicon contains two NlaIII recognition 
sequences (CATG). The resultant digested products therefore included (172 bp + 56 bp) for 
the G allele and (123 bp + 56 bp + 49bp) for the C allele; which were resolved together with 
a 100bp molecular weight marker and SYBER® Gold nucleic acid gel stain (Invitrogen 
Molecular ProbesTM, Oregon, USA) on a 2% agarose gel (Figure 7.2B). The gels were 
photographed under UV light using a Uvitec photodocumentation system (Uvitec Limited, 
Cambridge, UK) and genotypes were determined based the DNA fragment sizes (Figure 
7.2B). The 56 bp and 49 bp fragments were too small to be captured on the 2% agarose gel, 
however the diagnostic 172 bp and 123 bp fragments were sufficient to discriminate between 
the genotypes. Ninety-six % (n=99 of 103) of the cases and 97% (n=145 of 150) of the 
controls were successfully genotyped for IL-6 rs1800795. 
 
7.2.2.3 IL-6R rs2228145 (A/C) 
The IL-6R rs2228145 (A/C) was genotyped by means of restriction fragment length 
polymorphism (RFLP) analyses. A 259 bp fragment containing the HindIII (SNP rs2228145, 
A/C) was amplified by means of PCR. The PCR reaction was performed in a final volume of 




40μl containing at least 100ng DNA, 20pmol of the forward and reverse primers (Table 7.1), 
2.0mM MgCl2, 50mM KCl, 10mM Tris-HCl (pH 8.3), 200μmol of dNTPs (dATP, dTTP, dCTP 
and dGTP) and 1 unit of DNA Taq polymerase (New England Biolabs, Ipswich, 
Massachusetts, USA). The amplification was performed with an initial denaturation step of 
92°C for 3 minutes, followed by 25 cycles of a denaturation step at 92°C for 30 seconds, 
annealing step at 55.5°C for 30 seconds and an extension step at 72°C for 45 seconds 
followed by a final extension step of 5 minutes at 72°C on a thermal cycler (Hybrid, PCR 
Express, Middle sex, UK). The 259 bp PCR product was digested with the restriction 
endonuclease, HindIII to produce 259 bp for the A allele and 181 bp and 78 bp for the C 
allele. The resultant fragments were separated together with a 100bp molecular weight 
marker and SYBER® Gold nucleic acid gel stain (Invitrogen Molecular ProbesTM, Oregon, 
USA) on a 2% agarose gel (Figure 7.2C). The gels were photographed under UV light using 
a Uvitec photodocumentation system (Uvitec Limited, Cambridge, UK) and genotypes were 
determined based the DNA fragment sizes. Eighty-three % (n=85 or 103) of the cases and 
81% (n=122 of 150) of the controls were successfully genotyped for IL-6R rs2228145. 
 
7.2.2.4 CASP8 rs3834129 (-652 6N del, I/D) 
 The CASP8 rs3834129 (-652 6N del, -/CTTACT [I/D]) variant was genotyped using custom 
designed fluorescence-based Taqman® polymerase chain reaction (PCR) assays (Applied 
Biosystems, Foster City, California, USA).  Allele-specific primer and probe sets (Table 7.1) 
were used along with a pre-made PCR mastermix containing ampliTaq DNA polymerase 
Gold (Applied Biosystems, Foster City, California, USA) in a final reaction of 8 μl following 
the manufacturer’s recommended cycling conditions as described in section 4.2.3. The PCR 
reactions were carried out in the Applied Biosystems StepOnePlus real-time PCR System 
(Life Technologies, Applied Biosystems, Foster City, California, USA). Ninety-one % (n=94 
of 103) of the cases and 88% (n=132 of 150) of the controls were successfully genotyped for 











7.2.2.5 VEGFA rs699947 (-2578C/A) 
The VEGFA rs699947 (-2578C/A) was genotyped by means of restriction fragment length 
polymorphism (RFLP) analyses. A 285 bp fragment containing the BglII (SNP rs2228145, 
A/C) was amplified by means of PCR. The PCR reaction was performed in a final volume of 
40μl containing at least 100ng DNA, 20pmol of the forward and reverse primers (Table 5.1), 
2.0mM MgCl2, 50mM KCl, 10mM Tris-HCl (pH 8.3), 200μmol of dNTPs (dATP, dTTP, dCTP 
and dGTP) and 1 unit of DNA Taq polymerase (New England Biolabs, Ipswich, 
Massachusetts, USA). The amplification was performed with an initial denaturation step of 
95°C for 5 minutes, followed by 30 cycles of a denaturation step at 93°C for 25 seconds, 
annealing step at 54.4°C for 30 seconds and an extension step at 72°C for 45 seconds 
followed by a final extension step of 5 minutes at 72°C on a thermal cycler (Hybrid, PCR 
Express, Middle sex, UK). The 285 bp PCR product was digested with the restriction 
endonuclease, BglII to produce 285 bp for the C allele and 206 bp and 79 bp for the A allele. 
The resultant fragments were separated together with a 100bp molecular weight marker and 
SYBER® Gold nucleic acid gel stain (Invitrogen Molecular ProbesTM, Oregon, USA) on a 2% 




agarose gel (Figure 7.2D). The gels were photographed under UV light using a Uvitec 
photodocumentation system (Uvitec Limited, Cambridge, UK) and genotypes were 
determined based the DNA fragment sizes. Eighty-two % (n=84 of 103) of the cases and 
87% (n=131 of 150) of the controls were successfully genotyped for VEGFA rs699947. 
 
7.2.3 Statistical Analysis 
No allele frequency data was available for the Coloured, South African population in the 
public databases (http://www.ncbi.nlm.nih.gov/snp/). For this reason, the sample size for this 
study was calculated based on the range of the reported minor allele frequencies, 33.3 to 
50.0% for IL-1β rs16944, 0.0 to 35.2% for IL-6 rs1800795, 6.2 to 38.6% for IL-6R rs2228145, 
21.7 to 50.0% for CASP8 rs3834129 and 11.9 to 46.0% for VEGFA rs699947 previously 
described for populations in this public database (Table 7.2).  Quanto V.1.2.4 was used to 
determine the statistical power for a given sample size and minor allele frequency26. A 
sample size of approximately 100 cases and 150 controls was found to be adequate to 
detect a genetic effect size ranging from 2.05 to 2.80 at a power of 80% and a significance 
level of 5%, assuming a minor allele frequencies ranging from 0.5 to 50.0%. 
 
 Data was analysed using STATISTICA (version 11, StatSoft Inc., Tulsa, Oklahoma, USA) 
and Graphpad Prism (version 5, GraphPad Software, San Diego, CA, USA, 
http://www.graphpad.com). A Pearson’s chi-squared test or a Fisher’s exact test was used to 
determine any significant differences between the genotype distributions or any other 
categorical data of the groups. An analysis of variance (ANOVA) was used to detect any 
significant differences between CTS and CON groups for continuous data. Where 
appropriate, values were adjusted for the effect of age at recruitment. A least squares 
difference (LSD) post-hoc test was used to identify specific differences when the overall F-
value was found to be significant. Statistical significance was accepted at p<0.05. Hardy-






4.0.10 (http://genepop.curtin.edu.au/)169,170. Linkage disequilibrium (LD) was calculated using 
CubeX: cubic exact solution (www.oege.org/software/cubex/)171. Inferred pseudo-haplotypes 
were constructed from the  IL-1β rs16944, IL-6 rs1800795 and IL-6R rs2228145 and other 
variants investigated in previous chapters using Chaplin (version 1.2.2, Emory University 
School of Medicine, Atlanta, Georgia, USA)172,173 and Hapstat software (version 3.0, 
University of North Carolina at Chapel Hill, North Carolina, USA)194. No adjustments were 
made for multiple testing  considering no obvious appropriate method currently exists174,175. 
The Bonferroni adjustment was considered too conservative since the statistical tests in this 
and following studies are all performed on the same group of participants175. Adjustment for 
multiple testing was also considered inappropriate since there is an a priori hypothesis that 










Table 7.2 Minor allele frequencies of the investigated polymorphisms in different populations. 






rs16944 (T/C) HAPMAP-YRI 226 C 42.0 
 HAPMAP-GIH 176 C 38.6 
 HAPMAP-LWK 180 C 33.3 
 HAPMAP-ASW 98 C 42.9 
 HAPMAP-MEX 100 T/C 50.0 
 HAPMAP-MKK 286 C 40.6 
 HAPMAP-TSI 176 T 37.5 
rs1800795 (G/C) HAPMAP-YRI 120 C 0.0 
 HAPMAP-GIH 176 C 12.5 
 HAPMAP-ASW 98 C 9.2 
 HAPMAP-MEX 100 C 16.0 
 HAPMAP-MKK 284 C 4.9 
 HAPMAP-TSI 176 C 35.2 
rs2228145 (A/C) HAPMAP-YRI 226 C 6.2 
 HAPMAP-GIH 176 C 27.8 
 HAPMAP-ASW 98 C 15.3 
 HAPMAP-LWK 180 C 7.2 
 HAPMAP-MKK 286 C 11.9 
 HAPMAP-TSI 176 C 38.6 
rs3834129 (I/D) EGP_YORUB-PANEL 24 I/D 50.0 
 EGP_HISP-PANEL 44 D 40.9 
 EGP_CEPH-PANEL 42 I 45.2 
 EGP_AD-PANEL 30 I 46.7 












Table 7.2 Continued 






rs699947 (C/A) HAPMAP-YRI 226 A 11.9 
 HAPMAP-GIH 176 A 34.7 
 HAPMAP-ASW 98 A 17.3 
 HAPMAP-LWK 180 A 13.9 
 HAPMAP-MEX 100 A 41.0 
 HAPMAP-MKK 286 A 21.0 
 HAPMAP-TSI 174 C 46.0 
 
HAPMAP-YR, Yoruba in Ibadan Nigeria; HAPMAP-GIH, Gujarati Indians in Houston TX USA; 
HAPMAP-LWK, Luhya in Webuye Kenya; HAPMAP-ASW, African ancestry in Northwest USA; 
HAPMAP-MEX, Mexican ancestry in Los Angeles CA USA; HAPMAP-MKK, Maasai in Kinyawa 
Kenya; HAPMAP-TSI, Toscani in Italy; EGP_YORUB-PANEL, population of DNA available from the 
Coriell Cell Repository for Sub-saharan African population; EGP_HISP-PANEL, population of DNA 
available from the Coriell Cell Repository for Hispanic population; EGP_CEPH-PANEL, population of 
DNA available from the Coriell Cell Repository for European population; EGP_AD-PANEL, population 
of DNA available from the Coriell Cell Repository for African American population; EGP_ASIAN-
















7.3.1 General characteristics 
The general characteristics of the participants recruited for this thesis were previously 
reported in section 4.2.1. The general characteristics for all participants successfully 
genotyped for at least one of the investigated variants in this chapter are shown in Table 7.2 
and were similar to all the participants recruited for this thesis (refer to table 4.1). Briefly, 
both groups were matched for age of surgery (age of recruitment was used for the CON 
group), sex, height and country of birth (Table 7.3). Both groups were also matched for 
weight and BMI after adjusting for the significant difference (p<0.001) in age of recruitment 
between the CTS (45.6 ± 10.6, n=103) and CON (40.3 ± 9.7, n=148) groups. There were two 
related participants in both the CTS and the CON groups (mother and daughter). Similar 
results were obtained when the analyses were repeated after excluding one of the related 
participants. 
 
Similar to the all the participants recruited for this thesis (section 4.2.1), bilateral carpal 
tunnel release surgery was performed in 50 (53.2%) of the CTS participants successfully 
genotyped for at least one of the investigated variants, while 33 (35.1%) only had surgery on 
their dominant hand and 9 (9.6%) had surgery on their non-dominant hand. Two (2.1%) 
participants who reported being ambidextrous had carpal tunnel surgery on their right hand.  
 
Participants within the CTS (25.2%, n=26) and CON (15.3%, n=23) groups self-reported 
similar histories (p=0.054) of medical condition(s), such as diabetes (9.7 % CTS, n=10 vs 
8.0% CON, n=12), osteoarthritis (OA, 6.8 % CTS, n=7 vs 5.3% CON, n=8), rheumatoid 
arthritis (RA, 2.9 % CTS, n=3 vs 0.7% CON, n=1), thyroid disorders (1.9 % CTS, n=2 vs 
0.7% CON, n=1), diabetes and OA (1.0 % CTS, n=1 vs 0.0% CON), RA and OA (0.0 % CTS 






disorder (1.0 % CTS, n=1 vs 0.0% CON), RA and systemic lupus erthematosus (1.0 % CTS, 
n=1 vs 0.0% CON), suggested to be associated with CTS 
 
Table 7.3 General characteristics of the carpal tunnel syndrome (CTS) and control (CON) groups 
successfully genotyped for at least one of the investigated variants.  
  CTS (n=103) CON (n=149) p-value 
Age of recruitment (yrs) 45.6 ± 10.6 (103) 40.3 ± 9.7  (148) <0.001 
Age of surgery (yrs) 42.1 ± 10.7 (91) 40.3 ± 9.7 (148)a 0.197 
Sex (% Female) 91.3 (103) 88.6 (149) 0.758 
Height (cm) 159.9 ± 7.6 (101) 160.4  ± 7.7 (148) 0.632 
Weight (kg) 82.8 ± 18.0 (102) 78.5 ± 19.1 (147) 0.198b 
BMI (kg/m2) 32.4 ± 6.9 (101) 30.4 ± 6.8 (146) 0.365b 
Country of birth (% SA) 99.0 (99)c 100.0 (140) 0.486 
 
Values are expressed as a mean ± standard deviation or a frequency (%). The number of participants 
(n) with non-missing data is indicated in parentheses. The maximum number (N) of participants in 
each group is also indicated. 
Significant p-values are indicated in bold. 
a age at recruitment.  
b co-varied for age at recruitment. 
 
 
Sixty-two percent (n=64) of the CTS and 42.2 % (n=62) of the CON participants self-reported 
a history of one or more other medical conditions (p=0.002).  These included hypertension 
(46.6% CTS, n=48 vs 26.0% CON, n=39), hypercholesterolemia (18.4% CTS, n=19 vs 3.3% 
CON, n=5), asthma (4.9% CTS, n=5 vs 3.3% CON, n=5), angina (6.8% CTS, n=7 vs 0.7% 
CON, n=1) and other conditions (4.9% CTS, n=5 vs 4.7% CON, n=7), which included 
hypotension, malignant disease, anaemia, aortic valve stenosis, epilepsy, kidney disease, 
spinal stenosis, Hirschsprung’s disease and autonomic insufficiency. This corresponds with 
the medical conditions of all participants recruited for this thesis (section 4.2.1).  




Similar to all the participants recruited for this thesis (section 4.2.1, table 4.2), the majority of 
the participants (27.2% CTS, n=28 and 50.0% CON, n=75) who were successfully 
genotyped for at least one of the five investigated variants, with non-missing data were 
general poultry processing workers or general workers within other industries where 
repetitive action is performed with the upper limbs. The other major self-reported 
occupations included administration (22.3% CTS, n=23 and 11.3% CON, n=17) and nursing 
(10.7% CTS, n=11 and 8.0% CON, n=12).  
 
Similar to all participants recruited for this thesis (section 4.2.1), there was also no significant 
difference (p=0.111) between the number of participants, successfully genotyped for at least 
one of the five investigated variants, who reported spending their whole working day (100%) 
performing manual labour requiring the use of their hands between the CTS (79.0%, n=79 of 
100) and CON (87.8%, n=130 of 140). Similarly, there was a significant difference (p=0.015) 
between CTS (Median = 50%, interquartile range 5% - 100%) and CON (Median = 100%, 
interquartile range 10% - 100%) participants who were successfully genotyped, for the 
percentage time spent standing during a normal working day. There was no significant 
difference (p=0.29) in number of successfully genotyped participants who reported repetitive 
leisure activities of the wrist (e.g. knitting/crocheting, gardening and kneading/rolling dough) 
within the CTS (55.6%, n=49 of 95) and CON (32.9%, n=60 of 140) groups. 
 
Participants with a TT genotype for IL-1β rs16944 had a significantly lower (p=0.028) BMI 
(29.3 ± 6.3 kg.m2, n=68) than those with a TC (31.7 ± 7.5 kg.m2, n=112) or CC (32.5 ± 5.4 
kg.m2, n=45) genotype (Supplementary table 7.1, Appendix B). Considering the low 
frequency of the CC genotype (n=2), the GC and CC genotypes were combined for IL-6 
rs1800795 (Supplementary table 7.2, Appendix B). Similarly, the AC and CC genotypes 
were also combined for IL-6R rs2228145 (Supplementary Table 7.3, Appendix B). Finally, 






(31.7 ± 6.8 kg.m2, n=115), I/D (29.9 ± 6.4 kg.m2, n=84) and D/D (33.6 ± 8.4 kg.m2, n=22) 
genotypes for Casp8 rs3834129. (Supplementary Table 7.4, Appendix B).There were no 
additional genotype effects on age of recruitment, age of surgery, height, weight or BMI for 
IL-1β rs16944, IL-6 rs1800795, IL-6R rs2228145, CASP8 rs3834129 and VEGFA rs699947 
(Supplementary Tables 7.1 – 7.5, Appendix B). 
 
7.3.2 Genotypes 
There were no significant differences between in any of the genotypes distributions between 
the CTS and CON groups for the IL-1β rs16944 and IL-6 rs1800795 variants (Table 7.4), nor 
the CASP8 rs3834129 and VEGFA rs699947 variants (Table 7.5). There was however a 
significant difference between the CTS and CON groups for IL-6R rs2228145 where AA was 
over-represented in the CON group (p=0.005, OR=0.41, 95% CI 0.22-0.75; Sensitivity 0.59, 
95% CI 0.48-0.69; Specificity 0.22, 95% CI 0.15-0.31) (Figure 7.4). All four variants were in 
Hardy-Weinberg equilibrium. Similar genotype distributions were observed when participants 
with a history of a medical condition believed to be associated with CTS were excluded from 
the analysis (Supplementary table 7.6, Appendix B).   
  






Table 7.4 Genotype frequency distributions of the IL-1β rs16944 (C/T) and IL-6 rs1800795 (C/G 
variants in carpal tunnel syndrome (CTS) and control (CON) groups for all participants (All) as well as 
the female participants (Female). 
 
All Female 
CTS CON CTS CON 
IL-1β rs16944 n=100 n=128 n=91 n=113 
 TT 25.0 (25) 35.2 (45) 23.1 (21) 31.9 (36) 
 TC 57.0 (57) 43.8 (56) 57.1 (52) 45.1 (51) 
 CC 18.0 (18) 21.1 (27) 19.8 (18) 23.0 (26) 
Genotype p-value  0.126 0.215 
C Minor allele 46.5 (93) 43.0 (110) 48.4 (88) 45.6 (103) 
Allele p-value 0.506 0.618 
HWE 1.000 0.892 
IL-6 rs1800795 n=99 n=145 n=91 n=128 
 GG 81.8 (81) 81.4 (118) 84.6 (77) 81.3 (104) 
 CG 16.2 (16) 18.6 (27) 13.2 (12) 18.8 (24) 
 CC 2.0 (2) 0.0 (0) 2.2 (2) 0.0 (0) 
Genotype p-value a 1.000 0.589 
C Minor allele 10.0 (20) 9.3 (27) 8.8 (16) 9.4 (24) 
Allele p-value 0.758 0.868 
HWE 1.000 0.694 
 
Values are expressed as a frequency (%) with the number of participants (n) in parentheses. The 
maximum number (n) of participants in each group is also indicated. Significant p-values are indicated 
in bold. 
HWE, Hardy-Weinberg equilibrium. 









Table 7.5 Genotype frequency distributions of the CASP8 rs3834129 (I/D) and VEGFA rs699947 
(C/A) variants in carpal tunnel syndrome (CTS) and control (CON) groups for all participants (All) as 
well as the female participants (Female). 
 
All Female 
CTS CON CTS CON 
CASP8 rs3834129 n=94 n=132 n=87 n=115 
 I/I 50.0 (47) 53.0 (70) 49.4 (43) 53.0 (61) 
 I/D 41.5 (39) 36.4 (48) 42.5 (37) 35.7 (41) 
 D/D 8.5 (8) 10.6 (14) 8.1 (7) 11.3 (13) 
Genotype p-value 0.698 0.532 
D Minor allele 29.3 (55) 28.8 (76) 29.3 (51) 29.1 (67) 
Allele p-value 0.917 1.000 
HWE 0.336 0.399 
VEGFA rs699947 n=84 n=131 n=77 n=114 
 CC 51.2 (43) 61.8 (81) 52.0 (40) 60.5 (69) 
 CA 42.9 (36) 34.4 (45) 41.6 (32) 36.0 (41) 
 AA 6.0 (5) 3.8 (5) 6.5 (5) 3.5 (4) 
Genotype p-value b 0.157 0.297 
A Minor allele 27.4 (46) 21.0 (55) 27.3 (42) 21.5 (49) 
Allele p-value 0.131 0.221 
HWE 0.573 0.556 
 
Values are expressed as a frequency (%) with the number of participants (n) in parentheses. The 
maximum number (n) of participants in each group is also indicated. Significant p-values are indicated 
in bold. 
HWE, Hardy-Weinberg equilibrium. 
a GG vs GC + CC; b AA vs AC + CC; b CC vs CA + AA 
 
  





Figure 7.4 Genotype frequency distributions of IL-6R rs2228145 (A/C) in carpal tunnel syndrome 
(CTS) and control (CON) groups for (A) all and (B) female participants. Because of the small sample 
size of the CC genotype in the CTS and CON groups, the CC genotype was compared to the 
combined CT and TT genotypes. The number of participants in each group is indicated. Significant 






7.3.3 Inferred Pseudo-Haplotypes 
Since a pathway-based approach was previously shown to be more informative60, inferred 
pseudo-haplotypes were constructed from the IL-6R rs2228145 (A/C), IL-1β rs16944 (T/C) 
and IL-6 rs1800795 (G/C) variants. Six of a possible eight pseudo-haplotypes were inferred 
at a frequency of greater than 2%. The C+C+C inferred pseudo-haplotype was significantly 
over-represented (p=0.002) in the CTS (12.2%) when compared to the CON (3.6%) group 
(Figure 7.5).  
 
The COL5A1 rs12722 and rs13946 variants were included in the inferred pseudo-haplotype 
analyses. However, the effect that was observed was that of COL5A1 rather than the 
interleukin genes’ influence and it was therefore not considered to add value to this chapter 
(Supplementary figure 7.1, Appendix B).  
 
 
Figure 7.5 Inferred pseudo-haplotypes constructed from the IL-6R rs2228145, IL-1β rs16944 and IL-6 
rs1800795 variants. Significant differences are indicated with the p-value. 





7.3.4 COL5A1 & IL-6R Protection Scores 
Since, the AA IL-6R rs2228145, TT COL5A1 rs13946, WW+CC COL5A1 
rs146776422/rs55748801 + rs12722, genotypes were all independently associated with 
reduced risk of CTS (Chapter 5 and Figure 7.4), additional genotype-genotype interactions 
were investigated. Each of the individual “protective” genotypes contributed a score of 2 
towards a participants′ genotype “protection” score. Participants with all the individual CTS 
“protective” genotypes therefore had a total score of 6, while those with none of the 
“protective” genotypes had a score of 0. Compared to the CTS group, the genotype 
“protection” score of 6 was significantly over-represented within the CON group (p<0.001, 
OR=0.08, 95% CI=0.02-0.39, sensitivity=0.03 (95% CI=0.00 – 0.10), specificity=0.75 (95% 
CI=0.66 – 0.83)) (Table 7.6 and Figure 7.6), and the genotype “protection” score of ≤2 was 
significantly under-represented within the CON group (p<0.001, OR=3.65, 95% CI=1.9-7.1, 























Figure 7.6 Genotype protective scores of the COL5A1 rs13946 (T/C), rs12722 (C/T) and IL-6R 
rs2228145 (A/C) variants for the carpal tunnel syndrome (CTS) (solid bars) and control (CON) (clear 
bars) groups, Each of the three individual “protective” genotypes (rs13946, TT; rs12722, CC; 
rs2228145, AA) contributed a score of 2 towards a participants′ genotype “protection” score while the 
“risk” genotypes (rs13946, CC; rs12722, TT; rs11126499, TT) contributed 0. Participants with all three 
individual CTS “protective” genotypes therefore had a total score of 6 while those with none of the 







The expression of structural proteins, such as the collagens, proteoglycans and 
endopeptidases (refer to chapters 4-6), are regulated by signalling cascades in response to 
external stimuli (refer to Figure 7.1) and previous studies have shown altered expression of 
several of these regulatory genes, including genes involved in the signal transduction 
response as well as those involved in apoptosis and angiogenesis, in tendon and ligament 
injuries37,41,65,66,211–214. Considering previous associations as well as the previously reported 
interaction between two of these genes and COL5A160, this study investigated variants 
within five different genes (IL-1β rs16944, IL-6 rs1800795, IL-6R rs2228145, CASP8 
rs3834129 and VEGFA rs699947) for its potential association with risk of carpal tunnel 
syndrome (CTS). The first main finding of this study was the independent association of IL-
6R rs2228145 (A/C) with risk of CTS whilst there were no individual associations of any of 
the other variants with CTS. Specifically the AA genotype of rs2228145 was over-
represented in the control group. Interestingly, there was a significant difference in BMI 
between the different genotype groups of IL-1β rs16944. This is, however, not surprising, 
since increased adiposity has been reported in, and thought to contribute to risk of 
tendinopathy225,226. It has also been hypothesized that tendinopathy might be mediated 
through the  cytokines involved in signal transduction, that are associated with increased 
adiposity60 .  
 
The C-allele of the non-synonymous IL-6R rs2228145 variant causes a coding change from 
aspartic acid to alanine. This then leads to an increase in shedding of the interleukin-6 
receptor (IL-6R) which, in turn, promotes IL-6 trans-signalling221. This particular variant is 
reported to be a modifier of lung function in participants with asthma221 and to play a role in 
causal pathway of coronary heart disease227. Furthermore, IL-6 trans-signalling has been 
implicated in various inflammatory diseases221. In this chapter, the C-allele was over-




represented in the CTS group when compared to the asymptomatic control (CON) group. 
However, hypercholesterolemia, which is considered a proxy for coronary heart disease228, 
was over-represented in the CTS group and this result should therefore be interpreted with 
caution.  
 
Interestingly, no independent associations were found between the IL-6 rs1800795 and IL-
1β rs16944 variants and CTS. IL-6, which is activated by IL-6R, is produced during injury229 
and is thought to play a role in apoptosis60. Increased IL-6 levels have been measured in 
tenocyte apoptosis214, typically seen in tendinopathy, and is also associated with other 
disease conditions229. IL-6 is also responsible for the up-regulation of transforming growth 
factor beta (TGF-β)215, which in turn leads to an increase in COL5A1 expression (Figure 
7.1)230.  Furthermore, increased levels of IL-6 it thought to lead to increased tenocyte 
apoptosis which in turn activated the apoptotic mediator caspase-8214 and the result of this 
pathway is ultimately an increase in the risk of tenocyte apoptosis60. These pathways are 
hypothesized to both ultimately lead to an increased risk of developing tendinopathy. Similar 
to IL-6, Interleukin-1β, (IL-1β, encoded by IL-1β) is also responsible for the up-regulation of 
TGF-β215. In addition, IL-1β up-regulates its own, as well as the expression of IL-6212. 
Considering the close interaction between IL-1β and IL-6 and by implication, IL-6R, the 
variants within the genes encoding for these cytokines were investigated in the form of an 
inferred pseudo-haplotype constructed from the IL-1β rs16944, IL-6 rs1800795 and IL-6R 
rs2228145 variants. It is interesting to note that the C-C-C inferred haplotype was over-
represented in the CTS group. The C-allele of IL-1β rs16944 leads to increased expression 
of IL-1β mRNA which in turns increases ECM degradation and is therefore proposed to 
associated with increased risk of injury. Similarly, previous research has implicated the C-
allele as part of the GC genotype of IL-6 rs1800795 to be associated with increased risk of 
non-contact ACL ruptures in females whereas the GG genotype was protective (S Mannion, 





protective against CTS in this study. Therefore, the C-C-C inferred pseudo-haplotype 
contains the potential risk allele of all three variants. This finding highlights the role of gene-
gene interactions in the aetiology of CTS.  
 
Similarly, no independent associations were found between the apoptosis and angiogenesis 
gene variants, CASP8 rs3834129 and VEGFA rs699947. These variants have been 
previously associated with risk of chronic Achilles tendinopathy65 and ACL ruptures66, 
respectively. Considering the role of caspase-8 in apoptosis, with increased levels being 
present in tendinopathy65, and VEGF in the up-regulation of the matrix metalloproteinases 
(MMPs)213, other variants within these and other genes within the cell signalling pathway 
should be investigated in the future.   
 
Although there are a large number of inferred pseudo-haplotypes that could be constructed 
from the various variants investigated in chapters 4-7, it is important to keep in mind that the 
results presented in this thesis were hypothesis-driven. Therefore only previously found 
associations or newly identified, independent associations were investigated as part of 
inferred pseudo-haplotype investigations. It is very likely that there are several other pseudo-
haplotype associations between various other variants, however the investigation of those 
interactions does not fall within the scope of this thesis.  
 
The second main finding of this thesis was that those participants with a low a “protection” 
score for CTS “protective” score (≤2), calculated from the IL-6R and COL5A1genotypes, 
were at 3.7-fold increased risk of developing CTS while those with a score of 6 were at 12.5-
fold decreased risk. When analysed separately the “protective” genotype of IL-6R rs2228145 
had a low specificity of 22% with a sensitivity of 59%. The inclusion of all the IL-6R and 
COL5A1 genotypes in the protection model increased the specificity to 75% whilst the 
sensitivity decreased significantly to 3%. Similarly, the specificity of the ‘at risk’ model, which 




includes all the risk genotypes, was 98% with a sensitivity of 8%. These findings support the 
hypothesis that many different genetic variants interact to modify the risk of CTS.  
 
A limitation of this study was the small sample size. Future research should aim to 
investigate these variants, as well as other variants within important genes in the cell 
signalling pathway in a larger sample.  
 
In conclusion, this study has shown that the IL-6R rs2228145 variant is independently 
associated with altered risk of CTS and that those with a low “protective” score, which was 
calculated using the IL-6R genotype data, were at reduced risk whereas those with a high 
score were at increased risk of CTS. This highlights the cell signalling pathway as a target 








CHAPTER 8: CONCLUSION 
 
CTS has been described as a condition resulting from the compression of the median nerve 
within the wrist and is commonly referred to as an occupational injury3.  The exact aetiology 
of this condition is still unclear135 and it is considered to be multifactorial3. There are several 
risk factors thought to be important in the aetiology of this condition  and these include3,8,26: 
 
 Non-occupational risk factors (including age, sex, obesity, increased wrist ratio, 
genetic factors and specific medical conditions such as diabetes, thyroid disorders 
and arthritis) 
 Occupational risk factors (including repetitive action of the wrist/hand, weight-bearing 
activity and extreme flexion and extension).  
 Psychosocial risk factors (including poor psychological well-being and having little job 
control) 
 
However, as discussed in the systematic reviews presented in chapters 2 and 3, the current 
level of certainty for these and other risk factors is currently low, except for one. The 
available evidence within the scientific literature is insufficient to facilitate reliable 
assessment or risk estimation70 because of (i) the limited number of studies investigating 
particular risk factors, ii) the sample sizes included in the published studies and (ii) 
inconsistency of the reported findings across individual studies70. Only sex was found to 
have a moderate certainty to modify the risk of CTS. Specifically, current research suggests 
that females are at increased risk of CTS, however the exact biological mechanisms 
underpinning this hypothesis has not been unravelled. Furthermore, it was noted that various 
non-occupational and occupational factors, widely believed to alter risk, had insufficient 
evidence to support them as risk factors for CTS. In contrast, blue-collar workers, which 
comprises occupations often associated with repetitive work, seemed to be at increased risk 
of CTS. One can hypothesise that in many cases the low level of certainty may not 





absence of good quality, prospective studies investigating these factors in the literature. 
Future research investigating risk factors for CTS should therefore focus on improving the 
research study designs. 
  
The current scientific literature suggests that the level of certainty for a family history and a 
genetic predisposition as a modulator CTS risk is low, however, they are both often 
mentioned as risk factors8. To date, only one study has investigated the association of 
specific genetic variants with CTS aetiology. This study looked at variants within the  
proteasome modulator 9 gene (PSMD9), which is considered a ‘risk gene’ for type 2 
diabetes and also found it to be associated with risk of CTS156. It is interesting to note that 
research has focused on the compression of the median nerve in the aetiology of CTS, 
however, the involvement of the flexor tendons and the subsynovial connective tissue 
(SSCT) in the aetiology of CTS cannot be excluded. In support of this, tendinopathy and 
tenosynovitis have both been mentioned as being comorbid conditions or a precursor of 
CTS12. Furthermore, flexor tenosynovitis can lead to an increase in carpal tunnel pressure3 
and it has also been suggested that fibrosis of the SSCT could be a cause of CTS13.  It is 
therefore reasonable to hypothesise that alterations in the properties of the connective tissue 
structures and/or tendons within the carpal tunnel structure may contribute to the 
pathogenesis of CTS. With this in mind, the specific candidate genes investigated in this 
thesis were selected based on their structural and biological function within tendons. In 
addition these genes have all previously been associated with tendon and/or ligament 
injuries as a result of participation in physical activity. The hypothesis tested in this thesis is 
that common genetic polymorphisms previously implicated with risk of exercise-associated 
musculoskeletal soft tissue injuries could also be associated with occupational overuse 






The first aim of this thesis was therefore to determine whether DNA sequence variants within 
genes encoding matrix building blocks (COL5A1, ACAN, BGN), matrix enzymes (MMP10, 
MMP1, MMP3, MMP12) and signalling factors (IL-1β, IL-6, CASP8 and VEGFA), were 
associated with CTS. A secondary aim of the thesis was to investigate hypothesis-driven 
interactions between the investigated variants.  
 
8.1 NOVEL FINDINGS 
 
The novel findings of this thesis highlight the possible role that various genetic factors, which 
play vital roles in tendon biology and function, and thus by implication pathology within the 
flexor tendons and other connective tissue structures in the carpal tunnel, have, at least in 
part, in the aetiology of CTS. 
 
This thesis investigated a self-reported South African Coloured study sample and found: 
 The novel association of four specific variants within three genetic loci to be 
independently associated with CTS (Table 8.1). The independent associations 
include the (1) COL5A1 rs13946 (T/C) and rs146776422 (C/T) /rs55748801 (G/A) 
(W/M where W=CG) + rs12722 (C/T)  variants (2) BGN rs1126499 (C/T) variant (3) 
IL-6R rs2228145 (A/C) variant (Chapters 5, 6 and 7) 
 An interaction between the independent associations between COL5A1 and BGN as 
well as COL5A1 and IL-6R to modulate the risk of CTS (Chapters 6 and 7).  
 Variants within the MMP genes (Chapter 4), the ACAN gene (Chapter 6) and IL-1β, 
IL-6, CASP8 and VEGFA genes (Chapter 7) were not independently associated with 
CTS (Table 8.1). 
 
This is to our knowledge the first research to investigate common polymorphisms, previously 
associated with musculoskeletal soft tissue injury risk, in a South African case-control study 







8.1.1 Independent associations to modify CTS risk 
As described in chapter 1, type V collagen plays a vital role in collagen fibril formation41. 
Considering the hypothesised involvement of the flexor tendons and tendon-structures in the 
aetiology of CTS, it was interesting to find that the combined WW+CC genotypes of 
rs146776422/rs55748801 + rs12722 was associated with reduced risk of CTS in a study 
sample of participants of self-reported Coloured ancestry231. The 3’-UTR of the COL5A1 
gene has been implicated in musculoskeletal injuries44–46 as well as other exercise-
associated phenotypes187–191,232,233, in participants of self-reported Caucasian ancestry. 
Specifically, the CC genotype of rs12722 has been associated with decreased risk of chronic 
Achilles tendinopathy44,45 and ACL injury in females46. The genotypes of the 
rs146776422/rs55748801 variants were not reported in the previously published studies 
because these variants are extremely rare in Caucasian population (minor allele frequency 
in the South African Caucasian population of 1.2%, M. Posthumus, personal communication) 
suggesting that the same WW+CC genotypes were also associated with reduced risk of 
chronic Achilles tendinopathy44,45 and ACL ruptures in females46. The COL5A1 rs146776422 
(C/T) and rs55748801 (G/A) variants, although not informative in Caucasian populations, 
should be genotyped together with rs12722 (C/T) in future studies investigating the 
association of COL5A1 3’-UTR variants with CTS and other musculoskeletal soft tissue 
injuries in non-Caucasian populations.  
 
In contrast to the previous musculoskeletal soft tissue injury genetic association findings44–46, 
the downstream COL5A1 3’-UTR rs13946 (C/T) variant was independently associated with 
CTS, while the upstream rs71746744 (−/AGGG) variant was not associated (Figure 8.1). 
One can hypothesise that these observations suggest that collectively all the studies are 
implicating a region within the COL5A1 3’-UTR region but that the functional genetic motifs 





unique. These observations therefore further highlight the complexities underlying the efforts 
to define an “at risk” profile for these complex multifactorial phenotypes  
 
Table 8.1 Summary of all the investigated variants and their associations (if any) with carpal tunnel 
syndrome (CTS), chronic Achilles tendinopathy (AT) and anterior cruciate ligament (ACL) injury. 
 Gene Polymorphism CTS AT ACL 
Matrix Building Blocks COL5A1 rs13946 (C/T) TT -44 -46 
 COL5A1 rs146776422/rs55748801 (W/M)a 
WW + CC 
(WW)44,b (WW)46,b 
 COL5A1 rs12722 (C/T) CC44 CC (F)46 
 COL5A1 rs71746744 (-/AGGG)  - AGGG/AGGG44 n.d. 
 ACAN rs1516797 (G/T) - n.d. G-allele56 
 BGN rs1126499 (C/T) CC n.d. 
C-allele in a BGN 
haplotype56 
Matrix Enzymes MMP1 rs1799750 (GG/GGGG) - n.d. -59 
 MMP3 rs679620 (G/A) - GG58 -59 
 MMP10 rs486055 (C/T) - n.d. -59 
 MMP12 rs2276109 (A/G) - n.d. G-allele59 
Signalling Factors IL-1β rs16944 (C/T) - T- and C-alleles 
in a IL-1β -IL-6 
haplotype60 
n.d. 
 IL-6 rs1800795 (G/C) - GGc 
 IL-6R rs2228145 (C/A) AA n.d. -d 
 CASP8 rs2228145 (I/D) - D/D65 n.d. 
 VEGFA rs699947 (C/A) - n.d. CC66 
 
Independent associations are indicated with the genotype/allele. Protective associations are indicated 
with green, increased risk associations are indicated in red and no associations (-) indicated in blue. 
White blocks (n.d.) indicate that no investigation has been performed. The citation to all investigations 
in AT and ACL are indicated. 
AT, Achilles tendinopathy; ACL, anterior cruciate ligament; n.d., not determined; F, female 
a rs146776422 (C/T)/rs55748801 (G/A) (W/M where W=CG) 
b Rare variants in Caucasian populations, with the WW genotype been present in the majority (99%) 
of individuals. 
c S. Mannion, personal communication 








Figure 8.1 Schematic representation of the COL5A1 gene with the regions associated with (A) 
chronic Achilles tendinopathy and (B) Carpal tunnel syndrome indicated in bold. The arrows indicate 
the position of the forward and reverse primers for the region amplified for the DpnII and BstUI RFLPs 
(not on scale).  
 
 
Similar to type V collagen, biglycan is also an important regulator of fibrillogenesis. Biglycan 
and type V collagen interact to regulate collagen fibrillogenesis which allows it to maintain 
the structure of the ECM204,206. Mice deficient in the small, leucine-rich proteoglycans 
(SLRPs), which include biglycan, decorin, fibromodulin and lumican, present with similar 
physical phenotype as humans with classic Ehlers-danlos syndrome (EDS)199–201, 
emphasizing the important role it plays in the maintenance of ECM structure. As previously 
mentioned in chapter 5, the majority of the classic forms of EDS is caused by rare mutations 
with COL5A142. The findings in chapter 6, where the CC genotype of the rs1126499 variant 
within the BGN gene (which encodes biglycan) played a protective role against CTS, are in 





associated with increased risk of ACL injury56.   In addition, the CG inferred haplotype 
constructed from rs1126499 and a second BGN variant, rs1042103 (G/A) was associated 
with a decreased risk of ACL injury in female participants56, suggesting that the C-allele of 
rs1126499, as found in chapter 6, contributes to a protective role of BGN for some 
musculoskeletal soft tissue injuries. Future studies should investigate the association of 
rs1042103 (G/A) and other BGN variants with CTS.  
 
It is important to keep in mind that there are signalling pathways that regulate the expression 
of the genes that encode structural components of the ECM, such as type V collagen and 
the proteoglycans, in response to a specific stimulus, such as mechanical loading. 
Disturbances in these pathways can therefore potentially influence risk of injury and previous 
studies have shown altered expression of several proteins involved in cell signalling, in 
tendon and ligament injuries37,41,65,66,211–214. A single functional variant that plays an important 
role in the cell signalling pathway, IL-6R rs2228145 was found to independently associate 
with CTS risk. Specifically, the AA genotype of this variant within the gene encoding the 
interleukin-6 receptor, was found to be associated with decreased risk of CTS.  
 
8.1.2 Gene-gene interactions modify risk of CTS 
The second novel findings of this thesis were the identification of gene–gene interactions 
between the independently associated variants, to collectively contribute to risk of CTS. As 
previously mentioned, biglycan and type V collagen interact to regulate collagen 
fibrillogenesis facilitating the structural integrity of the ECM204,206. Considering their roles in 
fibrillogenesis, it was not surprising to observe allele-allele combinations between COL5A1 
and BGN variants to cumulatively be associated with altered CTS risk profiles between the 
cases and control participants (Chapter 6).   The (i) independent associations of the  





COL5A1 and BGN variants collectively provide further evidence towards the theory that 
tendon pathology might play a significant role in the aetiology of CTS.  
 
Similarly, considering the effect of IL-6 and by implication, IL-6R which encodes the 
interleukin-6 receptor, on regulating type V collagen expression (Chapter 7), the interaction 
between the COL5A1 and IL-6R variants was also investigated. The observations of allele-
allele pairs between COL5A1 and IL-6R variants to be associated with modulating CTS risk 
were noted. These gene-gene interactions are highlighting the biological importance and the 
complexity of the cell signalling pathways contribution to modulating risk in a multifactorial 
condition.  
 
8.1.3 No associations with risk of CTS 
The third novel finding of this thesis was that several gene variants investigated in this thesis 
revealed no independent associations with CTS (Chapters 4-7). The selection of these 
candidate genetic loci was hypothesis-driven and based primarily on the biological function 
of gene products within the tendon as well as their previous associations with multifactorial 
conditions and injuries. The candidate genes included: MMP, ACAN, IL-1β, IL-6, CASP8 and 
VEGFA genes. However, these proteins still remain biologically relevant in tendon biology 
and future studies should include exploring additional functional variants within these same 
genes in the assessment of the aetiology of CTS. 
 
Interestingly, a previous study noted the collective contribution between variants in both the 
COL5A1 and MMP3 genes to modulate the risk of common musculoskeletal soft tissue 
injuries58,59. Considering the independent association of the combined COL5A1 
rs146776422/rs55748801 and rs12722 variants with CTS, it was reasonable that this thesis 
explored the cumulative effects between the COL5A1 rs12722 and MMP3 rs679620 genetic 





rs679620, an inferred pseudo-haplotype constructed from the COL5A1 rs12722 (T/C) and 
MMP3 rs679620 (G/A) variants were associated with increased risk of CTS (Chapter 5). 
These findings were in agreement with one previous study where the association between 
these two variants were observed in female participants with ACL injuries 59 but in contrast to 
another study where  the alternate inferred pseudo-haplotype was associated with risk of 
chronic Achilles tendinopathy58. This contrast is interesting and the biological significance of 
these difference are yet unknown. Posthumus et al. (2011) has however speculated that the 
difference in the risk factor profiles and the distinct difference between the injuries, could 
partially account for these different findings59. Further research is however required to 
elucidate the extent of these differences and the biological impact of MMPs on the 
pathogenesis of musculoskeletal injuries. 
 
Similarly, although no independent associations were noted between the IL-1β and IL-6 
variants, an inferred pseudo-haplotype constructed from these variants together with the 
independently associated IL-6R variant was significantly associated with increased risk of 
CTS (Chapter 7). A previous study also found inferred pseudo-haplotypes constructed from 
the IL-1β and IL-6 variants, which were also not independently associated, together with 
other interleukin variants and the COL5A1 rs12722 variant to collectively contribute to risk 
using a Achilles tendinopathy risk model60. This highlights that a pathway-based approach 
may be more informative to fully elucidate the role of genetic risk factors in multifactorial 
conditions, such as CTS60,65 and that the investigated gene variants might also additively 
contribute to risk of multifactorial musculoskeletal injuries.  
 
8.1.4 Biological mechanisms implicated by this thesis and future directions 
The independent associations together with the gene-gene interactions noted in this thesis 





collective associations are potentially highlighting specific biological pathways that may 
partially contribute to CTS injury pathogenesis.  
The independent association of variants within COL5A1 with CTS risk noted in this study, 
although differences were observed in comparison to previous publications, are in alignment 
with the proposed “type V collagen genotype and exercise-related phenotype hypothesis”184. 
All the associated COL5A1 variants are located within a functional region of the 3’-UTR, 
previously proposed to alter COL5A1 messenger RNA (mRNA) stability within the cytoplasm 
of the tenocyte191. Irrespective of the specific injury, all the reported “at risk” genotypes or 
alleles, as well as the inferred haplotypes constructed from these variants, within this and 
previous studies, are believed to be associated with increased COL5A1 mRNA stability. In 
support of this Laguette et al. (personal communication) has shown a significant increase in 
COL5A1 mRNA levels in primary skin fibroblasts with a COL5A1 rs12722 TT genotype when 
compared to those with a CC genotype. The increase in mRNA stability has been proposed 
to result in increased type V collagen production which potentially impacts on collagen fibril 
architecture, structure and its biomechanical properties and hereby, susceptibility to 
musculoskeletal soft tissue injuries (Figure 8.2). 
 
The 3’-UTR of eukaryotic genes contain many elements, such as microRNA (miRNA) 
binding sites, which are emerging as important post-transcriptional regulators197,198,234,235. 
MicroRNAs are a class of small (18–24 nucleotides) non-coding RNAs that can in animal 
cells induce translational repression197,198 and are directly involved in disease aetiology236. 
Several putative miRNA binding sites have recently been identified within the functional 
region of the COL5A1 3’-UTR (Y. Abrahams, personal communication). Future research is 
required to determine whether any of these miRNA are directly or indirectly involved in the 
aetiology of CTS and other musculoskeletal soft tissue injuries. It is also theoretically 
possible that these COL5A1 3’-UTR binding miRNAs could also be responsible for any 







Figure 8.2 A schematic diagram illustrating the proposed mechanism of how polymorphisms within 
COL5A1 potentially affect fibrillogenesis. (A) The associated COL5A1 variants are associated with 
increased risk of CTS and are located within a functional region of the 3’-UTR, which has been 
proposed to alter COL5A1 messenger RNA (mRNA) stability within the cytoplasm of the tenocyte. 
Increased mRNA degradation is indicated in the left panel while decreased mRNA degradation is 
indicated in the right panel. (B) The altered mRNA stability associated with these polymorphisms is 
believed to result in an altered α1(V) chain and leads to altered type V collagen production 
(decreased in the left and increased in the right panel). (C) Type V collagen regulate collagen 
fibrillogenesis and therefore the mechanical properties of the tendon. There is an inverse relationship 
between type V collagen and the content of the fibril and its diameter. Thinner, more densely packed 
collagen fibrils are produced due to increased type V collagen production (right panel). It has 
previously been proposed that thinner fibrils are associated with chronic Achilles tendinopathy. Figure 







Interestingly, type XI collagen share structural and functional homology with type V 
collagen238 and also plays an important role in regulating fibrillogenesis238,239. Although type 
XI collagen is predominately expressed in cartilage238, it is also expressed in developing 
tendons240. The protein is a heterotrimer, consisting of α1 (XI), α2(XI) and α3(XI) chains 
encoded by the COL11A1, COL11A2 and COL2A1 genes, respectively241. Rare mutations in 
all three type XI collagen encoding genes have been implicated in various inherited 
connective tissue disorders242, while common variants have also been associated with 
multifactorial musculoskeletal injuries and connective tissue disorders55,243–245. Although not 
independently associated, COL11A1 and COL11A2 variants interacted to modulate the risk 
with chronic Achilles tendinopapthy237. The type XI and COL5A1 genes were also shown to 
interact with one another to collectively modulate the risk for Achilles tendinopapthy237. It is 
therefore, reasonable to propose that future studies should investigate the possible 
interaction of types XI and V collagen genes in modulating the risk of CTS. 
 
Similar to types V and XI collagen, there are several other proteoglycans that also play 
important roles in the regulation of fibrillogenesis and, as mentioned earlier, murine models 
deficient in these proteoglycans exhibit symptoms similar to EDS in humans199–201.  Variants 
within the genes encoding these proteoglycans have been investigated for their potential 
association in ligament injuries and a variant within the gene (DCN) that encodes decorin 
was found to independently modify risk of injury56. Considering the function in fibrillogenesis 
and its previous association, as well as the findings of this thesis where a variant within BGN 
was independently associated with altered risk of CTS, it is therefore tempting to speculate 
that variants within the other SLRP genes could also potentially modify risk of CTS both 
independently and in combination with other related genes. Future studies should therefore 






Similarities and differences in the genetic profile of specific recreational musculoskeletal soft 
tissue injuries have previously been reported between males and females46,59, ligament and 
tendon injuries44,46,58,59, as well as, acute and chronic injuries40,44.  It is therefore expected 
that there will be important differences between the genetic profile of occupational and 
recreational musculoskeletal soft tissue injuries. The four experimental chapters in this thesis 
have therefore showed that this admix population has either shifted the genomic interval to 
include additional markers (Chapter 5), revealed no association where previous associations 
were found (Chapter 4, 6 and 7) or revealed similar variants to be associated with risk of 
injury in an occupational setting (Chapters 5 and 7). Furthermore, the various interactions 
between different genes that were observed require further investigation to increase the 
understanding of the underlying mechanisms of these interactions.   
 
The findings of this thesis therefore provide information about the regions containing 
associated variants which can now be further interrogated within this population to assist in 
identifying the “causal risk alleles”. 
 
8.2 STRENGTHS AND LIMITATIONS  
 
There are several strengths to this study design. One of the strengths is that the injury 
population consisted of a group of participants with confirmed diagnosis of an extreme form 
of CTS who were required to undergo carpal tunnel release surgery. Furthermore, these 
participants are from the occupational sector, therefore conservative treatments are 
required, typically lasting at least one year, before surgery can be considered should the 
conservative treatment, including NSAIDS, ice packs and physiotherapy, fail (personal 
communication, Dr Hanli de Wet). This further ensures an extreme phenotype of CTS. An 
additional strength is that the asymptomatic control group have worked in similar industries, 





recruited, it is of note that the control participants were recruited from the same companies 
and therefore the same geographical area as the cases, reducing the possible effect of 
migration in this population.  
Although there was little evidence to support ethnicity as risk factor for CTS (refer to chapter 
2), this thesis investigated a South African Coloured population, since this population group 
is seemingly the most affected ethnic group in the Western Cape area of South Africa (H. de 
Wet, personal communication). Idiopathic CTS is, on the other hand, reported to be rarely 
seen in Black South African populations5,6. Admixed populations, like the Coloured 
population, are not ideally suitable for investigation of new variants in disease/injury risk. 
However the genetic loci investigated in this thesis have, as previously been mentioned, 
been implicated in independent populations and more importantly, it has been implicated in a 
tendinopathy and/or ligament rupture risk model. This study sample investigated is of 
Coloured ancestry representative of the indigenous populations of South Africa and thereby 
is predicted to potentially contain more genetic variation compared to the South African 
populations of Caucasian ancestry246.  For this reason, this admixed population can be 
considered ideal to use in the characterisation and refining of the genetic interval containing 
functional genomic motifs that are relevant to both the common occupational and 
recreational, multifactorial soft tissue injuries246. The novel investigations presented in this 
thesis did therefore not aim to identify novel polymorphisms that are associated with soft 
tissue injury, but rather to (i) add to the proof of concept that already exists about the 
different investigated genetic loci that have previously been associated with other, 
multifactorial musculoskeletal conditions, (ii) to redefine the genetic intervals harbouring 
potential “at risk” genetic elements for future targeted sequencing projects, (iii) characterising 
the underlying involvement of these previously implicated genetic loci in the pathogenesis of 







The variants investigated in this thesis (chapters 4-7) were not previously described in a 
Coloured population; therefore, the minor allele frequencies of each of each of the variants 
were unknown at the start of this investigation. An assumption was made that the 
frequencies will fall within the range of previously reported populations (refer to tables 4.4, 
5.3, 6.1 and 7.1). The minor allele frequencies for this study sample were therefore only 
calculated retrospectively (Supplementary table 8.1, Appendix B). With the exception of 
COL5A1 rs12722 and rs71746744, all the minor allele frequencies fell within the predicted 
range of previously published frequencies reported for Caucasian populations and therefore 
the power calculation for each of these individual variants was reasonable. The subsequent 
calculated genetic effect size of rs12722 and rs7174677 (section 5.2.3), was also not 
influenced by the difference in minor allele frequency and still fell within the suspected 
genetic effect size range.  
 
Several limitations to this research were noted. One limitation of the thesis is that nerve 
conduction studies, the current gold standard in the diagnosis of CTS, was not performed on 
all CTS participants since this is not a requirement of the Commissioner for Workman’s 
compensation in South Africa. In addition, CTS is a syndrome which is believed to occur co-
morbidly with several medical conditions, such as diabetes, osteoarthritis and rheumatoid 
arthritis, even though there is limited evidence to support this belief (Chapter 2). It is highly 
unlikely that the reported associations within this study were as a result of these other 
medical conditions, since (i) the CTS and CON groups were similarly exposed to these 
conditions in all studies (ii) similar genotype distributions for CTS and CON groups were 
reported when these co-morbid medical conditions were excluded from the analysis. In 
chapters 4, 5 and 7 the exclusion of associated medical conditions had no effects on the 
findings of the study. However, in chapter 6 excluding those participants with a medical 
condition thought to be co-morbid with CTS, resulted in the loss of the independent 





interpreted with caution. However, considering the low positive association (p=0.0498) and 
the small sample size, this is not surprising but this highlights the necessity of this work 
being repeated in another, preferably larger cohort to confirm the findings made in this study. 
It was noted that the prevalence of other medical conditions, such as hypertension, 
hypercholesterolemia, asthma and angina, that are not suspected to be co-morbid with CTS, 
were on average, more prevalent in the CTS than the CON group. A possible explanation for 
this may be that the CTS group was significantly older at time of recruitment than the CON 
group, as some of these conditions, such as hypertension and angina, are more prevalent 
with increased age247,248. However, DNA sequence variants investigated in this thesis for 
their potential involvement in musculoskeletal injuries have also been investigated in other 
conditions, such as coronary artery disease and asthma221,249. Therefore, the observation of 
seemingly unrelated medical conditions to be more prevalent in the CTS than the CON 
group should be explored in future research.  
 
Further limitations in this thesis include the small sample size of the entire cohort as well as 
the fact that all samples could not be successfully genotyped for all the investigated variants 
reducing the total sample size further (Supplementary table 8.2). A possible explanation for 
the reduced genotype call rate could be the presence of other, unknown polymorphisms 
within the primer binding sites of the investigated polymorphisms. Evidence on this 
hypothesis was noted in the exploration of the COL5A1 3’-UTR investigation chapter 
(Chapter 5) regarding the polymorphism within the restriction enzyme cutting site (refer to 
Figure 5.9) where two additional, informative variants within COL5A1, rs146776422 and 
rs55748801, were genotyped together with rs12722231. The South African Coloured 
population has a different ancestral lineage, as described in section 4.2.1, than other, more 
regularly studied populations. The variants investigated in this thesis have mostly been 
investigated in Caucasian participants and, considering the difference in ancestry, it is 





binding in the DNA of this population group. It would be reasonable to sequence a proportion 
of this specific population group in order to identify novel variants and a similar sequencing 
study is currently underway.  
Finally, it is important to understand the limitations of genetic association studies. The 
associations in this thesis do not form part of a cause-effect relationship and it is suggested 
that genetic factors is one of various intrinsic risk factors that, together with environmental 
exposure, work together to alter the risk of CTS (Figure 8.2). It is also essential to remember 
that susceptibility to injury does not equal predetermination; it merely describes the relative 
risk of developing the injury. The associations made in this thesis should be evaluated in 
other, independent populations and, as mentioned, future research should also consider 
other variants, besides the ones investigated in these studies, since it is likely that various 
variants contribute collectively to alter the risk of CTS. Proposed molecular mechanisms 
from genetic association studies should then be tested using molecular biology techniques, 
which can assist in determining a cause-effect relationship between the different risk factors 
and CTS. Further research is also required to determine to what extent the non-genetic risk 
factors commonly believed to alter risk of CTS (as shown in grey in Figure 8.2) do in fact 









Figure 8.2 Schematic diagram indicating the relationship between non-occupational and occupational 
risk factors to alter the risk of developing CTS. Risk factors commonly believed to be associated with 
CTS, but with little evidence to support this, are indicated in grey whereas the risk factor with more 
supporting evidence (gender) is indicated in black. Since there is usually no particular inciting event 
causing CTS, further research should investigate possible reasons why only certain susceptible 
individuals eventually develop the injury.  
 
 
In summary, this thesis investigated CTS, a common entrapment neuropathy, from a genetic 
context by exploring sequence variants that have previously been associated with specific 
musculoskeletal injuries, as potential modifiers of CTS risk.  Variants within the COL5A1, 
BGN and IL-6R genes were shown for the first time to be independently associated with 
altered risk for CTS. Specifically, within the COL5A1 3’-UTR, (1) the rs13946 TT genotype 
and  the combined rs146774622/rs55748801 and rs12722 WW+CC genotypes, as well as, 
(2) the BGN rs1126499 CC genotype and (3) the IL-6R rs2228145 AA genotype were 
significantly over-represented in the CON group compared to the CTS group. In addition, 
CTS risk was also modulated by multiple gene-gene interactions. Finally, no independent 
associations were identified with CTS for the MMP10, MMP1, MMP3, MMP12, ACAN, IL-1β, 
IL-6, CASP8 and VEGFA variants, suggesting that although there were similarities, there 
were also differences in the genetic profile of CTS when compared to other common specific 
musculoskeletal injuries. The novel findings of this thesis therefore highlight the possible 
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important role that multiple genetic factors, and by implication pathology within the flexor 
tendons and other connective tissue structures in the carpal tunnel in part may be 
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Supplementary table 4.1 General characteristics for the MMP10 rs486055 (C/T) genotype groups for 




surgery (yrs) Height (cm) Weight (kg) BMI (kg/m
2) 
All n=227 - n=225 n=225 n=223 
CC 42.6 ± 10.5 (206) - 160.7 ± 7.8 (204) 80.4 ± 17.3 (204) 31.2 ± 6.9 (202)
CT 43.9 ± 9.6 (21) - 157.3 ± 8.6 (21) 78.2 ± 22.6 (21) 31.9 ± 6.9 (21) 
p-value 0.571 - 0.064 0.592 0.702 
CTS n=97 n=89 n=95 n=96 n=95 
CC 45.8 ± 10.3 (89) 42.0 ± 10.2 (81) 160.4 ± 7.9 (87) 83.1 ± 18.3 (88) 32.4  7.1 (87) 
CT 42.6 ± 11.5 (8) 38.1 ± 11.1 (8) 156.9 ± 5.5 (8) 78.1 ± 17.2 (8) 31.9 ± 6.4 (8) 
p-value 0.402 0.314 0.223 0.459 0.843 
CON n=130 - n=130 n=129 n=128 
CC 40.1 ± 10.0 (117) - 160.9 ± 7.7 (117) 78.3 ± 16.2 (116) 30.4 ± 6.7 (115)
CT 44.7 ± 8.6 (13) - 157.6 ± 10.3 (13) 78.2 ± 26.0 (13) 31.8 ± 7.5 (13) 
p-value 0.109 - 0.160 0.990 0.463 
Values are expressed as a mean ± standard deviation with the number of participants with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated.  
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 
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Supplementary table 4.2 General characteristics for the MMP1 rs1799750 (G/GG) genotype groups 




(yrs) Height (cm) Weight (kg) BMI (kg/m
2) 
All n=216 - n=215 n=216 n=214 
GG 38.9 ± 10.7 (43) - 159.8 ± 8.5 (43) 74.7 ± 20.4 (43) 29.6 ± 7.7 (43)
GGG 43.7 ± 11.3 (98) - 160.3 ± 8.0 (98) 81.8 ± 19.9 (97) 31.4 ± 6.5 (97)
GGGG 42.4 ± 9.0 (75) - 160.7 ± 7.6 (74) 81.3 ± 17.0 (76) 31.8 ± 7.1 (74)
p-value 0.048 - 0.857 0.108 0.246 
CTS n=88 n=78 n=87 n=88 n=87 
GG 39.2 ± 10.7 (20) 33.8 ± 10.3 (16) 158.9 ± 7.8 (20) 75.4 ± 20.1 (20) 30.1 ± 8.8 (20) 
GGG 48.1 ± 11.4 (37) 45.5 ± 10.9 (34) 160.1 ± 9.0 (37) 85.0 ± 17.4 (37) 33.1 ± 6.1 (37) 
GGGG 44.7 ± 8.4 (31) 41.3 ± 7.7 (28) 160.6 ± 6.6 (30) 85.0 ± 17.5 (31) 33.2 ± 6.5 (30) 
p-value 0.010 <0.001 0.750 0.118 0.224 
CON n=128 - n=128 n=128 n=127 
GG 38.7 ± 11.1 (23) - 160.7 ± 9.1 (23) 74.2 ± 21.1 (23) 29.2 ± 6.8 (23)
GGG 40.9 ± 10.4 (61) - 160.4 ± 7.4 (61) 79.9 ± 21.2 (60) 30.3 ± 6.5 (60)
GGGG 40.8 ± 9.1 (44) - 160.7 ± 8.3 (44) 78.7 ± 16.3 (45) 30.8 ± 7.3 (44)
p-value 0.639 - 0.981 0.495 0.664 
Values are expressed as a mean ± standard deviation with the number of participants with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 
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Supplementary table 4.3 General characteristics for the MMP3 rs679620 (G/A) genotype groups for 
all participants as well as the carpal tunnel syndrome (CTS) and the control (CON) participants. 
Age of 
recruitment (yrs)
Age of surgery 
(yrs) Height (cm) Weight (kg) BMI (kg/m
2)
All n=221 - n=220 n=221 n=219 
GG 42.9 ± 10.2 (107) - 160.9 ± 7.8 (107) 81.5 ± 18.1 (108) 31.6 ± 7.2 (107)
GA 42.8 ± 10.5 (92) - 159.8 ± 7.8 (91) 79.7 ± 18.4 (91) 31.4 ± 6.9 (90) 
AA 41.1 ± 11.7 (22) - 160.2 ± 8.2 (22) 76.6 ± 15.2 (22) 30.0 ± 6.4 (22) 
p-value 0.755 - 0.656 0.481 0.599 
CTS n=95 n=84 n=94 n=95 n=94 
GG 45.8 ± 10.7 (43) 42.6 ± 10.2 (38) 160.5 ± 7.5 (42) 85.7 ± 19.0 (43) 33.4 ± 7.4 (42) 
GA 45.9 ± 10.3 (44) 42.7 ± 11.2 (38) 160.0 ± 8.2 (44) 84.0 ± 16.9 (44) 32.9 ± 6.5 (44) 
AA 43.5 ± 13.2 (8) 40.3 ± 11.7 (8) 157.4 ± 7.5 (8) 70.5 ± 13.3 (8) 28.5 ± 5.6 (8) 
p-value 0.837 0.834 0.585 0.087 0.185 
CON n=126 - n=126 n=126 n=125 
GG 40.9 ± 9.4 (64) - 161.1 ± 8.1 (65) 78.7 ± 17.0 (65) 30.4 ± 6.9 (65) 
GA 40.0 ± 10.0 (48) - 159.7 ± 7.5 (47) 75.6 ± 19.0 (47) 30.1 ± 7.0 (46) 
AA 39.7 ± 11.1 (14) - 161.9 ± 8.4 (14) 80.1 ± 15.6 (14) 30.8 ± 6.9 (14) 
p-value 0.850 - 0.557 0.576 0.936 
Values are expressed as a mean ± standard deviation with the number of participants with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 
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Supplementary table 4.4 General characteristics for the MMP12 rs2276109 (A/G) genotype groups 




(yrs) Height (cm) Weight (kg) BMI (kg/m
2) 
All n=226 - n=224 n=224 n=222 
AA 42.3 ± 10.4 (201) - 160.6 ± 8.0 (199) 80.0 ± 18.0 (199) 31.2 ± 6.9 (197)
AG 44.8 ± 12.4 (25) - 158.7 ± 6.6 (25) 76.4 ± 13.1 (25) 30.4 ± 5.9 (25) 
GG N/A - N/A N/A N/A 
p-value 0.271 - 0.264 0.331 0.598 
CTS n=96 n=86 n=94 n=95 n=94 
AA 45.3 ± 10.6 (84) 41.3 ± 10.5 (74) 160.0 ± 8.1 (82) 82.9 ± 18.4 (83) 32.5 ± 7.2 (82) 
AG 47.4 ± 12.5 (12) 45.4 ± 13.0 (12) 158.8 ± 5.6 (12) 78.4 ± 12.6 (12) 31.0 ± 4.5 (12) 
GG N/A N/A N/A N/A N/A 
p-value 0.531 0.227 0.596 0.416 0.483 
CON n=130 - n=130 n=129 n=128 
AA 40.2 ± 9.8 (117) - 160.9 ± 8.0 (117) 77.9 ± 17.6 (116) 30.3 ± 6.6 (115)
AG 42.5 ± 12.2 (13) - 158.6 ± 7.6 (13) 74.5 ± 13.7 (13) 29.9 ± 7.1 (13) 
GG N/A - N/A N/A N/A 
p-value 0.470 - 0.325 0.497 0.855 
Values are expressed as a mean ± standard deviation with the number of participants with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 
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Supplementary table 4.5 Genotype frequency distributions of the MMP10 rs486055, MMP1 
rs1799750, MMP3 rs679620 and MMP12 rs2276109 variants in carpal tunnel syndrome (CTS) and 
control (CON) groups for all participants (All) as well as the female participants (Female), excluding 
medical conditions that are suggested to be associated with CTS.  
All Female 
CTS CON CTS CON 
MMP10 rs486055 n=72 n=112 n=65 n=96 
CC 91.7 (66) 90.2 (101) 90.8 (59) 88.5 (85) 
CT 8.3 (6) 9.8 (11) 9.2 (6) 11.5 (11) 
TT 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 
Genotype p-value 0.734 0.652 
T minor allele 4.2 (6) 4.9 (11) 4.6 (6) 5.7 (11) 
Allele p-value  0.740 0.661 
MMP1 rs1799750 n=66 n=109 n=59 n=94 
1G1G 25.8 (17) 18.4 (17) 28.8 (17) 20.2 (19) 
1G2G 37.9 (25) 48.6 (53) 35.6 (21) 50.0 (47) 
2G2G 36.4 (24) 33.0 (36) 35.6(21) 29.8 (28) 
Genotype p-value 0.322 0.200 
1G minor allele 44.7 (59) 41.0 (87) 46.6 (55) 45.2 (85) 
Allele p-value 0.504 0.811 
MMP3 rs679620 n=70 n=108 n=63 n=92 
GG 42.9 (30) 51.9 (56) 42.9 (27) 47.8 (44) 
GA 48.6 (34) 38.0 (41) 47.6 (30) 41.3 (38) 
AA 8.6 (6) 10.2 (11) 9.5 (6) 9.5 (10) 
Genotype p-value 0.375 0.738 
A minor allele 32.9 (46) 29.2 (63) 32.9 (42) 31.5 (58) 
Allele p-value 0.461 0.738 
MMP12 rs2276109 n=72 n=112 n=65 n=96 
AA 88.9 (64) 88.4 (99) 89.2 (58) 86.5 (83) 
AG 11.1 (8) 11.6 (13) 10.8 (7) 13.6 (13) 
GG 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 
Genotype p-value 0.918 0.601 
G minor allele 5.6 (8) 5.8 (13) 5.4 (7) 6.8 (13) 
p-value 0.920 0.613 
Values are expressed as a frequency (%) with the number of participants (n) in parentheses. The 
maximum number (n) of participants in each group is also indicated. Significant p-values are indicated 
in bold.HWE, Hardy-Weinberg equilibrium. 
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Supplementary table 5.1 General characteristics for the three COL5A1 rs13946 (C/T) genotype 




Age of surgery 
(yrs) Height (cm) Weight (kg) BMI (kg/m
2)
All n=218 - n=216 n=216 n=214 
CC 41.3 ± 9.6 (12) - 162.1 ± 9.4 (12) 82.1 ± 19.0 (12) 31.5 ± 7.8 (12) 
CT 42.2 ± 11.0 (73) - 161.0 ± 8.4 (71) 82.5 ± 20.2 (71) 32.0 ± 7.7 (70) 
TT 42.7 ± 10.5 (133) - 159.6 ± 7.4 (133) 79.6 ± 18.7 (133) 31.1 ± 6.7 (132)
p-value 0.893 - 0.332 0.570 0.674 
CTS n=91 n=81 n=89 n=90 n=89 
CC 42.3 ± 11.3 (8) 39.0 ± 11.9 (8) 161.5 ± 9.3 (8) 83.0 ± 21.1 (8) 31.9 ± 8.3 (8) 
CT 46.5 ± 9.8 (37) 42.3 ± 9.9 (31) 159.2 ± 7.5 (35) 85.9 ± 20.2 (36) 34.1 ± 7.7 (35) 
TT 45.5 ± 11.8 (46) 42.8 ± 11.8 (42) 160.1 ± 7.8 (46) 82.0 ± 15.9 (46) 32.0 ± 6.1 (46) 
p-value 0.604 0.671 0.714 0.628 0.365 
CON n=127 - n=127 n=126 n=125 
CC 39.5 ± 5.8 (4) - 163.3 ± 11.0 (4) 80.3 ± 16.5 (4) 30.8 ± 7.9 (4) 
CT 37.8 ± 10.5 (36) - 162.7 ± 8.9 (36) 79.1 ± 19.8 (35) 29.9 ± 7.2 (35) 
TT 41.2 ± 9.5 (87) - 159.3 ± 7.3 (87) 78.4 ± 20.0 (87) 30.6 ± 6.9 (86) 
p-value 0.220 - 0.070 0.971 0.880 
Values are expressed as a mean ± standard deviation with the number of participants (n) with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 
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Supplementary table 5.2 General characteristics for the three COL5A1 rs146776422/rs55748801 






Age of surgery 
(yrs) Height (cm) Weight (kg) BMI (kg/m
2)
All n=236 - n=234 n=234 n=232 
WW 42.4 ± 10.4 (210) - 160.4 ± 7.6 (209) 81.0 ± 18.7 (208) 31.5 ± 6.8 (207) 
WM 43.1 ± 12.2 (25) - 158.4 ± 6.2 (24) 74.8 ± 16.6 (25) 29.9 ± 6.5 (24) 
MM 35.0 ± 0.0 (1) - 165.0 ± 0.0 (1) 76.0 ± 0.0 (1) 28.0 ± 0.0 (1) 
p-value 0.742 - 0.379 0.277 0.499 
CTS n=98 n=86 n=96 n=97 n=96 
WW 45.4 ± 10.2 (88) 41.8 ± 10.2 (78) 160.1 ± 7.6 (86) 82.7 ± 16.9 (87) 32.4 ± 6.7 (86) 
WM 47.0 ± 15.9 (10) 43.6 ± 17.2 (8) 158.6 ± 8.6 (10) 74.0 ± 18.1 (10) 29.4 ± 6.3 (10) 
MM N/A N/A N/A N/A N/A 
p-value 0.668 0.652 0.127 0.569 0.181 
CON n=138 - n=138 n=137 n=136 
WW 40.1 ± 9.9 (122) - 160.6 ± 7.6 (123) 79.8 ± 19.9 (121) 30.8 ± 6.8 (121) 
WM 40.5 ± 8.5 (15) - 158.2 ± 3.6 (14) 75.3 ± 16.1 (15) 30.2 ± 6.9 (14) 
MM 35.0 ± 0.0 (1) - 165.0 ± 0.0 (1) 76.0 ± 0.0 (1) 28.0 ± 0.0 (1) 
p-value 0.865 - 0.429 0.697 0.888 
Values are expressed as a mean ± standard deviation with the number of participants (n) with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated. The wild-type (W) bases of both rs146776422 (C/T) and rs55748801 (G/A) are located 
in a BstUI restriction site. The restriction site is destroyed in all three of the remaining sequence 
combinations (M).  
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 
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Supplementary table 5.3 General characteristics for the three COL5A1 rs12722 (C/T) genotype 






Age of surgery 
(yrs) Height (cm) Weight (kg) BMI (kg/m
2)
All n=239 - n=237 n=237 n=235 
CC 41.7 ± 10.0 (116) - 160.4 ± 7.7 (114) 80.4 ± 17.4 (114) 31.4 ± 7.0 (113)
CT 41.8 ± 10.3 (102) - 160.0 ± 7.1 (101) 80.8 ± 20.5 (101) 31.3 ± 6.9 (100)
TT 48.2 ± 12.3 (21) - 160.7 ± 8.2 (22) 78.2 ± 15.0 (22) 30.3 ± 5.3 (22)
p-value 0.025 - 0.882 0.838 0.776 
CTS n=99 n=87 n=97 n=98 n=97 
CC 45.7 ± 10.0 (43) 42.0 ± 10.2 (39) 160.5  ± 7.0 (41) 82.3  ± 16.2 (42) 32.1  ± 6.6 (41)
CT 44.4 ± 9.9 (44) 39.8 ± 9.8 (37) 159.3  ± 8.0 (44) 82.4  ± 19.7 (44) 32.5  ± 7.2 (44)
TT 49.3 ± 15.7 (12) 48.7 ± 14.4 (11) 160.5  ± 9.02 (12) 
80.5  ± 17.3 
(12) 31.2  ± 5.6 (12)
p-value 0.368 0.055 0.753 0.941 0.827 
CON n=140 - n=140 n=139 n=138 
CC 39.4 ± 9.4 (73) - 160.3  ± 8.1 (73) 79.3  ± 18.2 (72) 31.0 ± 7.2 (72)
CT 39.8 ± 10.3 (58) - 160.5  ± 6.4 (57) 79.5 ± 21.8 (57) 30.4 ± 6.6 (56)
TT 46.8 ± 5.8 (9) - 160.9  ± 7.5 (10) 75.4  ± 12.1 (10) 29.2 ±  5.0 (10)
p-value 0.096 - 0.972 0.821 0.710 
Values are expressed as a mean ± standard deviation with the number of participants (n) with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated. Significant p-values are indicated in bold. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 
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Supplementary table 5.4  General characteristics for the three COL5A1 rs71746744 (-/AGGG) 






surgery (yrs) Height (cm) Weight (kg) BMI (kg/m
2)
All n=206 - n=205 n=205 n=203 
-/- 41.4 ± 10.8 (36) - 159.4 ± 7.1 (35) 79.1 ± 17.7 (35) 31.5 ± 7.6 (34) 
-/AGGG 42.0 ± 9.5 (88) - 160.1 ± 8.8 (89) 79.9 ± 19.6 (89) 31.2 ± 7.3 (89) 
AGGG/AGGG 43.0 ± 10.9 (82) - 160.6 ± 7.6 (81) 81.8 ± 19.9 (81) 31.4 ± 6.7 (80) 
p-value 0.702 - 0.760 0.741 0.973 
CTS n=83 n=72 n=82 n=83 n=82 
-/- 46.1 ± 7.8 (14) 42.0 ± 9.2 (13) 158.9 ± 5.9 (13) 83.2 ± 17.2 (14) 33.5  ± 7.4 (13) 
-/AGGG 43.8 ± 9.2 (36) 40.7 ± 9.5 (30) 159.7 ± 8.3 (36) 84.2 ± 20.3 (36) 33.0  ± 7.9 (36) 
AGGG/AGGG 46.0 ± 11.9 (33) 43.1 ± 11.9 (29) 160.5 ± 8.7 (33) 83.3 ± 16.7 (33) 32.3  ± 5.9 (33) 
p-value 0.620 0.674 0.834 0.976 0.859 
CON n=123 - n=123 n=122 n=121 
-/- 38.5 ± 11.6 (22) - 159.6 ± 7.9 (22) 76.4 ± 17.8 (21) 30.3 ± 7.6 (21) 
-/AGGG 40.8 ± 9.6 (52) - 160.3 ± 9.2 (53) 77.0 ± 18.8 (53) 30.0 ± 6.7 (53) 
AGGG/AGGG 41.0 ± 9.8 (49) - 160.6 ±6.8 (48) 80.7 ± 22.0 (48) 30.7 ± 7.1 (47) 
p-value 0.598 - 0.889 0.575 0.882 
Values are expressed as a mean ± standard deviation with the number of participants (n) with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 
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Supplementary table 5.5 General characteristics for the COL5A1 BstUI RFLP, containing 
rs146776422/rs55748801 (W/M) and rs12722 (T/C), genotype groups for all participants as well as 






Age of surgery 
(yrs) Height (cm) Weight (kg) BMI (kg/m
2)
All n=236 - n=234 n=234 n=232 
WW CC 40.4 ± 9.9 (82) - 160.4 ± 7.9 (81) 81.1 ± 17.3 (80) 31.7 ± 7.1 (80) 
WW CT 43.6 ± 10.8 (114) - 160.1 ± 7.2 (113) 81.4 ± 19.9 (113) 31.6 ± 6.8 (112)
WW TT 43.6 ± 8.1 (14) - 162.3 ± 8.4 (15) 77.6 ± 17.4 (15) 29.3 ± 5.4 (15) 
WM, MM CC, CT, TT 42.8 ± 12.0 (26) - 158.6 ± 6.2 (25) 74.8 ± 16.2 (26) 29.8 ± 6.4 (25) 
p-value 0.213 - 0.497 0.372 0.407 
CTS n=98 n=86 n=96 n=97 n=96 
WW CC 45.2 ± 8.8 (24) 42.0 ± 8.9 (22) 161.2 ± 6.7 (23) 83.0 ± 14.5 (23) 32.1 ± 6.7 (23) 
WW CT 46.1 ± 10.7 (58) 41.8 ± 11.0 (51) 159.1 ± 7.6 (57) 82.8 ± 17.3 (58) 32.9 ± 6.9 (57) 
WW TT 40.0 ± 9.5 (6) 40.2 ± 8.0 (5) 164.7 ± 9.3 (6) 81.2 ± 23.8 (6) 29.5 ± 6.0 (6) 
WM, MM CC, CT, TT 47.0 ± 15.9 (10) 43.6 ± 17.2 (8) 158.6 ± 8.9 (10) 74.0 ± 18.1 (10) 29.4 ±6.3 (10) 
p-value 0.589 0.958 0.287 0.502 0.361 
CON n=138 - n=138 n=137 n=136 
WW CC 38.5 ± 937 (58) - 160.0 ± 8.3 (58) 80.3 ± 18.3 (57) 31.5 ± 7.3 (57) 
WW CT 40.9 ± 10.3 (56) - 161.1 ± 6.8 (56) 80.0 ± 22.4 (55) 30.3 ± 6.6 (55) 
WW TT 46.4 ± 6.0 (8) - 160.8 ± 7.9 (9) 75.2 ± 12.8 (9) 29.2 ± 5.3 (9) 
WM, MM CC, CT, TT 40.1 ± 8.3 (16) - 158.7 ± 3.9 (15) 75.4 ± 15.5 (16) 30.1 ±6.6 (15) 
p-value 0.148 - 0.695 0.738 0.664 
Values are expressed as a mean ± standard deviation with the number of participants (n) with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 
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Supplementary table 5.6 Genotype frequency distributions of the COL5A1 3’-untranslated region 
(UTR) rs13946 (C/T), rs12722 (C/T) and rs71746744 (-/AGGG), as well as the adjacent rs146776422 
(C/T) and rs55748801 (G/A), variants in carpal tunnel syndrome (CTS) and control (CON) groups for 
all participants (All) as well as the female participants (Female), excluding medical conditions 
suspected to be associated with Carpal tunnel syndrome.
COL5A1 Genotype 
All Female 
CTS CON CTS CON 
rs13946 n=64 n=107 n=58 n=91 
TT 46.9 (30) 69.16 (74) 46.6 (27) 72.5 (66) 
CT 40.6 (26) 27.1 (29) 43.1 (25) 24.2 (22) 




C minor allele 32.8 (42) 17.3 (37) 31.9 (37) 15.4 (28) 
Allele p-value 0.001 <0.001 
rs146776422/rs55748801 n=72 n=118 n=65 n=103 
WW (CG/CG) 
a 89.0 (64) 86.4 (102) 89.4 (58) 85.4 (88) 
WM 11.1 (8) 12.7 (15) 10.8 (7) 13.6 (14) 
MM 0.0 (0) 0.9 (1) 0.0 (0) 1.0 (1) 
Genotype p-value 
c 0.661 0.640 
M minor allele 5.9 (8) 7.2 (17) 5.4 (7) 7.8 (16) 
Allele p-value 0.530 0.400 
rs12722 n=74 n=120 n=67 n=105 
CC 45.21 (33) 53.3 (64) 45.5 (30) 55.2 (58) 
CT 42.5 (31) 40.8 (49) 43.9 (29) 40.0 (42) 
TT 12.3 (9) 5.8 (7) 10.6 (7) 4.8 (5) 
Genotype p-value 0.230 0.237 
T minor allele 33.6 (49) 26.3 (63) 32.6 (43) 24.8 (52) 
Allele p-value 0.125 0.116 
rs71746744 n=62 n=105 n=55 n=90 
AGGG/AGGG 39.3 (24) 41.0 (43) 35.2 (19) 38.9 (35) 
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Supplementary table 5.6 Continued 
-/AGGG 41.0 (25) 41.0 (43) 44.4 (24) 43.3 (39) 
-/- 19.7 (12) 18.1 (19) 20.4 (11) 17.8 (16) 
Genotype p-value 0.963 0.881 
- minor allele 40.2 (49) 38.6 (81) 42.6 (46) 49.0 (71) 
Allele p-value 0.774 0.599 
Values are expressed as a frequency (%) with the number of participants (n) in parentheses. The 
maximum number (N) of participants in each group is also indicated. Significant p-values are 
indicated in bold. 
a The genotyping method was unable to distinguish between the adjacent rs146776422 (C/T) and 
rs55748801 (G/A) variants. The CG wild-type allele of these adjacent variants, which contains a BstUI 
restriction site, was designated as a W, while the three alternative nucleotide combinations CA, TG 
and TA were designated as an M. The BstUI restriction site is destroyed in all three alternative 
sequence combinations. 
b TT vs CT and CC. 
c WW vs WM and MM. 
HWE, Hardy-Weinberg equilibrium. 
SUPPLEMENTARY MATERIAL 
291 
Supplementary table 6.1 General characteristics for the three ACAN rs1516797 (C/T) genotype 





surgery (yrs) Height (cm) Weight (kg) BMI (kg/m
2)
All n=220 n=218 n=218 n=216 
G/G 42.4 ± 9.8 (69) 161.3 ± 8.1 (70) 80.6 ± 18.2 (68) 31.3 ± 7.3 (68) 
G/T 42.7 ± 11.5 (99) 160.3 ± 8.0 (97) 80.1 ± 20.4 (98) 30.8 ± 6.6 (97) 
T/T 43.6 ± 8.9 (52) 159.6 ± 7.6 (51) 80.5 ± 16.4 (52) 32.0 ± 6.5 (51) 
p-value 0.817 0.501 0.983 0.578 
CTS n=95 n=84 n=93 n=94 n=93 
G/G 46.2 ± 9.6 (29) 42.3 ± 9.6 (27) 162.6 ± 7.4 (29) 83.5 ± 18.1 (29) 31.6 ± 7.1 (29) 
G/T 45.3 ± 11.5 (45) 41.7 ± 11.5 (41) 158.8 ± 7.8 (43) 79.8 ± 18.6 (44) 31.6 ± 6.8 (43) 
T/T 45.5 ± 10.0 (21) 43.3 ± 10.6 (16) 159.1 ± 8.1 (21) 90.0 ± 15.1 (21) 35.9 ± 6.3 (21) 
p-value 0.932 0.874 0.107 0.100 0.062a 
CON n=125 n=125 n=124 n=123 
G/G 39.6 ± 9.0 (40) 160.3 ± 8.6 (41) 78.4 ±18.3 (39) 30.8 ± 7.5 (39) 
G/T 40.5 ± 11.1 (54) 161.6 ± 8.0 (54) 80.3 ± 22.0 (54) 30.1 ± 6.4 (54) 
T/T 42.3 ± 8.0 (31) 159.9 ± 7.4 (30) 74.1 ± 14.2 (31) 29.3 ± 5.2 (30) 
p-value 0.52 0.623 0.353 0.651 
Values are expressed as a mean ± standard deviation with the number of participants (n) with non-
missing data is indicated in parentheses. The maximum number (N) of participants in each group is 
also indicated. 
a co-varied for sex 
yrs, years; cm, centimeters; kg, kilograms; BMI, body mass index; m, meter. 
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Supplementary table 6.2 General characteristics for the three BGN rs1126499 (C/T) genotype 




Age of surgery 
(yrs) Height (cm) Weight (kg) BMI (kg/m
2)
All n=195 n=193 n=194 n=192 
C/C 43.0 ± 10.2 (128) 159.1 ± 6.6 (126) 79.5 ± 18.2 (127) 31.6 ± 7.1 (125) 
C/T 42.9 ± 11.1 (55) 158.3 ± 7.7 (55) 79.9 ± 16.8 (55) 31.9 ± 6.5 (55) 
T/T 43.7 ± 12.1 (12) 159.7 ± 8.8 (12) 80.2 ± 23.7 (12) 31.2 ± 7.0 (12) 
p-value 0.971 0.716 0.987 0.926 
CTS n=86 n=76 n=84 n=85 n=84 
C/C 46.3 ± 9.3 (50) 42.8 ± 10.2 (42) 159.1 ± 5.2 (48) 81.8 ± 17.8 (49) 32.5 ± 7.2 (48) 
C/T 43.5 ± 12.9 (32) 39.7 ± 12.3 (31) 157.8 ± 8.7 (32) 81.4 ± 18.4 (32) 32.6 ± 6.7 (32) 
T/T 47.3 ± 16.2 (4) 48.0 ± 8.5 (3) 158.0 ± 7.4 (4) 77.5 ±  15.3 (4) 31.3 ± 7.1 (4) 
p-value 0.503 0.300 0.690 0.898 0.939 
CON n=109 n=109 n=109 n=108 
C/C 40.8 ± 10.3 (78) 159.0 ± 7.4 (78) 78.1 ± 18.4 (78) 31.1 ± 7.0 (77) 
C/T 41.9 ± 8.1 (23) 158.9 ± 6.3 (23) 78.0 ± 14.4 (23) 31.1 ±6.27 (23) 
T/T 41.9 ± 10.3 (8) 160.5 ± 9.7 (8) 81.5 ± 27.9 (8) 31.1 ± 7.4 (8) 
p-value 0.875 0.853 0.880 1.000 
Values are expressed as a mean ± standard deviation with the number of participants (n) with non-
missing data is indicated in parentheses. The maximum number (N) of participants in each group is 
also indicated. 
yrs, years; cm, centimeters; kg, kilograms; BMI, body mass index; m, meter 
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Supplementary table 6.3 Genotype frequency distributions of the ACAN rs1516797 and BGN 
rs1126499 variants in carpal tunnel syndrome (CTS) and control (CON) groups for all participants (All) 
as well as the female participants (Female), excluding medical conditions suspected to be associated 
with Carpal tunnel syndrome.
All Female 
CTS CON CTS CON 
ACAN rs1516797 n=71 n=107 n=64 n=92 
GG genotype 33.8 (24) 29.9 (32) 31.3 (20) 28.3 (26) 
GT genotype 45.1 (32) 43.9 (47) 45.3 (29) 43.5 (40) 
TT genotype 21.1 (15) 26.2 (28) 23.4 (15) 28.3 (26) 
Genotype p-value 0.716 0.788 
T minor allele 43.6 (62) 48.1 (103) 46.1 (59) 50.0 (92) 
Allele p-value 0.408 0.497 
BGN rs1126499 - - n=63 n=92 
CC genotype - - 60.3 (38) 71.7 (66) 
CT genotype - - 34.9 (22) 19.6 (18) 
TT genotype - - 4.8 (3) 8.7 (8) 
Genotype p-value 
a - 0.165 
T minor allele - - 22.2 (28) 18.5 (34) 
Allele p-value - 0.418 
Values are expressed as a frequency (%) with the number of participants (n) in parentheses. The 
maximum number (N) of participants in each group is also indicated. Significant p-values are 
indicated in bold.  
a CC vs CT + TT 
HWE, Hardy-Weinberg equilibrium. 
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Supplementary table 7.1 General characteristics for the IL-1β rs16944 genotype groups for all 




(yrs) Height (cm) Weight (kg) BMI (kg/m
2)
All n=227 - n=225 n=227 n=225 
CC 43.8 ± 12.3 (45) - 159.1 ± 5.9 (45) 82.0 ± 13.6 (45) 32.5 ± 5.4 (45)a 
CT 42.6 ± 10.4 (112) - 160.3 ± 7.6 (112) 81.1 ± 18.8 (113) 31.7 ± 7.5 (112)b 
TT 41.3 ± 10.2 (70) - 160.9 ± 8.7 (68) 75.4 ± 17.1 (69) 29.3 ± 6.3 (68)a,b 
p-value 0.466 - 0.476 0.056 0.028 
CTS n=100 n=90 n=98 n=99 n=98 
CC 49.7 ± 12.1 (18) 45.5 ± 12.4 (17) 160.1 ± 5.1 (18) 87.7 ± 13.7 (18) 34.1 ± 4.8 (18) 
CT 45.6 ± 10.6 (57) 42.0 ± 10.6 (53) 159.5 ± 7.7 (57) 83.4 ± 18.8 (57) 32.9 ± 7.5 (57) 
TT 43.5 ± 9.3 (25) 39.4 ± 9.3 (20) 161.4 ± 9.0 (23) 78.3 ± 18.2 (24) 30.2 ± 6.6 (23) 
p-value 0.168 0.227 0.612 0.235 0.157 
CON n=127 - n=127 n=128 n=127 
CC 40.0 ± 10.9 (27) - 158.4 ± 6.5 (27) 78.3 ± 12.4 (27) 31.4 ± 5.6 (27) 
CT 39.6 ± 9.4 (55) - 161.2 ± 7.6 (55) 78.8 ± 18.8 (56) 30.5 ± 7.3 (55) 
TT 40.2 ± 10.5 (45) - 160.6 ± 8.7 (45) 73.8 ± 16.5 (45) 28.9 ± 6.2 (45) 
p-value 0.96 - 0.317 0.297 0.274 
Values are expressed as a mean ± standard deviation with the number of participants with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated.  
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 
a CC vs TT (p=0.017) 
b CT vs TT (p=0.025)
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Supplementary table 7.2 General characteristics for the IL-6 rs1800795 genotype groups for all 
participants as well as the carpal tunnel syndrome (CTS) and the control (CON) participants. 
Age of 
recruitment (yrs) 
Age of surgery 
(yrs) Height (cm) Weight (kg) BMI (kg/m
2) 
All n=243 - n=241 n=241 n=239 
GG 42.0 ± 10.8 (198) - 160.3 ± 7.9 (196) 79.6 ± 17.8 (196) 31.1 ± 6.9 (194) 
GC+CC
a 44.5 ± 8.8 (45) - 159.6 ± 7.5 (45) 82.7 ± 23.0 (45) 31.6 ± 7.0 (45) 
p-value 0.155 - 0.588 0.319 0.678 
CTS n=98 n=87 n=96 n=97 n=96 
GG 44.7 ± 11.0 (80) 42.1 ± 11.2 (71) 160.3 ± 7.6 (78) 82.1 ± 18.3 (79) 32.0 ± 6.8 (78) 
GC+CC
a 49.3 ± 7.9 (18) 42.4 ± 8.9 (16) 158.3 ± 6.8 (18) 84.6 ± 18.5 (18) 33.7 ± 7.6 (18) 
p-value 0.095 0.903 0.322 0.604 0.369 
CON n=144 - n=144 n=143 n=142 
GG 40.1 ± 10.2 (117) - 160.3 ± 7.8 (117) 77.8 ± 17.4 (116) 30.5 ± 7.0 (115) 
GC 41.3 ± 8.0 (27) - 160.4 ± 8.0 (27) 81.4 ± 25.9 (27) 30.2 ± 6.4 (27) 
p-value 0.572 - 0.951 0.384 0.857 
Values are expressed as a mean ± standard deviation with the number of participants with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 




Supplementary table 7.3 General characteristics for the IL-6R rs2228145 genotype groups for all 





(yrs) Height (cm) Weight (kg) BMI (kg/m
2) 
All n=206 n=204 n=205 n=203 
AA 43.1 ± 9.5 (144) 160.2 ± 7.4 (142) 80.3 ± 15.7 (144) 31.4 ± 6.3 (142) 
AC+CC
a
 43.5 ± 11.4 (62) 159.7 ± 8.1 (62) 82.0 ± 21.0 (61) 32.2 ± 8.1 (61) 
p-value 0.804 0.672 0.512 0.464 
CTS n=84 n=75 n=82 n=83 n=83 
AA 45.6 ± 9.6 (49) 41.6 ± 9.9 (42) 161.0 ± 8.5 (47) 84.2 ± 16.3 (48) 32.7 ± 6.4 (47) 
AC+CC 45.6  ± 9.6 (35) 44.1 ± 11.7 (33) 157.8 ± 6.7 (35) 81.5 ± 19.2 (35) 32.7 ± 7.3 (35) 
p-value 0.343 0.320 0.068 0.485 0.965 
CON n=121 n=121 n=121 n=120 
AA 41.6 ± 9.2 (94) 159.8 ± 6.8 (94) 78.3 ± 15.1 (95) 30.7 ± 6.2 (94) 
AC+CC
a
 37.9 ± 8.8 (27) 162.1 ± 9.1 (27) 82.8 ± 23.6 (26) 31.5 ± 9.1 (26) 
p-value 0.059 0.154 0.241 0.594 
Values are expressed as a mean ± standard deviation with the number of participants with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 




Supplementary table 7.4 General characteristics for the CASP8 rs3834129 (I/D) genotype groups for 




(yrs) Height (cm) Weight (kg) BMI (kg/m
2) 
All n=225 n=223 n=223 n=221 
I/I 42.5 ± 9.6 (117) 160.6 ± 8.3 (116) 81.6 ± 18.5 (115) 31.7 ± 6.8 (115) 
I/D 41.9 ± 11.3 (86) 160.4 ± 7.63 (85) 77.4 ± 18.1 (86) 29.9 ± 6.4 (84)a 
D/D 43.8 ± 11.1 (22) 158.5 ± 7.2 (22) 84.2 ± 22.1 (22) 33.6 ± 8.4 (22)a 
p-value 0.754 0.498 0.172 0.045 
CTS n=94 n=84 n=92 n=93 n=92 
I/I 45.7 ± 9.7 (47) 41.6 ± 9.7 (42) 160.2 ± 9.0 (46) 84.9 ± 18.4 (46) 33.0 ± 6.8 (46) 
I/D 44.1 ± 11.5 (39) 41.5 ± 11.3 (34) 159.3 ± 6.1 (38) 79.2 ± 16.7 (39) 31.4 ± 6.9 (38) 
D/D 48.9 ± 5.9 (8) 45.8 ± 5.7 (8) 159.8 ± 6.0 (8) 88.9 ± 21.0 (8) 35.4 ± 8.7 (8) 
p-value 0.463 0.541 0.809 0.218 0.303 
CON n=131 n=131 n=130 n=129 
I/I 40.3 ± 9.0 (70) 160.8 ± 7.8 (70) 79.4 ± 18.3 (69) 30.8 ± 6.7 (69) 
I/D 40.1 ± 11.0 (47) 161.3 ± 8.1 (47) 76.0 ± 19.2 (47) 28.7 ± 5.7 (46) 
D/D 40.9 ± 12.4 (14) 158.3 ± 8.1 (14) 81.6 ± 23.0 (14) 32.6 ± 8.4 (14) 
p-value 0.971 0.464 0.514 0.087 
Values are expressed as a mean ± standard deviation with the number of participants with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 
a I/D vs D/D (p=0.024) 
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Supplementary table 7.5 General characteristics for the VEGFA rs699947 genotype groups for all 




(yrs) Height (cm) Weight (kg) BMI (kg/m
2) 
All n=214 n=212 n=212 n=210 
C/C 41.0 ± 10.1 (124) 160.2 ± 8.4 (122) 79.5 ± 19.7 (122) 30.9 ± 7.2 (121) 
C/A 43.5 ± 10.4 (80) 161.3 ± 8.7 (80) 82.6 ± 17.5 (80) 31.8 ± 6.3 (79) 
A/A 45.9 ± 13.2 (10) 159.9 ± 7.3 (10) 68.2 ± 11.4 (10) 26.7 ±5.0 (10) 
p-value 0.129 0.577 0.063 0.080 
CTS n=84 n=75 n=82 n=83 n=82 
C/C 42.7 ± 9.7 (43) 38.5 ± 9.7 (37) 160.7 ± 8.0 (42) 83.6 ± 17.9 (42) 32.3 ± 6.9 (42) 
C/A 48.0 ± 10.5 (36) 43.8 ± 11.1 (33) 159.9 ± 7.3 (35) 82.8 ± 16.8 (36) 32.6 ± 6.5 (35) 
A/A 50.0 ± 13.9 (5) 48.2 ± 14.1 (5) 159.0 ± 6.5 (5) 67.2 ± 12.0 (5) 26.6 ± 4.4 (5) 
p-value 0.053 0.105 0.832 0.133 0.162 
CON n=130 n=130 n=129 n=128 
C/C 40.1 ± 10.2 (81) 159.9 ± 8.6 (80) 77.3 ± 20.4 (80) 30.1 ± 7.3 (79) 
C/A 39.8 ± 8.9 (44) 162.4 ± 6.0 (45) 82.3 ± 18.2 (44) 31.1 ± 6.0 (44) 
A/A 41.8 ± 12.4 (5) 160.8 ± 8.6 (5) 69.2 ± 12.1 (5) 26.8 ± 6.1 (5) 
p-value 0.915 0.228 0.213 0.377 
Values are expressed as a mean ± standard deviation with the number of participants with non-
missing data is indicated in parentheses. The maximum number (n) of participants in each group is 
also indicated. 
yrs, years; cm, centimetres; kg, kilograms; BMI, body mass index; m, meter. 
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Supplementary table 7.6 Genotype frequency distributions of the IL-1β rs16944 (C/T), IL-6 
rs1800795 (C/G), IL-6R rs2228145 (A/C), CASP8 rs3834129 (I/D) and VEGFA rs699947 (C/A) 
variants in carpal tunnel syndrome (CTS) and control (CON) groups for all participants (All) as well as 
the female participants (Female) excluding medical conditions that are suggested to be associated 
with CTS. 
All Female 
CTS CON CTS CON 
IL-1β rs16944 (C/T) n=74 n=108 n=67 n=94 
TT 28.4 (21) 34.3 (37) 26.9 (18) 29.8 (28) 
TC 55.4 (41) 43.5 (47) 55.2 (37) 45.7 (43) 
CC 16.2 (12) 22.2 (24) 17.9 (12) 24.5 (23) 
Genotype p-value 0.278 0.450 
C Minor allele 43.9 (65) 44.0 (95) 45.5 (61) 47.3 (89) 
Allele p-value 0.991 0.747 
IL-6 rs1800795 (C/G) n=72 n=123 n=66 n=106 
GG 87.5 (63) 78.7 (96) 89.4 (59) 78.3 (83) 
GC 11.1 (8) 21.3 (26) 9.1 (6) 21.7 (23) 
CC 1.4 (1) 0.0 (1) 1.5 (1) 0.0 (0) 
Genotype p-value 
a 0.127 0.067 
C Minor allele 6.9 (10) 11.4 (28) 6.1 (8) 10.8 (23) 
Allele p-value 0.154 0.132 
IL-6R rs2228145 (A/C) n=61 n=100 n=55 n=86 
AA 62.3 (38) 77.0 (77) 58.2 (32) 80.2 (69) 
AC 36.1 (22) 22.0 (22) 40.0 (22) 18.6 (16) 




C Minor allele 19.7 (24) 12.0 (24) 21.8 (24) 10.5 (18) 
Allele p-value 0.061 0.009 
CASP8 rs3834129 (I/D) n=69 n=114 n=64 n=98 
I/I 47.8 (33) 50.9 (58) 46.9 (30) 51.0 (50) 
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Supplementary table 7.6 Continued 
I/D 43.5 (30) 36.8 (42) 43.8 (28) 35.7 (35) 
D/D 8.7 (6) 12.3 (14) 9.4 (6) 13.3 (13) 
Genotype p-value 0.587 0.528 
D Minor Allele 30.4 (42) 30.7 (70) 31.3 (40) 31.1 (61) 
Allele p-value 0.957 0.981 
VEGFA rs699947 (C/A) n=61 n=112 n=56 n=96 
CC 55.7 (34) 59.8 (67) 55.4 (31) 58.3 (56) 
CA 39.3 (24) 36.6 (41) 39.3 (22) 38.5 (37) 
AA 4.9 (3) 3.6 (4) 5.4 (3) 3.1 (3) 
Genotype p-value 
c 0.631 0.737 
A Minor Allele 24.6 (30) 21.9 (49) 25.0 (28) 22.4 (43) 
Allele p-value 0.565 0.605 
Values are expressed as a frequency (%) with the number of participants (n) in parentheses. The 




Supplementary figure 7.1 Inferred pseudo-haplotypes constructed from the (A) IL-6R rs2228145, IL-
1β rs16944, IL-6 rs1800795 and COL5A1 rs12722 variants as well as the (B) IL-6R rs2228145, IL-1β 




Supplementary table 8.1 Suspected and actual minor allele frequencies of the investigated 
variants 






MMP10 rs486055 (C/T) T 0.6 - 10.5 4.6 
MMP1 rs1799750 (G/GG) G/GG G: 47.0 - 47.9     GG: 37.5 - 43.3 G: 42.4 
MMP3 rs679620 (A/G) A 23.0 - 48.3 30.6 
MMP12 rs2276109 (A/G) G 0.0 - 15.9 5.5 
COL5A1 rs13946 (T/C) C 10.5 - 38.4 22.0 
COL5A1 rs12722 (C/T) T/C T: 13.6 - 22.1  C:43.4 T: 30.4 
COL5A1 rs71746744 (-/AGGG) AGGG 14.2 38.9 
BGN rs1126499 (C/T) C/T C: 47.2    T: 0.06 - 45.0    T: 20.2 
ACAN rs1516797 (G/T) G/T G: 24.0 - 33.5  T: 31.6 - 46.2 T: 45.9 
IL-1β rs16944 (T/C) C 33.3 – 50.0 44.5 
IL-6 rs1800795 (G/C) C 0.0 – 35.2 9.6 
IL-6R rs2228145 (A/C) C 6.2 – 38.6 15.5 
CASP8 rs3834129 (I/D) I/D I: 45.2 – 50.0  D: 21.7 – 50.0 D: 29.0 
VEGFA rs699947 (C/A) C/A C: 46.0  A:11.9 – 41.0  A: 23.5 
Values are presented as a range of frequencies with the actual frequency of the minor allele in the 
Coloured population, indicated.  
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Supplementary table 8.2 Percentage of successfully genotyped variants 
% successfully genotyped 
Gene Variant CTS (n=103) CON (n=150) 
MMP10 rs486055 94.2 (97) 87.3 (131) 
MMP1 rs1179750 85.4 (88) 86.0 (129) 
MMP3 rs679620 92.2 (95) 84.7 (127) 
MMP12 rs2276109 93.2 (96) 87.3 (131) 
COL5A1 rs13946 88.3 (91) 84.7 (127) 
rs12722 96.1 (99) 94.0 (141) 
rs71746744 80.6 (83) 82.7 (124) 
ACAN rs1516797 92.2 (95) 84.0 (126) 
BGN rs1126499 92.2 (95) 83.3 (125) 
IL-1β rs16944 97.1 (100) 85.3 (128) 
IL-6 rs1800795 96.1 (99) 96.7 (145) 
IL-6R rs2228145 82.5 (85) 81.3 (122) 
CASP8 rs3834129 91.3 (94) 88.0 (132) 
VEGFA rs699947 81.6 (84) 87.3 (131) 
Values are expressed as a frequency (%) with the number of participants (n) with non-missing data 
indicated in parentheses. The maximum number (n) of participants in each group is also indicated. 
